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Background: Opioid substitution therapy and needle exchanges have reduced blood-borne viruses (BBVs)
among people who inject drugs (PWID). Some PWID continue to share injecting equipment.
Objectives: To develop an evidence-based psychosocial intervention to reduce BBV risk behaviours and
increase transmission knowledge among PWID, and conduct a feasibility trial among PWID comparing the
intervention with a control.
Design: A pragmatic, two-armed randomised controlled, open feasibility trial. Service users were Steering
Group members and co-developed the intervention. Peer educators co-delivered the intervention
in London.
Setting: NHS or third-sector drug treatment or needle exchanges in Glasgow, London, Wrexham and
York, recruiting January and February 2016.
Participants: Current PWID, aged ≥ 18 years.
Interventions: A remote, web-based computer randomisation system allocated participants to a
three-session, manualised, psychosocial, gender-specific group intervention delivered by trained facilitators
and BBV transmission information booklet plus treatment as usual (TAU) (intervention), or information
booklet plus TAU (control).
Main outcome measures: Recruitment, retention and follow-up rates measured feasibility. Feedback
questionnaires, focus groups with participants who attended at least one intervention session and
facilitators assessed the intervention’s acceptability.
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Results: A systematic review of what works to reduce BBV risk behaviours among PWID; in-depth
interviews with PWID; and stakeholder and expert consultation informed the intervention. Sessions covered
improving injecting technique and good vein care; planning for risky situations; and understanding BBV
transmission. Fifty-six per cent (99/176) of eligible PWID were randomised: 52 to the intervention group
and 47 to the control group. Only 24% (8/34) of male and 11% (2/18) of female participants attended all
three intervention sessions. Overall, 50% (17/34) of men and 33% (6/18) of women randomised to the
intervention group and 47% (14/30) of men and 53% (9/17) of women randomised to the control group
were followed up 1 month post intervention. Variations were reported by location. The intervention was
acceptable to both participants and facilitators. At 1 month post intervention, no increase in injecting in
‘risky’ sites (e.g. groin, neck) was reported by participants who attended at least one session. PWID who
attended at least one session showed a trend towards greater reduction in injecting risk behaviours, a
greater increase in withdrawal planning and were more confident about finding a vein. A mean cost of
£58.17 per participant was calculated for those attending one session, £148.54 for those attending two
sessions and £270.67 for those attending all three sessions, compared with £0.86 in the control group.
Treatment costs across the centres vary as a result of the different levels of attendance, as total session
costs are divided by attendees to obtain a cost per attendee. The economic analysis suggests that a
cost-effectiveness study would be feasible given the response rates and completeness of data. However,
we have identified aspects where the service use questionnaire could be abbreviated given the low
numbers reported in several care domains. No adverse events were reported.
Conclusions: As only 19% of participants attended all three intervention sessions and 47% were followed
up 1 month post intervention, a future definitive randomised controlled trial of the intervention is not
feasible. Exposure to information on improving injecting techniques did not encourage riskier injecting
practices or injecting frequency, and benefits were reported among attendees. The intervention has the
potential to positively influence BBV prevention. Harm reduction services should ensure that the
intervention content is routinely delivered to PWID to improve vein care and prevent BBVs.
Future work: The intervention did not meet the complex needs of some PWID, more tailoring may be
needed to reach PWID who are more frequent injectors, who are homeless and female.
Limitations: Intervention delivery proved more feasible in London than other locations. Non-attendance at
the York trial site substantially influenced the results.
Trial registration: Current Controlled Trials ISRCTN66453696 and PROSPERO 014:CRD42014012969.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 72.
See the NIHR Journals Library website for further project information.
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Plain English summary
Opioid substitution therapy and needle exchanges have reduced blood-borne viruses (BBVs) amongpeople who inject drugs (PWID). Interventions that provide PWID with skills, and strategies, to reduce
risk behaviours are needed.
What we did
Interventions that reduced sharing of injecting equipment and unprotected sex, alongside the views of
PWID and other key stakeholders, were used to develop a three-session, gender-specific group intervention
to improve injecting techniques and BBV transmission knowledge, and to promote good vein care and
strategies to avoid risky injecting and sex situations. A study was done to find out whether or not PWID
would attend and take part in the intervention and what they thought about it. Ninety-nine PWID from
harm reduction services in London, York, Glasgow and Wrexham were allocated at random to receive:
l the group intervention plus an information leaflet on BBV transmission (n = 52) or
l the information leaflet only (n = 47).
What we found
Twenty-four per cent of men and 11% of women attended all three sessions and 48% of men and 43%
of women were interviewed 1 month after the intervention. The intervention was considered acceptable
by both staff who delivered it and the people who attended it. PWID who attended at least one session
tended to engage in fewer high-risk injecting behaviours, to plan more for withdrawal and to be more
confident about finding a vein than those who did not attend any sessions.
Conclusions
More frequent injectors, and those who were homeless or female, were less likely to attend the
intervention. Further development and testing is needed to meet the needs of all PWID.
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Scientific summary
Background
Although opioid substitution therapy and needle exchanges are effective in reducing blood-borne virus
(BBV) transmission among people who inject drugs (PWID), some PWID continue to share injection
equipment, putting them at risk of acquiring or transmitting BBVs. Preventing BBV transmission among
PWID remains a major public health concern. Psychosocial interventions (including cognitive–behavioural
therapy, contingency management and skills training) may help reduce BBV transmission by informing
PWID about transmission risks and providing them with the skills and strategies to reduce risky behaviours.
Objectives
The project contained six complementary phases to inform the development of an evidence-based psychosocial
intervention to reduce BBV transmission risk behaviours among PWID and conduct a feasibility trial comparing
the psychosocial intervention with an information leaflet. The main objectives were:
l to determine the efficacy of psychosocial interventions to reduce drug and sexual risk behaviours
associated with BBV transmission and/or reinfection among PWID (phase I)
l to qualitatively explore PWID influences on BBV risk-taking behaviour and views on psychosocial
interventions to address risks (phase II)
l to consult key stakeholders about the delivery and effectiveness of psychosocial interventions to reduce
BBV transmission among PWID (phase III)
l to develop a psychosocial intervention to reduce BBV risk behaviours among PWID (phase IV)
l to determine the feasibility, and acceptability, of recruiting PWID to a trial comparing the intervention
with control (phase V)
l to outline considerations for future research (phase VI).
Methods
Intervention design
The intervention was informed by findings from the following:
l A systematic review of the efficacy of psychosocial interventions compared with control interventions
(interventions of lesser time or intensity) in reducing BBV transmission risk behaviours among PWID.
Randomised control trials (RCTs) published from 2000 to May 2015 in MEDLINE, PsycINFO, Cumulative
Index to Nursing and Allied Health Literature (CINAHL), the Cochrane Collaboration and ClinicalTrials.gov
were included. A meta-analysis was performed, using a random-effects model.
l A scoping review of UK grey literature on the efficacy of psychosocial interventions, seeking sources
not identified in the systematic review.
l A mapping exercise of psychosocial provision to address BBVs among PWID of all agencies responsible
for alcohol and drug commissioning in the UK (i.e. alcohol and drug commissioners in England, alcohol
and drug partnerships in Scotland, health- and social-care trusts in Northern Ireland and substance
misuse area planning boards in Wales).
l In-depth interviews with a convenience sample of 60 PWID aged ≥ 18 years who had injected drugs
(other than image- and performance-enhancing drugs) within the past 4 weeks from drug treatment
and harm reduction centres, needle exchanges (including pharmacy and mobile), sexual health services
and homeless hostels in Glasgow, London, Yorkshire and North Wales. Briefly, the interview covered
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BBV transmission knowledge, perceptions of personal vulnerability to BBVs, influences on the sharing
of injection equipment and sexual risk practices. Participants were also asked for suggestions on the
psychosocial intervention being developed (content, format, venue, interventionist, duration, barriers/
facilitators). Interviews were analysed using qualitative framework analysis.
l Telephone consultation with 40 key stakeholders with responsibility for delivering and commissioning
services in BBV prevention in the UK identified any barriers to, or facilitators of, the delivery of
psychosocial interventions in substance use treatment.
The manualised psychosocial intervention was co-developed by service users, service providers, policy-makers
and academics and is available to download free of charge from the project website: www.kcl.ac.uk/ioppn/
depts/addictions/research/drugs/bloodborneviruses.aspx. The COM-B (‘capability’, ‘opportunity’, ‘motivation’
and ‘behaviour’) theory of behaviour change was used to inform the intervention, that is, that capability
(i.e. individual’s psychological and physical capacity to engage in the activity concerned including having the
necessary knowledge and skills), opportunity (i.e. factors outside the individual that make the behaviour
possible or prompt it), and motivation interact to generate behaviour change. The Steering Group was
responsible for final agreement of manual content. This group was supported by two development groups –
an expert group (comprising practitioners, academics, policy-makers) and a service user group with lived
experience of injecting drug use.
Feasibility trial
Design, participants and setting
A pragmatic, two-armed randomised controlled, open feasibility trial with equal randomisation delivered
across four UK sites (Glasgow, London, York and Wrexham) was conducted among PWID in the last month
(other than primary performance and image-enhancing drugs), who were aged ≥ 18 years and were
attending NHS or third-sector community addiction, harm reduction clinics or needle exchange programmes.
Randomisation
To maintain allocation concealment, randomisation sequence generation was undertaken by an independent
statistician at the University of York, and treatment allocation was performed by a secure and remote
telephone randomisation service based there. Participants were randomised by block randomisation,
ensuring balanced allocation within each location, service type and gender.
Interventions
Participants were randomised (1 : 1) to receive either:
l the intervention arm: a gender-specific psychosocial group (brief) intervention involving three 1-hour
weekly sessions facilitated by trained drugs workers (and co-facilitated by a gender-matched peer
educator in London), an information leaflet on reducing BBV transmission and treatment as usual (TAU)
from the service from which they are recruited; or
l the control arm: an information leaflet on reducing BBV transmission and TAU from the service from
which they are recruited.
Main outcome measures
Feasibility was measured by recruitment rates, retention in treatment and follow-up rates as well as the
extent to which health economic data were completed with the required information, in order to inform
the design and implementation of an economic evaluation of a full trial.
Secondary outcome measures
Differences in the number of injection risk events, BBV transmission knowledge, withdrawal planning,
self-efficacy around finding a vein, not sharing equipment, safer sex, cleaning injection equipment and
talking about safe drug use in past month were assessed at baseline, end of the intervention and 1 month
post intervention (or equivalent time period for those in the control arm) using intention-to-treat analysis.
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The economic analysis included intervention costing, calculation of NHS and wider social costs per patient,
EuroQol-5 Dimensions, five-level version, results and assessment of the pilot questionnaires in preparation
for a full, sufficiently powered RCT.
Acceptability
Intervention facilitators and participants completed feedback forms following each session and participated
in focus group discussions to establish the acceptability of the intervention. Focus groups were analysed
using thematic analysis.
Results
Intervention design
Thirty-two and 24 RCTS were included in the systematic review and meta-analysis, respectively. Psychosocial
interventions appear to reduce the sharing of needles/syringes compared with education/information
[standardised mean difference (SMD) –0.52, 95% confidence interval (CI) –1.02 to –0.03, I2 = 10%;
p = 0.04] or human immunodeficiency virus infection testing/counselling (SMD –0.24, 95% CI –0.44 to
–0.03, I2 = 0%; p = 0.02); however, moderate to high heterogeneity was reported for the sharing of other
injecting equipment (SMD –0.24, 95% CI –0.42 to –0.06, I2 = 0%; p < 0.01) and unprotected sex (SMD
–0.44, 95% CI –0.86 to –0.01, I2 = 79%; p = 0.04) compared with interventions of a lesser time/intensity.
The main functions described in these interventions were education, training (imparting skills), enablement
(increasing means/reducing barriers), incentivisation and persuasion (using communication to induce
positive or negative feelings or stimulate action). Effective interventions were sourced and their content
reviewed by the intervention development groups.
The scoping review of the UK grey literature, mapping exercise with drug and alcohol commissioners and
the consultation with key stakeholders confirmed that no current intervention met the needs identified
by PWID.
Analysis of 60 qualitative interviews with current PWID found that a range and combination of individual,
situational and structural factors contributed to BBV risk behaviours in this population. Relationships and
social networks are identified as crucial influences on risk behaviours, whereas access to needle exchanges
and safe injecting environments is vital for maintaining safer injecting behaviours. However, drug states,
such as withdrawal and craving, and the trajectory of drug use generate priorities of more immediate
concern to PWID than BBVs. Furthermore, perceptions of BBV transmission risks change over time as
knowledge is gained, and the interviews illustrate that there remains a great deal of uncertainty around
BBV acquisition. Participants described managing risk situations by planning ahead and being more vigilant
regarding hygiene practices when using with others. Although risk management strategies were not
necessarily intentionally BBV-protective, they were employed to manage other risks such as overdose and
soft-tissue infections. For many of those interviewed, any intervention aimed at reducing risk behaviours
should include behavioural and skills components, such as health advice, hygiene promotion and injecting
skills, as well as information about BBV transmission. Interventions that are delivered locally by informed
trainers and are cognisant of the challenges PWID encounter in attending were considered important.
Based on these findings, the need to address symbiotic goals of PWID and develop strategies to avoid risk
situations (e.g. withdrawal) and lack of preparedness were central to the intervention aims. Three weekly
sessions of 1 hour were developed: improving injecting technique and good vein care (session 1); planning
for risky situations (session 2); and understanding BBV transmission (session 3). The intervention was
intended to be delivered to groups of eight participants of the same gender.
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Feasibility trial
Participants were predominantly male, in their late thirties/early forties and had been injecting for between
14 and 22 years on average. Baseline characteristics were comparable between randomised treatment
groups for males. Potential imbalances were observed in the smaller group of women (e.g. with a greater
number of heroin users and homeless women in the intervention arm).
Primary outcomes
Fifty-six per cent (99/176) of eligible PWID were randomised into the feasibility trial: 52 were allocated to
the intervention group and 47 to the control group. Only 24% (8/34) of male [ranging from zero men in
York to 44% (4/9) in London] and 11% (2/18) of female participants (both from London) attended all three
intervention sessions. More participants attended at least one intervention session in London (10/16, 63%)
and Wrexham (7/13, 54%) than in Glasgow (3/12, 25%) and York (0/11). Compared with participants who
attended at least one intervention session (n = 20), participants who did not attend any sessions (n = 32)
were more likely to be homeless (56% vs. 25%; p = 0.044) and injected drugs for a greater number of days
in the last month (median 25 vs. 6.5 days; p = 0.019). Follow-up at a minimum of one time point was also
highest in London (83%) and Wrexham (63%), and significantly lower in Glasgow (55%) and York (43%),
which may in part be linked to factors associated with higher homelessness and injecting frequencies in
Glasgow and York. Follow-up attendance was associated with fewer days of injecting in the last month
(median 14 vs. 27 days; p = 0.030) and fewer injections of cocaine (13% vs. 30%; p = 0.063). Women
were more likely to attend follow-up in London and York than in Glasgow and Wrexham.
A mean cost per participant was calculated for attendance at one (£58.17), two (£148.54) and three
(£270.67) sessions, and compared with the mean cost per participant in the control group (£0.86).
Treatment costs across the centres vary as a result of the different levels of attendance, as total session
costs are divided by attendees to obtain a cost per attendee.
The content of the intervention was considered acceptable by both facilitators and participants. Intervention
participants welcomed the opportunity to talk about topics that are not normally discussed at harm
reduction services, and the amount and variety of information provided. No adverse events were recorded as
a result of participating in the feasibility trial. At 1 month post intervention, those who attended at least one
intervention session reported no increase in injecting in more ‘risky’ sites (e.g. groin, neck) and no increase in
the number of days in the past 28 days on which drugs were injected was observed.
Secondary outcomes
Improved (fewer) injecting risk practices, improved self-efficacy, better hepatitis C and hepatitis B transmission
knowledge and greater use of withdrawal prevention techniques were reported in the intervention than in
the control group. This was true at both follow-up time points and both analyses for randomised groups and
groups based on attendance at the intervention. The economic analysis suggests that a cost-effectiveness
study would be feasible given the response rates and completeness of data. However, we have identified
aspects where the service use questionnaire could be abbreviated given the low numbers reported in several
care domains.
Conclusions
Criteria were not predetermined regarding the feasibility parameters required for progression to a future
definitive RCT of the psychosocial intervention. The recruitment (56%), intervention attendance (19%
attended all three sessions) and 1 month post-intervention follow-up (47%) rates suggest that a future
RCT of the intervention is not justifiable. Intervention delivery proved more feasible in London than at
other sites. Potential reasons for differences in attendance and compliance across sites include payment in
cash, reimbursement of travel and intervention co-delivery by peer educators in London, and higher
homelessness and injecting frequencies in Glasgow and York. The findings suggest that the intervention
did not meet the complex needs of some PWID, particularly in York and Glasgow. The intervention may
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need to be more tailored to reach PWID who are more frequent injectors, who are homeless and who are
female. Further development and testing of the intervention is warranted among other groups of PWID.
Although the findings suggest that the PReventing blood-bOrne virus infecTion in people who injECT
(PROTECT) intervention has the potential to positively influence some PWID BBV risk behaviour, non-attendance
at the intervention at the York trial site substantially influenced the results. Despite this, considerable and
valuable insights have been obtained, showing the need for a greater embedding of BBV risk reduction in
the work of substance misuse services and highlights an urgent unmet health need for PWID.
The study resulted in the co-production of an evidence-based brief psychosocial intervention that was
acceptable to both facilitators and participants. Exposure to information on improving injecting techniques
did not encourage riskier injecting practices or injecting frequency, and benefits were reported among
those who attended at least one intervention session.
Implications for policy and practice
Although it was assumed by many policy-makers and practitioners that harm reduction information about
BBV transmission is part of usual conversations with key workers in drug services and practitioners in
needle exchange and specialist services, PWID confirmed this does not always happen. This may be a result
of the deskilling of the substance use workforce as a result of cuts in service provision and/or the limited
opportunity for harm reduction to be delivered in pharmacy needle exchanges. Alternatively, the recent
drug policy shift from harm reduction to recovery may mean that the needs of those who are not engaged
in treatment are not being addressed. Harm reduction services should ensure that the intervention content
is routinely delivered to PWID to improve vein care and prevent BBV. The provision of drug consumption or
injecting rooms should be considered in the UK.
Future research
l There remains a need to understand the needs of women who inject drugs and new injectors (especially
those who were injecting novel psychoactive substances), to ensure that key BBV transmission messages
are appropriately targeted. As it proved difficult to engage these groups of PWID in the research, we
recommend that ethnographic research is undertaken to better understand the typology and potentially
changing risks of contemporary drug use in the UK by exploring the specific concerns and barriers from
the lived experience of PWID in terms of accessing help, advice and treatment, as well as what mode of
delivery would work best for these groups.
l We propose to adapt the intervention to meet the needs of chemsex (the use of psychoactive substances
either immediately before or during sex) injectors and test the intervention in a future feasibility trial.
l A future quasi-experimental trial of worker training is proposed to test the individual delivery of
intervention content delivered at needle exchanges and tailored to individual PWID needs.
Trial registration
This trial is registered as ISRCTN66453696 and PROSPERO 014:CRD42014012969.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction and background
This report presents the findings from a Health Technology Assessment (HTA)-funded programme ofwork to develop an evidence-based psychosocial intervention aimed at reducing blood-borne virus (BBV)
transmission risk behaviours and increasing BBV transmission knowledge among people who inject drugs
(PWID), and explore the feasibility of recruiting PWID to a trial comparing the intervention with control.
This first chapter provides the background and rationale for conducting this research, and describes the
research objectives. The remainder of the report is divided into the following chapters representing the
phases of the study: Chapter 2, Determining the evidence base: a systematic review of psychosocial
interventions to reduce drug and sexual blood-borne virus transmission risk behaviours among people who
inject drugs; Chapter 3, Understanding people who inject drugs’ influences on behaviour and views on
psychosocial interventions; Chapter 4, Consultation with key stakeholders on the delivery and effectiveness
of psychosocial interventions to reduce blood-borne virus transmission risks among people who inject
drugs; Chapter 5, Intervention development; Chapter 6, Feasibility trial; Chapter 7, Protocol changes;
Chapter 8, Implications and dissemination of findings; and Chapter 9, Discussion and conclusions.
Background
Prevalence
Preventing the transmission of BBVs among PWID is a major public health issue. Hepatitis C virus (HCV) is
the most prevalent BBV among PWID, with 56% in Scotland (61% among needle exchange attenders),1
approximately 50% in England and Wales and 23% in Northern Ireland being HCV positive.2 The rate of
human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection among PWID in the UK is low,
ranging from 0% in Wales and Northern Ireland to 1.4% in England for HIV and from 6% in Northern
Ireland to 18% in England for HBV.2
Risk factors for blood-borne viruses
Hepatitis B virus and HIV are transmitted via blood or body fluids. Sharing injecting equipment poses the
greatest risk of HCV transmission among PWID.3 Although there is no increased risk of HCV transmission in
a long-term heterosexual relationship, the risk of transmission increases with multiple sexual partners and
among women who are infected with HIV or other sexually transmitted diseases.4 Sex trading, younger
age, cocaine injecting, depression, requiring help injecting, having unsafe sex with a regular partner and
having an HIV-positive sexual partner are associated with HIV infection among PWID.5–9 Risk factors for
HCV among PWID include sharing needles and other injection equipment,10 longer duration of injecting
career,11 increased frequency of injection,11,12 requiring help injecting,13 being female14 and a history
of imprisonment.11,12 Research suggests that a gap in HCV transmission knowledge among PWID is
contributing to the high prevalence.15–17 Higher HIV and HCV infection rates have been reported among
people with mental health disorders.6,18,19 PWID with mental health disorders report greater sharing of
injection equipment, lower rates of condom use, multiple sexual partners, sex trading and having sex with
PWID.5,6,20,21 Depressive symptoms are also associated with drug21–23 and sexual risk behaviours.23–25 The
prevalence of intimate partner violence is high among people who use drugs.23,26,27 Women who are
survivors of intimate partner violence are less likely to use condoms and more likely to share needles, to
have multiple sexual partners and to trade sex,26,28 all of which increase susceptibility to BBV transmission.28
BBV transmission risk behaviours should be understood in the context of PWIDs’ sexual and drug-using
relationships.29 Some females who inject drugs share injecting equipment with their partners for trust and
intimacy, perceiving less risk in such relationships.30
Current policy and practice
Policy and practice with regard to public health generally, and the management of BBVs specifically, are
driven by different policies and agendas in the four nations of the UK, although the overarching recovery
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agenda has dominated drug policy for a number of years.31 In Scotland, The Road to Recovery: A New
Approach to Tackling Scotland’s Drug Problem was published in 2008,32 and recovery became a central
tenet of UK policy in 2010.33 In a corresponding publication, Putting Full Recovery First: The Recovery
Roadmap,34 the authors outlined the roadmap for the ways in which recovery would be fostered in
communities in England and Wales, including the creation and utilisation of ‘recovery champions’.34
Although the rhetoric of drug policy may have altered in the UK over the last 8 years from that of harm
reduction to that of recovery, the extent to which the realities of drug treatment provision (including
prevention) have changed remains largely unknown. Indeed, as commented by Duke ‘at the level of
practice, it will be interesting to examine how day-to-day practice develops and changes with drug users
under the new framework’.31
With specific regard to the management and prevention of BBV infections, and HCV in particular, all four
nations published their first action plans for the prevention and management of HCV around 10 years ago,
and have had varying degrees of success. Very broadly, the action plans in all four countries set out key
objectives that would need to be achieved in the realms of HCV prevention and treatment, with particular
foci on PWID, in order to tackle the burden of HCV on individuals and on public health. Common
objectives of the plans included developing a better evidence base for establishing prevalence figures
through better monitoring and surveillance systems; increasing information on the disease; increasing the
number of persons being tested and, therefore, diagnosed with HCV (as high numbers of people with the
disease are undiagnosed); and increasing the number of people entering into treatment for HCV infection.
It might be argued that harm reduction, rather than recovery, has been at the heart of the HCV action
plans in the sense that other objectives of the plans involved not only providing more needle exchange
outlets (including outreach distribution, as in Northern Ireland), but also increasing the number of needles,
syringes and other injecting equipment that PWID can access.
Harm reduction approaches recognise that there is a need to reduce the risks associated with drug misuse
(including injecting). This approach is facilitated in the UK by the provision of opioid substitution therapy
(OST; e.g. with methadone or buprenorphine), key worker support, needle and syringe programmes that
offer PWID free injecting equipment (and equipment), and information to reduce sharing behaviour and,
therefore, the transmission of BBV, as well as support for stopping injecting. The use of psychosocial
interventions to reduce risk behaviours among PWID is not routinely practised in the UK. Harm reduction
messages are mainly provided by key workers, drug treatment staff and needle exchange staff, peer
educators and BBV nurses.
Harm reduction approaches
Although advances have been made in treatment and pre-exposure prophylaxis for HIV infections and a
vaccine is available for HBV, there is currently no vaccine available to prevent HCV infection. There is
evidence to suggest that OST and needle exchanges35–38 are effective in reducing HIV and HCV infection
prevalence among PWID. However, recent research stresses that, although increasing the coverage of
these interventions can reduce HCV prevalence among PWID, these reductions are modest and
psychosocial interventions are required to further decrease HCV prevalence36 by informing PWID about
transmission risks and motivating them to reduce risky sexual and drug-taking behaviours. Although OST
has been successful in reducing BBV, some PWID continue to inject and, therefore, may be at risk of
acquiring or transmitting BBV. A meta-analysis found that the incidence of HCV reinfection following
successful treatment for HCV among PWID was 2.4 per 100 person-years and 6.4 per 100 person-years
among those who reported injecting drug use post sustained viral response (SVR).39 A recent retrospective
record linkage study in Scotland reported similar reinfection rates, 1.7 per 100 person-years among PWID
and 5.7 per 100 person-years among those who had been admitted to hospital for injection-related
causes.40 Although there is a low risk of reinfection following successful treatment for HCV, a large cohort
study in Scotland found that 10.6% of 1170 PWID who had achieved a SVR following treatment for HCV
had been hospitalised for, or had died from, an injection-related cause in the first 3 years post SVR.41
Moreover, findings highlight a rise in injection-related hospitalisation or death with time with increasing
year of SVR attainment. In addition, women were more likely to have multiple injection-related
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hospitalisations post SVR. These findings highlight that ‘harm reduction interventions aimed at reducing
the risk of HCV transmission should also continue to be promoted once treatment ceases’.41
Recent systematic reviews and meta-analyses of psychosocial interventions to reduce HIV and HCV risk
behaviours among PWID have reported modest effects42–44 and conclude that ‘limited progress [has been
made] in developing more effective interventions’43 and that ‘multi-component interventions are required’.44
A recent Cochrane review on Psychosocial Interventions for Reducing Injection and Sexual Risk Behaviour for
Preventing HIV in Drug Users43 reported minimal differences identified between multisession psychosocial
interventions and standard educational interventions for both injection and sexual risk behaviour. However,
there were large pre–post changes for both groups, suggesting that both were effective in reducing risk
behaviours. They also found evidence of benefit for multisession psychosocial interventions when compared
with minimal controls. Moreover, people in formal treatment were more likely to respond to multisession
psychosocial interventions, and single-gender groups were associated with greater benefit.
Harm reduction approaches mostly address risk factors associated with the sharing of injecting equipment and
unprotected sex. Research has highlighted that PWID sometimes have different priorities, such as avoiding
injecting-related scars or marks and maintaining venous access, which results in the use of sterile injecting
equipment.45 PWID have also stressed a need for ‘non-judgemental venous care and access advice’.45 PWID
who plan ahead to ensure that they have access to sterile injecting equipment are more likely to store clean
needles; avoid sharing needles and syringes and other injecting equipment; and provide clean needles
to sex partners.46 Therefore, it is vital that harm reduction interventions include protective practices and
strategies to avoid and plan for injecting risk situations, such as withdrawal and lack of preparedness.47,48
Research has demonstrated that ‘symbiotic’ goals that are not directly focused on BBV risk reduction are
important to PWID, such as avoiding withdrawal, maintaining social support, venous access and care, and
image management,45,49 and may help them to ‘stay safe’ and avoid BBV.50 Strategies described to avoid
withdrawal include ‘back up methods, resorting to credit, collaborating with others, regimenting drug
intake, balancing drug intake with money available, and/or resorting to treatment’.47 PWID who have not
become infected with HCV report protective practices, including principles about normative injecting
practices; preparedness and contingency planning to avoid disruption to risk management; and the
capacity for flexibility to adapt to changes in normative practices or intentions.51
Rationale
Research suggests that, although rates of HIV and HBV are low and stable among PWID in the UK, the
prevalence of HCV remains high. There remain opportunities for BBV prevention among hard-to-reach
groups who may not be engaged in drug treatment, such as new injectors,52 women, black and minority
ethnic PWID, those who are homeless53 or those who are involved in prostitution.6,20 Public Health
England’s Shooting Up: Infections Among People Who Inject Drugs in the United Kingdom 2012 report54
highlighted that, although needle and syringe sharing is lower than a decade ago, around one in seven
PWID continue to share needles and syringes, and those who inject amphetamines and amphetamine-type
drugs (e.g. mephedrone) are at increased risk of infection.55 Therefore, the need to address the risks and
increase knowledge to reduce infection and transmission among PWID remains priority. This research was
a response to the commissioned call from the HTA programme.
Research objectives
The PReventing blood-bOrne virus infecTion in people who injECT (PROTECT) project contained six
complementary phases to inform the development of an evidence-based psychosocial intervention to
reduce BBV transmission risk behaviours and increase BBV transmission knowledge among PWID, and
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conduct a feasibility trial, comparing the psychosocial intervention to an information leaflet, to inform the
future parameters of a large multisite randomised control trial (RCT).
The main objectives were as follows.
Phase I: determining the evidence base
l To update recent systematic reviews of the efficacy of psychosocial interventions to reduce drug and
sexual risk behaviours associated with HIV, HCV and HBV transmission and/or reinfection.
l To conduct a brief scoping exercise of the UK grey literature to identify ongoing research, information
about current services relevant to preventing the spread of BBV and reducing risk behaviours
among PWID.
l To survey all UK-commissioning drug partnerships (previously Drug Action Teams) for information on
psychosocial interventions available and their effectiveness in reducing BBV risk behaviours among PWID.
Phase II: understanding people who inject drugs’ influences on behaviour and views on
psychosocial interventions
l To elicit why PWID engage in risk behaviours.
l To determine the type of psychosocial intervention acceptable and required by PWID to reduce BBV
risk behaviours.
Phase III: key stakeholders’ views on the delivery and effectiveness of
psychosocial interventions
l To ascertain key local and national stakeholders’ views on the delivery and effectiveness of
psychosocial interventions.
Phase IV: intervention development
l To source and review content of all effective psychosocial interventions to reduce BBV risk behaviours
among PWID.
l To develop a psychosocial intervention to reduce BBV risk behaviours among PWID.
Phase V: feasibility randomised controlled trial
l To demonstrate the feasibility of recruiting PWID to a group psychosocial intervention and delivering
the intervention across four regions in the UK.
l To test the feasibility of training staff from existing services to deliver the developed intervention.
l To evaluate the level of intervention retention by participants randomised to the developed intervention.
l To explore staff and PWID views, acceptability and experiences of the intervention and the study process.
l To explore treatment effectiveness through quantitative outcome data.
l To explore the feasibility of collecting data for a large, definite RCT.
l To assess the feasibility of conducting a future large-scale effectiveness RCT.
Phase VI: considerations for future research
l To recommend specific interventions which could be tested in future research.
l To outline considerations for future research.
INTRODUCTION AND BACKGROUND
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Chapter 2 Determining the evidence base: a
systematic review of psychosocial interventions to
reduce drug and sexual blood-borne virus transmission
risk behaviours among people who inject drugs
Objectives
To identify effective psychosocial interventions to reduce drug and sexual BBV transmission risk behaviours
among PWID by systematically reviewing the evidence from RCTs and a scoping review of the grey
literature; and mapping drug and alcohol partnerships’ provision of psychosocial interventions throughout
the UK.
Review questions
To determine the efficacy of psychosocial interventions to:
l reduce BBV injection risk behaviours among PWID
l reduce BBV sexual risk behaviours among PWID
l increase BBV transmission knowledge among PWID.
Introduction
Several systematic reviews and meta-analyses of psychosocial interventions to reduce HIV and HCV risk
behaviours among drug users have reported modest effects.42–44,56 More recently, MacArthur et al.37
published a review of reviews conducted during 2000–11 to determine the effectiveness of harm
reduction interventions (including education, information and counselling interventions) in relation to
HIV transmission, HCV transmission and injecting risk behaviour. The authors found that, although harm
reduction interventions, especially OST and needle exchange programmes, can reduce injecting risk
behaviours, the review or reviews found little evidence that such interventions prevented HCV transmission
among PWID. In a systematic review and meta-analysis, Meader et al.56 found that multisession psychosocial
interventions had modest additional benefits compared with educational interventions and large positive
effects compared with minimal interventions on the HIV sex risk behaviours by people who use drugs.
This review included RCTs and quasi-experimental studies published during 1998–2012. Sacks-Davis et al.44
conducted a systematic review of behavioural interventions (peer-intervention training and counselling
interventions) for preventing HCV among PWID and included controlled trials until 2010. Authors concluded
that it was ‘unlikely that behavioural interventions can have a considerable effect on HCV transmission’
(p. 176),44 but suggested that multicomponent interventions were required to address HCV transmission.
Hagan et al.42 conducted a systematic review with meta-analysis of published and unpublished studies from
2000 to April 2010 of interventions (including behavioural and multicomponent interventions) to reduce
unsafe drug injection and HCV seroconversion among PWID. This review found that combined substance use
treatment and support for safe injection were the most effective interventions to reduce HCV seroconversion.
Meader et al.43 conducted a Cochrane review and reported minimal differences between multisession
psychosocial interventions and standard educational interventions for preventing HIV infection among people
who use drugs, for both injection and sexual risk behaviours. Randomised and quasi-randomised trials
published until 2006 were included.
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People who inject drugs are more likely to have BBVs than people who use drugs but do not inject.57,58
As well as the elevated risks from sharing injecting equipment, PWID (especially polysubstance injectors),
report high-risk sexual behaviours including sex trading, multiple sex partners and sex without a
condom20,57,59,60 than people who use drugs but do not inject. Despite this, there has been no recent
systematic review focusing on the efficacy of psychosocial interventions to reduce injecting and sexual risk
behaviours among samples of PWID, rather than people who use drugs, regardless of their injecting status.
Thus, this review aims to address this evidence gap.
Aim
The aim of the present systematic review and meta-analysis was to determine the efficacy of psychosocial
interventions in reducing injecting and sexual risk behaviours compared with usual care, education or
information, HIV infection testing and counselling, or ‘an intervention of lesser time or intensity’44 (with and
without OST). Psychosocial interventions including ‘brief interventions, motivational interviewing (MI), cognitive
behavioural therapy, contingency management (CM), graded exposure therapy and self-help groups’ were
defined as interventions that aimed ‘to change behaviour through the exchange of information, typically
delivered by a clinician or educator’.61
Methods
The review was registered with International prospective register of systematic reviews (PROSPERO 2014:
CRD42014012969). A systematic review of RCTs was conducted and a meta-analysis performed, using a
random-effects model. This systematic review and meta-analysis were undertaken in accordance with the
principles recommended by the Cochrane Handbook for Systematic Reviews of Interventions62 and the
Centre for Reviews and Dissemination guidance for undertaking systematic reviews.63 The reporting
procedures followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.64 EndNote (X8; Thomson Reuters, CA, USA) was used for reference management and Microsoft
Excel (2010; Microsoft Corporation, Redmond, WA, USA) was used for recording decisions.
The PICO (patient, intervention, comparison, outcomes) model was used to develop the search strategy,
and is described below.
Participants/population
People who inject drugs aged ≥ 18 years. Studies of people who use drugs were included if the results
were presented separately for PWID.
Interventions
Psychosocial interventions [e.g. cognitive–behavioural therapy (CBT), MI, CM, counselling, harm reduction,
skills training] delivered to individuals, groups, couples or a mix of delivery methods.
Comparators/control
Usual care, education or information, HIV infection testing and counselling, or interventions of lesser
frequency or intensity than the intervention (with or without OST).
Outcomes
l Any injecting risk behaviour (including sharing of needle/syringes or other injecting equipment), and
frequency of injecting, reported separately or as an aggregated outcome.
l Any sexual risk behaviour (including unprotected sex or number of sexual partners), reported separately
or as an aggregated outcome.
DETERMINING THE EVIDENCE BASE
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Search strategy
The following databases were searched for relevant RCTs published from 2000 until 26 May 2015:
MEDLINE, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane
Collaboration, with an update search in MEDLINE to 9 December 2016. Searches were restricted to trials
from 2000 onwards to ensure that up-to-date information about BBV transmission was included.
Additionally, ClinicalTrials.gov databases were searched to identify additional publications, including any
ongoing trials in this area and related publications. These databases were searched using the search
strategy with keywords described in Table 1. In addition, forward and backward searching was conducted
and the reference lists of recent relevant reviews and review of reviews37,42–44,56,61 were cross-checked to
verify that all relevant trials had been included in the current systematic review.
TABLE 1 Description of search terms
Database Keywords
MEDLINE Key words for population: people who inject; people who inject drugs; PWID; substance abuse;
intravenous substance abuse; injecting drug use; intravenous drug use; IDU; injection drug use;
injector; IVDU; intravenous drug abuse; injecting drug abuse; injection drug abuse
Key words for BBV: blood-borne pathogens, BBV, blood-borne virus, blood-borne bacteria, HIV
infection, human immunodeficiency virus, HIV, hepatitis C, hepatitis C virus, hep c, HCV, hepacivirus,
hepatitis B, hepatitis B virus, HBV
Key words for intervention: psychosocial adjacent to intervention, prevention, support, rehabilitation,
treatment, or therapy; psychological adjacent to therapy, treatment, or intervention; CBT; cognitive
adjacent to therapy, behaviour therapy, intervention, or remediation; behaviour adjacent to therapy,
control, modification, change, or intervention; psychotherapy; counseling; social support; motivational
adjacent to intervention, interview, or support; brief advice; brief intervention; family adjacent to
therapy, intervention, or counselling, couple adjacent to therapy, intervention, or counselling; peer
adjacent to therapy, intervention, or counselling; talking therapy; contingency management;
psychoeducation; route transition; network therapy
Key words for outcomes: risk adjacent to taking, reduction, protection, minimisation, prevention,
decrease, avoidance, or behaviour; harm adjacent to reduction, protection, minimisation, prevention,
decrease, avoidance; unsafe injecting; needle sharing; intravenous injection; injecting adjacent to
equipment, paraphernalia, or risk; sexual risk behaviour; unsafe sex; multiple sexual partners; multiple
casual partners; one time sex encounter; sex holiday; casual sex; casual partner; non-regular sex
partner; unprotected intercourse; unprotected sex; condomless adjacent to sex or intercourse; condom
free adjacent to sex or intercourse; barebacking; bareback sex; bug chase; anal intercourse; anal sex;
condom; condom use; safe sex; health adjacent to knowledge, attitudes, or practice, or behaviour;
transmission knowledge or understanding
PsycINFO Key words for population: people who inject; people who inject drugs; PWID; substance abuse;
intravenous substance abuse; injecting drug use; intravenous drug use; IDU; injection drug use;
injector; IVDU; intravenous drug abuse; injecting drug abuse; injection drug abuse
Key words for BBV: blood-borne pathogens, BBV, blood-borne virus, blood-borne bacteria, HIV
infection, human immunodeficiency virus, HIV, hepatitis C, hepatitis C virus, hep c, HCV, hepacivirus,
hepatitis B, hepatitis B virus, HBV
Key words for intervention: psychosocial adjacent to intervention, prevention, support, rehabilitation,
treatment, or therapy; psychological adjacent to therapy, treatment, or intervention; CBT; cognitive
adjacent to therapy, behaviour therapy, intervention, or remediation; behaviour adjacent to therapy,
control, modification, change, or intervention; psychotherapy; counseling; social support; motivational
adjacent to intervention, interview, or support; brief advice; brief intervention; family adjacent to
therapy, intervention, or counselling, couple adjacent to therapy, intervention, or counselling; peer
adjacent to therapy, intervention, or counselling; talking therapy; contingency management;
psychoeducation; route transition; network therapy
Key words for outcomes: risk adjacent to taking, reduction, protection, minimisation, prevention,
decrease, avoidance, or behaviour; harm adjacent to reduction, protection, minimisation, prevention,
decrease, avoidance; unsafe injecting; needle sharing; intravenous injection; injecting adjacent to
continued
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TABLE 1 Description of search terms (continued )
Database Keywords
equipment, paraphernalia, or risk; sexual risk behaviour; unsafe sex; multiple sexual partners; multiple
casual partners; one time sex encounter; sex holiday; casual sex; casual partner; non-regular sex
partner; unprotected intercourse; unprotected sex; condomless adjacent to sex or intercourse; condom
free adjacent to sex or intercourse; barebacking; bareback sex; bug chase; anal intercourse; anal sex;
condom; condom use; safe sex; health adjacent to knowledge, attitudes, or practice, or behaviour;
transmission knowledge or understanding
CINAHL Key words for population: people who inject; people who inject drugs; PWID; substance abuse;
intravenous substance abuse; injecting drug use; intravenous drug use; IDU; injection drug use;
injector; IVDU; intravenous drug abuse; injecting drug abuse; injection drug abuse
Key words for BBV: blood-borne pathogens, BBV , blood-borne virus, blood-borne bacteria, HIV
infection, human immunodeficiency virus, HIV, hepatitis C, hepatitis C virus, hep c, HCV, hepacivirus,
hepatitis B, hepatitis B virus, HBV
Key words for intervention: psychosocial adjacent to intervention, prevention, support, rehabilitation,
treatment, or therapy; psychological adjacent to therapy, treatment, or intervention; CBT; cognitive
adjacent to therapy, behaviour therapy, intervention, or remediation; behaviour adjacent to therapy,
control, modification, change, or intervention; psychotherapy; counseling; social support; skills
training; motivational adjacent to intervention, interview, or support; brief advice; brief intervention;
family adjacent to therapy, intervention, or counselling, couple adjacent to therapy, intervention, or
counselling; peer adjacent to therapy, intervention, or counselling; talking therapy; contingency
management; psychoeducation; route transition; network therapy
Key words for outcomes: risk adjacent to taking, reduction, protection, minimisation, prevention,
decrease, avoidance, or behaviour; harm adjacent to reduction, protection, minimisation, prevention,
decrease, avoidance; unsafe injecting; needle sharing; intravenous injection; injecting adjacent to
equipment, paraphernalia, or risk; sexual risk behaviour; unsafe sex; multiple sexual partners; multiple
casual partners; one time sex encounter; sex holiday; casual sex; casual partner; non-regular sex
partner; unprotected intercourse; unprotected sex; condomless adjacent to sex or intercourse; condom
free adjacent to sex or intercourse; barebacking; bareback sex; bug chase; anal intercourse; anal sex;
condom; condom use; safe sex; health adjacent to knowledge, attitudes, or practice, or behaviour;
transmission knowledge or understanding
Cochrane
Collaboration
Key words for population: people who inject; people who inject drugs; PWID; substance abuse;
intravenous substance abuse; injecting drug use; intravenous drug use; IDU; injection drug use;
injector; IVDU; intravenous drug abuse; injecting drug abuse; injection drug abuse
Key words for BBV: blood-borne pathogens, BBV, blood-borne virus, blood-borne bacteria, HIV
infection, human immunodeficiency virus, HIV, hepatitis C, hepatitis C virus, hep c, HCV, hepacivirus,
hepatitis B, hepatitis B virus, HBV
Key words for intervention: psychosocial adjacent to intervention, prevention, support, rehabilitation,
treatment, or therapy; psychological adjacent to therapy, treatment, or intervention; CBT; cognitive
adjacent to therapy, behaviour therapy, intervention, or remediation; behaviour adjacent to therapy,
control, modification, change, or intervention; psychotherapy; counseling; social support; skills
training; motivational adjacent to intervention, interview, or support; brief advice; brief intervention;
family adjacent to therapy, intervention, or counselling, couple adjacent to therapy, intervention, or
counselling; peer adjacent to therapy, intervention, or counselling; talking therapy; contingency
management; psychoeducation; route transition; network therapy
Key words for outcomes: risk adjacent to taking, reduction, protection, minimisation, prevention,
decrease, avoidance, or behaviour; harm adjacent to reduction, protection, minimisation, prevention,
decrease, avoidance; unsafe injecting; needle sharing; intravenous injection; injecting adjacent to
equipment, paraphernalia, or risk; sexual risk behaviour; unsafe sex; multiple sexual partners; multiple
casual partners; one time sex encounter; sex holiday; casual sex; casual partner; non-regular sex
partner; unprotected intercourse; unprotected sex; condomless adjacent to sex or intercourse; condom
free adjacent to sex or intercourse; barebacking; bareback sex; bug chase; anal intercourse; anal sex;
condom; condom use; safe sex; health adjacent to knowledge, attitudes, or practice, or behaviour;
transmission knowledge or understanding
ClinicalTrials.gov Key words for BBV: HIV, hepatitis
Key words for intervention: psychosocial, behavioral
IVDU, intravenous drug user.
DETERMINING THE EVIDENCE BASE
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Eligibility
Citations were included if the full text was published in English, regardless of country of origin. Trials were
eligible for inclusion if (1) they were published during 2000–15; (2) participants were all PWID or the
results were presented separately for PWID and other study participants; (3) studies were RCTs; (4) the
outcome(s) included (i) any injecting risk behaviour (including sharing of needle/syringes or other injecting
equipment), and frequency of injecting, reported separately or as an aggregated outcome and (ii) any
sexual risk behaviour (including unprotected sex or number of sexual partners), reported separately or as
an aggregated outcome; and (5) the RCTs compared psychosocial interventions with a control group, who
received usual care, education or information, HIV infection testing and counselling, or ‘an intervention of
lesser time or intensity’44 (with or without OST).
Authors Gail Gilchrist and Noreen Mdege independently assessed all abstracts and potentially eligible
full-text manuscripts against the eligibility criteria. Where there was disagreement, the decision whether to
include or exclude each trial was reached through referral to additional reviewers (EH, DS or KW).
Data extraction
Authors Davina Swan, Kideshini Widyaratna, Julia Elena Marquez-Arrico and Gail Gilchrist independently
extracted the following information for each study using a data extraction form specifically designed and
piloted for use for this review. The following data were extracted, which included intervention description
items from the TIDieR (Template for Intervention Description and Replication) checklist:65 authors and
publication year, country, aim of intervention, participants (percentage who were PWID, percentage of
females, mean age), intervention delivery setting/staff who delivered intervention, description of intervention
(intervention description, frequency and duration of sessions, adherence to intervention) and control
interventions (intervention description, frequency and duration of sessions) and length of follow-up (see
Table 2). Data were extracted independently by one reviewer and checked by a second. Differences in data
extraction were resolved through discussion.
Assessment of methodological quality
Each study included in the review was independently assessed for methodological quality by two authors
(from GG, DS, JM and JT) using the Cochrane risk-of-bias tool for RCTs.66 These assessments were then
compared with the quality assessment information in available reviews.37,42–44 Differences in quality
assessment decisions between the authors and published reviews were resolved through discussion and
consensus with a third assessor (EH). The risk-of-bias tool produces a quality interpretation with ratings of
‘yes’ (low risk of bias), ‘no’ (high risk of bias), and ‘unclear’ (uncertain risk of bias) for six key domains:
(1) sequence generation; (2) allocation concealment; (3) blinding of participants, personnel and outcome
assessors; (4) incomplete outcome data; (5) selective outcome reporting; and (6) other sources of bias.
For each domain a rating of low risk of bias equates to high methodological quality.
Describing the interventions
The behaviour change wheel was used to categorise intervention functions of the interventions included
in the review.67 Intervention functions were coded only where they related directly to the target behaviour
of the intervention. The following intervention functions were coded: education (increasing knowledge or
understanding, e.g. ‘The 30 min pre-test counseling session provided basic information about AIDS and
how to reduce the risk of HIV infection, as well as similar information about HCV’);68 persuasion (using
communication to induce positive or negative feelings or stimulate action, e.g. ‘The facilitators would often
praise their effective communication strategies and offer additional’69 and ‘Reviewed progress, developed
DOI: 10.3310/hta21720 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 72
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilchrist et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
strategies for overcoming obstacles, and reaffirmed commitment to change’);70 incentivisation (creating
expectation of reward, e.g. ‘Contingent vouchers were given when a participant provided a cocaine-
negative urine specimen’);71 training (imparting skills, e.g. ‘intervention included psychosocial training and
skills building to teach personal risk reduction and negotiation skills’72 and ‘technical condom use and
syringe disinfection skills’);73 modelling (providing an example for people to aspire to or imitate, e.g. ‘model
injection and sexual risk reduction behaviors with their risk network members’74 and ‘demonstration and
rehearsal of syringe cleaning and condom application’);70 and enablement (increasing means/reducing
barriers, e.g. ‘women created a personalized risk reduction plan’,75 ‘goal-setting for HIV risk reduction
and outreach’76 and ‘a short role play was then used to help her identify barriers to safer injection’77).
Gail Gilchrist and Davina Swan independently determined the intervention functions of the intervention
conditions, with differences in intervention function coding resolved through discussion. In addition, the
intervention functions determined by Gail Gilchrist and Davina Swan of five trials were validated by a
behaviour change expert (see Acknowledgements).
Statistical analysis
The principal summary measure was the standardised mean difference (SMD). As outcome data were
presented as dichotomous or continuous data across included trials, odds ratios were recalculated as SMDs
to allow pooling of data.78 The standard errors of the log-odds ratios were converted to standard errors of a
SMD by multiplying by the same constant (√3/pi = 0.5513). This allowed the standard error for the log-odds
ratio and, hence, a confidence interval (CI) to be calculated.79 For each RCT, the SMD and corresponding
95% CIs for the assessed outcome were retrieved or calculated. Data entry and statistical analysis were
performed with the use of Review Manager software (version 5; The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark). Where trials reported data from various follow-up periods, data
from the latest follow-up period were included in the meta-analysis, combining outcomes assessed at
multiple time periods. To determine whether or not trials included in the meta-analysis were consistent, the
degree of heterogeneity was calculated. An I2 of 25% was considered low heterogeneity, 50% moderate
heterogeneity and 75% high heterogeneity.80 In the inverse variance method, individual effect sizes were
weighted according to the reciprocal of their variance calculated as the square of the standard error.
Main and subgroup analysis
In line with a recent Cochrane review,43 and in an attempt to address the complexity of clinical
heterogeneity of interventions, subgroup analyses were conducted to compare psychosocial interventions
with (1) treatment as usual (TAU); (2) education or information; (3) HIV infection testing and counselling;
(4) control interventions of lesser time or intensity with OST; and (5) control interventions of lesser time or
intensity without OST. As follow-up duration may affect intervention effectiveness, further subgroup analyses
were conducted where possible, comparing length of time, in months, from the end of the intervention to
the final follow-up of included trials (i.e. ≤ 3 months, 4–6 months and ≥ 9 months follow-up).
Injecting risk behaviour and sexual risk behaviour (as described in Eligibility) were used as outcomes of
interest for meta-analysis. The Cochrane handbook (section 16.5) stresses that trials with multiple treatment
arms ‘that compare more than two intervention groups need to be treated with care’ to avoid ‘making
multiple pair-wise comparisons between all possible pairs of intervention groups’ in the meta-analysis.62
Therefore, where trials included in the meta-analysis had more than one intervention group, data from the
most relevant psychosocial intervention to address the aims of the systematic review were compared with
the control intervention in the meta-analysis. For Booth et al.,68 the most relevant intervention condition was
considered TAU plus HIV/HCV infection counselling and education, rather than TAU plus a therapeutic
alliance to facilitate treatment entry. For Sterk et al.,81 the enhanced negotiation intervention was considered
more relevant to the aims of the systematic review than the enhanced motivation intervention. For Schroder
et al.,71 TAU plus weekly CBT plus CM (CBT + CM) was considered superior to both weekly CBT plus
DETERMINING THE EVIDENCE BASE
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non-contingent vouchers and CM plus weekly group therapy and, therefore, was selected as the intervention
condition for the meta-analysis. Go et al.82 conducted a multilevel intervention using a 2 × 2 (four-arm) factorial
design consisting of (1) standard of care (i.e. HIV infection testing and counselling); (2) a structural-level
community stigma reduction programme; (3) individual-level post-test counselling and skill-building support
groups; and (4) both individual-and structural-level activities. For the purpose of this systematic review, the
individual-level post-test counselling and skill-building support groups will be compared with individual
standard of care.
Random-effects models were applied to compare the following outcomes of interest for meta-analysis by
type of control intervention, and by type of control intervention and length of follow-up post intervention:
any injecting risk behaviour (see Figures 3 and 4), including sharing of needle/syringes (see Figures 5 and 6),
or other injecting equipment (see Figures 7 and 8) and frequency of injecting (see Figures 9 and 10),
reported separately or as an aggregated outcome; and any sexual risk behaviour (see Figures 11 and 12),
including unprotected sex (see Figures 13 and 14) or number of sexual partners (see Figure 15), reported
separately or as an aggregated outcome.
Results
Study selection and assessment
The electronic database searches to 26 May 2015 resulted in 2493 citations; an additional 77 citations were
identified from 1 January 2015 to 9 December 2016 (Figure 1). One additional manuscript was identified from
hand-searching other reviews’ reference lists. After removal of duplicates, 1903 citations remained. In total
1771 abstracts were excluded as they did not meet eligibility criteria and 132 abstracts were selected for
full-text assessment, including four related manuscripts referenced in these selected texts.83–86 Eighty-nine articles
were excluded for the following reasons: they were not RCTs (n= 34);47,68,87–118 the outcomes of interest for this
review were not assessed or presented at follow-up (n= 29);86,119–146 outcomes were not presented by PWID
(n = 6);147–152 the number of PWID was not reported (n = 4);153–156 or the intervention studied was not
psychosocial (n = 4).157–160 Additionally, 10 manuscripts were excluded as the results did not compare
intervention groups161–166 or did not evaluate the effect of the intervention.167–170 One further manuscript
was excluded because the same psychosocial intervention was delivered to each treatment group, and the
difference between treatment groups was receipt of a coupon for 90 days of free methadone maintenance
treatment (MMT).171 One manuscript published in Chinese was excluded.172
In total, 42 manuscripts from 32 trials were eligible,22,68–77,81–85,173–198 41 originating from the electronic database
searches, and one from hand-searching recent reviews and review of reviews178 was added as a result of this
process. Twenty-four trials were included in the meta-analysis.22,68–73,75,76,81,82,173,175,179,180,182,186,188,189,192–195,197
The reasons for excluding eight trials from the meta-analysis were not providing the number of PWID for
control and intervention groups at follow-up,84,174,176,177,196 only providing risk ratios,178 outcome combined
HIV infections with sexually transmitted infections77 and data for ‘unsafe injection practices’ were presented
only at baseline.74
Quality and publication bias assessment
The summary of authors’ judgements about the quality of each trial included in the systematic review is
described in Figure 2. The risk of bias varied between trials. Incomplete outcome data was the most common
risk of bias found in the trials included in the review, but selective outcome reporting also contributed to
potential risk of bias for some trials. Other potential sources of bias included altering randomisation protocols
depending on the number of participants enrolled on a particular day;182 statistically significant differences
between groups at baseline in the injecting subscale;173 variation in the TAU group across sites;68 possible
crossover contamination between groups;69,75,179,180,182,194 a high proportion of excluded individuals with
the excluded individuals differing significantly to those included;71 and large variations reported in the
follow-up period.74
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Study characteristics
The characteristics of the RCTs included in the systematic review are described in Table 2. In total, 12,840
participants (35% female, range 0–100%) were enrolled in the trials; the majority were PWID (84.5%)
(the proportion of participants enrolled in the trials who were PWID ranged from 16% to 100%). The
majority (n = 18) of trials were conducted in the USA,22,68,70–72,76,81,84,174,176,177,179,182,186,189,193,195,196 three were
conducted in Russia,74,75,194 two were conducted in Canada,175,178 two were conducted in Vietnam,82,180 one
was conducted in Kazakhstan,73 one was conducted in Georgia,188 one was conducted in Australia,197
one was conducted in the UK,173 one was conducted in Mexico,77 one was conducted in Puerto Rico192
and one was conducted in both the USA and Thailand.69
Trials included in the systematic review compared psychosocial interventions with usual care (n = 4),22,68,178,195
education or information (n = 9),70,76,77,175,176,180,188,196,197 HIV infection testing and counselling (n = 5),69,82,84,192,193
interventions of lesser time or intensity with OST (n = 12)72–74,81,173,174,177,179,182,190,194 and without OST (n = 2).71,186
Of the 32 interventions delivered in the RCTs included in the systematic review, most (n = 14) were delivered
to individual participants,22,68,70,71,75,77,81,173,175,178,192,195–197 eight were delivered to groups of participants69,74,174,
176,179,180,182,193 and two were delivered to couples.84,177 The remaining eight trials delivered interventions in
more than one way (e.g. individual and couples sessions,187,188 individual and group sessions,69,76,186,190,194
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TABLE 2 Description of trials included in the systematic review
First author
Participants
(% female)
Intervention
delivery
setting/staff
Description
Length of
follow-up
Intervention group Control group
Intervention groups Number of sessions
Intervention
functions Control intervention
Number of
sessions
Abou-Saleh et al.173 95 HCV –ve PWID
(26%)
Outpatient drug
treatment/treatment
staff
Enhanced prevention
counselling (n= 43)
Four 40- to 60-minute
sessions
Education,
enablement
Simple educational
counselling (n= 52)
One 10-minute
session
6 months post
randomisation
Avants et al.174 220 PWID in MMT
(69%)
MMT/clinician Standard care+ harm
reduction group
(n= 108)
Twelve 90-minute
weekly group sessions
Education,
enablement,
training
Standard care+ single
HIV risk reduction
session (n= 112)
One 2-hour session Post intervention
Bertrand et al.175 219 PWID who
shared drugs
or injection
equipment (18%)
Not specified/
researcher
MI (n= 111) One session Enablement,
persuasion
Education intervention
(n= 108)
One 30–45 minutes
session
6 months post
randomisation
Booth et al.68 632 PWID (24%) Residential
detoxification/
interventionist
TAU+HIV/HCV
counselling and
education (n= 212);
TAU+ intervention to
facilitate treatment entry
(n= 209)
Two individual
sessions; individual
session
Education,
enablement,
training
TAU: HIV/HCV infection
risk assessment
screening and referral
for testing and
counselling (n= 211)
HIV/HCV infection
risk assessment
screening and
referral for testing
and counselling
6 months post
randomisation
Dushay et al.176 669 drug users
(64% injecting)
(27%)
Not reported Ethnic cultural enhanced
intervention (n= 453)
Five sessions Education,
enablement,
training
AIDS video educational
programme (n= 216)
Two video sessions 5–10 months post
randomisation
(20% interviewed
12 months post
randomisation)
El-Bassell et al.177 282 HIV-negative
drug-using
couples (16%
PWID) (50%)
Not reported/trained
facilitator
Couple-based risk
reduction (n= 190);
individual-based HIV
infection risk reduction
delivered to male or
female drug-using
partner (n= 183)
Seven sessions Enablement,
training
Couple-based wellness
promotion (n= 190)
Seven sessions 12 months post
randomisation
Gagnon et al.178 260 PWID (31%) Needle exchange/
computerised
intervention
Standard intervention
(needle exchanges,
psychosocial support
and social and health
service referrals)+
computer-tailored
messages (n= 130)
Four sessions Education,
enablement,
modelling,
persuasion
Standard intervention
(n= 130)
4 weeks 3 months post
intervention
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First author
Participants
(% female)
Intervention
delivery
setting/staff
Description
Length of
follow-up
Intervention group Control group
Intervention groups Number of sessions
Intervention
functions Control intervention
Number of
sessions
Garfein et al.;179
Purcell et al.;191
and Mackesy-Amiti
et al.
183–185
654 HIV-negative
and HCV-negative
PWID (34%)
Not reported/trained
facilitators
Peer education (n= 431) Six sessions Education,
enablement,
training
Video discussion
(n= 423)
Six sessions 6 months post
intervention
Gilbert et al.73 40 HIV-negative
couples who inject
drugs (50%)
Needle exchange/
facilitators
Couple-based HIV risk
reduction (20 couples)
Three single gender
group
sessions+ couple
session
Education,
modelling,
training
Wellness promotion
condition (20 couples)
Four group sessions 3 months post
intervention
Go et al.180 419 index
HIV-negative
PWID (0%)
Not reported Peer network oriented
(n= 210)
Six sessions+ three
booster sessions
Education,
enablement,
training
TAU+HIV pamphlet
(n= 209)
N/A 12 months post
intervention
Go et al.82 455 HIV-positive
PWID (0%)
Community
intervention
education sessions
delivered by a trained
community mobiliser;
individual HIV
knowledge and
skill-building group
sessions conducted
by two facilitators
Individual level: HIV
infection testing and
counselling, plus two
individual post-test
counselling sessions,
two small group sessions
(HIV infection knowledge
and skill-building)+
optional dyad session
(n= 95)
Four individual
sessions+ two group
sessions+ optional
dyad session
Education,
enablement,
training,
education
Individual level: HIV
infection testing and
counselling (n= 89)
Two sessions 24 months post
randomisation
Community and
individual level:
community-wide
programme consisting of
a two-part video and a
series of six HIV
education sessions
(n= 132)
Two-part video and a
series of six HIV
education sessions
Community level:
standard messages
on HIV through
village weekly public
loudspeakers and
educational pamphlets
already being provided
by community health
stations (n= 139)
Hoffman et al.74 432 PWID (33%) Research centre/
facilitators
Psychological-
communicative
behavioural training;
peer educator (n= 99);
network members
(n= 127)
Seven group+ one
individual
session+ four booster
meetings
Education,
modelling,
persuasion,
training
Group sessions devoted
to areas of interest
(n= 92); network
members (n= 114)
Eight sessions 24 months post
randomisation
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TABLE 2 Description of trials included in the systematic review (continued )
First author
Participants
(% female)
Intervention
delivery
setting/staff
Description
Length of
follow-up
Intervention group Control group
Intervention groups Number of sessions
Intervention
functions Control intervention
Number of
sessions
Latka et al.;182
Kapadia et al.198
418 HCV-positive
PWID (24%)
Three research sites/
facilitators
Peer-mentoring
behavioural intervention
(n= 222)
Six sessions Education,
training
Video discussion
(n= 196)
Six sessions 6 months post
intervention
Latkin et al.72 250 (47% PWID)
(39%)
Clinic/indigenous
paraprofessional
facilitators
Small group that
encouraged peer
outreach (n= 81)
10 group sessions Enablement,
education,
training
Equal-attention control
condition (n= 36)
10 sessions 6 months post
intervention
Latkin et al.69,199 414 networks
with 1123
HIV-negative
participants (91%
PWID) (3% in
Thailand; and
20% in the USA)
Not reported/
facilitator
HIV C&T+ group peer
education (n= 204
networks)
Two individual+ six
group+ two booster
sessions
Education,
enablement,
persuasion,
training
HIV C&T (n= 210
networks)
Two sessions Up to 30 months
(24 months in
Thailand) post
randomisation
Margolin et al.186 90 PWID HIV
positive entering
MMT (30%)
MMT/counsellor Enhanced MMT
(6 months of daily
methadone and weekly
individual substance
abuse counselling and
case management)+HIV
harm reduction
programme (n= 45)
Six sessions Enablement,
persuasion,
training
Enhanced MMT+ active
control that included
harm reduction
components (n= 45)
Six sessions 9 months post
randomisation
McMahon et al.84,187 330 HIV-negative
drug users (48%
PWID) (100%) and
male partners
Field office/
interventionist
1. Couple-based HIV
C&T (n= 110)
(43% PWID)
2. Women only,
relationship-focused
HIV C&T (n= 104)
(51% PWID)
Two sessions Education,
enablement
HIV C&T (n= 116)
(51% PWID)
Two sessions 9 months post
intervention
Otiashvili et al.188 40 drug users
(98% PWID) (0%)
and drug-free
female partners
Research unit/
counsellor
MI for drug user and
couple, CM+ naltrexone
(n= 20). Female partners
invited to attend couples
counselling
22 sessions Enablement,
incentivisation
Education sessions.
Referral drug treatment
(n= 20)
22 sessions 6 months post
intervention
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First author
Participants
(% female)
Intervention
delivery
setting/staff
Description
Length of
follow-up
Intervention group Control group
Intervention groups Number of sessions
Intervention
functions Control intervention
Number of
sessions
Purcell et al.189,190 966 HIV-positive
PWID (36%)
Not reported/peers Peer-mentoring
intervention (n= 486)
10 sessions: seven
group sessions; two
individual sessions;
and one ‘peer activity’
Education,
enablement,
training
Video discussion
(n= 480)
Eight sessions 12 months post
intervention
Robles et al.192 557 PWID (4%) Assessment facility or
drug treatment/nurse
HIV/AIDS infection
risk intervention+
counselling+ case
management (n= 285)
Two sessions; six
sessions
Education,
enablement,
training
HIV/AIDS infection risk
intervention (n= 272)
Two sessions 6 months post
randomisation
Rotheram-Borus
et al.;193 and
Hershberger et al.181
1116 drug users
(65% PWID)
(33%)
Field office/
counsellors/outreach
workers
HIV C&T+HIV
prevention programme
(group skills-focused
workshops, individual
counselling, outreach/
social events) (n= 558;
359 PWID)
Two HIV C&T
sessions+ five sessions
(two groups, one
individual+ two or
more structured
outreach)
Enablement,
training
HIV C&T (n= 559;
364 PWID)
Two sessions 9 months post
randomisation
Samet et al.194 700 HIV positive
with risky sex and
heavy alcohol
consumption
(60% PWID)
(41%)
Hospital setting/peers Healthy relationships
intervention (n= 350;
212 PWID)
Two individual+ three
small group sessions
Education,
enablement,
modelling,
training
Attention control
(n= 350; 211 PWID)
Two
individual+ three
group sessions
12 months post
randomisation
Schroeder et al.;71
and Esptein et al.83
81 drug users
(96% PWID)
(52%)
Research clinic/
counsellor
MMT+ individual
counselling followed by
12 weeks of intervention
condition, followed by a
12-week standard
treatment:
1. Weekly CBT+
CM (n= 16)
2. Weekly CBT+
non-contingent
vouchers (n= 19)
3. CM plus weekly
group therapy
(n= 22)
29 weeks
(methadone+
5-weekly individual
counselling, 12 weeks
of intervention,
followed by 12 weeks
standard treatment)
Education,
enablement,
incentivisation,
modelling,
training
Standard dose of
methadone (70–80mg/
day)+weekly individual
counselling (5 weeks)
followed by 12 weeks
of control condition,
followed by a 12-week
standard treatment.
Group therapy+
non-contingent vouchers
(n= 24)
29 weeks
(methadone+
5-weekly individual
counselling,
12 weeks of
intervention,
followed by
12 weeks standard
treatment)
Post intervention
continued
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TABLE 2 Description of trials included in the systematic review (continued )
First author
Participants
(% female)
Intervention
delivery
setting/staff
Description
Length of
follow-up
Intervention group Control group
Intervention groups Number of sessions
Intervention
functions Control intervention
Number of
sessions
Stein et al.195 109 PWID who
drink hazardously
(38%)
Research site/social
worker
Referrals for substance
use and medical
treatment+ brief MI
(n= 60)
Two sessions Enablement Referrals for substance
abuse and medical
treatment provided
(n= 49)
N/A 6 months post
randomisation
Stein et al.22 109 PWID (36%) Outpatient academic
research office/clinical
psychologist
CBT+ pharmacotherapy
for depression (n= 53)
Eight CBT
sessions+ three
pharmacotherapy visits
Education,
enablement,
training
Assessment (n= 56) Assessment visit 9 months post
randomisation
Stein et al.196 277 HCV-negative
drug users (28%
PWID) (37%)
Not stated/
interventionist
MI (n= 140) Four sessions Education,
enablement,
persuasion
Leaflet about local
resources (n= 137)
N/A 24 months post
randomisation
Sterk et al.81 68 HIV-negative
PWID (100%)
Health intervention
project house/
interventionists
Enhanced MI (n= 20);
enhanced negotiation
intervention (n= 21)
Four sessions; four
sessions
Education,
enablement,
training
NIDA standard
intervention (n= 27)
Two sessions 6 months (not
clear if post
intervention
or post
randomisation)
Strathdee et al.;77
Vera et al.85
584 sex workers
who inject drugs
(100%)
Not reported/
counsellors
Interactive injection risk
and didactic sexual risk
intervention (n= 146);
interactive sexual risk
and didactic injection
risk intervention
(n= 148); interactive
injection and sexual risk
intervention) (n= 146)
One session; one
session; one session
Education,
enablement,
modelling,
persuasion,
training
Didactic injection and
sexual risk intervention
(n= 144)
One 60-minute
session
12 months post
randomisation
Tobin et al.76 227 PWID (45%) Research clinic/not
reported
Peer-educator
intervention (n= 114)
Seven sessions
(five group+ one
individual+ one with
participant and
enrolled risk network
members)
Education,
enablement,
training
Group information
(n= 113)
Five sessions 18 months post
intervention
Tucker et al.197 145 PWID (26%) Outpatient clinical
and research
organisation/clinical
researcher
Tailored brief behavioural
intervention (n= 73)
One session Education,
enablement
HCV educational leaflet
(n= 72)
N/A 1 month post
randomisation
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First author
Participants
(% female)
Intervention
delivery
setting/staff
Description
Length of
follow-up
Intervention group Control group
Intervention groups Number of sessions
Intervention
functions Control intervention
Number of
sessions
Wechsberg et al.75 100 PWID (100%) Inpatient
detoxification/
psychologist
Woman-focused
intervention (n= 51)
Two sessions Education,
enablement,
training
Nutrition intervention
(n= 49)
Two sessions 3 months post
randomisation
Zule et al.70 851 PWID (27%) Not reported/lay
community members
HCV risk reduction MI
(n= 423)
Six sessions Education,
enablement,
modelling,
persuasion
Video HCV educational
intervention (n= 428)
Six sessions 12 months post
randomisation
AIDS, acquired immunodeficiency syndrome; C&T, counselling and testing; N/A, not applicable; NIDA, National Institute on Drug Abuse.
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group and couples sessions73) and one trial provided both individual- and structural-level activities.82 For
interventions with more than one session, retention or adherence to the intervention ranged from 50%68
to 95%.81
Eight interventions incorporated peer mentoring from an index participant to change the behaviours of other
PWID.69,72,74,76,179,180,182,190 The majority of interventions contained at least three sessions (n = 25),22,69–74,76,81,82,
173,174,176–180,182,186,188,190,192–194,196,197 four interventions contained two sessions,68,75,187,195 and three interventions
contained only one session.77,175,197
Most interventions were delivered in drug treatment settings, including outpatient and hospital clinics,71,72,
173,192–194 methadone maintenance clinics,174,186 inpatient or residential detoxification units,68,75,197 needle and
syringe exchanges73,178 or outreach193 (settings not mutually exclusive). In addition, the vast majority of
studies were delivered by clinic staff in the treatment setting rather than by a researcher (or not specified).
Assessed outcomes
Various validated and other purposely developed instruments were used to assess injecting risk behaviour in
32 trials22,68–77,81,82,84,173–180,182,186,188,190,192–195,197 and sexual risk behaviour in 23 trials.68–77,81,82,84,173,174,176,177,179,180,
186,190,193,194,197 The most common reporting time frame for outcomes was in the past 30 days (n = 19),22,68,69,
73–77,81,174–176,186,188,192–195,197 followed by the past 3 months (n = 10),74,82,84,174,177,179,180,182,190,194 or 6 months
(n = 3),72,76,196 past week (n = 2),71,178 or behaviour at the last sexual encounter or injecting event (n = 1)70
(answers not mutually exclusive as three trials reported a different reporting time frame for different
outcomes).74,76,194
Results of individual studies not included in the meta-analyses
Of the eight trials not included in the analysis, three trials reported that psychosocial interventions were
more effective than control conditions in reducing injecting risk behaviour77,84,178 and three reported
reductions in sexual risk behaviours84,174,177 for participants receiving the psychosocial intervention. Avants
et al.174 found that, post intervention, the total number of weeks in which unsafe sex was reported by
PWID receiving methadone treatment was significantly lower for participants in the harm reduction group
(2.40 ± 3.42 weeks) than for those in the standard care group (3.67 ± 3.89 days) [F(1,218) = 6.63;
p = 0.01]. In addition, 32% (14/44) of the participants in the harm reduction group reported using
condoms, compared with 13% (6/48) in the standard care group [χ2(1) = 5.04; p = 0.02]. El-Bassel et al.177
reported a 30% reduction in the incidence rate of unprotected sex acts with study partners for those who
had received the couple-based risk reduction intervention compared with participants in the attention
control arm over 12 months’ follow-up. In addition, a 29% reduction was found in the same outcome in
the couple arm compared with the individual arm, with a 41% reduction at the 12-month follow-up.
Gagnon et al.178 found that at the end of the 4-week intervention PWID who received the standard
intervention plus the computer-tailored messages reported using fewer used syringes than PWID who
received the standard intervention alone [relative risk 0.47, 95% CI 0.28 to 0.79; p = 0.004]. However,
these changes were not sustained at 3 months’ follow-up. McMahon et al.84 found that, 9 months post
intervention, women who attended a couples-based HIV counselling and testing intervention reported
significantly less frequent receptive syringe sharing with primary partners (mean = 1.4 vs. 8.3; p = 0.0002)
and less frequent unprotected anal intercourse with a primary male partner (mean = 0.7 vs. 5.7; p = 0.005)
than women receiving standard care. In one trial, in two sites in Mexico among female drug-injecting sex
workers, a significantly greater reduction in receptive needle sharing was reported by participants receiving
an interactive intervention than among those receiving a didactic intervention in one site only (85% vs.
71%, respectively; p = 0.04).77
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Meta-analyses
Any injecting risk behaviour
Twenty-two trials assessed any injecting risk behaviour. Psychosocial interventions independently reduced
injecting risk behaviours more than control interventions in seven trials.72,73,76,179,182,188,192 A total of 3096 PWID
were included in the intervention groups and 2971 in the control groups. Overall, psychosocial interventions
showed a greater reduction in any injecting risk behaviour (SMD –0.29, 95% CI –0.42 to –0.15, I2 = 61%;
p < 0.01) than the control interventions (Figure 3). Psychosocial interventions also demonstrated greater
reductions in any risk behaviours than education/information (SMD –0.41, 95% CI –0.79 to –0.04, I2 = 62%;
p = 0.03), HIV infection testing and counselling (SMD –0.24, 95% CI –0.44 to –0.03, I2 = 0%; p = 0.02) and
interventions of a lesser time or intensity (SMD –0.34, 95% CI –0.56 to –0.12, I2 = 75%; p < 0.01), but no
difference was found when compared with interventions of a lesser time or intensity that included OST
(SMD 0.23, 95% CI –0.51 to 0.97, I2 = 0%; p < 0.01) or TAU (SMD –0.09, 95% CI –0.32 to 0.15, I2 = 26%;
p = 0.54). Where outcomes were assessed ≤ 3 months or 4–6 months post intervention, psychosocial
interventions reduced any injecting risk behaviour when compared with interventions of lesser time or
intensity. Where outcomes were compared ≥ 9 months post intervention, psychosocial interventions reduced
any injecting risk behaviour more than interventions that provided education/information alone. (Figure 4).
Study or subgroup
Usual care
Booth 2011;68 4 – 6 months
Stein 2002;195 4 – 6 months
Stein 2005;22 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 2.70, df = 2 (p = 0.26); I 2 = 26%
Test for overall effect: z = 0.71 (p = 0.48)
HIV testing and counselling
Go 2015;82 ≥ 9 months
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.61, df = 2 (p = 0.45); I 2 = 0%
Test for overall effect: z = 2.30 (p = 0.02)
Intervention lesser frequency or intensity without OST
Abou-Saleh 2008;173 4 – 6 months
Garfein 2007;179 4 – 6 months
Gilbert 2010;73 ≤ 3 months
Latka 2008;182 4 – 6 months
Latkin 2003;72 4 – 6 months
Purcell 2007;190 ≥ 9 months
Samet 2015;194 ≥ 9 months
Sterk 2003;81 4 – 6 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.08; χ2 = 32.37, df = 8 (p < 0.0001); I 2 = 75%
Test for overall effect: z = 3.00 (p = 0.003)
Intervention lesser frequency or intensity with OST
Margolin 2003;186 ≥ 9 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.52, df = 1 (p = 0.47); I 2 = 0%
Test for overall effect: z = 0.61 (p = 0.54)
0 .0581
0.6558
0.4467
0.7006
45
16
61
 
0.06 (– 0.82 to 0.93)
0.66 (– 0.72 to 2.03)
0.23 (– 0.51 to 0.97)
45
24
69
1.9
0.9
2.7
Total (95% CI)
Heterogeneity: τ2 = 0.05; χ2 = 54.17, df = 21 (p < 0.0001); I 2 = 61%
Test for overall effect: z = 4.23 (p < 0.0001)
Test for subgroup differences: χ2 = 4.86, df = 4 (p = 0.30); I 2 = 17.7%
3096 2971 100.0 – 0.29 (– 0.42 to – 0.15)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
0
– 0.5279
– 0.048
 
– 0.3447
– 0.1513
– 0.4745
 
– 0.0163
– 0.1888
– 1.1944
– 0.3509
– 0.859
– 0.1396
0.1119
– 0.3709
– 0.4095
 
0.1062
0.3032
0.2031
 
0.2829
0.1236
0.2396
 
0.2284
0.0877
0.2437
0.1261
0.2366
0.1614
0.1334
0.2936
0.2126
 
212
60
53
325
 
106
204
285
595
 
43
431
40
222
81
486
212
21
51
1587
 
211
49
56
316
 
68
210
272
550
 
52
423
40
196
36
480
211
27
49
1514
 
7.3
3.2
5.0
15.5
 
3.5
6.9
4.2
14.6
 
4.5
7.7
4.2
6.8
4.3
5.9
6.6
3.4
4.8
48.2
 
0.00 (– 0.21 to 0.21)
– 0.53 (– 1.12 to 0.07)
– 0.05 (– 0.45 to 0.35)
– 0.09 (– 0.32 to 0.15)
 
– 0.34 (– 0.90 to 0.21)
– 0.15 (– 0.39 to 0.09)
– 0.47 (– 0.94 to – 0.00)
– 0.24 (– 0.44 to – 0.03)
 
– 0.02 (– 0.46 to 0.43)
– 0.19 (– 0.36 to – 0.02)
– 0.19 (– 1.67 to – 0.72)
– 0.35 (– 0.60 to – 0.10)
– 0.86 (– 1.32 to – 0.40)
– 0.14 (– 0.46 to 0.18)
0.11 (– 0.15 to 0.37)
– 0.37 (– 0.95 to 0.20)
– 0.41 (– 0.83 to 0.01)
– 0.34 (– 0.56 to – 0.12)
Education/information
Bertrand 2015;175 4 – 6 months
Go 2013;180 ≥ 9 months
Otiashvili 2012;188 4 – 6 months
Tobin 2011;76 ≥ 9 months
Tucker 2004;197 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.10; χ2 = 10.51, df = 4 (p = 0.03); I 2 = 62%
Test for overall effect: z = 2.19 (p = 0.03)
 
– 0.3822
– 0.2376
– 0.2343
– 0.4281
0.0037
 
0.2674
0.5084
0.348
0.177
0.1813
 
111
210
20
114
73
528
 
108
209
20
113
72
522
 
3.8
1.5
2.7
5.6
5.5
19.0
 
– 0.38 (– 0.91 to 0.14)
– 0.24 (– 1.23 to 0.76)
– 1.23 (– 1.92 to – 0.55)
– 0.43 (– 0.78 to – 0.08)
0.00 (– 0.35 to 0.36)
– 0.41 (– 0.79 to – 0.04)
FIGURE 3 Efficacy of psychosocial interventions vs. control interventions in reducing any injecting risk behaviours
among PWID. df, degrees of freedom; IV, inverse variance; SE, standard error.
DOI: 10.3310/hta21720 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 72
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilchrist et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
Study or subgroup
Usual care 4 – 6 months
Booth 2011;68 4 – 6 months
Stein 2002;195 4 – 6 months
Stein 2005;22 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 2.70, df = 2 (p = 0.26); I 2 = 26%
Test for overall effect: z = 0.71 (p = 0.48)
Education/information 6 months
Bertrand 2015;175 4 – 6 months
Otiashvili 2012;188 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.27; χ2 = 3.77, df = 1 (p = 0.05); I 2 = 73%
Test for overall effect: z = 1.83 (p = 0.07)
Intervention lesser frequency or intensity without OST 6 months
Abou-Saleh 2008;173 4 – 6 months
Garfein 2007;179 4 – 6 months
Latka 2008;182 4 – 6 months
Latkin 2003;72 4 – 6 months
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 8.81, df = 4 (p = 0.07); I 2 = 55%
Test for overall effect: z = 2.86 (p = 0.004)
– 0 .0163
– 0.1888
– 0.3509
– 0.859
– 0.3709
0.2284
0.0877
0.1261
0.2366
0.2936
43
431
222
81
21
798
 
– 0.02 (– 0.46 to – 0.43)
– 0.19 (– 0.36 to – 0.02)
– 0.35 (– 0.60 to – 0.10)
– 0.86 (– 1.32 to – 0.40)
– 0.37 (– 0.95 to 0.20)
– 0.32 (– 0.55 to – 0.10)
52
423
196
36
27
734
4.5
7.7
6.8
4.3
3.4
26.7
Intervention lesser frequency or intensity with OST ≤ 3 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.94 (p = 0.35)
0 .6558 0.7006 16
16
 
0.66 (– 0.72 to 2.03)
0.66 (– 0.72 to 2.03)
24
24
0.9
0.9
Intervention lesser frequency or intensity without OST ≤ 3 months
Gilbert 2010;73 ≤ 3 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.26; χ2 = 5.89, df = 1 (p = 0.02); I 2 = 83%
Test for overall effect: z = 2.02 (p = 0.04)
– 1 .1944
– 0.4095
0.2437
0.2126
40
51
91
 
– 1.19 (– 1.67 to – 0.72)
– 0.41 (– 0.83 to 0.01)
– 0.79 (– 1.56 to – 0.02)
40
49
89
4.2
4.8
8.9
Total (95% CI)
Heterogeneity: τ2 = 0.05; χ2 = 54.17, df = 21 (p < 0.0001); I 2 = 61%
Test for overall effect: z = 4.23 (p < 0.0001)
Test for subgroup differences: χ2 = 14.83, df = 10 (p = 0.14); I 2 = 32.6%
3096 2971 100.0 – 0.29 (– 0.42 to – 0.15)
SMD SE Total Total
Intervention Comparator SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
0
– 0.5279
– 0.048
 
– 0.3822
– 1.2343
 
0.1062
0.3032
0.2031
 
0.2674
0.348
 
212
60
53
325
 
111
20
131
 
211
49
56
316
 
108
20
128
 
7.3
3.2
5.0
15.5
 
3.8
2.7
6.5
 
0.00 (– 0.21 to 0.21)
– 0.53 (– 1.12 to 0.07)
– 0.05 (– 0.45 to 0.35)
– 0.09 (– 0.32 to 0.15)
 
– 0.38 (– 0.91 to 0.14)
– 1.23 (– 1.92 to – 0.55)
– 0.78 (– 1.61 to 0.05)
Education/information ≤ 3 months
Tucker 2004;197 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.02 (p = 0.98)
 
0.0037
 
0.1813
 
73
73
 
72
72
 
5.5
5.5
 
0.00 (– 0.35 to 0.36)
0.00 (– 0.35 to 0.36)
Education/information ≥ 9 months
Go 2013;180 ≥ 9 months
Tobin 2011;76 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.13, df = 1 (p = 0.72); I 2 = 0%
Test for overall effect: z = 2.44 (p = 0.01)
 
– 0.2376
– 0.4281
 
0.5084
0.177
 
210
114
324
 
209
113
322
 
1.5
5.6
7.1
 
– 0.24 (– 1.23 to 0.76)
– 0.43 (– 0.78 to – 0.08)
– 0.41 (– 0.74 to – 0.08)
HIV testing and counselling ≥ 9 months
Go 2015;82 ≥ 9 months
Latkin 2009;69 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.39, df = 1 (p = 0.53); I 2 = 0%
Test for overall effect: z = 1.61 (p = 0.11)
 
– 0.3447
– 0.1513
 
0.2829
0.1236
 
106
204
310
 
68
210
278
 
3.5
6.9
10.4
 
– 0.34 (– 0.90 to 0.21)
– 0.15 (– 0.39 to 0.09)
– 0.18 (– 0.40 to 0.04)
HIV testing and counselling 6 months
Robles 2004;192 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.98 (p = 0.05)
 
– 0.4745
 
0.2396
 
285
285
 
272
272
 
4.2
4.2
 
– 0.47 (– 0.94 to – 0.00)
– 0.47 (– 0.94 to – 0.00)
Intervention lesser frequency or intensity without OST ≥ 9 months
Purcell 2007;190 ≥ 9 months
Samet 2015;194 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 1.44, df = 1 (p = 0.23); I 2 = 31%
Test for overall effect: z = 0.02 (p = 0.98)
 
– 0.1396
0.1119
 
0.1614
0.1334
 
486
212
698
 
480
211
691
 
5.9
6.6
12.6
 
– 0.14 (– 0.46 to 0.18)
0.11 (– 0.15 to 0.37)
0.00 (– 0.24 to 0.25)
Intervention lesser frequency or intensity with OST ≥ 9 months
Margolin 2003;186 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.13 (p = 0.90)
 
0.0581
 
0.4467
 
45
45
 
45
45
 
1.9
1.9
 
0.06 (– 0.82 to 0.93)
0.06 (– 0.82 to 0.93)
Weight (%)
FIGURE 4 Efficacy of psychosocial interventions vs. control interventions in reducing any injecting risk behaviours
among PWID by control intervention and length of follow-up post intervention. df, degrees of freedom; IV, inverse
variance; SE, standard error.
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Heterogeneity was moderate in psychosocial interventions compared with education/information (I2 = 62%),
possibly as a result of the variations in the mode of delivery and intervention components (see Table 2).
The education/information interventions in the control conditions included a pamphlet compared with a
six-session education/enablement intervention180 and ranged from comparing a one-session education
intervention with a one-session motivational intervention175 to comparing 22 education sessions with referrals
to drug treatment with a 22-week intervention including MI counselling sessions for both the male participant
and the couple, monetary incentives for drug abstinence and research-supported detoxification followed by
naltrexone treatment.188 There was high heterogeneity in the analysis of psychosocial interventions compared
with interventions of a lesser time or intensity (without OST) (I2 = 75%), for similar reasons to those
mentioned above. Six trials included equal-attention control conditions ranging from 275 to 10182 sessions,
and three included control interventions with fewer sessions, ranging from four sessions versus one
session173 to 10 versus eight sessions190 (see Table 2). All but one trial173 had at least two sessions in the
control and/or intervention conditions. One trial compared a two-session woman-focused intervention with
a two-session nutritional intervention.75 The variation in intervention duration and content across conditions
contributes to the high heterogeneity.
Sharing needles and syringes
Thirteen trials assessed the sharing of needles and syringes (Figure 5). Psychosocial interventions reduced
with behaviour compared with the control interventions in five of those trials.72,73,186,188,192 A total of 1411
PWID were included in the intervention groups and 1315 in the control groups. A total of 1411 and 1315
PWID were included in the intervention and control group, respectively. Overall, psychosocial interventions
reduced sharing of needle/syringes (SMD –0.43, 95% CI –0.69 to –0.18, I2 = 68%; p < 0.01) compared with
Study or subgroup
Usual care
Stein 2002;195 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.74 (p = 0.08)
HIV testing and counselling
Go 2015;82 ≥ 9 months
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.61, df = 2 (p = 0.45); I 2 = 0%
Test for overall effect: z = 2.30 (p = 0.02)
Intervention lesser frequency or intensity
Gilbert 2010;73 ≤ 3 months
Latkin 2003;72 4 – 6 months
Samet 2015;194 ≥ 9 months
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.40; χ2 = 28.57, df = 3 (p < 0.00001); I 2 = 90%
Test for overall effect: z = 1.68 (p = 0.09)
OST and psychosocial intervention
Margolin 2003;186 ≥ 9 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.50; χ2 = 2.73, df = 1 (p = 0.10); I 2 = 63%
Test for overall effect: z = 0.22 (p = 0.83)
– 0 .5988
0.6558
0.2919
0.7006
45
16
61
 
– 0.60 (– 1.17 to – 0.03)
0.66 (– 0.72 to 2.03)
– 0.13 (– 1.32 to 1.05)
45
24
69
7.8
2.7
10.5
Total (95% CI)
Heterogeneity: τ2 = 0.12; χ2 = 37.24, df = 12 (p = 0.0002); I 2 = 68%
Test for overall effect: z = 3.40 (p = 0.0007)
Test for subgroup differences: χ2 = 2.41, df = 4 (p = 0.66); I 2 = 0%
1411 1319 100.0 – 0.43 (– 0.69 to – 0.18)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
– 0.5279
 
– 0.3447
– 0.1513
– 0.4745
 
– 1.1944
– 0.859
0.1119
– 0.3709
 
0.3032
 
0.2829
0.1236
0.2396
 
0.2437
0.2366
0.1334
0.2936
 
60
60
 
106
204
285
595
 
40
81
212
21
354
 
49
49
 
68
210
272
550
 
40
36
211
27
314
 
7.6
7.6
 
8.0
11.7
9.0
28.7
 
8.9
9.1
11.5
7.8
37.2
 
– 0.53 (– 1.12 to 0.07)
– 0.53 (– 1.12 to 0.07)
 
– 0.34 (– 0.90 to 0.21)
– 0.15 (– 0.39 to 0.09)
– 0.47 (– 0.94 to – 0.00)
– 0.24 (– 0.44 to – 0.03)
 
– 1.19 (– 1.67 to – 0.72)
– 0.86 (– 1.32 to – 0.40)
0.11 (– 0.15 to 0.37)
– 0.37 (– 0.95 to 0.20)
– 0.56 (– 1.22 to 0.09)
Education/information
Bertrand 2015;175 4 – 6 months
Go 2013;180 ≥ 9 months
Otiashvili 2012;188 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 2.22, df = 2 (p = 0.33); I 2 = 10%
Test for overall effect: z = 2.07 (p = 0.04)
 
– 0.13
– 0.2376
– 0.8821
 
0.4555
0.5084
0.3329
 
111
210
20
341
 
108
209
20
337
 
4.9
4.3
6.9
16.1
 
– 0.13 (– 1.02 to 0.76)
– 0.24 (– 1.23 to 0.76)
– 0.88 (– 1.53 to – 0.23)
– 0.52 (– 1.02 to – 0.03)
FIGURE 5 Efficacy of psychosocial interventions vs. control interventions in reducing sharing of needles or syringes
among PWID by control intervention. df, degrees of freedom; IV, inverse variance; SE, standard error.
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control interventions. Psychosocial interventions reduced needle and syringe sharing compared with
education/information (SMD –0.52, 95% CI –1.02 to –0.03, I2 = 10%; p = 0.04), or HIV infection testing and
counselling (SMD –0.24, 95% CI –0.44 to –0.03, I2 = 0%; p = 0.02). However, no difference was found
when psychosocial interventions were compared with interventions of a lesser time or intensity (SMD –0.56,
95% CI –1.22 to 0.09, I2 = 90%; p = 0.09) or interventions of lesser time or intensity that included OST
(SMD –0.13, 95% CI –1.32 to 1.05, I2 = 63%; p = 0.83) or TAU (SMD –0.53, 95% CI –1.12 to 0.07;
p = 0.08; one trial195). Where outcomes were assessed ≤ 3 months or 4–6 months post intervention,
psychosocial interventions reduced needle and syringe sharing compared with interventions of lesser time or
intensity. Where outcomes were assessed 4–6 months post intervention, psychosocial interventions reduced
any injecting risk behaviour compared with HIV infection testing and counselling (Figure 6). There was
moderate and high heterogeneity in the analysis of psychosocial interventions compared with interventions
of a lesser time or intensity with OST (I2 = 63%) and without OST (I2 = 90%), again potentially explained by
the differences in intervention content and delivery. The two trials that compared psychosocial interventions
with OST with interventions of a lesser time/intensity with OST varied in length of OST treatment. Both
included a 12-week psychosocial intervention; however, the trial in which methadone was prescribed for
6 months independently reduced needle and syringe sharing186 and the trial that prescribed methadone for
3 months did not.71 Four trials compared psychosocial interventions with interventions of a lesser time or
intensity without OST: the interventions that were delivered to couples73 or encouraged peer outreach72
independently reduced needle and syringe sharing, whereas those interventions delivered to individuals on
their own or in groups did not.81,194
Sharing other injecting equipment
Seven trials assessed the sharing of injecting equipment (other than needles and syringes). None of
these trials independently found the psychosocial intervention to be more efficacious than the control
interventions. A total of 1209 and 1157 PWID were included in the intervention and the control group,
respectively. Overall, psychosocial interventions reduced sharing of other injecting equipment (SMD –0.21,
95% CI –0.34 to –0.09, I2 = 0%; p < 0.01) compared with control interventions. Psychosocial interventions
reduced the sharing of other injecting equipment compared with interventions of a lesser time or intensity
without OST (SMD –0.24, 95% CI –0.42 to –0.06, I2 = 0%; p < 0.01), but were no different when compared
with education/information (SMD –0.42, 95% CI –0.98 to 0.14; p = 0.15; one trial175) and HIV infection
testing and counselling (SMD –0.17, 95% CI –0.34 to 0.00, I2 = 0%; p = 0.05) (Figure 7). Where outcomes
were compared 4–6 months post intervention, psychosocial interventions reduced sharing of other injecting
equipment compared with interventions of lesser time or intensity (Figure 8).
Frequency of injecting
Eight trials assessed the frequency of injecting (Figure 9). Psychosocial interventions independently reduced
frequency of injecting compared with control interventions in four trials.81,188,192,193 A total of 1168 PWID
were included in the intervention group and 1177 in the control group. Overall, psychosocial interventions
showed no difference in reducing frequency of injecting (SMD –0.17, 95% CI –0.35 to 0.00, I2 = 61%;
p = 0.05). Psychosocial interventions reduced the frequency of injecting compared with education/
information (SMD –1.05, 95% CI –2.07 to –0.03; p = 0.04; one trial188), but no showed difference when
compared with interventions of a lesser time or intensity with OST (SMD 0.09, 95% CI –0.61 to 0.79,
I2 = 76%; p = 0.20; one trial71) and without OST (SMD –0.46, 95% CI –1.02 to 0.21, I2 = 66%; p = 0.80),
HIV infection testing and counselling (SMD –0.16, 95% CI –0.40 to 0.08, I2 = 76%; p = 0.20) and TAU
(SMD 0.00, 95% CI –0.20 to 0.21; p = 0.96; one trial68). Where outcomes were compared 4–6 months
post intervention, psychosocial interventions reduced the frequency of injecting compared with education/
information (Figure 10). There was moderate to high heterogeneity in the analysis comparing psychosocial
interventions with HIV infection testing and counselling (I2 = 76%) and with interventions of a lesser time/
intensity with OST (I2 = 66%) and without OST (I2 = 66%), again potentially explained by the differences in
intervention content and delivery described above (see Study Characteristics). All HIV infection testing and
counselling intervention control groups received two sessions whereas in the intervention conditions the
number of sessions ranged from seven193 to 10.69
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Study or subgroup
Usual care 4 – 6 months
Stein 2002;195 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.74 (p = 0.08)
Education/information 4 – 6 months
Bertrand 2015;175 4 – 6 months
Otiashvili 2012;188 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.12; χ2 = 1.78, df = 1 (p = 0.18); I 2 = 44%
Test for overall effect: z = 1.54 (p = 0.12)
Intervention lesser frequency or intensity without OST 4 – 6 months
Latkin 2003;72 4 – 6 months
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.05; χ2 = 1.68, df = 1 (p = 0.20); I 2 = 40%
Test for overall effect: z = 2.67 (p = 0.008)
– 0 .859
– 0.3709
0.2366
0.2936
81
21
102
 
– 0.86 (– 1.32 to – 0.40)
– 0.37 (– 0.95 to – 0.20)
– 0.65 (– 1.12 to – 0.17)
36
27
63
9.1
7.8
16.8
Intervention lesser frequency or intensity with OST ≤ 3 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.94 (p = 0.35)
0 .6558 0.7006 16
16
 
0.66 (– 0.72 to 2.03)
0.66 (– 0.72 to 2.03)
24
24
2.7
2.7
Intervention lesser frequency or intensity without OST ≤ 3 months
Gilbert 2010;73 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 4.90 (p < 0.00001)
– 1 .1944 0.2437 40
40
 
– 1.19 (– 1.67 to – 0.72)
– 1.19 (– 1.67 to – 0.72)
40
40
8.9
8.9
Total (95% CI)
Heterogeneity: τ2 = 0.12; χ2 = 37.24, df = 12 (p = 0.0002); I 2 = 68%
Test for overall effect: z = 3.40 (p = 0.0007)
Test for subgroup differences: χ2 = 30.65, df = 9 (p = 0.0003); I 2 = 70.6%
1411 1319 100.0 – 0.43 (– 0.69 to – 0.18)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
– 0.5279
 
– 0.13
– 0.8821
 
0.3032
 
0.4555
0.3329
 
60
60
 
111
20
131
 
49
49
 
108
20
128
 
7.6
7.6
 
4.9
6.9
11.9
 
– 0.53 (– 1.12 to 0.07)
– 0.53 (– 1.12 to 0.07)
 
– 0.13 (– 1.02 to 0.76)
– 0.88 (– 1.53 to – 0.23)
– 0.57 (– 1.30 to 0.16)
Education/information ≥ 9 months
Go 2013;180 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.47 (p = 0.64)
 
– 0.2376
 
0.5084
 
210
210
 
209
209
 
4.3
4.3
 
– 0.24 (– 1.23 to 0.76)
– 0.24 (– 1.23 to 0.76)
HIV testing and counselling ≥ 9 months
Go 2015;82 ≥ 9 months
Latkin 2009;69 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.39, df = 1 (p = 0.53); I 2 = 0%
Test for overall effect: z = 1.61 (p = 0.11)
 
– 0.3447
– 0.1513
 
0.2829
0.1236
 
106
204
310
 
68
210
278
 
8.0
11.7
19.7
 
– 0.34 (– 0.90 to 0.21)
– 0.15 (– 0.39 to 0.09)
– 0.18 (– 0.40 to 0.04)
HIV testing and counselling 4 – 6 months
Robles 2004;192 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.98 (p = 0.05)
 
– 0.4745
 
0.2396
 
285
285
 
272
272
 
9.0
9.0
 
– 0.47 (– 0.94 to – 0.00)
– 0.47 (– 0.94 to – 0.00)
Intervention lesser frequency or intensity without OST ≥ 9 months
Samet 2015;194 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.84 (p = 0.40)
 
0.1119
 
0.1334 212
212
 
211
211
 
11.5
11.5
 
0.11 (– 0.15 to 0.37)
0.11 (– 0.15 to 0.37)
Intervention lesser frequency or intensity with OST ≥ 9 months
Margolin 2003;186 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.05 (p = 0.04)
 
– 0.5988
 
0.2919
 
45
45
 
45
45
 
7.8
7.8
 
– 0.60 (– 1.17 to – 0.03)
– 0.60 (– 1.17 to – 0.03)
FIGURE 6 Efficacy of psychosocial interventions vs. control interventions in reducing sharing of needles or syringes
among PWID by control intervention and length of follow-up post intervention. df, degrees of freedom; IV, inverse
variance; SE, standard error.
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Study or subgroup
Education/information
Bertrand 2015;175 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.46 (p = 0.15)
HIV testing and counselling
Go 2015;82 ≥ 9 months
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.53, df = 2 (p = 0.77); I 2 = 0%
Test for overall effect: z = 1.94 (p = 0.05)
Intervention lesser frequency or intensity without OST
Garfein 2007;179 4 – 6 months
Sterk 2003;81  4 – 6 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.47, df = 2 (p = 0.48); I 2 = 0%
Test for overall effect: z = 2.67 (p = 0.008)
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 2.82, df = 6 (p = 0.83); I 2 = 0%
Test for overall effect: z = 3.49 (p = 0.0005)
Test for subgroup differences: χ2 = 0.82, df = 2 (p = 0.66); I 2 = 0%
1209 1157 100.0 – 0.21 (– 0.34 to – 0.09)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
– 0.4163
 
– 0.3447
– 0.1735
– 0.1077
 
– 0.1735
– 0.4354
– 0.4095
 
0.2859
 
0.2829
0.1124
0.1639
 
0.1057
0.2946
0.2126
 
111
111
 
106
204
285
595
 
431
21
51
503
 
108
108
 
68
210
272
550
 
423
27
49
499
 
4.6
4.6
 
4.7
30.0
14.1
48.8
 
33.9
4.4
8.4
46.6
 
– 0.42 (– 0.98 to 0.14)
– 0.42 (– 0.98 to 0.14)
 
– 0.34 (– 0.90 to 0.21)
– 0.17 (– 0.39 to 0.05)
– 0.11 (– 0.43 to 0.21)
– 0.17 (– 0.34 to 0.00)
 
– 0.17 (– 0.38 to 0.03)
– 0.44 (– 1.01 to 0.14)
– 0.41 (– 0.83 to 0.01)
– 0.24 (– 0.42 to – 0.06)
FIGURE 7 Efficacy of psychosocial interventions vs. control interventions in reducing sharing of other injecting
equipment (not needle/syringes) among PWID by control intervention. df, degrees of freedom; IV, inverse variance;
SE, standard error.
Study or subgroup
Education/information 6 months
Bertrand 2015;175 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.46 (p = 0.15)
HIV testing and counselling 6 months
Robles 2004;192 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.66 (p = 0.51)
Intervention lesser frequency or intensity ≤ 3 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.93 (p = 0.05)
Intervention lesser frequency or intensity 6 months
Garfein 2007;179 4 – 6 months
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.70, df = 1 (p = 0.40); I 2 = 0%
Test for overall effect: z = 2.04 (p = 0.04)
– 0.1735
– 0.4354
0.1057
0.2496
431
21
452
 
– 0.17 (– 0.38 to 0.03)
– 0.44 (– 1.01 to 0.14)
– 0.20 (– 0.40 to – 0.01)
423
27
450
33.9
4.4
38.2
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 2.82, df = 6 (p = 0.83); I 2 = 0%
Test for overall effect: z = 3.49 (p = 0.0005)
Test for subgroup differences: χ2 = 1.81, df = 4 (p = 0.77); I 2 = 0%
1209 1157 100.0 – 0.21 (– 0.34 to – 0.09)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
– 0.4163
 
– 0.1077
 
– 0.4095
 
0.2859
 
0.1639
 
0.2126
 
111
111
 
285
285
 
51
51
 
108
108
 
272
272
 
49
49
 
4.6
4.6
 
14.1
14.1
 
8.4
8.4
 
– 0.42 (– 0.98 to 0.14)
– 0.42 (– 0.98 to 0.14)
 
– 0.11 (– 0.43 to 0.21)
– 0.11 (– 0.43 to 0.21)
HIV testing and counselling ≥ 9 months
Go 2015;82 ≥ 9 months
Latkin 2009;69 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.32, df = 1 (p = 0.57); I 2 = 0%
Test for overall effect: z = 1.88 (p = 0.06)
 
– 0.3447
– 0.1735
 
0.2829
0.1124
 
106
204
310
 
68
210
278
 
4.7
30.0
34.7
 
– 0.34 (– 0.90 to 0.21)
– 0.17 (– 0.39 to 0.05)
– 0.20 (– 0.40 to 0.01)
 
– 0.41 (– 0.83 to 0.01)
– 0.41 (– 0.83 to 0.01)
FIGURE 8 Efficacy of psychosocial interventions vs. control interventions in reducing sharing of other injecting
equipment (not needle/syringes) among PWID by control intervention and length of follow-up post intervention.
df, degrees of freedom; IV, inverse variance; SE, standard error.
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Any sexual risk behaviour
Ten trials assessed any sexual risk behaviour (Figure 11). Psychosocial interventions were independently
more likely to reduce any sexual risk behaviour than the control interventions in two trials.73,75 A total of
1359 and 1409 PWID were included in the intervention and control groups, respectively. Overall,
psychosocial interventions reduced any sexual risk behaviour compared with control interventions (SMD
–0.19, 95% CI –0.39 to 0.01, I2 = 58%; p = 0.07). Psychosocial interventions were no different in reducing
any sexual risk behaviours compared with education/information (SMD –0.12, 95% CI –0.32 to 0.09,
I2 = 34%; p = 0.27), interventions of a lesser time or intensity with OST (SMD –0.26, 95% CI –0.67 to
0.15, I2 = 78%; p = 0.21), without OST (SMD –0.17, 95% CI –1.41 to 1.07, I2 = 72%; p = 0.79) and HIV
infection testing and counselling (SMD 0.14, 95% CI –0.81 to 1.09; p = 0.77; one trial82). Where outcomes
were compared ≤ 3 months post intervention, psychosocial interventions reduced any sexual risk behaviour
compared with interventions of a lesser time or intensity (without OST) (Figure 12). The high heterogeneity
in the analysis comparing psychosocial interventions with interventions of a lesser time or intensity with
OST (I2 = 78%) and without OST (I2 = 72%) has already been discussed.
Unprotected sex
Eight trials assessed unprotected sex. Psychosocial interventions were more effective than control
interventions in four trials.73,75,81,186 A total of 876 and 930 PWID were included in the intervention and
control group, respectively. Psychosocial interventions were independently more effective than the control
interventions in four trials.73,75,81,186 A total of 876 and 930 PWID were included in the intervention and
control groups, respectively. Overall, psychosocial interventions reduced unprotected sex compared with
control interventions (SMD –0.27, 95% CI –0.54 to –0.01, I2 = 68%; p = 0.04). Psychosocial interventions
reduced unprotected sex compared with interventions of a lesser time or intensity (without OST) (SMD
–0.44, 95% CI –0.86 to –0.01, I2 = 79%; p = 0.04), but there was no difference when compared with
Study or subgroup
Usual care
Booth 2011;68 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.05 (p = 0.96)
HIV testing and counselling
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Rotheram 2010;193 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 8.47, df = 2 (p = 0.01); I 2 = 76%
Test for overall effect: z = 1.28 (p = 0.20)
Intervention lesser frequency or intensity without OST
Sterk 2003;81 4 – 6 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.13; χ2 = 2.94, df = 1 (p = 0.09); I 2 = 66%
Test for overall effect: z = 1.28 (p = 0.20)
Intervention lesser frequency or intensity with OST
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.26 (p = 0.80)
0 .0921 0.3564 16
16
 
0.09 (– 0.61 to 0.79)
0.09 (– 0.61 to 0.79)
24
24
5.1
5.1
Total (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 17.74, df = 7 (p = 0.01); I 2 = 61%
Test for overall effect: z = 1.93 (p = 0.05)
Test for subgroup differences: χ2 = 5.71, df = 4 (p = 0.22); I 2 = 29.9%
1168 1177 100.0 – 0.17 (– 0.35 to 0.00)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
0.0048
 
0.0464
– 0.3325
– 0.2384
 
– 0.754
– 0.1228
 
0.1062
 
0.0753
0.133
0.1083
 
0.3018
0.2105
 
212
212
 
204
285
359
848
 
21
51
72
 
211
211
 
210
272
364
846
 
27
49
76
 
18.7
18.7
 
21.6
16.3
18.5
56.4
 
6.5
10.6
17.1
 
0.00 (– 0.20 to 0.21)
0.00 (– 0.20 to 0.21)
 
0.05 (– 0.10 to 0.19)
– 0.33 (– 0.59 to – 0.07)
– 0.24 (– 0.45 to – 0.03)
– 0.16 (– 0.40 to 0.08)
 
– 0.75 (– 1.35 to – 0.16)
– 0.12 (– 0.54 to 0.29)
– 0.40 (– 1.02 to 0.21)
Education/information
Otiashvili 2012;188 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.01 (p = 0.04)
 
– 1.0459
 
0.5206
 
20
20
 
20
20
 
2.7
2.7
 
– 1.05 (– 2.07 to – 0.03)
– 1.05 (– 2.07 to – 0.03)
FIGURE 9 Efficacy of psychosocial interventions vs. control interventions in reducing frequency of injecting among
PWID by control intervention. df, degrees of freedom; IV, inverse variance; SE, standard error.
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education/information (SMD 0.03, 95% CI –0.18 to 0.24; p = 0.79; one trial70), interventions of a lesser
time or intensity with OST (SMD –0.13, 95% CI –1.21 to 0.94, I2 = 70%; p = 0.81) and HIV infection
testing and counselling (SMD 0.14, 95% CI –0.81 to 1.09; p = 0.77; one trial82). (Figure 13) Where
outcomes were compared ≤ 3 and 4–6 months post intervention, psychosocial interventions reduced
unprotected sex compared with interventions of a lesser time or intensity (without OST). Where outcomes
were assessed ≥ 9 months post intervention, psychosocial interventions reduced unprotected sex compared
with interventions of a lesser time or intensity (with OST) (Figure 14).
Study or subgroup
Usual care 4 – 6 months
Booth 2011;68 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.05 (p = 0.96)
Education/information 6 months
Otiashvili 2012;188 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.01 (p = 0.04)
HIV testing and counselling ≤ 3 months
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Rotheram 2010;193 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 8.47, df = 2 (p = 0.01); I 2 = 76%
Test for overall effect: z = 1.28 (p = 0.20)
Intervention lesser frequency or intensity without OST 4 – 6 months
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.50 (p = 0.01)
– 0 .754 0.3018 21
21
 
– 0.75 (– 1.35 to – 0.16)
– 0.75 (– 1.35 to – 0.16)
27
27
2.6
2.6
Intervention lesser frequency or intensity with OST ≤ 3 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.26 (p = 0.80)
0 .0921 0.3564 16
16
 
0.09 (– 0.61 to 0.79)
0.09 (– 0.61 to 0.79)
24
24
2.0
2.0
Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 34.68, df = 13 (p = 0.0009); I 2 = 63%
Test for overall effect: z = 2.86 (p = 0.004)
Test for subgroup differences: χ2 = 9.51, df = 7 (p = 0.22); I 2 = 26.4%
2864 2869 100.0 – 0.16 (– 0.26 to – 0.05)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
0.0048
 
– 1.0459
 
0.0464
– 0.3325
– 0.2384
 
0.1062
 
0.5206
 
0.0753
0.133
0.1083
 
212
212
 
20
20
 
204
285
359
848
 
211
211
 
20
20
 
210
272
364
846
 
8.9
8.9
 
1.0
1.0
 
10.7
7.5
8.8
27.0
 
0.00 (– 0.20 to 0.21)
0.00 (– 0.20 to 0.21)
 
– 1.05 (– 2.07 to – 0.03)
– 1.05 (– 2.07 to – 0.03)
 
0.05 (– 0.10 to 0.19)
– 0.33 (– 0.59 to – 0.07)
– 0.24 (– 0.45 to – 0.03)
– 0.16 (– 0.40 to 0.08)
HIV testing and counselling ≥ 9 months
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Rotheram 2010;193 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 8.47, df = 2 (p = 0.01); I 2 = 76%
Test for overall effect: z = 1.28 (p = 0.20)
 
0.0464
– 0.3325
– 0.2384
 
0.0753
0.133
0.1083
 
204
285
359
848
 
210
272
364
846
 
10.7
7.5
8.8
27.0
 
0.05 (– 0.10 to 0.19)
– 0.33 (– 0.59 to – 0.07)
– 0.24 (– 0.45 to – 0.03)
– 0.16 (– 0.40 to 0.08)
HIV testing and counselling 4 – 6 months
Latkin 2009;69 ≥ 9 months
Robles 2004;192 4 – 6 months
Rotheram 2010;193 4 – 6 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 8.47, df = 2 (p = 0.01); I 2 = 76%
Test for overall effect: z = 1.28 (p = 0.20)
 
0.0464
– 0.3325
– 0.2384
 
0.0753
0.133
0.1083
 
204
285
359
848
 
210
272
364
846
 
10.7
7.5
8.8
27.0
 
0.05 (– 0.10 to 0.19)
– 0.33 (– 0.59 to – 0.07)
– 0.24 (– 0.45 to – 0.03)
– 0.16 (– 0.40 to 0.08)
Intervention lesser frequency or intensity without OST ≤ 3 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.58 (p = 0.56)
 
– 0.1228
 
0.2105
 
51
51
 
49
49
 
4.5
4.5
 
– 0.12 (– 0.54 to 0.29)
– 0.12 (– 0.54 to 0.29)
FIGURE 10 Efficacy of psychosocial interventions vs. control interventions in reducing frequency of injecting among
PWID by control intervention and length of follow-up post intervention. df, degrees of freedom; IV, inverse
variance; SE, standard error.
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Number of sexual partners
Two trials76,81 assessed the number of sexual partners (Figure 15). A total of 135 PWID were included in
the intervention group and 140 in the control group. There was no difference between psychosocial
interventions and education/information in reducing the number of sexual partners (SMD 0.01, 95% CI
–0.14 to 0.17; p = 0.89; one trial76). Interventions of a lesser time or intensity (without OST) reduced the
number of sexual partners compared with psychosocial interventions (SMD 3.24, 95% CI 2.36 to 4.12;
p < 0.01; one trial81).
Discussion
The aim of the review and meta-analysis was to identify and evaluate the impact of psychosocial
interventions which were designed to reduce injecting risk and sexual risk behaviours among PWID. A total
of 24 trials were included in the analysis. Overall, psychosocial interventions reduced some of the target
injecting (sharing of needle and syringes and other injecting equipment) and sexual risk behaviour
(unprotected sex) outcomes among PWID when compared with control conditions. More specifically, the
meta-analysis found that psychosocial interventions reduced the sharing of needles and syringes compared
with education/information or HIV infection testing and counselling, reduced the sharing of other injecting
equipment compared with interventions of a lesser time or intensity, reduced the frequency of injecting
compared with one trial of education/information, and reduced unprotected sex compared with
interventions of a lesser time or intensity. Although psychosocial interventions targeted injecting risk
behaviours rather than a reduction in injecting behaviour per se, one trial188 reported that a significant
effect (p = 0.05) was found with regard to reduced frequency of injecting. Psychosocial interventions were
no more likely than control interventions to reduce the number of sexual partners. However, only two
trials76,81 were pooled in this specific meta-analysis, and many participants reported being in a steady
relationship. Interestingly, they also reported a reduction in unprotected sex, a factor which may be more
important in reducing BBV transmission than the number of sex partners.76,81
Study or subgroup
Education/information
Tobin 2011;76 ≥ 9 months
Tucker 2004;197 ≤ 3 months
Zule 2009;70 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 3.02, df = 2 (p = 0.22); I 2 = 34%
Test for overall effect: z = 1.10 (p = 0.27)
HIV testing and counselling
Go 2015;82 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.29 (p = 0.77)
Intervention lesser frequency or intensity without OST
Abou-Saleh 2008;173 4 – 6 months
Gilbert 2010;73 ≤ 3 months
Purcell 2007;190 ≥ 9 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.13; χ2 = 13.91, df = 3 (p = 0.003); I 2 = 78%
Test for overall effect: z = 1.26 (p = 0.21)
Intervention lesser frequency or intensity with OST
Margolin 2003;186 ≥ 9 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.58; χ2 = 3.55, df = 1 (p = 0.06); I 2 = 72%
Test for overall effect: z = 0.27 (p = 0.79)
– 0.7554
0.5136
0.4044
0.539
45
16
61
 
– 0.76 (– 1.55 to 0.04)
0.51 (– 0.54 to 1.57)
– 0.17 (– 1.41 to 1.07)
45
24
69
4.9
3.1
8.0
Total (95% CI)
Heterogeneity: τ2 = 0.05; χ2 = 21.61, df = 9 (p = 0.01); I 2 = 58%
Test for overall effect: z = 1.84 (p = 0.07)
Test for subgroup differences: χ2 = 0.73, df = 3 (p = 0.87); I 2 = 0%
1359 1409 100.0 – 0.19 (– 0.39 to 0.01)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
– 0.2909
– 0.2084
0.028
 
0.1421
 
0.19
– 0.6223
0.0059
– 0.6788
 
0.1724
0.181
0.1061
 
0.4853
 
0.2289
0.2292
0.1234
0.2165
 
114
73
423
610
 
68
68
 
43
40
486
51
620
 
113
72
428
613
 
106
106
 
52
40
480
49
621
 
12.9
12.4
16.6
41.9
 
3.7
3.7
 
10.1
10.1
15.6
10.7
46.4
 
– 0.29 (– 0.63 to 0.05)
– 0.21 (– 0.56 to 0.15)
0.03 (– 0.18 to 0.24)
– 0.12 (– 0.32 to 0.09)
 
– 0.14 (– 0.81 to 1.09)
– 0.14 (– 0.81 to 1.09)
 
0.19 (– 0.26 to 0.64)
– 0.62 (– 1.07 to – 0.17)
0.01 (– 0.24 to 0.25)
– 0.68 (– 1.10 to – 0.25)
– 0.26 (– 0.67 to 0.15)
FIGURE 11 Efficacy of psychosocial interventions vs. control interventions in reducing ANY sexual risk behaviours
among PWID by control intervention. IV, inverse variance.
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Individual, group and couple psychosocial interventions, but not mixed (individual + group session) interventions,
reduced any injecting risk behaviour compared with control interventions. Psychosocial interventions of three
sessions or more are more likely to reduce injecting risk behaviours, and psychosocial interventions of one or two
sessions are more likely to reduce sexual risk behaviours. The meta-analyses using data on outcomes collected at
≥ 9 months post intervention found that psychosocial interventions produced more reported behaviour change
than controls, suggesting that booster sessions may be required to sustain positive behaviour change.200
One study found reported that intervention effects were stronger for those who had known their
HCV-positive status for at least 6 months than for those who had known their HCV-positive status for
> 12 months,182 suggesting that there may be a window of opportunity following HCV diagnosis to
address transmission risks.
Study or subgroup
Education/information ≤ 3 months
Tucker 2004;197 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.15 (p = 0.25)
Education/information ≥ 9 months
Tobin 2011;76 ≥ 9 months
Zule 2009;70 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 2.48, df = 1 (p = 0.12); I 2 = 60%
Test for overall effect: z = 0.65 (p = 0.51)
HIV testing and counselling ≥ 9 months
Go 2015;82 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.29 (p = 0.77)
Intervention lesser frequency or intensity without OST 6 months
Abou-Saleh 2008;173 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.83 (p = 0.41)
0 .19 0.2289 43
43
 
0.19 (– 0.26 to 0.64)
0.19 (– 0.26 to 0.64)
52
52
10.1
10.1
Intervention lesser frequency or intensity without OST ≥ 9 months
Purcell 2007;190 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.05 (p = 0.96)
0 .0059 0.1234 486
486
 
0.01 (– 0.24 to 0.25)
0.01 (– 0.24 to 0.25)
480
480
15.6
15.6
Intervention lesser frequency or intensity with OST ≤ 3 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.95 (p = 0.34)
Intervention lesser frequency or intensity with OST ≥ 9 months
Margolin 2003;186 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.87 (p = 0.06)
– 0 .7554 0.4044 45
45
 
– 0.76 (– 1.55 to 0.04)
– 0.76 (– 1.55 to 0.04)
45
45
4.9
4.9
0 .5136 0.539 16
16
 
0.51 (– 0.54 to 1.57)
0.51 (– 0.54 to 1.57)
24
24
3.1
3.1
Total (95% CI)
Heterogeneity: τ2 = 0.05; χ2 = 21.61, df = 9 (p = 0.01); I 2 = 58%
Test for overall effect: z = 1.84 (p = 0.07)
Test for subgroup differences: χ2 = 18.24, df = 7 (p = 0.01); I 2 = 61.6%
1359 1409 100.0 – 0.19 (– 0.39 to 0.01)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
– 0.2084
 
– 0.2909
0.028
 
0.1421
 
0.181
 
0.1724
0.1061
 
0.4853
 
73
73
 
114
423
537
 
68
68
 
72
72
 
113
428
541
 
106
106
 
12.4
12.4
 
12.9
16.6
29.4
 
3.7
3.7
 
– 0.21 (– 0.56 to 0.15)
– 0.21 (– 0.56 to 0.15)
 
– 0.29 (– 0.63 to 0.05)
0.03 (– 0.18 to 0.24)
– 0.10 (– 0.41 to 0.20)
 
0.14 (– 0.81 to 1.09)
0.14 (– 0.81 to 1.09)
Intervention lesser frequency or intensity without OST ≤ 3 months
Gilbert 2010;73 ≤ 3 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.03, df = 1 (p = 0.86); I 2 = 0%
Test for overall effect: z = 4.14 (p < 0.0001)
 
– 0.6223
– 0.6788
 
0.2292
0.2165
 
40
51
91
 
40
49
89
 
10.1
10.7
20.7
 
– 0.62 (– 1.07 to – 0.17)
– 0.68 (– 1.10 to – 0.25)
– 0.65 (– 0.96 to – 0.34)
FIGURE 12 Efficacy of psychosocial interventions vs. control interventions in reducing ANY sexual risk behaviours
among PWID by control intervention and length of follow-up post intervention. IV, inverse variance.
DETERMINING THE EVIDENCE BASE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Study or subgroup
Education/information
Zule 2009;
70
 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.26 (p = 0.79)
HIV testing and counselling
Go 2015;
82
 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.29 (p = 0.77)
Intervention lesser frequency or intensity without OST
Gilbert 2010;
73
 ≤ 3 months
Samet 2015;
194
 ≥ 9 months
Sterk 2003;
81
 4 – 6 months
Wechsberg 2012;
75
 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.14; χ2 = 14.29, df = 3 (p = 0.003); I 2 = 79%
Test for overall effect: z = 2.02 (p = 0.04)
Intervention lesser frequency or intensity with OST
Margolin 2003:
186
 ≥ 9 months
Schroeder 2006;
71
 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.43; χ2 = 3.29, df = 1 (p = 0.07); I 2 = 70%
Test for overall effect: z = 0.25 (p = 0.81)
– 0.5988
0.5136
0.2919
0.539
45
16
61
 
– 0.60 (– 1.17 to – 0.03)
0.51 (– 0.54 to 1.57)
– 0.13 (– 1.21 to 0.94)
45
24
69
11.0
4.9
15.9
Total (95% CI)
Heterogeneity: τ2 = 0.08; χ2 = 21.96, df = 7 (p = 0.003); I 2 = 68%
Test for overall effect: z = 2.02 (p = 0.04)
Test for subgroup differences: χ2 = 3.93, df = 3 (p = 0.27); I 2 = 23.7%
876 930 100.0 – 0.27 (– 0.54 to – 0.01)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
0.028
 
0.1421
 
– 0.6223
0.0077
– 0.6053
– 0.6788
 
0.1061
 
0.4853
 
0.2292
0.1014
0.298
0.2165
 
423
423
 
68
68
 
40
212
21
51
324
 
428
428
 
106
106
 
40
211
27
49
327
 
19.8
19.8
 
5.8
5.8
 
13.6
20.0
10.7
14.3
58.6
 
– 0.03 (– 0.18 to 0.24)
– 0.03 (– 0.18 to 0.24)
 
– 0.14 (– 0.81 to 1.09)
– 0.14 (– 0.81 to 1.09)
 
– 0.62 (– 1.07 to – 0.17)
0.01 (– 0.19 to 0.21)
– 0.61 (– 1.19 to – 0.02)
– 0.68 (– 1.10 to – 0.25)
– 0.44 (– 0.86 to – 0.01)
FIGURE 13 Efficacy of psychosocial interventions vs. control interventions in reducing unprotected sex among PWID
by control intervention. IV, inverse variance.
Study or subgroup
Education/information ≥ 9 months
Zule 2009;70 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.26 (p = 0.79)
HIV testing and counselling ≥ 9 months
Go 2015;82 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.29 (p = 0.77)
Intervention lesser frequency or intensity without OST ≤ 3 months
Gilbert 2010;73 ≤ 3 months
Wechsberg 2012;75 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.03, df = 1 (p = 0.86); I 2 = 0%
Test for overall effect: z = 4.14 (p < 0.0001)
Intervention lesser frequency or intensity without OST 6 months
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.03 (p = 0.04)
– 0 .6053 0.298 21
21
 
– 0.61 (– 1.19 to – 0.02)
– 0.61 (– 1.19 to – 0.02)
27
27
10.7
10.7
Intervention lesser frequency or intensity without OST ≥ 9 months
Samet 2015;194 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.08 (p = 0.94)
0 .0077 0.1014 212
212
 
0.01 (– 0.19 to 0.21)
0.01 (– 0.19 to 0.21)
211
211
20.0
20.0
Intervention lesser frequency or intensity with OST ≤ 3 months
Schroeder 2006;71 ≤ 3 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.95 (p = 0.34)
Intervention lesser frequency or intensity with OST ≥ 9 months
Margolin 2003;186 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.05 (p = 0.04)
– 0 .5988 0.2919 45
45
 
– 0.60 (– 1.17 to – 0.03)
– 0.60 (– 1.17 to – 0.03)
45
45
11.0
11.0
0 .5136 0.539 16
16
 
0.51 (– 0.54 to 1.57)
0.51 (– 0.54 to 1.57)
24
24
4.9
4.9
Total (95% CI)
Heterogeneity: τ2 = 0.08; χ2 = 21.96, df = 7 (p = 0.003); I 2 = 68%
Test for overall effect: z = 2.02 (p = 0.04)
Test for subgroup differences: χ2 = 21.93, df = 6 (p = 0.001); I 2 = 72.6%
876 930 100.0 – 0.27 (– 0.54 to – 0.01)
SMD SE Total Total
Intervention Comparator
Weight (%)
SMD
IV, random, 95% CI
SMD
IV, random, 95% CI
– 2 – 1 0 1 2
Favours intervention Favours comparator
 
0.028
 
0.1421
 
– 0.6223
– 0.6788
 
0.1061
 
0.4853
 
0.2292
0.2165
 
423
423
 
68
68
 
40
51
91
 
428
428
 
106
106
 
40
49
89
 
19.8
19.8
 
5.8
5.8
 
13.6
14.3
27.9
 
0.03 (– 0.18 to 0.24)
0.03 (– 0.18 to 0.24)
 
0.14 (– 0.81 to 1.09)
0.14 (– 0.81 to 1.09)
 
– 0.62 (– 1.07 to – 0.17)
– 0.68 (– 1.10 to – 0.25)
– 0.65 (– 0.96 to – 0.34)
FIGURE 14 Efficacy of psychosocial interventions vs. control interventions in reducing unprotected sex among PWID
by control intervention and length of follow-up post intervention. IV, inverse variance.
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SMD
IV, fixed, 95% CI
– 4 – 2 0 2 4
SMD
IV, fixed, 95% CISMDStudy or subgroup
Education/information ≥ 9 months
Intervention lesser frequency or intensity without OST 4 – 6 months
SE Total Total
Intervention Comparator
Weight (%)
97.0
97.0
3.0
3.0
100.0
0.01 (– 0.14 to 0.17)
0.01 (– 0.14 to 0.17)
3.24 (2.36 to 4.12)
3.24 (2.36 to 4.12)
0.11 (– 0.05 to 0.26)
113
113
27
27
140
114
114
21
21
0.079
0.4514
0.0109
3.2398
Tobin 2011;76 ≥ 9 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.14 (p = 0.89)
Sterk 2003;81 4 – 6 months
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 7.18 (p < 0.00001)
Total (95% CI)
Heterogeneity: χ2 = 49.65, df = 1 (p < 0.00001); I2 = 98%
Test for overall effect: z = 1.37 (p = 0.17)
Test for subgroup differences: χ2 = 49.65, df = 1 (p < 0.00001), I2 = 98.0%
135
Favours intervention Favours comparator
FIGURE 15 Efficacy of psychosocial interventions vs. control interventions in reducing number of sexual partners among PWID by control condition and length of follow-up
post intervention. IV, inverse variance.
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Overall and regardless of intervention or control content, 16 of the 32 trials included in the systematic
review reported greater reductions in injecting or sexual risk behaviours in participants in the intervention
compared with the control groups.72,73,75–77,81,84,174,177–179,182,186,188,192,193 Only two trials71,188 in the review (with
small sample sizes) included CM (incentivisation). One of these trials reported that reductions in injecting
risk behaviours were greater in the intervention group [22 sessions of MI for the male participant and
couple (female partner drug free), plus CM and naltrexone] than in the control group (22 sessions of
education, including referrals to a detoxification programme and aftercare that may or may not have
included naltrexone).188 The other reported no significant difference in injecting or sexual risk behaviours
between the intervention [29-week intervention including 12 weeks of CBT and contingent vouchers as
well as standard care (methadone + 5-weekly individual counselling), followed by 12 weeks of standard
treatment] and the control groups [29-week standard care intervention (same as intervention group),
including 12 weeks of group therapy and non-contingent vouchers]71 (see Table 2). However, only
three77,178,186 of the seven trials69,70,77,175,178,186,196 of psychosocial interventions including MI found greater
reductions in some injecting and sexual risk behaviours. As these three interventions varied in content
and participant group [e.g. one interactive session for female sex workers,77 computerised intervention
(69% male),178 and PWID entering OST (70% male)],186 results about the effectiveness of specific intervention
functions (e.g. incentivisation or persuasion) in reducing BBV risk behaviours among PWID are inconclusive.
Limitations
Limitations include the small number of studies for inclusion in some of the subgroup analyses of
behavioural outcomes and intervention delivery modes. In addition, there was heterogeneity in terms of the
interventions studied and their duration, as well as differences in sample sizes and characteristics, length of
follow-up and assessment methods used to determine risk behaviours. This lack of consistency across studies
may have contributed to the moderate levels of heterogeneity noted in the meta-analyses. The most
common risk of bias in included RCTs was selective outcome reporting and possible crossover contamination
between groups. A further limitation is that authors of the eight trials not included in the meta-analysis were
not contacted to determine whether or not they could supply the additional data required to include the
trial in the meta-analysis. It is acknowledged that this could have resulted in a potential source of bias in the
findings. These limitations need to be considered when interpreting the results.
Conclusions
Although indications from the meta-analysis suggest that psychosocial interventions (when compared with
control) reduce risk-taking behaviour outcomes, more research is needed. The findings highlight the difficulty
and complexity involved in attempting to examine the effectiveness of interventions that include different
content and functions, modes of delivery, dosage and number of sessions. This heterogeneity in both the
control and intervention conditions resulted in challenges to fully interpret the findings. It will be important
to determine what types of psychosocial interventions work for whom and in what settings.56 Our findings
suggest that psychosocial interventions could boost the impact of current harm reduction interventions
delivered as routine care and could be included with other harm reduction approaches, including OST and
needle and syringe exchange, to reduce BBV transmission risks among PWID. Further trials should address
some of the limitations in terms of target populations, dose and frequency and timing of outcome measures.
Scoping review of grey literature
Methods
A scoping review of UK grey literature was conducted during April 2015 to determine if any unpublished
evidence on the efficacy of psychosocial interventions was available that had not been identified through
the systematic review. Thirty-one databases were searched to identify psychosocial interventions to reduce
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injecting and sexual risk behaviours among PWID in the UK (Table 3). A combination of the following
search terms were used to search for relevant interventions:
l UK/England/Scotland/Wales/Ireland
l Intervention/behavio*r/motivational counselling
l Inject*/intravenous
l Drug*/opiate/heroin/crack/cocaine
l Blood borne virus/hepatitis/HIV.
In addition, 64 academics/BBV experts identified by the Steering Group were sent requests for information
on unpublished research in the UK that had taken place or that was ongoing on psychosocial interventions
to reduce injecting and sexual risk behaviours associated with the transmission of BBV among PWID.
TABLE 3 Databases, search engines and websites
Databases, search engines and websites Records (UK)
Grey literature sites
Open Grey 0
CADTH Grey Matters 0
NYAM Grey Lit 0
Clinical trials
UK Health Forum 0
UKCRN 0
EUCTR 0
Healthcare Improvement Scotland 0
NIHR Horizon Scanning Centre (via CADTH) 0
NIHR HTA programme 0
NIHR Evaluation, Trials and Studies 0
SIGN 0
MRC CTU 0
ClinicalTrials.gov 0
Theses and dissertations
EThOs 0
ProQuest Dissertations and Theses 0
OATD 0
OpenThesis 0
BBV organisations
Hepatitis Scotland 0
British Liver Trust 0
Hepatitis C Trust 2
DETERMINING THE EVIDENCE BASE
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Results
The search provided no UK-based reports, papers or study protocols (in progress or completed) directly
related to psychosocial interventions aimed at preventing or reducing BBV transmission risk behaviours
among PWID and delivered in the UK, although three evaluations of two peer-to-peer projects (in Scotland
and Liverpool) were found (see Table 3).
During a grey literature search for UK-based interventions, a number of international manuals were found
(Table 4).
TABLE 3 Databases, search engines and websites (continued )
Databases, search engines and websites Records (UK)
Waverley Care 0
Hep C Positive 0
NHS Hepatitis C Resource Centre 0
Hepatitis C UK Forum 0
Positive Help 0
Lanarkshire HIV & Hepatitis 0
British HIV Association 0
Terrence Higgins Trust 0
C-Clear Peer Education Project Fife 0
Other
Health Scotland 1
Drug and Alcohol Findings 0
Web of Science 0
Social Care Institute for Excellence 0
EMCDDA 0
BioMed Central 1
PLOS 0
SSRN 0
The British Library 0
Search engines
Bing (Microsoft Corporation, Redmond, WA, USA) 0
Yahoo! (Verizon Communications, Sunnyvale, CA, USA) 0
Google Scholar (Google Inc., Mountain View, CA, USA) 0
CADTH, Canadian Agency for Drugs and Technologies in Health; EMCDDA, European Monitoring Centre for Drugs and
Drug Addiction; EThOs, Electronic Theses Online Service; EUCTR, EU Clinical Trials Register; MRC CTU, Medical Research
Council Clinical Trials Unit; NIHR, National Institute for Health Research; NYAM, New York Academy of Medicine;
OATD, Open Access Theses and Dissertations; PLOS, Public Library of Science; SIGN, Scottish Intercollegiate Guidelines
Network; SSRN, Social Science Research Network; UKCRN, UK Clinical Research Network.
Note
Other manuals identified from grey literature review outwith the UK.
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TABLE 4 International manuals with potential utility in BBV intervention design
Manual Outline Criteriaa Rankingb Origin
Evidence
based/evaluated
REDUCE: Reducing Hepatitis C Risk
Behaviours Among Female Drug Users in
Europe201
Three-session group intervention for females who
inject drugs:
1. understanding HCV transmission risks
2. HCV and sexual well-being: negotiating safety
3. HCV and emotional well-being: reducing
negative mood
BBV (hepatitis/HIV); psychosocial
intervention; risk behaviours
(injecting/sexual); PWID;
instructions
High European Yes/yes
Training Guide for HIV Prevention Outreach
to Injecting Drug Users202
A package designed to aid the set-up of workshops
designed to familiarise and train public health policy-
makers, programme developers, programme managers,
implementers and field workers in outreach to injecting
drug users. It includes four workshop modules in a set
order to enable the training of a wide range of
participants, with varying training needs:
1. orientation workshop
2. programme development workshop
3. programme management workshop
4. field worker training
BBV (hepatitis/HIV); risk
behaviours (injecting/sexual);
PWID; instructions. (Requires
CD-ROM for use with manual)
High WHO Yes/?
The NIDA Community-Based Outreach
Model: A Manual to Reduce the Risk of
HIV and Other Blood-Borne infections in
Drug Users203
A manual containing information to assist community
planners, policy-makers, programmers and service
providers with developing and implementing programmes
to better prevent the spread of HIV and other blood-borne
infections. Specifically, the manual provides:
l research-based principles of HIV prevention for
drug using
l populations not in drug treatment
l background information on community-based HIV
prevention, including how it works, why it works,
where it works, and for whom it works
l a discussion of the roles and personal characteristics
of effective community-based outreach workers
l step-by-step instructions for conducting community-
based outreach and risk reduction
l counselling sessions for out-of-treatment drug users
and their sex partners
BBV (hepatitis/HIV); psychosocial
intervention; risk behaviours
(injecting/sexual); PWID;
instructions
High USA Yes/yes
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Manual Outline Criteriaa Rankingb Origin
Evidence
based/evaluated
l information for programme managers on how to
establish a community-based outreach HIV/AIDS risk
reduction prevention programme locally, establish a
field station and provide training and supervision
to staff
l cue cards to be used or adapted during educational
and risk reduction counselling sessions
UFO Model Replication Manual: A Hep C
Intervention for Young Adult IDU204
The UFO model provides a 4-week education and
support group for young adult IDUs who are at risk of
or infected with HCV. These 1-hour group sessions
takes place once a week for 4 consecutive weeks at a
convenient time for participants. Ideally, the group
should be offered on a regular basis, perhaps running
the group three or four times per year. Participants may
complete all sessions in one group, or may make up
missed sessions during the next scheduled group.
Participants are not required to complete all sessions,
and may wish to return to certain sessions for boosters:
l session 1: hepatitis ABCs
l session 2: keeping you and your friends healthy –
how to decrease HCV transmission risk
l session 3: body and mind – how drugs, alcohol and
HCV affect your physical and mental health
l session 4: relationships and risk
l add-on session: HCV treatment 101
BBV (hepatitis/HIV); psychosocial
intervention; risk behaviours
(injecting/sexual); PWID;
instructions
High USA Yes/?
REMAS: A Gender-Focused HIV & Sexual Risk
Reduction Intervention for Men in Substance
Abuse Treatment205
Developed by the National Drug Abuse Treatment
Clinical Trials Network Gender Specific HIV Prevention
Intervention Protocol Development Team and used by
male counsellors delivering the REMAS intervention to
substance abuse treatment clients enrolled in protocol
CTN-0018, ‘Reducing HIV/STD Risk Behaviours: A
Research Study for Men in Drug Abuse Treatment’. It is
a five-session group-delivered intervention package
designed to help clients in substance abuse treatment
reduce their HIV risk [www.ctndisseminationlibrary.org/
protocols/ctn0018.htm (accessed 10 October 2017)]
BBV (HIV); psychosocial
intervention; risk behaviours
(injecting/sexual); MWID;
instructions
High USA Yes/yes
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TABLE 4 International manuals with potential utility in BBV intervention design (continued )
Manual Outline Criteriaa Rankingb Origin
Evidence
based/evaluated
Safety Counts Program Manual: A
Cognitive–Behavioural Intervention to Reduce
HIV/Hepatitis Risks Among Drug Users Who
Are Not in Drug Treatment206
The Safety Counts intervention comprises nine sessions
focusing on developing and implementing a
personalised risk reduction plan. First, two individual
standard pre- and post-test counselling sessions
incorporate drug-focused prevention education to
review basic HIV/AIDS information and provide optional
HIV infection testing and counselling. Next, two
interactive group workshop sessions, employing stages
of change framework, are implemented with structured
exercises involving three to seven clients to help them
develop a personal HIV risk reduction plan, consider
potential barriers and solutions, identify sources of social
support through group discussion, view role model
videos and complete two worksheet exercises to identify
their own HIV risks and place themselves in on a stages-
of-change continuum for each risk behaviour. Then a
one-on-one individual counselling session is conducted
to refine the client’s personal risk reduction plan,
strengthen commitment to personal goals, ensure
availability of social support for risk reduction, and
assess and arrange referral needs. One month after
the client receives the individual counselling session,
a minimum of two 15- to 20-minute field-based
supportive follow-up outreach contacts are scheduled to
reinforce progress towards risk reduction and encourage
achievement and maintenance of personal risk reduction
goals. Also, a minimum of two monthly social events,
each lasting 2 hours, are provided, including lunch and
planned HIV risk reduction activities, games and skits for
clients and their peer-support buddies (15–25 clients
and 10–15 guests), to provide support for HIV risk
reduction, influence perceived social norms and increase
self-efficacy for reducing HIV risks. Finally, food bank
grocery bags and food coupons are made available to
clients in storefront offices as a programme incentive
every other week
BBV (hepatitis/HIV); psychosocial
intervention; risk behaviours
(injecting/sexual); MWID;
instructions
High USA Yes/yes
IDU, injection drug user; MWID, men who inject drugs; REMAS, REal Men Are Safe; WHO, World Health Organization.
a Inclusion criteria: BBV (hepatitis/HIV); psychosocial intervention (e.g. MI, CBT, peer led); risk behaviours considered (injecting/sexual); PWID; instructions to facilitators.
b Ranking criteria: high, all criteria included; moderate, no instructions but includes psychosocial intervention for BBV risk reduction and includes evidence and references; low, no
instructions, no psychosocial intervention for BBV risk reduction/no evidence and references.
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Experts
Sixty-one per cent (39/64) of the academics/experts responded to the request for information about
psychosocial interventions to reduce BBV transmission behaviours among PWID. A contact at the National
Needle Exchange Forum (NNEF) cascaded the request to their membership via Facebook (Facebook, Inc.,
Menlo Park, CA, USA) and e-mail; however, no further responses were gathered from NNEF members.
Two respondents provided relevant information:
1. Dr Magdalena Harris from the London School of Hygiene & Tropical Medicine shared publications,
presentations and resources from three research studies:
i. Staying Safe: A Sociology of How People Who Inject Drugs Avoid Hepatitis C in the Long Term
[funded by the Economic and Social Research Council; RES-062-23-1766; www.youtube.com/watch?
v%20=%20PsWn0_gOT4Q (YouTube, LLC, San Bruno, CA, USA; accessed 10 October 2017)]207
ii. The Hepatitis C Treatment Journey: A Prospective Qualitative Longitudinal Study Addressing
Patient, Provider and System Perspectives (funded by National Institute for Health Research,
PDF-2011-04-031)208
iii. HCV Treatment: Barriers and Facilitators to Hepatitis C Treatment For People Who Inject Drugs (the
European Commission Directorate of Health and Consumers and the World Health Organization’s
Regional Office for Europe; Grant Agreement 2008 52 02 work package 4).209
These projects further highlighted the need among PWID for information about HCV prevention,
transmission, diagnosis, testing, treatment, symptoms and natural history. Findings from Staying Safe
determined the protective networks and environments for PWID and concluded that addressing
pragmatic short-term meaningful goals for PWID could result in harm reduction (e.g. image management,
venous access and care). Findings from this research were used to inform the intervention development
and Dr Harris became a member of the PROTECT intervention development group. The following
manuscripts were downloaded to inform intervention development from these studies: Harris and
Rhodes,45,210,211 Harris et al.50,212,213 and McGowan et al.51
2. Alexis Llewellyn from the Centre for Reviews and Dissemination, University of York, provided a draft
Cochrane review paper entitled ‘Multi-Session and Brief Psychosocial Interventions For Preventing HIV in
People Who Use Drugs’.
Further information was provided by five respondents, although none directly related to psychosocial
interventions.
Drug and alcohol commissioning mapping exercise
Aim
To survey all agencies responsible for alcohol and drug commissioning in the UK for information on
psychosocial interventions available and their effectiveness in reducing BBV risk behaviours among PWID.
Methods
A brief survey was sent by e-mail to all agencies responsible for alcohol and drug commissioning in the UK
(i.e. alcohol and drug commissioners in England, alcohol and drug partnerships in Scotland, health- and
social-care trusts in Northern Ireland and substance misuse area planning boards in Wales). The survey
was sent up to three times during January and February 2015, 1 week apart, to maximise response
rates. Where contacts were out of date, telephone contact was made in an attempt to update the
contact details.
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Results
Surveys were emailed to 164 alcohol and drug commissioners in England from 150 commissioning teams.
In Scotland, surveys were sent to 30 alcohol and drug partnerships. In Northern Ireland, surveys were sent
to five health- and social-care trusts and, in Wales, surveys were sent to seven substance misuse area
planning boards. In England, 93 surveys from 84 alcohol and drug commissioners were returned (84/150,
56%). In total, 26 surveys from 21 alcohol and drug partnerships in Scotland were returned (21/30, 70%).
Two of the five health- and social-care trusts in Northern Ireland responded to the survey (2/5, 40%). In
Wales, seven surveys were returned from five substance misuse area planning boards (5/7, 71.4%).
Table 5 describes the proportion of alcohol and drug commissioners by country that reported providing
psychosocial interventions to PWID to reduce BBV risk behaviours. The most common psychosocial
interventions used were CBT, coping skills training, relapse prevention training and MI/enhancement therapy.
If alcohol and drug commissioners reported providing any psychosocial interventions, they were asked
whether or not it was evidence based (Table 6) and available as a manual or in written form (Table 7).
A review of the manuals/written materials identified suggested that no UK areas were currently delivering
interventions (group or individual) that focused exclusively on BBV and injecting/sexual risk behaviours,
although the interventions that were delivered could include discussion of BBV transmission risks and
prevention within the wider context of substance use reduction or abstinence. The majority of
interventions were delivered on a one-to-one basis by a key worker to a client. Group work primarily
involved family members/significant others. Several areas had adapted toolkits from other instruments.
TABLE 5 Psychosocial interventions provided to reduce BBV risk behaviours in the UK
Psychosocial intervention
Location in the UK (%)
England (n= 93) Scotland (n= 26)
Northern Ireland
(n= 2) Wales (n= 7)
CBT 82.8 53.8 50 71.4
Coping skills training 66.7 76.9 100 71.4
Behavioural self-control training 39.8 23.1 50 42.9
Relapse prevention therapy 87.1 73.1 100 85.7
MI/motivational enhancement therapy 95.7 96.2 100 85.7
Contingency management 53.8 23.1 50 42.9
Some family approaches 64.5 30.8 100 28.6
Psychoeducation 57.0 69.2 100 57.1
Behavioural couples therapy 31.2 65.4 50 –
Social behaviour and network therapy 32.3 11.5 50 42.9
Other (please describe) 16.1a 34.6b – 14.3c
ITEP, International Treatment Effectiveness Project.
a Coaching, goal-setting, e-therapy, information, volunteering and self-help groups, structured groups (ITEP/5 Ways to
Well-being/CBT), harm minimisation, harm reduction, life skills course, mindfulness, mindfulness-based relapse
prevention, node-link mapping, peer support, pre- and post-testing support and Making Every Contact Count framework.
b Break the cycle, community reinforcement approach, cognitive–behavioural integrated therapy, complimentary therapies,
sleep hygiene, facilitate entry to mutual aid and self-help, counselling, integrated therapy, mindfulness (based)
approaches, reality therapy.
c No details provided.
DETERMINING THE EVIDENCE BASE
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TABLE 6 Evidence-based psychosocial interventions provided to reduce BBV risk behaviours
Psychosocial intervention
Not evidence
based (%)
Yes, evidence
known from
service dataa (%)
Yes, evidence known
from outcome
evaluation/triala (%)
Do not
know (%)
CBT (n= 90) 25.6 30.0 36.6 7.8
Coping skills training (n= 82) 28.0 32.9 25.6 13.4
Behavioural self-control training (n = 44) 18.2 38.6 34.1 9.1
Relapse prevention therapy (n = 100) 21.0 34.0 32.0 13.0
MI/motivational enhancement therapy
(n = 113)
24.8 29.2 34.5 11.5
Contingency management (n= 58) 20.7 37.9 36.2 5.2
Some family approaches (n= 64) 21.9 37.5 35.9 4.7
Psychoeducation (n= 70) 27.1 35.7 24.3 12.9
Behavioural couples therapy (n= 29) 24.1 31.0 41.4 3.4
Social behaviour and network therapy
(n = 36)
13.9 41.7 36.1 8.3
a If a respondent marked evidence from both service data and outcome evaluation/trial, their response was recorded as
evidence known from outcome evaluation/trial, as the weight of the evidence was considered greater if an evaluation or
trial had been conducted.
TABLE 7 Psychosocial interventions available as manuals or in written form
Psychosocial intervention Available as manual/written form (n)
CBT 38
Coping skills training 37
Behavioural self-control training 24
Relapse prevention therapy 57
MI/motivational enhancement therapy 50
Contingency management 21
Some family approaches 23
Psychoeducation 35
Behavioural couples therapy 15
Social behaviour and network therapy 19
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Figure 16 describes that, although 116 manuals/written materials (56 after duplicates removed) were
identified from the survey, only 11 were considered potentially useful to the design of a BBV risk reduction
intervention for PWID. Table 8 provides links and information to potentially useful content currently used in
the UK.
Summary
A scoping of the UK grey literature provided no UK-based reports, papers or study protocols (in progress or
completed) directly related to psychosocial interventions aimed at preventing or reducing BBV transmission
risk behaviours among PWID and delivered in the UK. An information request about psychosocial
interventions to reduce BBV transmission behaviours among PWID was sent to 64 UK academics/experts
and the information provided was used in the development of the PROTECT intervention. In addition, a
brief survey was sent by e-mail to all agencies responsible for alcohol and drug commissioning in the UK
for information on psychosocial interventions available and their effectiveness in reducing BBV risk
behaviours among PWID. A range of evidence-based psychosocial interventions were reported, with the
most commonly used being CBT, coping skills training, relapse prevention training and MI/enhancement
therapy. A review of the manuals/written materials suggested that there are currently no interventions that
focus exclusively on BBV and injecting/sexual risk behaviours, although a small proportion was considered
potentially useful to the design of the PROTECT intervention.
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Manuals after duplicates removed
(n = 56)
Manuals screened
(n = 56)
Manuals excluded
(n = 35)a
Manuals excluded
(n = 10)
• Clinical guidelines for MI,
   n = 3
• Self-help resource booklets,
   n = 3
• Resources for family members 
   of drug users, n = 2
• Clinical guidelines for alcohol
   and drug users, n = 1
• Brief intervention for
   children/young people living
   with parental substance
   use, n = 1
Manuals assessed for eligibility
(n = 21)
UK manuals included
(n = 11)
FIGURE 16 Flow diagram of drug and alcohol partnership survey. a, No BBV information or PSI included in
manuals. PSI, psychosocial intervention.
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TABLE 8 Manuals/written materials, from the UK, with potential utility in BBV intervention design
Manual Outline Criteriaa Rankingb UK areas utilised Evidence based/evaluated
Common Sense Ideas for HIV
Prevention and Sexual
Health214
Based on TCU mapping-enhanced counselling
manuals for adaptive treatment. Handouts and
activities used in the HIV/AIDS module
incorporate node-link mapping, a visual
representation system for helping clients improve
personal problem-solving and decision-making
skills. Its goal is to present workable approaches
for educating clients about HIV/AIDS and helping
them develop the skills needed for effective,
consistent reduction of HIV-risky behaviours
BBV; psychosocial
intervention; risk behaviours
(injecting/sexual); PWID;
instructions
High Torbay and Torquay Yes/yes
Routes To Recovery 1, 2, 4, 5,
6215
Routes to recovery ITEP 1 and 2: based on a
cognitive approach known as node-link
mapping. Provides a model for systematic
cause-and-effect thinking and problem-solving,
which clients can begin to adopt. Based on
cognitive therapy and MI. Parts 4, 5, 6 and 7,
‘The BTEI Manuals’, are tools for implementing
the full BTEI intervention – covering care
planning, building motivation (for individuals
and groups) and treatment exiting
Health awareness maps;
brief mention of BBV
instructions; no specific
mention of PWID, injecting/
sexual risk behaviours
Moderate Telford, Walsall, Leicester,
Shropshire, Staffordshire,
Solihull, Kensington and
Chelsea, Hammersmith
and Fulham, Enfield,
Maidenhead, Kirklees,
Bury, Gloucestershire,
Durham, Knowsley,
Cheshire and Halton
Yes/yes
Routes to Recovery Via the
Community: Mapping User
Manual216
MI and cognitive–behavioural approaches.
Node-link mapping is used as a unifying
element, presenting clinical tools in a simple to
use map format
PWID; BBV; risk behaviours;
no instructions
Moderate Middlesbrough, Walsall,
Gloucester, Kirklees and
Solihull
Yes/not known
Routes to Recovery
Psychosocial Interventions for
Drug Misuse. A Framework
and Toolkit For Implementing
NICE-Recommended
Treatment217
Framework and toolkit including: classifying
psychosocial interventions; framework for the
delivery of psychosocial interventions for drug
misuse; delivery of competence-based
psychosocial interventions for drug misuse
Mentions BBV and assessing
risk and risk behaviour CM
Moderate Grampian region and
Durham
Yes/not known
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TABLE 8 Manuals/written materials, from the UK, with potential utility in BBV intervention design (continued )
Manual Outline Criteriaa Rankingb UK areas utilised Evidence based/evaluated
Criminal Justice Drugs Brief
Intervention Tool Kit
Designed to help workers carry out a structured
6-week brief intervention following screening
using ASSIST
Includes:
l ASSIST screening tool, which gives a score
for each substance used in the last 3 months
and helps discuss substance use with a
criminal justice worker. The core tells clients
where their level of use is (low risk, moderate
risk or high risk) and what support might be
best for their level of use
l Drugs quiz: knowledge about different
substances
l Drug diary to help clients get an accurate
picture of how much they are actually using
l Making the decision to change explores
clients’ reasons for starting to use drugs
and the reasons that they use now
l To change or not to change: table to fill
which helps reach a clear decision to change
l Cues for drug use: identifies triggers and
risk factors and works towards assisting
clients with a relapse prevention plan/
trigger solution plan
l Tips for cutting down
l Keeping yourself safe: safe injecting/sex tips
l Reduce the risk of overdose
l Readiness to change questionnaire
BBV (hepatitis/HIV); risk
behaviours (injecting/sexual);
PWID; instructions
Moderate Angus Not known
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Manual Outline Criteriaa Rankingb UK areas utilised Evidence based/evaluated
Straight Ahead: Transition
Skills for Recovery218
Based on TCU mapping-enhanced counselling
manuals for adaptive treatment. A 10-part
workshop to reinforce key recovery concepts.
The module is best suited for those who are not
in deep crisis, who seem to be making progress
in recovery, and who have made optimal use of
individual and group counselling services and
other opportunities for resolving their problems
with substance use. Ideally, it can be used as an
aftercare ‘readiness’ package for helping clients
frame and focus their goals for continued
recovery and the steps needed to realise those
goals
No specific mention of
PWID, injecting/sexual risk
behaviours, BBV
Low Staffordshire, Torbay and
Torquay
Yes/not known
Tools For Change219 Self-assessment of substance and associated
problems. Workbook on decision to change and
steps
No mention of BBV, PWID,
risk behaviours; no
instructions for workers
Low Northern Ireland and
SEHT
Workbook is based on work
from the Syracuse University
and originally funded
through NIAAA grant
number 5R01AA13655 – 04
The Bouncing Back Workbook:
Building Skills That Strengthen
Resilience220
Workbook that includes:
l information on seven identified factors that
support resilience
l pillars of change: skills that build resilience –
pillar 1, believe change is possible; pillar 2,
habits can be broken: even thinking habits;
pillar 3, make a committed decision
to change
l positive steps to emotional health and
well-being
No mention of BBV, PWID,
risk behaviours
Low Northern Ireland and
SEHT
Some of the material in this
booklet has been taken from
the work of researchers
at the University of
Pennsylvania. Karen Reivich
and Andrew Shatte are
authors of The Resilience
Factor: 7 Keys to Finding
Your Inner Strength and
Overcoming Life’s Hurdles221
Drug and Alcohol Recovery
and Treatment Tool (DARTT)222
Based on Medications in Recovery
Re-Orientating Drug Dependence Treatment
[URL: www.nta.nhs.uk/uploads/medications-in-
recovery-main-report3.pdf (accessed 10 October
2017)]. Treatment within context of a behaviour
change model
Requires subscription Unable
to rank
Kensington and Chelsea
and Hammersmith and
Fulham
continued
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TABLE 8 Manuals/written materials, from the UK, with potential utility in BBV intervention design (continued )
Manual Outline Criteriaa Rankingb UK areas utilised Evidence based/evaluated
Core Behavioural and CBT
Skills for Relapse Prevention
and Recovery Management:
Facilitator Handbook and
Portfolio Exercises
Overview and step-by-step guide for core
behavioural and CBT skills for relapse
prevention and recovery management:
l motivational enhancement
l functional analysis
l relapse prevention and controlling
impulsive behaviour
l overview of reinforcement management
and recovery
l recovery management
No mention of BBV, PWID,
risk behaviours
Low Greater Glasgow and
Dumfries and Galloway
Yes/not known
Core Behavioural and CBT
Skills for Relapse Prevention
and Recovery Management:
Portfolio Exercises
Exercises cover a range of skills, which are
included in motivational enhancement, coping
and social skills to prevent relapse, and
reinforcement management. Training and
exercise worksheets (also designed to be used
collaboratively with service users) include:
l identifying problems
l identifying things to work on
l daily routine worksheet
l exploring the relationships between
substance use and mental health
l exploring the pros and cons of using
this substance
l exploring the pros and cons of making
a change
l exploring the pros and cons of changing
l discovering triggers
l self-management plan
l problem-solving worksheet
l seemingly irrelevant decisions
No mention of BBV, PWID,
risk behaviours,
Low Greater Glasgow and
Dumfries and Galloway
Yes/not known
AIDS, acquired immunodeficiency syndrome; ASSIST, Alcohol, Smoking and Substance Involvement Screening Test; BTEI, Birmingham Treatment Effectiveness Initiative; ITEP, International
Treatment Effectiveness Project; NIAAA, National Institute on Alcohol Abuse and Alcoholism; SEHT, South Eastern Health and Social Care Trust; TCU, Texas Christian University.
a Inclusion criteria: BBV (hepatitis/HIV); psychosocial intervention (e.g. MI, CBT, peer led); risk behaviours considered (injecting/sexual); PWID; and instructions to facilitators.
b Ranking criteria: high, all criteria included; moderate, no instructions but includes psychosocial intervention for BBV risk reduction and includes evidence and references; and low, no
instructions, no psychosocial intervention for BBV risk reduction/no evidence and references.
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Chapter 3 Understanding people who inject
drugs’ influences on behaviour and views on
psychosocial interventions
Aims
To inform the development of a psychosocial intervention to reduce BBV risk behaviours among PWID in
the UK, a qualitative interview study was conducted exploring:
l why PWID engage in BBV risk behaviours
l the type of psychosocial intervention acceptable to, and required by, PWID to reduce BBV risk behaviours.
Methods
Settings
People who inject drugs aged ≥ 18 years who had injected drugs within the past 4 weeks were recruited
from drug treatment and harm reduction centres, needle exchanges (including pharmacy and mobile),
sexual health services and homeless hostels in Glasgow, London, Yorkshire and north Wales during
May–July 2015. Settings were chosen to reflect the range of settings that PWID attend for substance use
and sexual health-related issues and settings attended by particular at-risk PWID who are not engaged
with addiction treatment.
Sample
A convenience sample of 60 PWID (15 from each locality) were recruited using a purposive sampling
approach to ensure that a variety of perspectives were accessed, including those most at risk (Table 9).
Sampling was thus stratified according to known BBV risk variables, including gender, length of time
injecting, drugs injected, involvement in sex trading and homelessness.
Service users at each setting were eligible to participate if they were aged ≥ 18 years, had injected illicit
drugs [other than image- and performance-enhancing drugs (IPEDs)] within the past 4 weeks and were
able to speak English well enough to complete a 45-minute interview. Given inability to provide informed
consent, service users were not recruited if/when experiencing withdrawal or intoxication.
Data collection
A number of recruitment approaches were taken to achieve the purposive sampling parameters. Flyers
were left in participating services to promote the study to service users. Staff at each of the services also
informed eligible service users about the study and either passed on the researcher’s details to those who
were interested or, with the service user’s permission, passed their contact details to the researcher, who
rang potential participants to discuss the study. Researchers also recruited participants from the waiting
rooms in services (except sexual health clinics) using a short screening questionnaire to ascertain study
eligibility. All participants received a written study information leaflet (see Appendix 1) and verbal
explanation of the study from the researcher, and were given an opportunity to ask any questions.
Participants indicated their consent to participate in the study by signing a consent form (see Appendix 1).
Participants received a £20 voucher in compensation for their time and expenses on completion of
the interview.
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Semistructured in-depth interviews were conducted with individual participants within a private room at
each setting by trained researchers (DS, AS, NM and ST). Interviews lasted approximately 45 minutes and
were audio-recorded with the interviewee’s permission. The interview topic guide (see Appendix 2)
included questions on participants’ knowledge and perceptions of BBV transmission (HIV, HCV and HBV),
perceptions of personal vulnerability to BBV, influences on the sharing of needles, syringes and other
drug-using equipment, influences on sexual risk taking (such as non-condom use), and past interventions
they had received on safer drug use and safer sex. Participants were also asked for their suggestions on
how to support safer drug use and safer sex in the light of the influences on risk identified and their
preferences for the PROTECT psychosocial intervention (content, format, venue, interventionist, duration,
barriers/facilitators).
Ethics approval
The study was approved by the National Research Ethics Service Committee South East Coast – Brighton &
Sussex (reference number 15/LO/0387).
Data coding and analysis
Interviews were transcribed by professional transcription services and analysed using qualitative framework
analysis.223 The framework approach allows the description and interpretation of what is happening among
a predesigned sample with a set of a priori issues. The approach involves five key steps: familiarisation with
TABLE 9 Sampling framework and number of participants (n= 60)
Sampling parameter Number of participants % of the total
Gender
Male 35 58
Female 25 42
Length of time injecting
< 2 years (new PWID) 17 28
≥ 2 years 43 72
Drugs injected
Mostly heroin/opiates 35 58
Mostly stimulants (cocaine/crack/methamphetamines) 13 22
Mostly both 12 20
Living situation
Alone 18 30
With sexual partner and children 8 13
With sexual partner alone 6 10
With children alone 1 2
With parents 2 3
With family 5 8
With friends/flatmates 6 10
Homeless 22 37
No stable arrangements 1 2
Other living arrangements 2 3
Involvement in sex trading (previous/current) 9 15
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the data; identifying a thematic framework; indexing the data; charting categories and themes; and
mapping and interpretation. The framework approach was developed to answer policy-relevant research
questions and can facilitate inductive, deductive or combined approaches to analysis. It is especially
amenable to projects where analysis will be conducted by more than one researcher.224
The research team (DS, GG, AS, AM, NM, EH, ST and NC) independently coded the first six interview
transcripts, then reviewed the coding at a face-to-face team meeting and collaboratively generated an
initial thematic framework. This coding framework was applied to the remaining interviews (indexing) by
Davina Swan, April Shaw, Noel Crane and Kideshini Widyaratna. Weekly Skype (Microsoft Corporation,
Redmond, WA, USA) meetings were held between the analysts to ensure consistency of coding across the
interviews and to agree new codes to be added to the framework. This also included the researchers analysing
one interview independently and reviewing how each had coded it to ensure validity. When first-level coding
had been completed, Davina Swan and April Shaw reviewed all coding and charted and mapped the data.
Qualitative software (NVivo 10, QSR International, Warrington, UK) was used to manage and code the
interviews. Several methods were utilised to enhance the validity of our findings: (1) triangulation of data
across multiple settings and localities; (2) triangulation of coding across several co-researcher perspectives;
(3) presentation of analysis and supporting quotes to service user representatives for feedback/critique
(credibility); and (4) identification and questioning of researchers’ underlying assumptions at the weekly
skype meetings between analysts (reflexivity).225
Patient and public involvement
Two service user representatives from London, two from Wales and two peer educators from Glasgow
helped develop the patient information leaflet and consent form, to ensure that appropriate language was
used and the aims of the research were clear and jargon free. In addition, they helped develop the topic
guide for use in the in-depth interviews with PWID.
Results
Factors influencing risk behaviour for blood-borne viruses
Drug states
Withdrawal/craving: balancing need and availability of equipment
When asked under what circumstances the sharing of needles, syringes and injecting equipment was most
likely to take place, most participants cited the experience of withdrawal when they were without their
own injecting equipment. Reasons for being without injecting equipment were varied, including lack of
preparedness and running out of needles because of a ‘drug binge’ or repeated unsuccessful attempts to
access a vein. Participants explained that the ‘desperation’ and urgency induced by withdrawal means that
their main priority is about taking the drug ‘as quick as possible’ and they will use equipment belonging to
anyone else that is available and to hand. Participants also noted that chemists and needle exchanges are
not open during evening times or at weekends, so there is no opportunity to obtain sterile equipment if
experiencing withdrawal at these times:
Normally when you’re desperate, when you’re needing your drug and the diarrhoea’s comin’ out ye’,
and you’re being sick. They’re not, people, myself, I don’t want tae be runnin’ tae the chemist, you
know, and havin’ tae run tae the chemist tae get new stuff. Maybe it’s a Sunday and the chemist isn’t
open. Maybe I’m gonnae miss out in havin’ drugs if I don’t take them there and then. So that’s the
way I put myself at risk.
Scotland ID4, female, aged 45 years, cocaine
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. . . when I have no needles and there’s no, sort of, access to a needle exchange, it’s after, like, sort of,
6 or 7 o’clock in the evening and there’s no way you feel you can get any fresh needles and you’re
starting to feel that, sort of, withdrawal and you know you want the heroin and the person has
needles and so you take the risk.
York ID2, male, aged 42 years, heroin
Some participants reported that the sickness of withdrawal had deterred them from accessing an open
needle exchange because the distance and effort required to get there was too great. Thus, convenient
access to equipment in situations in which the need to use drugs is high is important:
. . . it comes to times, you know, if you’re in (name of place/area) you can’t get no works unless you’re
in (name of street/road) and that’s like a 20, 30 minute walk and if you ain’t got money for a bus or
Oyster card you know you have to walk. If you’re sick you don’t want to do that so you use your old
ones you know what I mean, I’ll share them if you’re really that desperate.
London ID5, male, aged 25 years, heroin/crack cocaine
After 5 [pm]? You have to share, or use ones you’ve already used. So I break into my sin bin. I actually
cut my sin bin open and I get my used needles out. Don’t get me wrong, I clean them out with hot
water and everything, but I have to re-use what I’ve already used.
York ID9, female, aged 31 years, heroin/crack cocaine
Interviewer: Because you can’t access . . .
Interviewee: Yeah. The same as weekends, it’s closed. And a lot of people don’t like going to
chemists. They’d rather come to the drug worker and ask for help, but it’s closed.
Interviewer: OK. So when you go in you cannot access the needles. The only option there is to re-use.
Interviewee: Re-use or share.
The urgency to inject generated by withdrawal was also reported to expose people to other risks as they
may to continue to inject even if they are having difficulty finding a vein, increasing their risk of
getting abscesses.
Craving was similarly described as exerting a pressure to use drugs, which led participants to share
equipment, including needles, when without their own. Cocaine and crack cocaine, with their shorter
euphoric effect, were thought to increase the sharing of needles as a result of more frequent injection:
. . . like wi’ coke you get a, you get a, a . . . what do you call it, euphoria . . . you get a high. And then
you come doon. But wi, so you’re, you’re ****, you’re going through a lot o’ needles. But whereas
heroin, you know, having one hit and you’re, you’re no chasing that high a’ the time because you,
you feel the same. You know what I mean, you’re doon.
Scotland ID 15, male, aged 41 years, heroin
Interviewee (London ID1, male, aged 42 years, heroin/crack cocaine): . . . crack or cocaine could make
you do it. Because if you get so high and wired, you might really, really need to calm down, and come
down. So you could take that chance of, of, of sharing or using, just so you can get that, phew, that
release off, off your brain, you know?
Interviewer: Yeah, yeah.
Interviewee: Just to calm yourself down. Hmm.
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Participants noted that in situations where they use others’ equipment, they are reliant on others to be
open and honest about their BBV status. However, there is scepticism about whether or not others are
always honest about their status:
And obviously not a lot of people are truthful as well, a lot of people wouldn’t say, I’ve got it, some
people do and they’re the people you look at and think I admire this person because at least he’s
honest. 95% of the people say no I’m clean I ain’t got nothing, really they might have do you know
what I mean and you’re taking someone’s word on it.
London ID2, male, aged 28 years, heroin
Interviewer: And do people tell other people if they have Hep C or HIV for instance?
Interviewee (York ID10, male, aged 26 years, heroin): Not all the time, not everyone’s . . . not honest,
because it’s something you don’t want anyone to go broadcasting, is it, it’s not like you want to go on
the radio station and shout out, I’ve got Hep B so, you know, please don’t share my needle.
Intoxication: clouded judgement and reduced inhibitions
Participants reported that drug- and/or alcohol-induced intoxication undermined their ability to manage
injection-related risks. Similar to cocaine/crack cocaine, alcohol and/or benzodiazepines were reported to cloud
judgement and reduce inhibitions, leading to intentional sharing of equipment and also to inadvertent risks:
. . . if . . . I’d been drinking all day, and I was with, well, a few of my friends in the hostel, I could be a
bit laxy in my way of thinking. I would never share a needle or that, but I could draw up from the
same cook pot.
London ID1, male, aged 42 years, heroin/crack cocaine
They just get sloppy don’t they. They forget tae dae things. They forget tae put caps on things.
Scotland ID10, male, aged 30 years, heroin
Trajectory of drug use
Addiction progression: increased willingness to take risks
Some participants described how, as their drug use progressed into addiction, their lifestyle began to
revolve around drug use and they became willing to take greater risks and there was a loss of personal
standards held in the past:
. . . once you become physically addicted, I don’t know it just changes everything and using needles
changes everything, er, so much that you I don’t know like morals that you kept in the past seem to
just go and, er, yeah I’ve shared needles, I’ve had unsafe sex and I knew that I could be at risk of that
and it wasn’t important anymore.
London ID14, female, aged 32 years, heroin/crack cocaine
I’ve seen people like, smoking it and then going to inject it and change their way of everything, from
their hygiene to who they bother with to not caring how they get it or where they’re digging
[injecting] it.
Wales ID4, female, aged 25 years, heroin
Needing help injecting: dependence on others and risk of injury, rather than
blood-borne virus transmission, are paramount concerns
In the early stages of their injecting drug use, particularly at injecting initiation, participants lacked the
experience and skill to inject themselves and were reliant on others to inject them. Needing help injecting
lessened participants’ control over the injecting process. When being injected, participants’ main concerns
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were the risk of injury (e.g. if the person injecting them missed the vein or hit an artery or nerve) and their
dependence on others to obtain their drug/hit, rather than any risk of BBV transmission:
I was obviously a bit scared if they missed me and if they knew what they were doing . . . well they
obviously knew what they were doing but sometimes it would miss me. You know you give them a lot
of responsibility.
Wales ID14, female, aged 39 years, heroin/crack cocaine
Interviewer: . . . when you first started, OK. How did you feel about somebody else injecting you, were
you happy about that?
Interviewee (Wales ID13, female, aged 30 years, amphetamines): Not really got really anxious
and nervous.
Interviewer: OK, were you worried about somebody else transmitting blood-borne viruses to you or
was it about . . .
Interviewee: . . . it was more about me going over [overdosing] at the time.
In addition, when people had difficulties with venous access because of collapsed veins, they would need
others to inject them as their viable injecting sites might be in awkward places and/or it could be a long
and laborious process to try and ‘get’ themselves:
Yeah, well, where I’m going in my neck is a massive risk, I wouldn’t dare do it to myself, I only trust
one person to do it, but they don’t like doing it to me, you know, but I know the risk in your neck is
really high, it’s not a good place to go. I’ve been everywhere else, I can’t get nowhere else, it’s like the
last place left, you know.
York ID4, female, aged 36 years, heroin
. . . there are people that cannae get tae theirselves. But there’s a vein that they cannae get tae.
Maybe like the back of the knee or something, I don’t know. Somebody would need to go and dae it
for them.
Scotland ID10, male, aged 30 years, heroin
At time of interview, nine participants (seven females and two males) currently required injecting assistance
and four had been injecting for < 2 years (three females, one male).
Injecting others: pressure and risk of legal ramifications, rather than blood-borne virus
transmission, are paramount concerns
Most participants reported being asked by others to administer drug injections at some point although just
five participants (three females and two males) reported currently injecting others and all had been
injecting for ≥ 2 years. A couple of interviewees were very willing to assist others with injections:
I have injected other people before because I’m really good at getting . . . I know it sounds bad but if
someone’s got bad veins I’m very good at getting them first time so I often get asked. [. . .] I’ve even
been walking down the road and someone I know from my group said oh [participant’s name], I’m
not well, can you help me, can you help me, I can’t get myself and gone in a block, injected her and
then she’s fine and I’ve gone off or she’s gone off so if someone can’t do it and they need help . . .
London ID6, female, aged 27 years, heroin
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Other interviewees had mixed feelings about injecting others and avoided doing so where possible as
where venous access was an issue it could be a high-stress situation:
As a general rule, I don’t like doing it ‘cause it’s just – it’s an unpleasant thing to do, because if
somebody needs you to inject, it’s generally because they’ve got bad veins in the start and then it
becomes a whole kind of nightmare as well. It becomes very stressful . . . if you can’t kind of get
it immediately.
London ID7, male, aged 50 years, heroin/crack cocaine
Aye well I’ve done loads o’ people. I mean I’ve, I mean see if I’m being honest, I mean I’ve injected
people in the neck and everything. You know it’s . . . very very dangerous. Very, very dangerous.
Scotland ID9, male, aged 41 years, heroin
Besides the stress of missing the other’s vein, participants’ main concerns when injecting others were the
legal ramifications if the recipient overdosed, rather than BBV transmission. As the participant below
explained about injecting his friend who was HIV positive:
Interviewer: Do you feel it’s safe for you to do it and say, for him to be injected? [IV sighs] I just want
to get your thoughts on it, I suppose – how you feel about it.
Interviewee (London ID7, male, aged 50 years, heroin/crack cocaine): It’s not – you know, deep down,
it’s not an ideal situation. [OK.] I would really, I would kind of rather not do it. I know I shouldn’t be
doing it.
Interviewer: Like, what risk might there be to you doing it, in terms of blood-borne viruses?
Interviewee: The risk is, if he drops down dead, I’m in trouble. [OK, OK.] I’m in trouble, you know,
legally and morally. I’m in trouble.
As the above extracts illustrate, when participants injected others it was usually out of pressure or because
it was relatively easy to do so.
Relationships and social networks
Intimate relationships: the primacy of trust and familiarity
Although not universal, the sharing of equipment and needles was more likely within couples, based
largely on trust and familiarity. Many participants felt comfortable sharing injecting equipment with their
partners but not with anyone else. Participants were confident that they knew their intimate partner’s BBV
status, which was in contrast to their scepticism generally regarding others’ honesty about their BBV status.
Thus, trust often took precedence in intimate relationships over safer practice:
I share with him but only because he’s clean. Like we both got tested but I wouldn’t share with
anyone else.
York ID12, female, aged 19 years, heroin
I’ve been with my partner 20 years, and if she used a needle I’d use it after her, because I know that
she hasn’t got anything, do you know what I mean? If you know that somebody hasn’t got ‘owt, and
they’ve always been clean, then you’re at a higher percentage to use their needle, than you are
somebody’s who you know who has.
York ID5, male, aged 36 years, heroin
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When disclosure of a positive BBV status was made, some couples continued to share equipment
regardless, as they were already engaged in a sexual relationship without the use of condoms:
. . . because we sleep together, it doesnae matter if we share needles. Same again. ‘Oh you take
drugs, I take drugs so there’s nae use taking a condom’.
Scotland ID5, male, aged 45 years, heroin
Sharing within couples was not always consensual, however. One participant related her experience of
being in a violent relationship where she lacked control over her injecting practice:
I was in a domestic violence relationship [. . .] If he had one needle I had no choice of getting
anyone’s. I had to have what he had. He would actually do his and instead of washing it out, the
blood would be still in the end of it and he’d suck mine up. I had to have it. I was ill.
York ID9, female, aged 31 years, heroin/crack cocaine
It was noted that inadvertent sharing can also happen when couples are using drugs together as they are
less careful with each other and their equipment can become mixed up.
Injecting in groups: negotiating safe practice is challenging for injectors who are
less assertive
Negotiating drug preparation and injecting practices within group injecting situations could be challenging.
Some participants reported feeling under pressure to go along with unsafe practices, including sharing
equipment, as they felt intimidated by others or feared causing offence:
I’ve been in those situations where I’ve felt uncomfortable saying to the person about sharing spoons,
because I don’t know how they’re going to take it, you know, they might be, like, well what are you
trying to say, are you trying to say that I’ve got HIV or hepatitis? And some of them are dangerous
people, you know, they’ve been in prison for violence and stuff, so, you know, it can be intimidating.
York ID2, male, aged 42 years, heroin
Interviewee (Scotland ID4, female, aged 45 years, cocaine): I’ve felt a bit intimidated wi’, at being in
somebody’s house and somebody’s saying well, you know, I . . . I dae everythin’ on this table and
that’s his personal space. So, and they take control and sometimes I’ve felt intimidated tae say, you
know, get a bit too, a bit, felt a bit intimidated and I’ve not wanted tae say, you know, halt. I want
tae do my own thing wi’ my own drugs, and I want tae take control of my own . . .
Interviewer: Preparation.
Interviewee: Yeah. And . . . I’ve just felt that because I’m in that person’s house that I’ve got tae go
with their rules.
Those selling drugs were considered to be the ones with the power (‘powder power’) within a group, and
some participants reported that you do what they want to get what you need:
Interviewee (Scotland ID3, male, aged 30 years, heroin): Aye I have been in situations like that myself
just because they’re the mair dominant one. They’re buying it and so you’ll just sit back and they go
and get the drugs. They’ll make it up. And . . . they’ll gie you it, what they think you should have
instead o’ me going ‘oh you’ve got it, let me see what you’ve got and de de de de’.
Interviewer: And like they sort of control, like you’re saying like they control sort of how much you
get. They, they might prepare it and . . .
Interviewee: Aye and there’s another risk. They prepare it so you’re using the exact same filter,
spoon, water.
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The pressures of using drugs within a group influenced drug preparation. For example, some participants
reported that, when dividing up drugs within a small group, the spoon and filter may be shared to ensure
fair distribution:
. . . if there’s like three of you and you’ve only got like two bags of heroin then it would be like we’ll
put them all in together into the spoon. Even though we’ve all got our own pins we still share the
spoon and the filter to separate it out evenly.
London ID15, female, aged 34 years, heroin
When injecting in groups, equipment can also become inadvertently contaminated:
. . . if you’re using with other people there’s always going to be a risk when you turn your back he
might stick his needle in the water do you know what I mean and draw up and then you turn around,
anything could happen.
London ID2, male, aged 28 years, heroin
. . . but sometimes if there’s two bottles o’ water opened you get mixed up. So I don’t know if he’s
sometimes took water oot the wan’ I’ve used, and I sometimes took water oot the wan’ he’s used.
You know what I mean? So that’s what I’m saying. No intentionally but you get mixed up.
Scotland ID11, male, aged 41 years, heroin
Access to resources: homelessness and limited opening hours of needle and syringe
programme/pharmacies restricted opportunities for safer injecting
Homelessness
Homelessness was highlighted by most participants as an important risk factor for the sharing of injecting
equipment, as people who were homeless lacked access to resources and to control over their injecting
environments. Sleeping rough or living in a hostel often meant people had to inject outdoors or in public
places. To avoid being caught injecting outside, PWID might inject in small groups (while someone keeps
lookout) and the process was often rushed, leading to the intentional sharing of needles, syringes and
equipment, as well to injection site wounds:
. . . it’s more when we’ve got naewhere tae go. So we’re doing out o’ quickness . . . in car parks, in
closes . . . You’re trying no tae get caught. That’s when you will just go into at least do it quickly, you
know in and out . . . That’s when you just go, ‘**** it, I’ll share that needle with you’. You know,
‘oh just give me yours’.
Scotland ID14, female, aged 30 years, heroin
When you’re homeless you tend to go about in twos or threes. You have a little clique of people so if
you’re going to use you’re more likely to use together and then the chances are it’s all going to be on
the same spoon.
York ID15, female, aged 33 years, heroin
The unsuitability of many of these environments (e.g. stairwells, public toilets) for drug preparation and
drug use meant there were also risks of needlestick injury or equipment becoming accidently contaminated
with another’s blood:
. . . if you were doing it in, erm, housing, tower blocks, and things like that, erm, because I know
hepatitis C stays quite alive outside the bloodstream for a while . . . [I]f the, like, you, you, you put the
filter in the spoon and it rolled off, you don’t know if it’s rolled on an old, a bit of blood, from
someone else whose used on the thing. You put it back in your thing, thinking there’s nothing on it –
bosh, you’ve got hepatitis C.
London ID1, male, aged 42 years, heroin/crack cocaine
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Interviewee (Scotland ID4, female, age 45, cocaine): Maybe when I was out prostituting. I would score
the drugs there and then and I wouldn’t want tae be waiting tae I got the bus or a taxi up tae [area]
or wherever I’d came fae. And I went in tae maybe a hotel toilet or, and you’re rushing, you know,
and you’re, and you’re rushing that much that you’re maybe leaving the needle in the toilets.
Interviewer: So you might be rushing the injection?
Interviewee: Yes, definitely. Which then can lead tae, rushin’ can lead tae not getting’ in the vein,
which then leaves ye’ poppin’. It then leaves ye’ not getting’ your, not getting’ your fix right, which
then leads tae abscesses and things like that. And I’m puttin’ other people at risk by just leavin’ my
stuff behind . . . because I’ve not been compos mentis enough tae, tae grab everythin’ and make it,
make sure everythin’s, I’ve got everythin.
Access to the resources necessary for safer drug use (e.g. sterile water) was difficult when people were
homeless and homelessness was also linked by some to a sense of apathy or hopelessness which fostered
risk taking:
. . . when you’re on the streets you know . . . you can’t exactly put a tap on or something to get your
own water, you know you have to share water from a bottle.
London ID5, male, aged 25 years, heroin/crack cocaine
Interviewee (Scotland ID10, male, aged 30 years, heroin): Dae I take risks injecting outside?
Interviewer: Yeah, yeah.
Interviewee: Definitely, aye. I’ve used dirty water oot a puddle oot o’ desperation. Couldnae get water.
And that was ma best thinking. Water oot a puddle!
Interviewer: And you said you’ve picked up needles from outside.
Interviewee: Aye, aye, aye.
Interviewer: Did you clean them at all?
Interviewee: See if I’ve been, this is embarrassing, if I’m being honest. And it’s just, I’ve done it oot a
desperation, oot o’ pure desperation. Don’t get me wrang, there’s times that I’ve been fine where I’ve
no went tae them lengths. But there’s other times I’ve went tae them lengths.
Access to needle and syringe programme/pharmacies
Many participants highlighted evenings and weekends as times when needle and syringe sharing were
more likely as pharmacies and needle and syringe programmes/pharmacies (NSPs) were closed, so there
was no possibility of obtaining sterile injecting equipment. Some interviewees also felt there were not
enough pharmacies offering needle exchange and not enough NSPs in smaller cities:
Interviewee (Wales ID10, male, age unassigned, heroin/amphetamines): I just reckon rattling, or on a
Sunday where places are shut, most places are shut and then you can’t get anything, so you’re more
likely to share. You’ve got no choice but to ask someone else.
Interviewer: Are there any certain situations which you think people who inject drugs might be more
likely to share needles and equipment?
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Interviewee (York ID13, male, aged 38 years, heroin): When chemist shut or when certain places shut
where they can’t get their supply from and if they’re ill and someone’s got some stuff what he’s
already used and if it’s been used and after that not clean them up properly or sterilise them then . . .
It’s mainly when they can’t get any of the equipment because why else would they need to share?
One participant highlighted stigma and fear of exposure as barriers to obtaining sterile equipment
from pharmacies.
Values: compassion and the individualisation of responsibility influenced risk behaviour
The role of values in risk behaviour was implicit in many narratives.
Compassion
Compassion for others was cited as driving distributive sharing and willingness to inject others:
Interviewer: How did you feel when you were helping them inject, in terms of the risk?
Interviewee (York ID8, female, aged 37 years, heroin): Very nervous, but it was somebody that was
very poorly at the time, they couldn’t get any methadone, they were absolutely desperate, it was a
close friend, and I just felt I had to help.
Interviewer: OK, so you were feeling like sympathy to them?
Interviewee: Yes.
Interviewer: Because, of what they were going through?
Interviewee: Yes.
Interviewer: . . . is there a bit of a pressure on you to kind of give your stuff or is it easy to say sorry
I don’t . . .
Interviewee (London ID6, female, aged 27 years, heroin): No, my first reaction would be I don’t really
feel comfortable, is there like anybody else, can you not find one and then if like it really comes down
to it then I’d have to because I couldn’t really say no if they’re not well or if they’ve been out grafting
and they’re tired or whatever but what I do is if you’re going to use someone else’s works boil a
kettle, hold it over the kettle the needle bit like and it sanitises it as much as possible and then to run
boiling hot water through it as well.
Individualisation of responsibility
Many participants rationalised their distributive sharing by viewing the risk taken by those who re-use
equipment as their own responsibility:
. . . so if I’ve got my equipment and someone else aint if they want to use it after me that’s your,
that’s up to you but I know I’m going first.
London ID15, female, aged 34 years, heroin
I’ve got a routine. I, I open up a pin [mhmm], a 1-ml packet, I take half of the paper off and then I fill
up that pin what I’ve just opened up – that packet, with water [mhmm] straight from the tap. That’s
what I use. Whoever uses it after that, I don’t give a shit. It’s their problem. They, they should know
what they’re doing.
London ID4, male, aged 39 years, heroin/crack cocaine
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Mental health
Poor mental health promotes lack of self-care
Poor mental health (e.g. psychosis, depression and low mood) was reported to cause indifference to one’s
health and reduced care around safe injecting. Some participants reported that being diagnosed with a
BBV, having serious injuries or conditions or experiencing a traumatic event were points at which they had
little regard for their own safety in terms of drug use and risk behaviours:
My sister died and I’ve been so depressed . . . that I’ve thought, you know, who cares? You know.
I don’t want to be here anyway so . . . What does it matter if I use her set, her syringe, you know.
Scotland ID4, female, aged 45 years, cocaine
I think I probably started out more, yeah it’s, er, it kind of depends I guess how – how sick I was, er,
how depressed I was, how desperate I was, how bad things were. Er, you know I’d go through waves
of – of being maybe having more money, using more drugs, being more functional, er, when there’d
be periods of no money and no drugs, I’d be an absolute mess. So I’d be more desperate. So when it
came to hitting up I’d use something dirty or I wouldn’t prepare it properly or you know so it would it
very much depended on where my mindset was I think yeah. So throughout the years it would kind of
peak and I don’t know yeah – yeah it was all to do with self care and you know if I was with it and
together, you know, the self care kicks in, it’s like once I don’t know that can go very quickly, that
always surprised me because I never thought I’d live like that.
London ID14, female, aged 32 years, heroin/crack cocaine
One participant reported experiencing a psychotic and suicidal episode in the past, when he actively made
sure he went last when sharing equipment.
Perceptions of risk
Perceptions of risk are not only based on knowledge of BBV transmission routes, but also on the physical
appearance of others and the trust and familiarity which has been built up over time with injecting
partners. In addition, other injecting-related risks are often more paramount than BBV transmission.
Knowledge of transmission risk
Participants reported that in the past they had unknowingly placed themselves at risk of contracting a BBV
as they had not known that sharing equipment was risky:
I mean I don’t think people realise how easy it is to catch, I didn’t know how easy it was to catch.
I thought like if you share a pin that is how you catch it but I know that’s not, it can be through saliva,
it can be left on a filter from someone else you know because it can stay alive.
London ID15, female, aged 34 years, heroin
Well I contracted hepatitis C so I know more now than before I contracted it. Before I contracted it I
really didn’t know much you know, I didn’t know that shaving, using someone’s razor or somebody
using your razor could give it, I didn’t know that, I didn’t know about the toothbrushes, didn’t know
about the water, when you’re injecting sharing water, I knew you couldn’t share needles but I didn’t
know you couldn’t share water so that’s obviously how I contracted it. I didn’t know that, it just didn’t
come into my head, I didn’t know, no one told me, you just didn’t know.
London ID6, female, aged 27 years, heroin
Participants thought that younger and/or new injectors were especially vulnerable, as they may be less
aware or informed about BBVs:
. . . if you’re only new to injecting, you don’t really have any clue about, like, the life, you know, so
you would be more vulnerable.
York ID4, female, aged 36 years, heroin
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Interviewee (Scotland ID8, female, aged 40 years, heroin): Just, I thought at that point [novice injector]
I thought, ‘if you did it with a new needle you were fine’. Do you know what I mean?
Interviewer: Yeah.
Interviewee: I didnae think aboot the filter, the spoon, the water. Nothing like that. Do you know
what I mean.
Some participants noted that, although they had since been educated regarding BBV transmission routes,
some of this information had been conflated or forgotten with the passing of time. Current knowledge of
HBV was poor, and some interviewees were uncertain how long the HCV could live outside the body.
Some participants who had HCV reported sharing equipment with others who had HCV as a few held the
belief that if both you and your injecting partner have HCV then it is OK to share equipment.
Human immunodeficiency virus is considered the worst blood-borne virus to contract
Human immunodeficiency virus is still considered the worst BBV to contract, partly because HCV is
considered curable, whereas HIV infection requires lifetime treatment, and partly because HIV infection is
considered more stigmatising. This hierarchy of BBVs is evident in the description by one participant of an
agreed dynamic with his friend who is HIV positive, whereby the participant draws up drugs first to avoid
contracting HIV. However, the participant has HCV and so also poses a risk to his friend:
I always use mine first, I draw mine up first then his one, I wouldn’t put his used works in it first, then
I use it because I know I’d get HIV and even he told me that he was aware, he said yeah no you do
your bit first because if we share the spoon you know. So yeah we are aware you know what I mean.
London ID5, male, aged 25 years, heroin/crack cocaine
Hepatitis C virus is considered the easiest blood-borne virus to contract
Hepatitis C virus is considered, by most participants, to be the easiest virus to contract because there is a
greater prevalence of this virus within their social networks (‘it’s more virulent in the drug community’) and
because the virus lives longer outside the body.
Hepatitis C virus infection may be seen as inevitable
A couple of participants thought that there is an attitude that ‘everyone has the [hepatitis C] virus anyway’
and so people may be more willing to take risks as they assume they must have already contracted it:
. . . some o’ them just say I’ve probably got it anyway, you know. Everybody I meet’s got hepatitis C.
Scotland ID4, female, aged 45 years, cocaine
Interviewee (Scotland ID7, male, aged 44 years, heroin): Yes if there’s a group o’ people sharing is
more likely to take place, yeah, definitely.
Interviewer: How’s that then?
Interviewee: Because people are, people are sitting there, you know. They’re no really, you know, I
think…there isn’t really that fear factor about blood-borne viruses any more. I mean it ain’t as scary as
what it used to be, do you know what I mean, is what I’ve found is when I was dain’ ma job as well, I
found that people ain’t as scared o’ it as what, what it used to be, you know, because they know wi’
hepatitis C it doesn’t really, might, you could live wi’ it forever and it might never affect you. And it’ll
take 30, 40 year before it does kill your liver and whatever, whatever it’s gonnae dae tae you. And I
think that fear factor’s gone about it.
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Hierarchy of risk: blood-borne virus infection is not the paramount risk concerning
people who inject
Throughout the discussions of risk situations above, it was clear that BBV transmission risks were not
always the paramount risk in participants’ minds. Participants were concerned with risks of abscesses,
collapsed veins, hitting an artery or a nerve, bacterial infections, amputation, overdose and the legal
ramifications of injecting others.
Hierarchy of importance: other priorities besides blood-borne virus protection may
be paramount
Similarly, in situations where risk behaviour happens, it is often because other priorities take precedence
(e.g. alleviating withdrawal/craving, sustaining trust and intimacy).
How risks are currently being reduced/managed
Managing injecting risks
Most participants managed their own injecting risks by using clean needles and equipment, although some
reported sharing equipment with injecting partners. Managing injecting risks are closely tied with levels of
trust engendered in long-term relationships and may also be contingent on the outward appearance of
fellow injectors, as illustrated by the two excerpts below:
Interviewer: You mentioned earlier that you never inject in a group, you inject with your partner.
So with your partner would you ever share like a needle or . . . ?
Interviewee (York ID7, female, aged 47 years, heroin): No, never.
Interviewer: OK. What about the cooking pans or . . . ?
Interviewee: We have . . . I mean I know you can spread it through the cooking pans but to be fair we
just . . . I’ve been with her 9 years now, but we do share stuff but I know she’s got nothing, she
knows I’ve got nothing because we’ve all been tested, you know, and we don’t bother with anybody
else really. We keep ourselves to ourselves. You know, we don’t really socialise with anybody really,
you know?
Yeah, people I’ve shared, felt more comfortable sharing with, are people that I’ve known for a long
time, I, kind of, look at their, sort of, general, sort of, state and if they physically look healthy I’m more
comfortable, kind of like, taking that risk and also how honest they are and I’ll ask them, like, have
you got any diseases? You know, and if they’re honest people, then they’re more likely to tell the
truth, you know, and then you have an informed decision to make . . . So I’m more willing to share
with people who are honest, I’ve known for a long time and they look healthy.
York ID2, male, aged 42 years, heroin
A few participants reported planning ahead and collecting enough new equipment to ensure that a clean
injection each time required or not injecting at all until new equipment could be obtained:
When I come [to the needle exchange] I always get, like, 40 to 50 to last me a couple of days and
then I know for a fact that I won’t need to go scraping around in a sin bin or whatever . . .
York ID10, male, aged 26 years, heroin
I’ve never, ever, ever, ever shared a pin. I’ve been that desperate, I’ve been that poorly where
someone says, look, you can use mine, and I still haven’t resorted to . . . I had to wait until the
morning. So I had a night of hell but I would not because I was scared of taking that blunt needle . . .
York ID7, female, aged 47 years, heroin
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The use of OST to alleviate withdrawals until clean equipment could be sought was reported, whereas
alternative routes of administration, such as smoking or snorting, were substitutes to injecting if no sterile
needles/syringes were available:
I might use once a fortnight and put it down and I won’t touch it again [OK], but that’s because I’ve
got a methadone script and I don’t need to use on top of that any more.
London ID7, male, aged 50 years, heroin/crack cocaine:
Interviewer: So for you if you cannot inject it, then you will just . . .
Interviewee (York ID10, male, aged 26 years, heroin): Smoke it. [. . .] Yeah, or if you don’t have no foil,
just put it in a Rizla and smoke it like that.
For those unable to defer use until clean equipment could be sought, previously used needles (either their
own or another person’s) would be cleaned using water (boiling and/or cold), bleach, washing-up liquid or
alcohol swabs:
Stick it [needle/syringe] in the kettle and boil it.
Wales ID9, male, aged 31 years, amphetamines
Water, bleach, remember Vaporub, alcohol in the hospital, they bottles o’ Vaporub. [I: Yep] That.
I’ve used Fairy Liquid before.
Scotland ID12, male, aged 30 years, heroin
Vigilance was used when injecting in company to ensure that equipment did not become mixed up, with
some participants keeping their equipment close to hand, marking their barrels or using colour-coded syringes:
I just don’t let mine oot ma sight. If I was going tae the toilet I would take it wi’ me.
Scotland ID12, male, aged 30 years, heroin
Sometimes if I’ve got a bit of tape I’ll tape round the end or burn the end of the syringe with a lighter
and then it’s, you can distinguish it.
London, ID9, male, aged 19 years, mephedrone
Other BBV avoidance strategies included drawing up first (or, in the case of participants wo are HCV
positive, allowing the injecting partner to draw up first) or asking injecting partners their HCV status before
sharing equipment. A small number of participants mentioned having BBV tests to monitor their status,
particularly if they considered that they might have put themselves at risk either sexually or through
drug use.
A few participants reported being at low risk of BBVs because they injected alone or with their intimate
partner only. Participants who injected in their own homes, as opposed to on the street, perceived
themselves to be at less risk and hygiene practices (such as using sterile wipes or cleaning hands, surfaces
and/or injection sites before injecting) were mentioned by a small number of participants:
You see I’ve got like sterile wipes and then there’s a little thingy in shed so I wipe it all down, put the
little pan, I do all me hands and wipe everything, I’ve got all my wipes, I wipe all myself down. I’m a
bit of a clean freak so there’s no worries there. I have all that at home, sterile stuff it’s all sterile.
York ID11, female, aged 38 years, heroin
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Protecting others
Participants mitigated BBV transmission risk to others by disposing of equipment, breaking equipment to
avoid re-use and refusing people use of their used equipment. However, refusing to lend people used
needles/syringes could be difficult for some participants, as they were aware of the effect of withdrawals/
cravings, so in some cases they would disclose their BBV status and leave the decision to use to the recipient:
I try not to (share needles/syringes), but if they were pestering me and pestering me and . . . on and
on and on at me and I just want to chill out, I tell them, I say, listen, I’m positive for Hep C, if you
want to use it, it’s your problem.
York ID3, male, aged 31 years, heroin
Well I use it first. If they want tae use it after me they’re mair than welcome tae but I tell them no tae.
I tell them I’ve got hepatitis C. They go like that, ‘so what’.
Scotland ID1, female, aged 28 years, heroin
More unusually, some participants reported refusing to lend equipment to others despite direct requests in
order to protect them from onward transmission as illustrated in the quotations below:
Interviewer: What about when people are injecting in groups? Does that carry a certain amount of risks?
Interviewee (Scotland ID8, female, aged 40 years, heroin): It depends who it is. There is, I know a lot
o’ people still to this day . . . now for instance the other day there’s a guy and . . . he knew I had . . .
Interviewer: Say it a bit louder.
Interviewee: . . . he knew I had done a hit and he says to me, ‘have you done that [NAME]?’ And I was
like that, ‘aye’. He was like that, ‘wantae gie me your tools’. And I was like, ‘no I don’t’. And he’s like
that, I said ‘there’s nothing in them’, do you know what I mean. He went, ‘aye even if you’ve done a
flush and you cannae get at it I can dae that’. And I mean there is people out there like that, do you
know what I mean.
Interviewer: What do you mean there’s nothing in it? What do you mean? Like any residual drugs?
Interviewee: Mmhmm. He’s like that, ‘aye but you says you never get your flush’. I went, ‘aye cause
I was dain’ the flush and the door went and it was you so I just done that, oh bugger it’. He went
like that, ‘gie me that and let me thingwy it’. And I was like that, ‘no’. And I says tae him. He’s like,
‘I don’t care’. And I was like that, ‘no, no’.
Interviewer: No.
Interviewee: I says, ‘I will not be responsible’. I says, ‘I wish somebody would have said no tae me [. . .]
Or said something tae me rather than just let me get on wi’ it. And I wouldn’t gie him it.’ I done it
right doon the sink. He went like that, ‘that’s oot o’ order, that’s oot o’ order’. I went, ‘that’s no oot
o’ order’. I said, ‘that’s probably saved your life’, do you know what I mean.
Scotland ID8, female, aged 40 years, heroin
Interviewer: OK. Do you think you are at risk of passing hep C, for example, to another person?
Interviewee (York ID6, female, aged 25 years, heroin): Oh yeah, you are. But that’s just giving
someone a death wish, that, if you share your kit with someone else and they haven’t got it. I couldn’t
do that, no.
Interviewer: OK. So how would you avoid . . . ?
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Interviewee: There’s people out there who don’t give a shit and would share with someone that hasn’t
got anything and they’ve got it, but I’m not like that. I don’t share with nobody. I’ve got my own
equipment. I do everything myself. If they want to use they go get their own. I don’t give them
anything of mine.
Interviewer: OK. So if someone comes to you and says please may I share . . .
Interviewee: No, they’ve got no chance [. . .] No. It’s a death wish on someone. It’s wrong.
York ID6, female, aged 25 years, heroin
Participants would often mention managing risks other than BBV transmission. For example, participants
mentioned managing overdose risks by injecting with at least one other person; injecting in private settings
to avoid stigmatisation, getting caught in public or protecting children; and managing infections or vein
care by rotating injecting sites and avoiding groin injecting. As participants developed the skills to inject
themselves, their control over the injecting process was improved; however, knowing how to inject could
also lead to increased risks as participants would be asked to inject those who had difficulty finding veins
or had not yet learned to inject. The main concern was the potential risk of fatal overdose:
Interviewer: Would you ever help anyone else inject?
Interviewee (London ID4, male, aged 39 years, heroin/crack cocaine): I have done but . . . I wouldn’t
these days, man. There’s too much risk; too much bullshit involved and too much red tape, yeah.
[Yeah] That person will put it on you like, ‘Oh, help me,’ and they will put it on you, ‘You bastard.
You’re not helping me.’ It ain’t like that though. Anything happens to that **** mate, I’m – it’s me.
That’s my liberty mate or that’s his death on my hands. I don’t need shit like that, no. Don’t need it.
I’ve got enough bullshit of my own. Extra bullshit, I don’t need it.
Two participants noted that they were more careful about sharing equipment at the start of their injecting
drug use, but as their addiction developed they became more ‘lax’ in their risk management. However,
some participants reported being more careful as their drug use developed, and receiving a BBV diagnosis
was often a catalyst for changes in risk behaviours:
Interviewee (York ID4, female, aged 36 years, heroin): I always try now, well, I never share anything,
I’m really, really careful now that everything is clean and new and I make sure, like, I must have had it
years and years and, you know, when I’ve had partners in the past used old needles, you know, again
and put them on the same spoon, now I won’t do that, everything is totally new, you know, so I’m
really aware now.
Interviewer: OK. So what is the motivation for you now not to share and to use clean?
Interviewee: Because I don’t want to catch HIV.
Interviewer: OK.
Interviewee: You know, because now I know that I have got a . . . before you just think you’re
invincible, I thought I wouldn’t get anything and now I have, I’m not invincible and now, obviously,
there’s something other than Hepatitis C I could get, you know, so now I’m more careful.
Risk management strategies, however, may be dependent on the types of drug used. As explained here,
stimulant drugs may complicate the user’s capacity to manage injecting risks:
Well, when you inject the cocaine you get that much o’ a rush, you’re not really as much in tae, you’re
more involved in talkin’ away and, and more engrossed in your . . . more engrossed in the buzz that
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it’s givin’ ye’, that you would just maybe put the needle down and in among the other people that are
using. Whereas with heroin I would maybe take my injection and then I would scrape the numbers off
ma’, ma’ injection, ma’ needle. And I would normally scrape ma’ numbers, or burn a wee bit of it, and
that’s generally how I would know mines from somebody else’s.
Scotland ID4, female, aged 45 years, cocaine
Factors which promote change in risk behaviour (i.e. reduced risk behaviour)
Addiction progression
As drug use became more central in participants’ lives, their level of preparedness increased, so they were
more likely to have their own drug-using equipment and less likely to need to borrow others:
Interviewer: OK, and what’s changed that you have access to new equipment now and you didn’t
back then?
Interviewee (London ID4, male, aged 39 years, heroin/crack cocaine): Now, I would go to a chemist.
I would make sure I would go to the chemist and pick up a bag of pins . . .
Interviewer: But you didn’t before.
Interviewee: . . . whereas before, I wasn’t really doing it all the time, so I was only around certain
people. I was only doing it when I was around them people.
Getting older and wiser
Experience and knowledge over time was reported to lead to safer behaviour. Also, some interviewees
described maturing out of heavy drug use as they became older, leading to less frequent injection:
I don’t use anywhere near as often, you know [OK]. I might use once a fortnight and put it down and I
won’t touch it again [OK], but that’s because I’ve got a methadone script and I don’t need to use on top
of that any more. And I have lost the desire, you know – I just can’t – I couldn’t live like that any more.
London ID7, male, aged 50 years, heroin/crack cocaine
Addressing addiction
Where participants were addressing their addiction (e.g. went to rehab), had a ‘recovery plan’ or were on
OST, their injection drug use decreased or (temporarily) ceased:
I’m trying to get off that, but I do every once in a while. I used to do it quite a bit more or less every
day I used to inject heroin but do it once a month around here, trying to cut off altogether, the
injecting, trying to stay clean.
Wales ID6, male, aged 34 years, heroin/amphetamines
Sometimes participants reported that this entailed distancing themselves from the people and places associated
with their drug use. Being on OST not only reduced frequency of injection drug use but also facilitated
participants to collect new injecting equipment while they picked up their OST, again increasing preparedness.
Life events
Health scares prompted some participants to change risk behaviour. For example, one participant
described being in hospital with pneumonia and this provided the motivation for her not to share again:
I was in hospital a couple of years ago, and I had pneumonia, and it was then that I was tested for
everything, because I had a strain of pneumonia that a lot of people with HIV get, and I was very
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worried, obviously, about getting the results and stuff. But, I was so pleased when they came back all
clean, for hepatitis as well, and from then on I’ve never shared.
York ID8, female, aged 37 years, heroin
Similarly, another participant who contracted HCV but cleared the virus was now very cautious. Other
participants described experiencing needlestick injuries in the past which prompted greater mindfulness
and care around injecting and safe disposal.
Other health scares, such as overdose or the risk of having an amputation, reduced or deterred injecting
(at least temporarily):
I have just come out of hospital, this is from injecting, I had to sign a piece of paper to say that they
might not be able to save my thumb, that if they can’t save it, do I give them permission to amputate,
it was bad, I almost lost my hand and everything, it was really bad [. . .] so since I had that scare I
haven’t been doing it (injecting) as much.
London ID6, female, aged 27 years, heroin
Other participants cited life events, such as having children or close relatives dying, as events that
influenced them to change risk behaviours. As one participant described, the responsibility of family meant
‘I’ve got to be clean and tidy.’
Stable housing/lifestyle
Having stable housing and a more stable lifestyle also facilitated safer drug use as people injected in their
own homes:
I suppose when things changed for me was, you know, I – I thought – I moved away from the
situation I was in. I moved away from my life being chaotic. I moved into my flat; I’ve lived there for
ten years. I live a kind of fairly normal, stable life now [yeah]. I don’t use anywhere near as often,
you know.
London ID7, male, aged 50 years, heroin/crack cocaine
Intervention preferences for reducing blood-borne virus risk behaviours
Previous help and support for injecting behaviour change was mostly provided by key workers or nurses
at drug treatment services, although information had also been provided through outreach services
(specifically for sex workers and/or homeless), residential rehabilitation, prison services, drug treatment
testing orders and drug rehabilitation requirement courses, and a BBV charity. Most information was
provided through leaflets and usual treatment, although some had received information through BBV
infection testing and HCV infection treatment. Although some participants reported attending group
work sessions, few of these interventions focused specifically on BBVs or injecting/sexual behaviour
change, but these were rather a component of the sessions. Information and advice on BBVs was generally
well received and seen as useful, although some participants noted that it was not personally helpful as
they were unable to retain the information, already knew the information or were not motivated to
be informed:
I’ve done courses on this and I’ve read leaflets but actually when you ask me you know what are the
differences and like how – how are these things transmitted, I don’t really know, I forget. So yeah it’s –
it is quite important stuff isn’t it to be telling people again and again and again.
London ID14, female, aged 32 years, heroin/crack cocaine
I know the pros and cons o’, I know the rights and wrongs. I’ve been educated . . . but it’s doon tae
desperation. Basically I couldnae give a ****. As long as I get the drugs I don’t care.
Scotland ID10, male, aged 38 years, heroin
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Information and advice on overdose prevention strategies, where to access injecting equipment and help
with housing and benefits were perceived to be helpful, as was practical information on safer injecting
strategies, including how and where to inject safely on the body:
. . . when I done a medical trial in (hospital), the doctor there, he actually showed me, cos my arms are
terrible and my injection sites were really bad and I’ve never gone in my groin but he actually showed
me where to go if I was going to do it properly and safely yeah, so I don’t know if that . . . but him
showing me that that has helped me, it really has because I haven’t got any luckily any abscesses or
anything like that so people say well he shouldn’t have showed you that but I think well he’s helped
me because I’m quite you know been doing it 8 years now touch wood I’ve not had anything major
go wrong but before my arms were really bad, I had really bad like I did used to get bad abscesses,
they weren’t abscesses but really bad hard lumps and bruises all up my arm so yeah a doctor really
showed me how to do it properly.
London ID15, female, aged 34 years, heroin
Intervention content
When asked for their views on the development of an intervention for PWID, almost all of the participants
recommended the need for information on BBVs (including risk behaviours and consequences), safer sex
information and equipment provision (needles and condoms, including supply of and information on
where to access equipment):
. . . just find out all the different ways you can catch the Hep and HIV, just understanding more about
how you can catch it and what might happen if you’ve got it, things like that.
Wales ID6, male, aged 34 years, heroin/amphetamines
The majority also recommended content that would inform behaviour and skills. Thirty-one participants
recommended being taught injecting skills and techniques and nine of these wanted practical
demonstrations of injecting in order to reduce risks such as skin and soft-tissue infections, amputations
and venous damage:
Yes, you could maybe do groups where they show people how to inject properly, how to use the right
things, like tourniquets, like damage limitation.
York ID15, female, aged 33 years, heroin
Health and hygiene, overdose training and relapse prevention were also mentioned. In terms of health and
hygiene, participants suggested that promoting physical cleanliness, providing antibacterial hand wipes,
showing people how to clean injecting equipment, providing dietary advice and emphasising liver health
(particularly for those who have contracted a BBV), and encouraging PWID to move from injecting
to smoking:
. . . there should be something involved in some scheme or whatever, to promote keeping clean
physically, yourself, more than what there is. Because you don’t see it. I’ve never been in a class or, in
all my time of drug use, anything . . . and talking about keeping yourself clean, washing, blah, blah,
blah, you know, hand washing.
London ID1, male, aged 42 years, heroin/crack cocaine
Yeah, if they have a solution that they can say, right, look, if a needle is being used, if you do this and
clean it out in this way, this makes it much more likely to get rid of any blood-borne viruses, I think
people would definitely take notice of that. You know, obviously it’s not the safest thing, but if they’re
going to do it anyway, it’s best to show them how to do it the safest way, I think people would take
notice to that.
York ID2, male, aged 42 years, heroin
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Just over one-third recommended various psychosocial content including help with motivation and self-
esteem, assertiveness training and the involvement of family members and partners. A few participants
mentioned the value of encouraging PWID to think of other injectors’ safety when injecting in groups.
Teaching people to be more assertive with injecting and/or sexual partners was recommended by a
few participants:
Yeah, absolutely, you know, because there is a lot of bed hopping, there is a lot of, I’ll do anything
for a tenner, you know what I mean, but I’m sure half of these people aren’t aware of the dangers
they’re putting themselves in, you know, and it’s like . . . Alright, you might switch off when you’re
doing the business but, you know, you’re putting yourself at risk, you’re putting him at risk and you’re
putting anyone else at risk, you know, and that person could get into a relationship who’s never been
with anybody at all. It just takes one. You know, it’s silly and they need . . . it’s education, education,
education, education, you know?
York ID7, female, aged 47 years, heroin
Delivery style
The style of delivery favoured by most participants was a group format. They thought that it was useful
to share and learn from the experiences of others, although slightly fewer preferred one-to-one sessions
as they were uncomfortable engaging in groups because they either had mental health issues or had
concerns about other group participants. (This last concern was particularly prevalent among participants
in Wales, who were recruited from a rural area where anonymity or privacy is more difficult to maintain.)
A small number of participants in Scotland and London suggested separate groups for men and women,
although four participants also advocated interventions for couples. Online sessions or applications were
suggested, although most participants thought access may be limited (telephones sold or do not support
applications, unfamiliar with computers). Some participants thought that leaflets would be a useful
addition to face-to-face information delivery, although issues were raised around literacy and that some
PWID may not bother to read. Visual information as opposed to written or lecture-style delivery was
recommended so videos/digital versatile discs and leaflets with graphics were mentioned. Importantly,
information on safer injecting would be preferable if it was demonstrated rather than given in a leaflet:
Keep it tight, keep it tae the point, keep it interestin’, keep it relevant to their specific needs . . . Keep
it relevant tae their situation, so they can identify wi’ it. And if they identify wi’ it they’ll tune in tae it,
ken. You know what I mean? . . . get them involved and, you know what I mean, keep them involved
and interested.
Scotland ID11, male, aged 40 years, heroin
Duration, venue and personnel
The preferred length of sessions varied and ranged from < 30 minutes to 2 hours over one to six sessions,
although the preference was for multiple sessions:
Interviewer: How many times do you think you would, you would need to go to get . . . the
information? Would that be a on- off or . . .
Interviewee (Scotland ID2, male, aged 27 years, heroin): No I’d need tae go quite a couple o’ times
anyway, for a couple o’ weeks probably.
Interviewer: Yeah, yeah.
Interviewee: I dunno, I would need a few sessions o’ it probably.
Interviewer: Yeah OK. So be a few sessions though for a couple o’ weeks or something yeah?
Interviewee: Aye.
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Interviewer: And how long do you think the sessions should last?
Interviewee: Don’t know. Any time, anything between 15 minutes tae aboot half an hour
or something.
Scotland ID2, male, aged 27 years, heroin
Interviewer: OK. And how many sessions would be realistic?
Interviewee (York ID4, female, aged 36 years, heroin): I don’t know. See I don’t think one would be
enough, because I don’t think people would listen. Maybe three or four, you know, like, one a week
over a month or something.
Interviewer: OK. And how long do you think each session should be?
Interviewee: Oh, I don’t know, about an hour.
York ID4, female, aged 36 years, heroin
Drug services and needle exchanges were considered appropriate venues for intervention delivery by most
participants, while outreach/street teams were also suggested:
Interviewer: So where do you think it would be best delivered and who do you think it would be best
delivered by? So this workshop you’re talking about like where should we deliver it and who should
we get to deliver it?
Interviewee (London ID15, female, aged 34 years, heroin): I think um at a treatment centre because
that’s where most people go um yeah most people that use drugs will come to a treatment centre to
get their scripts so you’ve got them here already so you know they’re going to turn up.
London ID15, female, aged 34 years, heroin
Interviewer: [W]here do you think this would be best delivered?
Interviewee (York ID1, female, aged 32 years, amphetamines): [name of service].
Interviewer: [name of service], you’re saying [name of service], is that what you think?
Interviewee: Yeah.
Interviewer: So if [name of service] . . . why do you think [name of service] is the best place?
York ID1, female, aged 32 years, amphetamines
Interviewee: Because obviously that’s where most users go, you know, to have their treatment or their,
you know, just go for counselling or just for clean syringes, obviously, you know.
Other venues included chemists, sexual health clinics/services for sex workers, gay men’s services and
homeless hostels/homeless services, probation/offender programmes, residential rehabilitation units,
pre-existing groups (e.g. recovery cafes, Cocaine Anonymous, Narcotics Anonymous) and
participants’ homes:
Erm, centres like (name of service for women involved in prostitution), erm, they are – they are
extremely good, and because the women that work there, erm, they really do care, like.
London ID13, female, aged 32 years, heroin/crack cocaine
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[L]ocal housing estates just at the community centres, things like that. Maybe the chemists after they
close. Put the seats doon and dae it there. Things like that.
Scotland ID12, male, aged 30 years, heroin
In rehabs and that. Know what I mean, when they’re clean, getting clean. Or else see going intae
homeless places. But I don’t know. It’s just, just need tae gie them information. It’s whether they take
that on board or not. Know what I mean. If there’s two oot o’ ten there’s still, know what I mean,
they take it in [laughs]. There’s just places like that, homeless places and that.
Scotland ID13, male, aged 34 years, heroin
Although drug/needle exchange workers, health professionals and ex-drug users/sex workers were all
recommended to deliver an intervention, there were some slight differences across the four areas. For
example, in London and York, key workers, health professionals to teach safer injecting and ex-drug users/
sex-workers were favoured:
Interviewer: OK, and who do you think would be the best person to deliver this information?
Interviewee (York ID12, female, aged 19 years, heroin): Staff here could do it, couldn’t they?
Interviewer: OK, so, you know, key workers?
Interviewee: Yeah, a key worker, yeah.
Interviewer: OK, and why do you think a key worker?
Interviewee: Because they know you, don’t they, like they know most about you than anyone else
here, so.
I’m not a professional or anything, you know, I’m just picking up and going, oh like that. I should have
some professional help, like you know proper nurse telling you how to do it with a tourniquet, you
know what I mean, like how to let loose once it’s like comes out, do it all, wipe your skin before you
use you know with the alcohol wipes and all that so you don’t get dirt in them, all that, you know
what I mean like.
London ID5, male, aged 25 years, heroin/crack
Interviewer: OK. And who do you think, for example, if we decide to do a workshop, who do you
think would be the best person to give people this information, to talk to people about this issue?
Interviewee (York ID14, male, aged 24 years, heroin): People that had it happen to them. A person who’s
got HIV or Hepatitis, and that, for them to tell their story about how they caught it, and stuff like that.
Interviewer: OK. So you think it’s important to get someone with lived experience of what they’re
talking about?
Interviewee: Yeah.
The Welsh participants favoured drug workers to deliver the intervention:
Interviewer: If there is somebody who is going to deliver it to you, who would you want to deliver it?
Would you like drug workers, GPs [general practitioners], needle exchange . . . ?
Interviewee (Wales ID12, female, aged 28 years, heroin/crack): Needle exchange yeah.
Wales ID12, female, aged 28 years, heroin/crack
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Interviewer: OK, and who do you think would be best to deliver it, so you know would it be like for
instance harm reduction worker, needle exchange, GP [general practitioner], key worker, chemist?
Interviewee (Wales ID6, male, aged 34 years, heroin): Harm reduction or a key worker I think.
Interviewer: OK.
Interviewee: If you’re not with a key worker, the harm reduction would do, but one or the other.
Interviewer: So why would you find them most beneficial?
Interviewee: It’s cos you got partnership with them, you see them more often, doctor you only see
when you’re poorly but harm reduction you’re always around them, you always see more, more often
and listen to them more as well.
Wales ID6, male, aged 34 years, heroin
In Scotland, ex-drug users or a combination of peers and drug workers, general practitioners (GPs) and
needle exchange workers were recommended. Ex-drug users were considered relevant as they had ‘lived
experience’ of injecting and/or BBVs:
I’d say people like . . . the street team or people like who work in the [drug service]. I think the, the
street team are amazing . . . the street team are ex drug users.
Scotland ID14, female, aged 30 years, heroin
[I]t’d definitely have tae be somebody that’s been there and done it because they’re no gonnae really
listen tae somebody that’s like . . . nae offence or anything like that but I say you’ve never, you’ve
never stuck a needle in yourself.
Scotland ID9, male, aged 41 years, heroin
Barriers to attending psychosocial interventions
The main barriers to PWID attending psychosocial interventions were considered to be being too busy
earning money and using drugs, having a short attention span and being uninterested or considering the
intervention irrelevant. Feeling stigmatised, not wanting to disclose their BBV status and learning difficulties
were additional barriers. Travel to the intervention may be a barrier for some, especially those in rural
areas, whereas family responsibilities could make it difficult to attend, particularly for women with child
care responsibilities.
Facilitators of attendance
The most frequently suggested facilitators were cash or vouchers to incentivise attendance. Providing food
and refreshment on the day was also important. In Scotland, additional suggestions included vouchers for
haircuts, shoes or clothes, or gym passes. It was considered important to have an ‘informal’ and ‘relaxed’
atmosphere, and some suggested holding the sessions later in the day, keeping them short and interesting
and making attendance mandatory. Further suggestions for improving uptake included holding the
sessions on the same day as people are picking up their prescriptions or attending appointments and
ensuring that staff are delivering consistent information:
I think in, like, a group setting, but, like, an informal thing. Don’t make – cause it needs to be, kind of,
a relaxed atmosphere so people can open up and that sort of stuff, and, like, not – like, although it’s a
serious subject, like, you’ve got to, kind of – no one wants to sit there and listen to a lecture because,
at the end of the day, like I said, they’re sitting there when they could be earning money or taking
drugs. So, if they’re not enjoying themselves to a certain extent, then, like, people are going to lose
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concentration. Umm, so it kind of needs to be, like I said, with the concentration thing as well, like,
relatively short, and informal, like, people will just, kind of – I don’t know, just a relaxed atmosphere
and obviously the person delivering it needs to be quite charismatic as well.
London ID13, female, aged 32 years, heroin/crack cocaine
Summary of key findings
The above analysis of 60 qualitative interviews with current PWID highlights that a wide range of
individual, situational and structural factors contribute to injecting risk behaviours in this population, and
thus preventing BBV infection and transmission among PWID is a challenge that will require a multilayered
response. Figures 17 and 18 summarise the identified themes and subthemes. Relationships and social
networks are identified as crucial influences on risk behaviours, whereas access to needle exchanges and
safe injecting environments are vital for maintaining safer injecting behaviours. Drug states, such as
withdrawal and craving, and the trajectory of drug use generate priorities of more immediate concern to
PWID than BBVs. Furthermore, perceptions of BBV transmission risks change over time as knowledge is
gained and the interviews illustrate that there remains a great deal of uncertainty around BBV acquisition.
The perceived seriousness of HCV infection may be undermined by the view that it is an inevitable
consequence of injecting drug use, thereby leading to less safe injecting practices. Despite this, participants
described managing risk situations by planning ahead and being more vigilant regarding hygiene practices
when using with others. In addition, changes in life circumstances, such as access to stable housing,
facilitated improvements in risk behaviours. Risk management strategies were not necessarily intentionally
BBV protective, but were often employed to manage other risks such as overdose and soft-tissue
infections. For many of those interviewed, any intervention aimed at reducing risk behaviours should
include behavioural and skills components such as health advice, hygiene promotion and injecting skills.
Functional content, such as BBV information and injecting equipment/condom provision, along with
psychosocial content, such as assertiveness training, were also suggested. No consensus was drawn from
the participants regarding the length of sessions, preferred venues or style of delivery, suggesting that one
size will not necessarily fit all. However, interventions that are delivered locally by informed trainers and are
cognisant of the challenges PWID encounter in attending were considered important by the participants.
Implications for intervention development
The wide range of factors identified, which contribute to risk behaviours for BBVs, highlights the
importance of maintaining other efficacious interventions as well as developing psychosocial interventions
(including OST, adequate access to NSP and harm reduction advice). Consideration should also be given to
the provision of injecting rooms in the UK. The findings from the qualitative interviews with PWID were
used to develop the PROTECT intervention focusing on increasing knowledge about BBV transmission and
protective practices, and strategies to avoid risk situations such as withdrawal and lack of preparedness.
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Trajectory of drug use
• Addiction progression: increased willingness to take risks
• Needing help injecting: dependence on others and risk of injury,
   rather than BBV transmission, are paramount concerns
• Injecting others: pressure and risk of legal ramifications, rather than
   BBV transmission, are paramount concerns
Relationships and social networks
• Intimate relationships: the primacy of trust and familiarity
• Injecting in groups: negotiating safe practice is challenging
   for injectors who are less assertive
Access to resources
• Homelessness
• Restricted access to NSP
Values
• Compassion
• Individualisation of responsibility
Mental health
• Poor mental health promotes lack of
self-care
Perceptions of risk
• Knowledge of transmission risk
• HIV is considered the worst BBV to get
• HCV is considered the easiest BBV to get
• HCV infection may be seen as inevitable
• Hierarchy of risk: BBV infection is not the paramount risk concerning people
   who inject
• Hierarchy of importance: other priorities besides BBV protection may be
   paramount
Drug states
• Withdrawal/craving: balancing need and availability of
   equipment
• Intoxication: clouded judgement and reduced inhibitions
Factors influencing risk behaviour for BBVs
FIGURE 17 Themes and subthemes relating to factors influencing risk behaviours for BBVs.
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Participants’ intervention preferences for reducing
BBV risk behaviours
Intervention content 
• Safer injecting
• BBV transmission
• BBV testing/treatment
• Consequences of injecting and BBVs
• Promote BBV disclosure
• Cleaning equipment
• Where to get free needles/condoms
• Assertiveness training
• Working on self-esteem/self-worth
• Injecting relapse prevention
Format
• Group
• Individual
• Leaflets
• Application
• Couples
Barriers to attending 
• Too busy: need to earn money, drug use
• Not interested
• Not perceived as relevant
• Intoxication/withdrawal/craving
• Attention span
• Boredom
• Learning difficulties/mental health difficulties
• Childcare/family responsibilities
• Distance
• Desire for privacy/stigma/embarrassment
• Forgetfulness 
Venue
• Drug treatment centre
• Needle exchange
• Services for women involved in sex work
• Homeless hostels/homeless services
• Rehabilitation
• Pre-existing groups (eg. NA)
• Community centres
• Outreach
• Other
Personnel
• Key worker/drug worker
• Needle exchange worker
• Harm reduction worker
• Health professional
• Ex-drug user/sex worker
• Former drug user with lived
   experience of BBV  
Duration
• Length of session
• Number of sessions
Facilitators to attendance
• Money/vouchers
• Pre-formed groups (‘captive audience’)
• Refreshments
• Certificates
• Transport costs covered
• Non-judgemental
• Informal/relaxed setting
• Keep it short/interesting
• Later in day/evening
• Mandatory
• Service that seems to care
FIGURE 18 Themes and subthemes relating to participants’ intervention preferences for reducing BBV risk behaviours. NA, Narcotics Anonymous.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
1
7
2
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
7
V
O
L
.
2
1
N
O
.
7
2
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
7
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
G
ilch
rist
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
aljo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
7
3
Chapter 4 Consultation with key stakeholders on
the delivery and effectiveness of psychosocial
interventions to reduce blood-borne virus
transmission risks among people who inject drugs
Aims
The main aims were to consult key stakeholders about the delivery and effectiveness of psychosocial
interventions in reducing BBV transmission risks among PWID, including highlighting any barriers to, or
facilitators of, delivery in substance use treatment in the UK to practically inform the implementation of the
feasibility trial (see Chapter 6).
Methods
A telephone consultation was carried out with 40 national and local stakeholders (from Scotland, England,
Wales and Northern Ireland), including service providers, policy-makers and commissioners. Selected
stakeholders were key informants in the sense that they had responsibility for delivering and/or commissioning
services in BBV prevention in the UK and would be in a position to identify the system barriers and facilitators
necessary for successful implementation of the intervention in phase V, and beyond, in phase VI. In the first
instance, key stakeholders in England and Wales were identified by Public Health England and Public Health
Wales, respectively, which have responsibility for overseeing the delivery of BBV action plans. In Scotland, key
stakeholders were identified by the co-applicants and selected from those people with responsibility for
delivering the Sexual Health and Blood Borne Virus Framework. In Northern Ireland, key stakeholders were
recruited through the Department of Health, Social Services and Public Safety, which has responsibility for
BBV. Some of the stakeholders that were approached or interviewed referred the researchers to other
appropriate colleagues who they felt would be well situated to respond to the consultation.
The consultation enquired about:
l key priorities for reducing BBV among PWID
l awareness of current delivery of psychosocial interventions to PWID in their area
l the need to develop psychosocial interventions to reduce BBV infections among PWID
l content of psychosocial interventions
l current barriers to, and facilitators of, delivering psychosocial interventions in harm reduction settings in
their area.
The topic guides can be found in Appendix 3.
Analysis
Interviews were transcribed by professional transcription services and qualitative software (NVivo 10)224 was
used to manage and code the interviews. Thematic analysis of the data was conducted by Davina Swan
and April Shaw. The researchers independently coded the first three interview transcripts, then reviewed
the coding at a Skype meeting and collaboratively generated an initial thematic framework. This coding
framework was applied to the remaining interviews (indexing) by Davina Swan and April Shaw.
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Ethics approval
Ethics approval was not sought for this consultation, as it was not considered to be research. As such, to
protect stakeholders’ anonymity, the findings have been compiled together rather than separately across
the four UK regions areas.
Results
Forty stakeholders, mostly policy-makers, from the four UK nations were consulted (Table 10).
Key priorities for reducing blood-borne viruses among people who
inject drugs
At the time of the consultation, stakeholders identified a range of activities and target groups which they
considered to be key priorities to reduce BBV transmission rates among PWID across the UK: BBV education,
needle exchange provision and access to counselling were the most often cited, followed by stabilising
and addressing client needs, OST, client-centred services and the reduction of sharing injecting equipment
(Table 11). Screening and diagnosis for BBVs, reducing HCV and HIV incidence, and access to BBV/HCV
infection treatment and HBV vaccinations were also key priorities. Stakeholders highlighted groups which
need particular attention regarding BBV prevention, such as men who have sex with men (MSM), particularly
chemsex injectors (i.e. MSM who inject psychoactive substances, such as crystal methamphetamine and
mephredone, immediately before or during sex), and PWID who have limited engagement with services,
novel psychoactive substance (NPS) users, migrant communities, IPED users and young people.
Issues in delivering on priorities
A number of issues were identified that impeded delivering on the priorities outlined above. These
included funding and resources, staff capacity, access to services (particularly in rural areas), stigma in
relation to drug use, and challenges with recruitment and retention of clients in services. Other difficulties
identified included fractured care pathways, complex commissioning landscapes and lack of integrated
services. Stakeholders identified a need for services to have a person-centred approach and it was
suggested that service users be involved in the design of services. Finally, evidence is required to
understand BBV transmission and identify gaps in service provision among people who inject NPSs.
Funding and resources were the most commonly cited, along with challenges around commissioning
structures. A number of stakeholders suggested that it was challenging for different local authority
structures to work together as there are often competing priorities within the same local authority area.
Competing priorities within central government departments also present a challenge to commissioners
and policy-makers. For example, it was mentioned that the recovery agenda (i.e. the focus on freedom
from drug dependence, and improved well-being and citizenship) may threaten adequate provision of
TABLE 10 Sample of professional stakeholders
Role
Location in the UK (n)
Northern Ireland Scotland England Wales
Policy 6 10 6 2
Practitioner 3 1 0 4
Policy and practice 0 0 5 3
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needle and syringe programmes and opiate substitution treatment in some areas. Co-ordinated and
joined-up working between services, including pharmacy, statutory and voluntary organisations, was also
an issue that needs addressing.
It was thought by some that there was an over-reliance on pharmacy needle exchanges, which may be
detrimental to the needs of opiate users and MSM, in that the standard of care and assessment of needs
may be better met at drug treatment services. Also, the sheer number of local authorities, all with different
priorities, made delivering and maintaining extensive and effective high-quality needle and syringe programmes
and adequate penetration of opiate substitution treatment across all areas challenging. Ensuring access to
OST for PWID who prefer low-threshold services (i.e. services for drug users not in treatment that do not
attempt to control drug use but endeavour to reduce barriers to service access and provide counselling and
treatment only if requested), rather than therapeutic services, was deemed important.
TABLE 11 Key priorities for reducing BBV among PWID
Priority Number of stakeholders who mentioned this
Priority activities
BBV education 14
Needle exchange provision/coverage 11
Access to counselling/services 11
Stabilise PWID lifestyle/address multiple complex needs 7
Opiate substitution treatment 4
Client-centred services 3
Reducing sharing of needles and syringes 3
Priority BBVs
BBV infection screening/diagnosis 13
HCV infection incidence 9
Access to BBV/HCV infection treatment 9
HIV infection incidence 7
HBV vaccination 3
Priority risk groups
Chemsex injectors/MSM 7
PWID with limited engagement with services 7
NPS users 7
Young people (aged 18–24 years) 5
Migrant communities 4
IPED users 4
Recreational drug users 2
Prisoners 2
Ex-users 1
PWID’s social networks/partners/children 1
Homeless 1
Lesbian, gay, bisexual, transgender 1
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A number of stakeholders suggested that there were issues regarding the offer of BBV infection testing
and HBV vaccinations as there remains a substantial number of service users who do not take the
opportunity to be tested and/or do not engage with services frequently enough to complete the full course
of HBV vaccination. Moreover, access to HCV infection treatment was considered inadequate by some, as
hepatology services were not appropriately structured for this client group and there needs to be more
outreach into the community. Fractured care pathways between prisons and community services were
another area of concern, particularly for prisoners with HCV infections post release.
Particular concerns were raised for those living in rural areas as it was often difficult to access harm
reduction and hepatology services, as these could be some distance from the communities in which PWID
live. Additionally, it is difficult to access the new and hard-to-reach groups who are not engaged with
services (recreational users, MSM, IPED users, some migrant communities, club drug users, those aged
18–24 years, homeless groups and stimulant users). Providing access to harm reduction and hepatology
services through outreach and ‘embracing new approaches’ may help increase access to HBV vaccines and
HCV infection treatment for the hard-to-reach groups.
Current delivery of psychosocial interventions to reduce blood-borne
virus transmission risk behaviours
Although some stakeholders were aware of psychosocial interventions that included BBV infection
reduction components within a programme of harm reduction, most were unaware of any specifically
designed to reduce BBV infection. Most stated that BBV information and education was incorporated into
‘usual’ harm reduction conversations by key workers in drug and alcohol services and practitioners in
needle exchange and specialist services.
Support for the delivery of psychosocial interventions to reduce
blood-borne virus transmission risk behaviours among people who
inject drugs
Around half of the respondents agreed there was a ‘need to develop psychosocial interventions to reduce
BBV among PWID’; however, almost as many were unsure or were unconvinced. Lack of evidence of
effectiveness or reservations around whether or not anything new could be added to existing BBV
infection prevention strategies were the main reasons for the uncertainty. However, for those who
agreed, some stressed that psychosocial interventions were one of a range of options within a holistic
package of care.
There was a range of views on the delivery of psychosocial interventions for PWID. When asked for their
views on the content, and development, of the psychosocial intervention for this project, most thought
that it should be targeted to drug users at all stages of drug use and not at any particular point in the
trajectory of drug use, although a few suggested targeting novice or new PWID. A few suggested some
degree of tailoring of a psychosocial intervention, for example to the type of drugs injected, to the
‘individual’ and to the intervention setting. There was no consensus on the delivery format, with
stakeholders suggesting a psychosocial intervention to reduce BBV infection among PWID should be brief
and opportunistic, delivered one to one, a mix of individual and group work, group work only and as an
online intervention. When specific settings were mentioned, they included needle exchanges and drug
treatment services, sexual health services (for MSM), and gyms and fitness clubs (for IPED users). Other
settings included outreach, BBV treatment services, homeless accommodation/hostels, satellite GP
surgeries, ancillary services (e.g. housing/welfare support services), mental health services, pharmacies,
hospitals, gay clubs/saunas, nightclubs and individuals’ homes.
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When asked who should deliver such psychosocial interventions, a variety of facilitators were suggested,
including keyworkers, drug workers or harm reduction staff in drug treatment settings and needle
exchanges; trained peer educators (in specific communities of users such as MSM and IPED users or,
generally, within harm reduction services); pharmacists; allied health professionals (e.g. sexual health
workers, hospital staff, health visitors, community nurses); GPs; and psychologists. Stakeholders were clear
that any facilitators should be trained and supported to deliver the intervention.
Table 12 shows the content suggested by stakeholders. They can be categorised as (1) BBV specific
(e.g. education on disease transmission); (2) addressing behaviour and skills (e.g. reducing risk behaviours,
improving injecting skills); and (3) addressing individual needs (e.g. improving self-efficacy, addressing
reasons for injecting). As well as ensuring any psychosocial intervention is ‘culturally sensitive and culturally
acceptable’ for the range of PWID, a few stakeholders suggested content that achieves goals other than
those directly related to BBV transmission reduction (e.g. good vein care and injecting technique to
maintain vascular access).
There was some ambivalence regarding the provision of incentives for attendance at psychosocial
interventions, with some stakeholders in favour of providing cash, vouchers or refreshment, whereas
others thought it unnecessary or were undecided.
Facilitators of the delivery of psychosocial interventions to reduce blood-
borne virus transmission risk behaviours among people who inject drugs
Stakeholders highlighted several key criteria to ensure the effective delivery of a psychosocial intervention
specifically aimed at reducing BBV transmission risk behaviours for PWID both nationally and locally.
The psychosocial intervention:
l should be evidence based for effectiveness and cost-effectiveness
l should have clear scope and clearly defined objectives for consistent delivery
l should have a practical time frame in terms of delivery and facilitator
l should be person centred and simple for staff to apply
l should include well-designed training and support materials
l should include appropriate pathways and management
l must meet the needs of the client group (peer input).
TABLE 12 Suggested content for psychosocial interventions
BBV specific Behaviours/skills Individual
Conducting/encouraging BBV infection
testing
Reducing risk behaviour Explore root cause of why injecting/having
risky sex
Education on transmission, risk of
infection, disease and disease
progression, health effects
Preventing initiation of injecting Looking at social support and social
networks
Information on/support with BBV
treatment
Identifying triggers of risk
behaviour
Address self-efficacy/self-esteem/
motivation to change
Hygiene, good vein care and
injecting technique
Look at values (helping to support others
not to share)
Other routes of administration Addressing impulsivity, ambivalence
Drug tolerance/reduced
tolerance
Assertiveness/negotiation skills training
and preparedness for situations of peer
pressure and enticement
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At the system level, such interventions should:
l be integrated into current service delivery rather than separate commissioning
l require political, management, commissioner, worker and client buy-in
l be adequately funded
l be delivered by a trained workforce
l ensure capacity for staff to be released for training/delivery
l be marketed to PWID
l be monitored and evaluated (e.g. inclusion in the National Drug Treatment Monitoring System for
reporting purposes).
In order to evaluate the effectiveness of a psychosocial intervention aimed at reducing BBV among PWID,
stakeholders mentioned several outcomes that should be measured, such as:
l behaviour changes (e.g. changes in injecting behaviours/skills, drug use and risks)
l knowledge (transmission, risks prevention and BBVs)
l health benefits
l HBV vaccination rates
l self-esteem, confidence
l process outcomes (e.g. number of staff trained, intervention uptake)
l impacts on delivery in different environments
l facilitator competencies
l acceptability of the intervention
l review of PWID needs following the intervention.
Additionally, a small number suggested BBV infection prevalence/acquisition as a measure of effectiveness,
but accepted that this would be difficult to do and the measures would need to be longitudinal. However,
it was also suggested that injecting site problems could be used as a proxy measure in place of BBV
infection prevalence.
Barriers to the delivery of psychosocial interventions to reduce
blood-borne virus transmission risk behaviours among people who
inject drugs
The barriers identified related to workforce, clients, structural issues and intervention design attributes
(Table 13). Workforce barriers included concerns around staff resources and capacity to deliver psychosocial
interventions within their current practice and ensuring that staff who deliver them are adequately skilled,
trained and supervised. Although staff competencies were considered a workforce barrier, some
stakeholders noted they already had highly skilled staff and workforce development teams in place.
Client barriers included client motivation and concentration, and some stakeholders were sceptical of the
ability to recruit and retain clients to such interventions. Improving access and reducing stigma may help
with the perceived client barrier to recruitment and retention, as might the provision of OST as an
incentive for engagement. Involving service users and workers in the design, development and delivery of
the intervention may ensure that it meets the needs of the clients and workers and is adaptable to
different target groups and sites.
The most frequently cited structural barrier was ensuring funding was available. Commissioner, staff and
client buy-in was also an issue for some, whereas others thought that BBVs were not considered as high
a priority within the current treatment climate, which focuses on the recovery agenda. In terms of
psychosocial intervention design attributes, the considered barriers were whether or not the intervention
meets the needs of clients, fits into current treatment, and provides sufficient training and support.
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TABLE 13 Barriers to, and facilitators of, delivering psychosocial interventions
Barriers Facilitators
Workforce
l Staff resources and capacity
l Staff competencies
l Staff perceptions of added value
l Lack of experience among staff outside of
treatment settings
l Different levels of experience, knowledge, training
and professional registration across the UK
l Existing skilled workforce in place
l Existing local workforce development team
l Existing outreach service/team
l Proper training and supervision of staff
l Staff engagement
l Having a local workforce development team
l Having suitable (e.g. nursing/social work) staff in an
organisation who could be trained up
Client
l Client recruitment and retention
l Motivating clients to change
l Client abilities to concentrate
l Stigma
l Involve peers in design and delivery
l Improve access to services
l Reduce stigma
l OST as ‘incentive’ for PWID engagement
Structural
Funding
Buy-in from clients and workers
Complex commissioning landscape
HCV (in general) does not integrate well with the
recovery agenda
Political climate does not support harm reduction but
rather exiting of treatment as organisational target
Commissioning cycles, difficult to change what is
currently in contracts
l Client and worker buy-in
l Existing appetite for brief interventions for risk behaviour
l Local and national champions/opinion leaders
l Effective community engagement
l Joint working between services (e.g. police, NHS, voluntary
services and education)
l Pharmacies and needle exchanges to deliver intervention
l Generally a positive strategic and political outlook on
tackling BBVs and other drug-related harms
l NICE backing/guidelines
l Orange Guidelines/backing
l Harm reduction philosophy exists within services,
marginalised but still there
l Governmental departmental buy-in
l All commissioners should have leverage to be able to
introduce this into existing contracts
l Include it as a requirement in future tender contracts
l Support of local authority chief executive and director of
public council active members
Design attributes
l Does the psychosocial intervention meet the needs
of the clients?
l Effective training with support
l Adapting psychosocial interventions to different
sites/clients
l Quality of evidence (of effectiveness)
l Systems in place to monitor and evaluate
l How to fit it in current treatment pathways (not an
add on)
l Evidence base
l Look to/learn from work done in alcohol field
l Tie in to human rights
l Involve key workers in the design, development and delivery
of the intervention
l Involve peers in design, development and delivery
l Not just delivered by drug and alcohol services but GPs and
sexual health workers
l Opportunistic intervention
Other
Location/distance
NICE, National Institute for Health and Care Excellence.
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Ensuring local and national champions are on board may encourage buy-in from commissioners,
managers, staff and clients.
The importance of monitoring and evaluation systems to measure effectiveness was highlighted.
Summary of stakeholder consultation findings
The findings from the consultations with 40 professional stakeholders highlight the current challenges and
potential facilitators for the delivery of psychosocial interventions to PWID. Although there are a range of
activities and priorities to reduce BBV transmission among this cohort of drug users, there are a number of
structural and systemic issues that may impede delivering on those priorities. Although current activities
and strategies include BBV components within harm reduction programmes, it was thought by a large
minority that there was a need to develop psychosocial interventions specifically to reduce BBV
transmission among PWID. Suggested content for future psychosocial interventions should include specific
content on BBVs, and content that addresses client behaviours, skills and individual needs including the
symbiotic goals identified by PWID. Although these may be related to goals other than BBV transmission,
they may still have a positive impact on safer injecting behaviours and in turn, BBV transmission. In order
to enable effective delivery of a psychosocial intervention, a range of workforce, client, structural and
design barriers need to be addressed, but there was some indication that current and future facilitators
could overcome some of these. The main criteria stakeholders required to ensure effective delivery of a
psychosocial intervention nationally and/or locally were that any intervention should be evidence based,
have clear objectives, be adequately funded and have clear buy-in from all relevant stakeholders. Ensuring
staff are trained and supported and that the psychosocial intervention meets the needs of PWID was
important, and any intervention development required input from peers and facilitators in its design
and delivery.
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Chapter 5 Intervention development
Intervention development
The intervention was co-developed by service users, service providers, policy-makers and academics.
The intervention content was informed by (1) a review of the evidence about what works to reduce BBV
risk behaviours among PWID (see Chapter 2); (2) qualitative interviews with PWID (see Chapter 3);
(3) consultation with key stakeholders (see Chapter 4); and (4) expert opinion. There were three tiers of
intervention development. The Steering Group was responsible for the final agreement of manual content.
This group was supported by two development groups: an expert group (comprising practitioners,
academics, policy-makers) and a patient and public involvement group with lived experience of injecting
drug use. These two groups met separately three times during the process (Figure 19). Intervention
development group members are listed in Appendix 4 with their consent.
The process of reaching consensus on key intervention content was undertaken through debate and
discussion to generate and prioritise ideas. At the first meeting, findings from the following phases of the
research were presented:
l review of the evidence about what works to reduce BBV risk behaviours among PWID
l qualitative interviews with PWID
l consultation with key stakeholders.
The systematic review identified 16 effective interventions in reducing BBV risks or increasing knowledge
about BBV among PWID. Authors of all these interventions were approached by e-mail and invited to share
their interventions with the intervention development group. Only five of these manual authors agreed to
provide the research team with a copy of their manual. Manual content was reviewed and described by the
intervention groups (Table 14). Most effective interventions were multisession and delivered to groups. The
main functions used in these interventions were education, training, enablement, persuasion, incentivisation
and persuasion.67 These findings and functions were used to inform the content of the PROTECT intervention.
Situations described by PWID during the qualitative interviews where they perceived they were more likely
to engage in BBV injecting or sexual risk behaviours were listed and intervention content from existing
interventions mapped against these risk situations. Where existing interventions did not include
intervention content to address the specific risks identified by PWID, the intervention group developed
appropriate materials using data from the qualitative interviews to illustrate risk behaviours, barriers and
potential solutions (Table 15).
Intervention content development
Service User Advisory Group
Sign-offIntervention
Development
Group
Three meetings
Service User 
Advisory
Group
Three meetings
Facilitators
Steering Group
FIGURE 19 Intervention development process.
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TABLE 14 Effective interventions
First
author
Behaviour successfully
changed in intervention
compared with control
group
Delivery
format
Intervention functions67
Education Persuasion Incentivisation Coercion Training Restriction
Environmental
restructuring Modelling Enablement
aAvants
et al.174
Reduction in unprotected
sex
Individual ✗ ✗
El-Bassell
et al.177
Reduction inunprotected
sex
Couple ✗ ✗
Gagnon
et al.178
Sharing syringes at
1 month not sustained
to 3 months
Individual ✗ ✗ ✗ ✗
aGarfein
et al.179
Any injecting risk Group/peer-
education
intervention
✗ ✗ ✗
aGilbert
et al.73
Sharing syringes/any sex
risk behaviour/reduction
unprotected sex
Couples ✗ ✗ ✗
Latka
et al.182
Any injecting risk Group ✗ ✗
aLatkin
et al.72
Any injecting risk/sharing
syringes
Group ✗ ✗ ✗
Margolin
et al.186
Sharing syringes/
reduction inunprotected
sex
Individual ✗ ✗ ✗
aMcMahon
et al.84
Receptive syringe sharing
with primary partners/
frequency of unprotected
anal intercourse
Couple/
individual
✗ ✗
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First
author
Behaviour successfully
changed in intervention
compared with control
group
Delivery
format
Intervention functions67
Education Persuasion Incentivisation Coercion Training Restriction
Environmental
restructuring Modelling Enablement
Otiashvilli
et al.188
Any injecting risk/sharing
syringes/frequency of
injecting
Couple ✗ ✗
Robles
et al.192
Any injecting risk/sharing
syringes/frequency of
injecting
Individual ✗ ✗ ✗
Rotheram-
Borus
et al.193
Frequency of injecting Group/
individual
✗ ✗
Sterk
et al.81
Frequency of injecting/
reduction inunprotected
sex
Group ✗ ✗ ✗
Strathdee
et al.77
In one site only, receptive
needle sharing
Group ✗ ✗ ✗ ✗ ✗
Tobin
et al.76
Any injecting risk Group ✗ ✗ ✗
Wechsberg
et al.75
Any sex risk behaviour/
reduction inunprotected
sex
Group ✗ ✗ ✗
a Manuals sourced and content reviewed.
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Based on the findings of interviews with PWID and the PPI intervention development group’s views, it was
decided that the intervention should therefore be brief, three 1-hour sessions and delivered once a week in
a group format. The PROTECT intervention (as it was named) sessions, would address:
l session 1: improving injecting technique and good vein care
l session 2: planning for risky situations
l session 3: understanding BBV transmission.
Following this meeting, a logic model describing anticipated delivery mechanisms, intervention
components, mechanisms of impact and intended outcomes was developed to further guide the
intervention development process (Figure 20).226 The COM-B (‘capability’, ‘opportunity’, ‘motivation’ and
‘behaviour’) model was the theory of behaviour change used to inform the intervention,67 that is that
capability (i.e. individual’s psychological and physical capacity to engage in the activity concerned including
having the necessary knowledge and skills), opportunity (i.e. factors outside the individual that make the
behaviour possible or prompt it), and motivation to interact to generate behaviour change.
The research team drafted the intervention based on the discussion in the first meeting and sent the revised
intervention to the groups to review as a homework task in advance of the second meeting. The refined draft
intervention was discussed at the second group meeting to identify further areas in need of development.
The remaining meeting was used to further refine the content. The intervention was also sent to facilitators
prior to the training. During the training event, facilitators also contributed to intervention refinement.
TABLE 15 Intervention to address risk factors for engagement in BBV risk behaviours identified by PWID
Risk factors for engagement in
BBV risk behaviours identified
by PWID (see Chapter 3) Intervention content
Intervention
function67
Withdrawal/cravings/intoxication Develop strategies/plan to prepare for or avoid risk situations Enablement
Access to/lack of sterile injecting
equipment
Knowing where to access equipment Education
Develop strategies/plan to prepare for or avoid risk situations Enablement
Administration methods other than injecting in situations where
there is no access to sterile injecting equipment
Education
Apathy/low mood Awareness of context Education
Homelessness Develop strategies/plan to prepare for or avoid risk situations Enablement
Inadvertent sharing Develop strategies/plan to prepare for or avoid risk situations Enablement
Lack of knowledge about
transmission risks
Educate PWID about transmission risks for BBV Education
Video about cross-contamination of sharing injecting equipment Education
Lack of assertiveness to insist on
safer practices
Develop strategies/plan to prepare for or avoid risk situations Enablement
Develop assertiveness skills Training
Sex trading Develop strategies/plan to prepare for or avoid risk situations Enablement
Requires help injecting Skills building to learn to inject self Training
‘Symbiotic’ goals that may impact on BBV risk behaviours
Help finding a vein/image
management
Video explaining how to inject safely Modelling
Education around how to find a vein and improve venous access
and good vein care
Education
Requires help injecting/injects
others
Skills building to learn to inject self Training
Administration methods other than injecting in situations where no
access to sterile injecting equipment
Education
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Inputs
Target
population
Theories and
assumptions
Activities Outputs
Using these
resources . . .
To reach . . . To guide the
intervention . . .
we will accomplish this . . . and produce these
products
Which will produce these
short-term outcomes . . .
with these
long-term outcomes . . .
Research/knowledge
• Reducing BBV risk
   behaviours/what works
• What influences PWID
   injecting/sexual risk
   behaviours
• What PWID said
   want/need from an
   intervention
Policies
• Harm reduction
• Recovery
Partnerships
• Clinical research
   networks
Funding
• NIHR HTA programme
• NHS support and
   treatment costs
• In kind support from
   third-sector
   organisations
Staff
• Academic
• Drug treatment service
   staff
• Peer educators
   (London)
Men and women
who have injected
drugs at least once
in the past month
and who are
engaged with
needle exchanges or
harm reduction
substance misuse
treatment services
COM-B model of
behaviour capability,
opportunity and
motivation interact to
generate behaviour
Develop a group
intervention and training
manual
Train staff/peer educators
to deliver PROTECT group
intervention
Develop recruitment
protocol for participants
Gather outcome and
process data
Training and
intervention
manuals
Increased understanding of
BBV transmission risks
Enhanced injecting skills
and understanding of the
implications of good vein
care
Reduction in risk behaviours
• Sharing of needles and
   other injecting equipment
• Unprotected sex
Increased self-efficacy
• Negotiating safer
   injecting and sexual
   behaviours
• Finding a vein
• Being prepared for risk
   situations
Developed solutions/plan
for ensuring safer injecting
and sexual practices in risk
situations
Reduced transmission of
BBV
FIGURE 20 The logic model for PROTECT intervention. COM-B, ‘capability’, ‘opportunity’, ‘motivation’ and ‘behaviour’.
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Content of the intervention
The intervention was manualised, including instructions for facilitators and PowerPoint slides (Microsoft
Corporation, Redmond, WA, USA) to accompany the manual. Handouts, as required, were prepared for
participants. Manualised interventions are recommended as they promote consistent evidence-based
practice, enhance treatment integrity and facilitate staff training.227 This is important as ‘the integrity and
discriminability of the treatments delivered’ are key components of internal validity of trials.228 The final
intervention content is outlined below.
Session 1: improving injecting technique and good vein care
Goals for session 1
l Introduce the PROTECT project and intervention.
l Build group cohesion.
l Establish group agreement.
l Engage participants.
l Increase knowledge about improving injecting techniques and good vein care.
Objectives
Participants will:
l understand what participating in the intervention requires
l feel a sense of group cohesion
l increase skills for injecting and achieving good vein care
l consider changing their risk behaviour.
Session 1 outline
l Introduction and welcome (10 minutes).
l Group agreement (10 minutes).
l Any questions about how to improve injecting techniques and good vein care? (10 minutes.)
l Skills building: how to improve injecting techniques (15 minutes).
l Skills building: how to achieve good vein care (15 minutes).
l Close.
Materials required
l PowerPoint presentation.
l Attendance register.
l Flipchart and pens.
l Participant folders.
l Name badges (ensure names written before sessions).
l Group agreement.
l Video: ‘collapsed vein’.
l Video: ‘how an abscess is formed’.
l Video: ‘spot the difference’.
l Video: ‘how to wash your hands’.
l Video: ‘safer Heroin Injecting’.
l Video: ‘how to clean a syringe’.
l Local needle exchange leaflet (localities and opening hours).
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Handouts
l Timetable of sessions.
l Group agreement.
l Local needle exchange leaflet (localities and opening hours).
Session 2: planning for risky situations
Goals for session 2
l Identify situations where injection and sexual risk behaviours are more likely.
l Identify barriers to reducing injection and sexual risk behaviours.
l Identify solutions for reducing injection and sexual risk behaviours.
l Plan for avoiding situations where injection and sexual risk behaviours are more likely.
l Motivate participants to plan for risk situations.
Objectives
Participants will:
l increase their awareness of situations where injection and sexual risk behaviours may be more likely
l understand why, in certain situations, some people who inject may engage in injection and sexual
risk behaviours
l be able to identify and provide solutions to injection and sexual risk behaviours
l use the TALK (Timing is everything; Assert what you want; List your reasons for being safe; Keep to
your bottom line) model to negotiate safer injecting and sexual practices
l develop a ‘be prepared’ plan for risk situations.
Session 2 outline
l Welcome and feedback on session 1 (5 minutes).
l Why do people do risky things that can put them at risk of BBVs? (20 minutes.)
l Skills building: using TALK to negotiate safer sex and injection.
l Behaviours (15 minutes).
l Developing a ‘be prepared’ plan for risk situations (20 minutes).
l Review and close.
Materials required
l PowerPoint presentation.
l Attendance register.
l Flipchart and pens.
l Participant folders.
l Name badges.
l Group agreement.
l Potential risk scenario cards.
l TALK poster.
l Be prepared plan.
Handouts
l TALK poster.
l Be prepared plan.
l Example of preparedness plan.
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Session 3: understanding blood-borne virus transmission
Goals for session 3
l Increase knowledge about BBVs and transmission injecting risk behaviours.
Objectives
Participants will:
l increase their knowledge about BBVs and transmission risk behaviours.
Session 3 outline
l Introduction and welcome (10 minutes).
l Myths and facts (game) about BBVs (20 minutes).
l Any questions about how BBVs are transmitted (10 minutes).
l Injecting risks: cross-contamination (video) (15 minutes).
l Close (certificate awards, 5 minutes).
Materials required
l PowerPoint presentation.
l Attendance register.
l Flipchart and pens.
l Participant folders.
l Name badges.
l Myths and facts cards.
l ‘Dye demo’ video.
Handouts
l Myths and facts cards.
l Certificates.
We are grateful to the following for their permission to use or adapt their resources for the
PROTECT intervention:
l The Drug Users Intervention Trial (DUIT) for permission to reproduce and adapt some sessions from
its intervention.179
l Exchange Supplies for permission to use extracts from its booklets/videos in this resource.229
l The Australian Injecting and Illicit Drug Users League for permission to use extracts from its website/
videos in this resource.230
l The London Joint Working Group on Substance Use and Hepatitis C for permission to use content from
its Booklet 1. Hep C Info. Understanding Hepatitis C and Staying Safe.231 This booklet has been
developed through a joint working initiative between Dr Magdalena Harris at the London School of
Hygiene & Tropical Medicine and the London Joint Working Group on Substance Use and Hepatitis C.
The booklet draws on the research of Dr Harris and is written by Danny Morris and Magdalena Harris.
l Merchants Quay Ireland Homeless & Drugs Services.232
l Drugs and Health Development Project.233
l The Self-Help in Eliminating Life-Threatening Diseases (SHIELD).72
l The Staying Safe Intervention.47
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Training in the delivery of intervention
Group training that follows a detailed treatment manual is best practice to ensure that interventionists
acquire skills and demonstrate competence in intervention delivery during the trial(s).228 A 1-day group
training was delivered in London in January 2016 face to face, facilitated by the chairperson of the
Steering Group who is also a clinical director for addiction services and a service educator. The training was
attended by facilitators from all four sites included in the feasibility study. Participants at the training event
were given the PowerPoint slides, videos and intervention manual in advance of the training event to
familiarise themselves with content and aims of the intervention.
The training event began with a presentation of the findings from the evidence of what works, risk
situations reported by PWID and the intervention development process. Thereafter, the principles of the
intervention delivery were presented and then each session of the intervention was delivered as if the
facilitators were the group members to allow the group to understand the group in practice. Facilitators
were encouraged to contribute to the final refinement of the model.
Patient and public involvement in the intervention development
Four service user representatives (two from London and two from Wales) and three peer educators (two
from Glasgow and one from England) were involved in co-producing the intervention content. Their
guidance around existing harm reduction materials was instrumental in developing the intervention and in
the choice of the intervention leaflet used in the feasibility trial. The use of an additional ‘bonus’ CM
payment for attending all three PROTECT intervention sessions was suggested by one service user
representative. Finally, one peer educator co-delivered the intervention training and another attended the
training. Facilitators found the discussion with peer educators to be extremely useful because of the
knowledge they shared on injecting practices.
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Chapter 6 Feasibility trial
Trial design
The PROTECT trial was a pragmatic, two-armed, randomised controlled, open feasibility trial, with equal
randomisation delivered across four UK sites. PWID aged ≥ 18 years, attending NHS or third-sector
community addiction, harm reduction clinics or needle exchange programmes, who consented to
participate were randomised (1 : 1) to receive either:
l the intervention arm: a psychosocial group (brief) intervention developed during the early phases of the
project work, involving three sessions facilitated by a drugs worker/peer mentor, an information leaflet
on reducing the transmission of BBVs and TAU from the service from which they are recruited
l the control arm: an information leaflet on reducing the transmission of BBVs and TAU from the service
from which they are recruited.
The study summary can be seen in Appendix 5.
Sample size
As a feasibility study, the main purpose was to assess the acceptability, feasibility and to obtain
information that would inform the design of a larger full-scale trial. Therefore, no formal sample size
calculation was conducted. However, we aimed to recruit 16 participants within each of the four locations
and two service settings (needle exchange or community drug service, i.e. 128 patients in total). Half were
to be allocated to the intervention arm and half to the control arm (64 patients per arm). This sample size
exceeded that recommended for feasibility studies of between 24 and 50234–236 and allowed feasibility
assessments within both community clinics and needle exchanges. Based on previous studies, retention
was estimated around 60–88% at the 1-month follow-up (77–113 participants).188,197,237
Approvals obtained
East Midlands – Leicester South Research Ethics Committee approved the study on 3 November 2015
(reference number 15/EM/0413).
Local research and development (R&D) approval was obtained, as well as agreement to participate from
the relevant services. The project was approved by South London and the Maudsley NHS Trust R&D
(reference number R&D2015/094) on 12 November 2015; by Greater Glasgow & Clyde Health Board R&D
on 11 December 2015; and by Betsi Cadwaladr University Health Board R&D Internal Review Panel on
16 December 2015.
The trial was assigned the International Standard Randomised Controlled Trial Number (ISRCTN) 66453696.
Trial sites
The study was conducted in four location services in England (London and York), Wales (Wrexham) and
Scotland (Glasgow) in the UK, to ensure that a mix of urban and semirural sites were included, as well as
different modes of service delivery.
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London
Participants were recruited from three drug and alcohol services (in two districts in the south of the city)
that provided a tier 2 service, including advice and needle exchange, and tier 3 treatment to people aged
over 18 years who have substance misuse (drug and/or alcohol)-related problems, including a prescribing
clinic within a hostel for homeless people. The intervention was delivered in one community drug and
alcohol service. Transport costs to attend the intervention were reimbursed.
York
Participants were recruited from a third-sector substance misuse organisation that provides tiers 1–3
addiction treatment. The service provides counselling and advice, as well as offering free needles, syringes,
condoms and specialist advice, assessment and referral to residential rehabilitation, specialist NHS drug
units and other agencies providing treatment for addiction and BBV infection testing. The intervention was
scheduled to be delivered in a third-sector service in the city centre.
Glasgow
Participants were recruited from a drugs crisis centre in the city centre which provides both treatment and
needle exchange services. The intervention was delivered in the drugs crisis centre.
Wrexham
Participants were recruited from a number of services including a NHS drug service, a drop-in centre
and needle exchange for homeless people and a mobile harm reduction service that reaches PWID who
are not currently engaged in treatment. The intervention was delivered at the drop-in centre and needle
exchange for homeless people. Transport costs for intervention participants were reimbursed where
requested.
Patient and public involvement in the feasibility trial
Four service user representatives (two from London and two from Wales) and three peer educators (two
from Glasgow and one from England) helped develop the patient information leaflet and consent form, to
ensure that appropriate language was used and the aims of the research were clear and jargon free. In
addition, they developed the ‘risk vignettes’ used in the evaluation and also advised on the instruments
suitable to measure outcomes of interest. In London, two peer educators co-facilitated the male and
female PROTECT groups.
Recruitment
Participant eligibility
Inclusion criteria
People who inject drugs who were aged ≥ 18 years and attending participating NHS and third-sector
community addiction and harm reduction clinics and needle exchange programmes (static and mobile)
were considered potentially eligible if they met all of the following criteria:
l have injected drugs at least once in the past 4 weeks
l plan to stay in the area for the next 3 months
l able to complete the assessment (alone or with help of researcher)
l can communicate in a group intervention in English.
FEASIBILITY TRIAL
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Exclusion criteria
People who inject drugs were excluded if they met any of the following criteria:
l were too intoxicated to give informed consent
l were in withdrawal
l had injected only performance-enhancing drugs in the past 4 weeks
l did not plan to be in the area for the next 3 months.
Recruitment into the trial
All clients in the waiting rooms of drug treatment and needle exchange services of participating sites were
considered potential participants by researchers and were screened for eligibility (see Appendix 6). In
addition, staff at the drug treatment and needle exchange services informed their clients about the study.
If interested, staff asked for permission to share their contact details with the researcher who then
contacted the potential participant to discuss the study with them in more detail.
Eligibility assessment
All potential participants were given a participant information sheet (PIS) (see Appendix 7) by the
researcher (London, Glasgow and Wrexham) or Clinical Research Network (CRN) nurse (York and London).
Those interested were screened for eligibility by the researcher/CRN nurse and given the opportunity to ask
any questions about participating in the research. If interested and eligible, they were invited to participate.
Potential participants were assured of confidentiality, but also informed regarding limitations to it (see
Consent procedure). They were also informed of what to expect during the study and given contact details
in case of complaint or need for further information. They were informed that participation was not
compulsory and that they could withdraw at any time without affecting their care.
Consent procedure
The researcher or CRN nurse fully explained the study to those eligible and interested in participating, providing
an opportunity for the PWID to ask questions. Those willing to participate signed a consent form including a
statement on limitations to confidentiality (see Appendix 7). These limitations referred to a need to revoke
confidentiality should they, at any time during the study, express current or future harm to themselves or
others, in which case their key worker would be informed by the researcher or CRN nurse. Potential participants
who were clearly intoxicated or under the influence of drugs were not considered as able to give consent.
In addition, consent was gained from participants for their contact details (mobile, house telephone, e-mail)
and those of a close friend/relative to be recorded, as well as e-mail and Facebook accounts (Facebook Inc.,
Menlo Park, CA, USA) to enable the researcher to call to remind participants of their appointments and to
arrange follow-up interviews. Participants were also asked to consent to researchers liaising with the service
from which they were recruited, should it not have been possible to contact them through details provided.
This method had been successfully used in the Reducing hepatitis C sexual and drug taking risk behaviours
among female drug users in Europe (REDUCE): translating evidence into practice study237 to improve
engagement and retention in research studies. In cases where participants did not show up three or more
times for their follow-up research appointment, telephone follow-up interviews were offered.
Baseline data were collected by the researcher or CRN nurse (see Appendix 8) after written informed
consent was obtained.
Outcomes
Participants in both arms were interviewed using structured questionnaires (see Appendix 8), administered
by researchers and/or CRN nurse at baseline and follow-up. Follow-up interviews were conducted at:
l the end of intervention delivery (or equivalent time period by those in the control arm); and
l 1 month post intervention (or equivalent time period by those in the control arm).
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Trial completion
Participants were deemed to have completed the trial when:
l their final follow-up had been completed.
Participants were deemed to have fully withdrawn from the trial when:
l they wished to exit the trial fully
l their service withdrew them fully from the trial.
Instead of withdrawing fully from the trial, participants had the option of:
l withdrawing only from receiving trial treatment, but continuing to complete follow-up data collection.
Participants electing to withdraw from both the trial treatment and the follow-up data collection were
deemed as full withdrawals.
Measurement and verification of primary measure
In conjunction with the qualitative aspect of the study, the feasibility of this current study and the potential
for a future large-scale study were measured by the following.
Recruitment rates
The quantitative assessment of the acceptability of the research was measured by numbers eligible and
those agreeing to participate.
Retention in treatment
Retention in treatment was evaluated by number of sessions attended as a measure of acceptability of the
interventions to participants.
Follow-up completion rates
A quantitative assessment of the number of follow-up questionnaires completed.
Secondary outcome assessment
The following outcome measures were collected at baseline, the end of intervention and 1 month post
intervention in the intervention arm, and equivalent time period by those in the control arm (see Appendix 8).
Injecting risk behaviour in past 30 days
The frequency with which participants had participated in specific injecting risk behaviours, that may have
exposed them to BBVs in the previous month, were assessed using questions from the Health Protection
Agency’s survey of PWID.2
Participants indicated whether or not they had engaged in nine different risk practices in the past month
relating to the use of sharing injection equipment. Events summed to a total ranging from 0 (engaged in
no risk events) to 9 (engaged in all of the risk events).
Self-efficacy around injecting and sexual behaviours
Using questions from the Injection Drug Users – Research and Evaluation (INSPIRE) study,190 self-efficacy
about injecting skills and about avoiding risk behaviours were measured. For example, ‘I can avoid sharing
a needle even if I am in withdrawal’.
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Self-efficacy about injecting drug use
Participants indicated agreement with eight self-efficacy questions around finding a vein, sharing
equipment, cleaning equipment and talking about safe drug use. Agreement was rated between 1
(absolutely cannot) and 4 (absolutely can). Responses were added up to arrive at a total score between
8 (low self-efficacy) and 32 (high self-efficacy).190
Number of sexual risk behaviours
Sexual risk behaviours were defined by seven items. The first two items related to having had sex with
more than one partner in the past month and not always having used a condom when having sex in the
past month. The remaining five items were based on the agreement with five self-efficacy questions about
being able to use a condom with regular or casual partners while intoxicated or not and being able to talk
about safe sex. Responses were counted as a risk behaviour if participants were not ‘absolutely sure’ they
would use a condom in a given situation or that they would be able to talk about safe sex. Events were
added up to a total ranging from 0 (no risk behaviours) to 7 (all risk behaviours).
Withdrawal Prevention Tactics scale
This five-item scale asks whether or not participants had done any of four listed tactics to avoid withdrawal
episodes in the last 6 months: saved a bag for the next morning; put aside additional drugs; stored
methadone; or put aside money for getting the next bag in an emergency.238 A fifth item asked about use
of other substances, such as painkillers, to avoid withdrawal symptoms until they are able to obtain their
drug of choice. Participants were asked how frequently they have undertaken each of the withdrawal
activities in the past month, with responses ranging from 0 (never) to 4 (very often). A total score was
calculated by adding up responses, resulting in a total score from 0 (never taken any of the preventative
actions) to 20 (taken preventative actions very often for all of the activities).
Blood-borne virus transmission knowledge
Human immunodeficiency virus transmission knowledge
Participants judged 14 statements about HIV transmission from the 18-item HIV Knowledge Questionnaire
as true, false or do not know.239 The total number of correct answers (range 0–14) was calculated.
Hepatitis C virus transmission knowledge
Participants judged 33 statements about HCV transmission as true, false or do not know. These statements
were a reduced version of the HCV Transmission Knowledge Questionnaire used in the Reducing Hepatitis C
Sexual and Drug Taking Risk Behaviours Among Female Drug Users in Europe (REDUCE): Translating Evidence
into Practice study,237 adapted from Balfour et al.240 and updated to include gender-specific questions and
questions that incorporated recent advances in sexual and vertical transmission.4 Two questions were
considered ambiguous and responses did not count towards the total. The total number of correct answers
(range 0–31) was calculated.
Hepatitis B virus transmission knowledge
Participants judged 15 statements about HBV across four domains (transmission, natural history,
epidemiology and prevention, and clinical management), as true, false or do not know.241 The total
number of correct answers (range 0–15) was calculated.
Motivation to change behaviour
Participants were asked to rate their motivation from extremely motivated to not at all motivated to protect
themselves and others from acquiring BBVs. Motivation scores for the two items ranged from 1 (not at all
motivated) to 5 (extremely motivated).
Vignettes
Three scenarios were presented to participants regarding risky situations. They were then asked to describe
what they would do if they found themselves in these situations. Responses were recorded verbatim.
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Health-related quality of life
The EuroQol-5 Dimensions, five-level version (EQ-5D-5L) is a standardised measure of health status
developed by the EuroQol group in order to provide a simple, generic measure of health for clinical and
economic appraisal, where health is characterised on five dimensions (mobility, self-care, ability to
undertake usual activities, pain, anxiety/depression).242
Health and social resource used
The feasibility of collecting details regarding hospital and primary health care service use, drug service use,
other health-related services and contact with the police and criminal justice system was tested in this
participant group. The service use questionnaire covered a retrospective 1-month period. Current
medications were also collected.
In addition, the following demographic data were collected at baseline: age, gender, age when they first
started injecting and type of service they had been recruited from.
Participants received £10 for their time involved in completing the baseline and each of the follow-up
questionnaires. Those in the intervention arm received a further £10 if they participated in a focus group
about their experience of participating in the trial and the group intervention. In all sites except London,
participants received a high-street gift voucher for their time. In London, participants received payment
in cash.
Focus groups with participants who attended the intervention and staff who delivered
the intervention
Researchers moderating the focus groups used topic guides to lead the group through a discussion of the
key issues, allowing and encouraging elaboration of views by participants as seemed appropriate (see
Appendix 9).
Gender-specific intervention focus groups were conducted in each region where the intervention was
delivered (London, Glasgow and Wrexham), with intervention group participants who had attended at
least one intervention session (see Appendix 10 for consent form and PIS). These examined barriers to
participation and what worked/worked less well within the intervention including:
1. overall impressions: views regarding the intervention as a whole and each individual session, reasons for
attendance/non-attendance at sessions, and thoughts on the trial randomisation process
2. intervention content: most/least useful aspects of the intervention, whether or not they had learned
anything new, whether or not any intervention content had been shared with others (if so, what and
with whom), and any other information they would have liked provided
3. logistics: views regarding the location and timing of the intervention, ease of getting to the group
sessions, whether or not anything would have made it more convenient, potential barriers to uptake of,
and attendance at, the intervention, and suggestions to improve uptake and attendance
4. quality, safety and comfort: views regarding facilitators delivering the intervention, intervention
materials used (videos, handouts), and whether or not they felt comfortable during the sessions and
safe sharing their experiences within the group
5. gendered groups: views regarding single versus mixed gender groups
6. behaviour changes: whether or not there had been any changes in behaviour as a result of taking part
in the intervention
7. final comments: whether or not they would recommend the intervention to others, including why/why
not, and any final thoughts.
Focus groups were also conducted in each region with staff who had delivered or who intended to deliver
the group intervention to determine the acceptability of delivering the intervention and to identify barriers
to, and facilitators of, its uptake and delivery. Staff were provided with a PIS and asked to complete a
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consent form (see Appendix 11). For the focus groups with intervention facilitators, the following topics
were covered:
1. training event: overall views regarding usefulness, comments regarding format (venue, duration,
delivery style), suggestions for improvement of training, what else facilitators did to prepare for
intervention delivery
2. intervention materials: comments regarding intervention manual (content, clarity, flow, layout, ease of
maintaining fidelity to manual), exercises/activities, videos, overheads and handouts
3. intervention delivery: time spent preparing for delivery of sessions, ease of incorporating intervention
delivery into overall workload, which parts of intervention they felt most confident/comfortable
delivering, which parts they found challenging to deliver, experience of staff/peer co-delivery in London,
views regarding what worked well/less well about the intervention, suggestions for changes/additions
to intervention, views regarding logistics of sessions (day/time, venue), whether or not they would use
the intervention in its entirety in their own practice [if not, what elements would they use (why, with
what clients)], other thoughts regarding how the intervention could be used or developed
4. facilitator learning: from intervention participants regarding injecting practices
5. participant engagement and attendance: views regarding participant engagement with intervention and
suggestions to improve attendance.
The topic guide can be seen in Appendix 12.
Randomisation
People who inject drugs who fulfilled the eligibility criteria and who provided written consent to take part
in the study were eligible for randomisation. In order to maintain allocation concealment, the generation
of the randomisation sequence was undertaken by an independent statistician at the University of York,
and treatment allocation was performed by a secure, remote, telephone randomisation service based at
the University of York. Participants were randomised by block randomisation, ensuring balanced allocation
within each location, drug service/setting (needle exchange or community drug service) and gender. The
three strata and covert block size ensured that the allocation sequence remained concealed to recruiting
staff. Periodic checks were made on the computerised randomisation system during the trial following
standard operating procedures. Owing to the nature of the intervention, it was not possible to conceal
treatment allocation from the participant or the professional delivering the intervention.
Trial interventions
Participants were randomised to receive either:
l psychosocial group intervention (information booklets plus TAU)
l the control arm (information booklets plus TAU only).
Intervention arm
Participants randomly allocated to the intervention arm were invited to attend three 1-hour sessions
(ideally, one a week for 3 consecutive weeks). Session 1 covered improving injection skills and good vein
care, session 2 covered planning for risk situations and session 3 aimed to increase participants’ knowledge
about BBVs and transmission risk behaviours. The content of the intervention was developed in an earlier
phase of work (as detailed in Chapter 5). Each session was scheduled to last 1 hour and it had been
anticipated that there would be up to eight people in the group. Separate groups were held for women
and men. The delivery of the intervention varied across sites to reflect current service delivery in each area.
In London the group was co-facilitated by a drugs worker and peer educator (gender of co-facilitators
matched that of the gender of the group), in Glasgow groups were co-facilitated by one male group
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worker and one female service co-ordinator, in Wrexham the groups were co-facilitated by one male and
one female harm reduction worker and in York the groups were to be delivered by one male BBV nurse.
Refreshments were provided at all sessions. The sessions used videos, games and exercise to facilitate
discussion and build skills, and strategies to reduce and avoid risk. All sessions also included a didactic
education session. Any questions that facilitators were unable to answer during the session were answered
at the following session, to ensure that participants’ needs were met.
In addition, at baseline assessment, all participants were provided with a booklet containing information
on HCV and a one-page information sheet developed specifically for the trial about a recent HIV outbreak
among PWID (see Appendix 13). The HCV booklet Booklet 1. Hep C Info. Understanding Hepatitis C and
Staying Safe231 was developed through a joint working initiative between Dr Magdalena Harris at the
London School of Hygiene & Tropical Medicine and the London Joint Working Group on Substance Use
and Hepatitis C. The booklet draws on the research of Dr Harris and was written by Danny Morris and
Dr Harris.
Participants also received TAU from the service from which they were recruited.
Contingency management was used to try and retain participants in the psychosocial intervention.
Contingency management, as recommended by the National Institute for Health and Care Excellence
(NICE), offers incentives or rewards (usually vouchers or privileges such as take-home methadone doses)
contingent on retention or positive engagement in treatment (e.g. drug-negative urine sample).243
Participants allocated to the intervention arm received £10 for each of the three sessions attended. A
‘bonus’ £10 was given to those who attended all three sessions. Participants in London were rewarded in
cash, in the other three sites payment was in the form of a high-street gift voucher.
Control arm
Participants randomly allocated to the control arm were given the same booklet containing information on
HCV and the information about the HIV infection outbreak. They also received TAU from the service from
which they were recruited.
Evaluation of each session
Intervention group participants anonymously self-completed evaluation forms immediately after each of
the three sessions. Evaluation forms asked participants to indicate the extent to which they agreed or
disagreed with a series of statements about the intervention materials and delivery, and the achievement
of session goals (e.g. increased knowledge, self-efficacy or motivation). Participants indicated their
agreement/disagreement with each statement on a five-point Likert scale from 1 (strongly disagree) to
5 (strongly agree). The higher the score, the more positively the session was rated. Participants were also
asked to give an overall rating for the session (‘in general how would you rate today’s session’) on a scale
of 1 to 5, where 1 was poor and 5 was excellent. Finally, they were asked three open-ended questions:
‘what did you like most about today’s session?’, ‘what did you like least about today’s session?’ and ‘how
could today’s session be improved?’.
Intervention facilitators also self-completed an evaluation form immediately after each of the three
sessions. Similar to the participant evaluation forms, the facilitator evaluation forms asked facilitators to
rate the extent to which they agreed or disagreed with a series of statements about the session materials
and delivery, the achievement of session goals, how well prepared they felt to deliver the session and their
ability to answer participants’ questions. Responses were given on a five-point Likert scale from 1 (strongly
disagree) to 5 (strongly agree). The higher the score, the more positively the session was rated. They were
also asked to give an overall rating for the session (‘in general how would you rate today’s session’) on
a scale of 1 to 5, where 1 was poor and 5 was excellent. Finally, they were asked four open-ended
questions: ‘what do you think worked best in today’s session?’, ‘what do you think worked less well in
today’s session?’, ‘how do you think today’s session could be improved?’ and ‘any additional comments?’.
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All sessions were observed by at least one researcher to assess the feasibility of the quality assurance
methods proposed for the main trial, including acceptability to drug worker/nursing staff and service users.
Following completion of this study, this information may also be used to inform refinement of the training
manual and/or the intervention itself and is expected to suggest the level of supervision likely to be
required. During each session, researchers completed a brief checklist to identify what aspects of the
manual were implemented. Participants and staff were also asked to complete an evaluation after each
session (see Appendix 14).
Adverse events
There were no anticipated risks arising directly as a result of the psychosocial intervention, but a
mechanism for recording them was in place if any arose.
Statistical analysis
As a feasibility trial, this study was not powered to determine the effectiveness of the intervention, but
used to estimate feasibility parameters for a future effectiveness trial. Therefore, outcomes were primarily
summarised descriptively. All analyses were conducted using Stata version 13.1 (StataCorp LP, College
Station, TX, USA).
Primary outcomes: feasibility parameters
Recruitment rates
The number of patients eligible and the number and proportion entering the study are presented with
reasons for not entering the trial where known.
Baseline data
Baseline characteristics of all the participants are summarised descriptively by intervention arm using
means, standard deviations (SDs), medians and minimum and maximum values for continuous measures,
and number and percentage for categorical measures. These are summarised by location, gender and
treatment arm. As compliance and retention became an issue during the trial, baseline characteristics are
further compared between participants who did and did not attend at least one treatment session, and
for participants who did and did not attend at least one follow-up session. On advice from the Data
Monitoring and Ethics Committee (DMEC), statistical tests are performed comparing these groups in order
to explore potential predictors of non-compliance and dropout. As numbers are small, non-parametric tests
(Mann–Whitney U-test and Fisher’s exact test) are used.
Follow-up completion rates
The flow of patients through the study is summarised by means of a Consolidated Standards of Reporting
Trials (CONSORT) diagram.244 The number and percentage of participants remaining in the study, attending
sessions and follow-up at each time point are reported by allocated group, with reasons for discontinuation
given where known.
Retention in treatment
The number of treatment sessions attended is presented by recruitment site and gender as a measure of
retention in treatment.
Secondary outcomes: intervention effectiveness
Intervention effectiveness was explored for selected outcome measures (see Outcome measures). An
overview of the time points at which trial data were collected is presented in Table 16. The original plan
was to present descriptive statistics for all outcomes across all stratification factors. However, given the low
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follow-up rates and small numbers for some strata, this was not deemed informative and average
outcomes are presented in total and by gender only. Tables include summaries grouped by randomised
allocation as well as grouped by attendance of intervention sessions.
Longitudinal regression analyses were conducted, predicting each outcome at the two follow-up points
from the outcome at baseline and allocation by follow-up interaction, adjusting for gender and recruitment
site. Estimated mean group differences from these analyses are presented by intention-to-treat (ITT) and
per-protocol groups together with 80% and 95% CIs. As a feasibility trial, no p-values are presented.
Focus group analysis
An essential aim of this feasibility study was to establish the acceptability of the group psychosocial
intervention to both the PWIDs and the services delivering the intervention.
Focus groups were digitally recorded and transcribed verbatim with participants’ consent. Researchers
checked the transcripts against the audio-recordings for accuracy and de-identified them. Service and
personal names were removed and a letter/number used to denote each focus group participant
(e.g. R1 = respondent 1).
Transcripts were analysed thematically. Qualitative software (NVivo 10) assisted with the management and
coding of transcripts. Initially, one transcript from each set of focus groups (i.e. one participant focus group
transcript and one facilitator focus group transcript) were independently coded by both Davina Swan and
April Shaw to generate an initial coding framework for each set of focus groups and to ensure reliability of
coding. Codes were derived deductively from the topic guide and inductively from focus group responses.
TABLE 16 Data collection schedule
Assessment
Time point
Baseline End of intervention 1 month post intervention
Baseline characteristics
Demographics/injecting history ✓
Quantitative evaluation
Injecting behaviours ✓ ✓ ✓
Sexual behaviours ✓ ✓ ✓
Self-efficacy ✓ ✓ ✓
HIV transmission knowledge ✓ ✓ ✓
HCV transmission knowledge ✓ ✓ ✓
HBV transmission knowledge ✓ ✓ ✓
Withdrawal prevention ✓ ✓ ✓
Motivation to change behaviour ✓ ✓ ✓
Qualitative evaluation
Vignettes ✓ ✓ ✓
Economic evaluation
EQ-5D ✓ ✓ ✓
Frequency of service use ✓ ✓ ✓
EQ-5D, EuroQol-5 Dimensions.
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Differences in coding between Davina Swan and April Shaw were discussed and resolved through revisiting
the relevant extracts. Then, Davina Shaw coded the remainder of the participant focus group transcripts and
April Shaw coded the remainder of the facilitator focus group transcripts. New codes were added to the
initial coding frameworks as additional transcripts were analysed. The developing analyses were discussed at
Research and Steering Group meetings and codes revised and renamed appropriately as the analytic
process continued.
Economic analysis methods
The economic component of the study assessed the feasibility of conducting an economic evaluation of an
adequately powered trial.245 The economic component evaluated whether or not data could be obtained
and the extent to which questionnaires were completed with the required information, in order to inform
the design and implementation of an economic evaluation of a full trial. The costs of providing the
intervention were collected from local data sources to establish the incremental cost of the psychosocial
intervention over and above TAU in each setting.
The study was not powered to perform a full economic evaluation at this stage, as the perspective adopted
includes criminal justice costs, which are high-tariff, low-frequency events. In a feasibility trial such as this,
the sample size is such that the distribution of these infrequent events between intervention and control
would have a significant bearing on cost-effectiveness results, which would be misleading in a small
sample: results that are likely to be more a result of chance than a demonstration of cost-effectiveness.
Therefore, the health economic component of this feasibility study piloted the service use questionnaires in
order to measure the use of health-care services, including primary and secondary care contacts. Data
returned would enable the revision of these instruments to improve the collection of data through further
development, with further information used to identify the major services and, hence, costs that are
associated with this population.
The economic analysis for the PROTECT feasibility trial includes intervention costing, calculation of NHS and
wider social costs per patient, EQ-5D-5L results and assessment of the pilot questionnaires in preparation
for a full sufficiently powered RCT. We do not present a full cost-effectiveness analysis, as the feasibility
trial is not powered to detect significant differences and conclusions, and cost-effectiveness ratios from a
small feasibility trial are likely to be misleading and contain a wide degree of uncertainty as a result of the
low-frequency, high-tariff items recorded in the wider health care and criminal justice system costs.
Results: statistical analysis
Trial progression
The flow of participants is shown in Figure 21. Of 176 eligible drug users, 99 individuals were randomised
into the feasibility trial during January and February 2016. One person was erroneously randomised twice
(therefore 100 randomisations); however, their second randomisation was subsequently withdrawn and
the person remained in the trial according to their initial allocation. Of the 99 individuals randomised, 52
were allocated to the intervention arm and 47 were allocated to the control arm. A total of 20 participants
attended at least one intervention session and just under half of participants were followed up until
1 month post intervention.
Participant randomisation was stratified by recruitment site (London, York, Glasgow or Wrexham), service
type (needle exchange or community drug service) and gender (male or female). Balanced allocation across
these factors was achieved (Table 17). Recruitment from needle exchanges was substantially lower than
anticipated. Owing to the small number of these participants, result summaries will not be presented
separately for these groups, as was originally planned. The focus of the results will be on the potential
population differences between recruitment sites and any differences between male and female participants.
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Randomised
(n = 100)
Identified as eligible
(n = 176)
Not entered
(n = 76)
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(leaflet alone)
(n = 47)
1 month post intervention
 
 
 
 
• Residential rehabilitation, n = 5
• In hospital, n = 2
• In prison, n = 2
• Did not attend, n = 20
Completed follow-up
(n = 22)
Did not complete follow-up
(n = 29)
1 month post intervention
 
 
 
 
• Residential rehabilitation, n = 1
• In hospital, n = 1
• Did not attend, n = 21
Completed follow-up
(n = 23)
Did not complete follow-up
(n = 23)
End of intervention
 
 
 
 
• Residential rehabilitation, n = 5
• In prison, n = 1
• Did not attend, n = 21
End of intervention
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FIGURE 21 Study flow diagram.
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Feasibility parameters
Feasibility was assessed as the proportion of patients consented and randomised, as well as compliance
with the intervention and attrition throughout follow-up. Recruitment was relatively straightforward in
most settings, with an expected number of presenting drug users being eligible for inclusion in the trial.
Many service users were not eligible as they did not currently inject drugs. In general, women were harder
to recruit, as fewer than anticipated attended the target services and not as many of those who did were
injecting drugs. The rate of recruitment was 57% (99 participants of 175 eligible, excluding the participant
who was randomised twice in error). Reasons for otherwise eligible drug users not being entered into the
trial (n = 76) included that they were not interested (n = 17), too busy to discuss study/participate (n = 18),
not able to (re)contact (n = 14), did not attend appointment (n = 14), intervention dates were not suitable
(n = 4), they entered rehabilitation treatment (n = 3), they were worried regarding confidentiality of
injecting status (n = 2), English was not their first language (n = 2), they were too ill (n = 1) or were with
others on day of recruitment (n = 1).
Compliance and attrition by recruitment site are summarised in Table 18. Attendance for at least one
intervention session was highest in London (63%) and Wrexham (54%), whereas only 25% attended in
Glasgow and no participants attended in York. Follow-up at a minimum of one time point (at the end of
the intervention or 1 month post intervention) was also highest in London (83%) and Wrexham (63%),
and significantly lower in Glasgow (55%) and York (43%).
TABLE 17 Randomisation by stratification factors
Recruitment site
Gender (n)
Male Female
Trial arm
Total
Trial arm
TotalIntervention Control Intervention Control
London 9 (CD, 8; NE, 1) 8 (CD, 8; NE, 0) 17 7 (CD, 6; NE, 1) 6 (CD, 6; NE, 0) 13
York 9 (CD, 9; NE, 0) 7 (CD, 7; NE, 0) 16 3 (CD, 3; NE, 0) 3 (CD, 3; NE, 0) 6
Glasgow 9 (CD, 6; NE, 3) 7 (CD, 5; NE, 2) 16 4 (CD, 3, NE, 1) 4 (CD, 3; NE, 1) 8
Wrexham 7 (CD, 3; NE, 4) 8 (CD, 6; NE, 2) 15 4 (CD, 4, NE, 0) 4 (CD, 3; NE, 1) 8
Total 34 30 64 18 17 35
CD, community drug service; NE, needle exchange.
TABLE 18 Compliance and attrition by recruitment site
Compliance and attrition
Location in the UK, n (%)
London York Glasgow Wrexham
Compliance (intervention arm only) n= 16 n= 11 n= 12 n = 13
Attended at least one session 10 (63) 0 (0) 3 (25) 7 (54)
Attended no sessions 6 (38) 11 (100) 9 (75) 6 (46)
Attrition (both arms) n= 30 n= 23 n= 22 n = 24
Attended at least one follow-up 25 (83) 10 (43) 12 (55) 15 (63)
Attended no follow-up 5 (17) 13 (57) 10 (45) 9 (38)
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Compliance and attrition were further broken down by gender (Tables 19–21). Overall, men were more
likely to attend at least one intervention session. Women were more likely to attend follow-up in London
and York, but not in Glasgow and Wrexham. The possible reasons behind these gender differences were
not clear. Possible associations of compliance and attrition rates with other characteristics of each
population were explored as part of the next section (see Baseline characteristics).
TABLE 19 Compliance by gender (intervention arm only)
Recruitment site
Randomised to
intervention, n
Compliance, n (%)
Attended
one session
Attended
two sessions
Attended
three sessions
Attended at least
one session
Males
London 9 2 (22.2) 1 (11.1) 4 (44.4) 7 (77.8)
York 7 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Glasgow 9 0 (0.0) 1 (11.1) 2 (22.2) 3 (33.3)
Wrexham 9 0 (0.0) 3 (33.3) 2 (22.2) 5 (55.6)
Total 34 2 (5.9) 5 (14.7) 8 (23.5) 15 (44.1)
Females
London 7 0 (0.0) 1 (14.3) 2 (28.6) 3 (42.9)
York 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Glasgow 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Wrexham 4 0 (0.0) 2 (50.0) 0 (0.0) 2 (50.0)
Total 18 0 (0.0) 3 (16.7) 2 (11.1) 5 (27.8)
TABLE 20 Compliance by gender: attrition (intervention)
Recruitment
site
Randomised to
intervention, n
Compliance, n (%)
Attended the end of
intervention follow-up
Attended the 1-month
post-intervention follow-up
Attended at least one
follow-up session
Males
London 9 8 (88.9) 8 (88.9) 8 (88.9)
York 7 3 (42.9) 1 (14.3) 4 (57.1)
Glasgow 9 5 (55.6) 3 (33.3) 5 (55.6)
Wrexham 9 2 (22.2) 5 (55.6) 5 (55.6)
Total 34 18 (52.9) 17 (50.0) 22 (64.7)
Females
London 7 4 (57.1) 4 (57.1) 5 (71.4)
York 4 0 (0.0) 0 (0.0) 0 (0.0)
Glasgow 3 1 (33.3) 0 (0.0) 1 (33.3)
Wrexham 4 1 (25.0) 1 (25.0) 1 (25.0)
Total 18 6 (33.3) 5 (27.8) 7 (38.9)
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Baseline characteristics
Characteristics of the trial population at baseline by allocation and gender are presented in Table 22.
Participants were predominantly males in their late thirties/early forties, with an average history of between
14 and 22 years of injecting. Baseline characteristics were comparable between randomised treatment
groups for males, despite the relatively small number of participants. Potential imbalances were observed
in the smaller group of women (e.g. with a greater number of heroin users and homeless women in the
intervention arm).
Following marked differences in compliance and follow-up at the four trial recruitment sites, population
characteristics were additionally compared between sites (Table 23), between those attending at least one
intervention session and those attending none [total including statistical test for differences (Table 24) and
by gender (Table 25)], and between those attending at least one follow-up session and those attending
none [including statistical test for differences (Table 26)].
Compared with participants who did attend at least one intervention session (n = 20), participants who did
not attend any sessions (n = 32) were more likely to be homeless (56% vs. 25%; p = 0.044), injected drugs
for a greater number of days in the last month (median 25 vs. 6.5 days; p = 0.019) and used a greater
number of needles from a needle exchange in the last month (median 31 vs. 20 needles; p = 0.056). They
were more likely to be predominant heroin injectors (69% vs. 40%; p = 0.055 for type of drug) and less
likely to inject crack (31% vs. 55%; p = 0.146) (see Table 24). These differences were true for males and
females, apart from homelessness, which did not show differences for women, although numbers were
small (see Table 25).
More participants attended at least one intervention session in London (63%) and Wrexham (54%) than in
Glasgow (25%) and York (0%) (see Table 18). Glasgow and York, however, had higher levels of homelessness,
and participants injected for a greater number of days and used more needles from a needle exchange (see
Table 23). As per the influential characteristics identified above, these factors may have contributed towards
lower attendance rates. Specific contributing factors to non-attendance in Glasgow were that two female
participants and three male participants had entered residential rehabilitation, and one male participant was
TABLE 21 Compliance by gender: attrition (control)
Recruitment
site
Randomised to
control, n
Compliance, n (%)
Attended the end of
intervention follow-up
Attended the 1-month
post-intervention follow-up
Attended at least one
follow-up session
Males
London 8 6 (75.0) 6 (75.0) 6 (75.0)
York 8 2 (25.0) 2 (25.0) 3 (37.5)
Glasgow 7 6 (85.7) 2 (28.6) 6 (85.7)
Wrexham 7 6 (85.7) 4 (57.1) 7 (100)
Total 30 20 (66.7) 14 (46.7) 22 (73.3)
Females
London 6 6 (100) 5 (83.3) 6 (100)
York 4 1 (25.0) 2 (50.0) 3 (75.0)
Glasgow 3 0 (0.0) 0 (0.0) 0 (0.0)
Wrexham 4 0 (0.0) 2 (50.0) 2 (50.0)
Total 17 7 (41.2) 9 (52.9) 11 (64.7)
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incarcerated. In addition, in York, text messages were sent to remind participants of intervention session
times and dates from the service (reported preference of participants), whereas in other sites the researcher
contacted participants by telephone to remind them of session dates and times 1 day in advance and also
sent a reminder text the day of the intervention. Thus, talking with the researcher and the additional
reminder may have resulted in increased attendance at the other sites. Moreover, as a result of the
dedicated researcher leaving their position at the University of York, four staff from the CRN York Teaching
Hospitals NHS Trust were responsible for recruitment and follow-up of participants, whereas in other sites
participants had contact with the same named researcher throughout the trial, and this established
relationship could also have contributed to increased attendance. Additional potential contributing factors
for the differences in compliance and attendance across trial sites include reimbursement of travel (bus ticket
or receipt for bus travel), reimbursement of time and CM paid in cash (vs. high-street vouchers in other sites)
and co-facilitation of the intervention by peer educators (in the London site only).
TABLE 22 Baseline characteristics by allocation and gender
Baseline characteristic
Gender
Male Female
Intervention
(N= 34)
Control
(N= 30)
Intervention
(N= 18)
Control
(N= 17)
Age (years)
Mean (SD) 41.7 (6.81) 41.4 (7.30) 35.8 (6.06) 37.9 (8.79)
Median 42.5 42 35 37
Minimum, maximum 26, 57 22, 54 26, 48 26, 62
Number of years injecting
Mean (SD) 21.4 (8.00) 19.5 (9.01) 11.9 (7.58) 16.1 (12.14)
Median 22 19 11.5 14
Minimum, maximum 3, 36 1, 42 0, 34 0, 44
Used needle exchange in the last month, n (%) 31 (91.2) 26 (86.7) 16 (88.9) 16 (94.1)
Detox/maintenance drug use, n (%) 26 (76.5) 26 (86.7) 17 (94.4) 16 (94.1)
Most frequently injected drug, n (%)
Heroin 15 (44.1) 23 (76.7) 15 (83.3) 10 (58.8)
Crack 1 (2.9) 2 (6.7) 0 (0.0) 0 (0.0)
Cocaine 4 (11.8) 1 (3.3) 0 (0.0) 1 (5.9)
Heroin and crack 8 (23.5) 2 (6.7) 3 (16.7) 3 (17.6)
Heroin and cocaine 1 (2.9) 0 (0.0) 0 (0.0) 1 (5.9)
Heroin and amphetamine 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.9)
Speedball 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0)
Amphetamine 3 (8.8) 2 (6.7) 0 (0.0) 1 (5.9)
Methadone, mephedrone 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0)
Homeless, n (%) 15 (44.1) 14 (46.7) 8 (44.4) 5 (29.4)
HIV positive, n (%) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0)
HCV positive, n (%) 17 (50) 15 (50) 5 (27.8) 6 (35.3)
HBV vaccinated, n (%) 27 (79.4) 22 (73.3) 18 (100) 14 (82.4)
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TABLE 23 Participant characteristics by recruitment site
Participant characteristic
Location in the UK
London
(N= 30)
York
(N= 23)
Glasgow
(N= 22)
Wrexham
(N= 24)
Gender, n (%)
Male 17 (57) 15 (65) 15 (68) 16 (67)
Female 13 (43) 8 (35) 6 (27) 8 (33)
Transgender 0 (0) 0 (0) 1 (5) 0 (0)
Age (years)
Mean (SD) 42.8 (7.53) 37.6 (6.13) 38.3 (6.85) 39.8 (8.33)
Median 42 37 40 42
Minimum, maximum 29, 62 27, 50 26, 50 22, 56
Number of years since first injected
Mean (SD) 20.6 (11.27) 15.9 (9.05) 17.6 (8.97) 17.9 (8.10)
Median 22 17 16 18.5
Minimum, maximum 0, 40 0, 32 4, 35 1, 32
Homeless, n (%) 8 (27) 12 (52) 15 (68) 7 (29)
Number of days injected drugs in last month
Mean (SD) 18.1 (9.87) 19.0 (10.28) 22.1 (9.48) 10.3 (8.83)
Median 20 26 28 8
Minimum, maximum 2, 28 2, 28 1, 28 1, 28
Most frequently injected drug, n (%)
Heroin 15 (50) 16 (70) 16 (73) 16 (67)
Crack 2 (7) 0 (0) 0 (0) 1 (4)
Cocaine 0 (0) 0 (0) 6 (27) 0 (0)
Heroin and crack 11 (37) 3 (13) 0 (0) 2 (8)
Heroin and cocaine 2 (7) 0 (0) 0 (0) 0 (0)
Heroin and amphetamine 0 (0) 0 (0) 0 (0) 1 (4)
Speedball 0 (0) 1 (4) 0 (0) 0 (0)
Amphetamine 0 (0) 3 (13) 0 (0) 3 (13)
Methadone, mephedrone 0 (0) 0 (0) 0 (0) 1 (4)
Any drugs injected in the last month, n (%)
Heroin 30 (100) 22 (96) 20 (91) 20 (83)
Crack 18 (60) 12 (52) 2 (9) 10 (42)
Amphetamine (speed) 0 (0) 7 (30) 1 (5) 7 (29)
Ketamine 1 (3) 0 (0) 0 (0) 1 (4)
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TABLE 23 Participant characteristics by recruitment site (continued )
Participant characteristic
Location in the UK
London
(N= 30)
York
(N= 23)
Glasgow
(N= 22)
Wrexham
(N= 24)
Methadone 0 (0) 0 (0) 0 (0) 0 (0)
Cocaine 2 (7) 2 (9) 12 (55) 3 (13)
Mephedrone 0 (0) 0 (0) 0 (0) 1 (4)
Methamphetamine 1 (3) 0 (0) 1 (5) 0 (0)
Other 3 (10) 1 (4) 1 (5) 0 (0)
Injected heroin and cocaine in last month
(speedball), n (%)
15 (50) 11 (48) 5 (23) 9 (38)
Any drugs used in the last month, n (%)
Cocaine 15 (50) 5 (22) 13 (59) 9 (38)
Amphetamine 1 (3) 7 (30) 1 (5) 10 (42)
Crack 29 (97) 14 (61) 12 (55) 19 (79)
Heroin 29 (97) 22 (96) 21 (95) 19 (79)
Mephedrone 2 (7) 0 (0) 3 (14) 5 (21)
Methamphetamine 1 (3) 1 (4) 2 (9) 0 (0)
Ecstasy/E 2 (7) 0 (0) 4 (18) 1 (4)
Cannabis 23 (77) 12 (52) 18 (82) 8 (33)
Solvents or glue 0 (0) 0 (0) 0 (0) 0 (0)
Ketamine 2 (7) 0 (0) 0 (0) 0 (0)
Benzodiazepines 12 (40) 10 (43) 20 (91) 17 (71)
Other drugs 5 (17) 6 (26) 5 (23) 3 (13)
Used needle exchange in the last month 28 (93) 21 (91) 22 (100) 18 (75)
Number of individual needles
Mean (SD) 51.3 (50.43) 49.7 (48.73) 96.1 (176.05) 41.7 (50.11)
Median 34 40 48 28
Minimum, maximum 0, 220 8, 210 1, 840 0, 200
Current detox/maintenance drug use, n (%) 29 (97) 22 (96) 19 (86) 15 (63)
Length of time on current script, n (%)
< 1 month 2 (7) 3 (13) 0 (0) 2 (8)
1–6 months 2 (7) 7 (30) 5 (23) 2 (8)
> 6 months 25 (83) 12 (52) 14 (64) 12 (50)
HIV positive, n (%) 0 (0) 0 (0) 1 (5) 0 (0)
HCV positive, n (%) 12 (40) 10 (43) 16 (73) 5 (21)
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TABLE 24 Participant characteristics by compliance (total)
Participant characteristic
Compliance
p-value for
differencea
Attended at least one
intervention session (N= 20)
Attended no intervention
sessions (N= 32)
Gender, n (%) 0.370
Male 15 (75) 19 (59)
Female 5 (25) 13 (41)
Transgender 0 (0) 0 (0)
Age (years) 0.243
Mean (SD) 41.5 (7.29) 38.5 (6.85)
Median 41.5 39
Minimum, maximum 29, 57 26, 50
Number of years since first injected 0.200
Mean (SD) 20.1 (8.12) 16.9 (9.45)
Median 22 18.5
Minimum, maximum 8, 36 0, 34
Homeless, n (%) 5 (25) 18 (56) 0.044
Number of days injected drugs in last month 0.019
Mean (SD) 13.0 (11.00) 19.3 (9.49)
Median 6.5 25
Minimum, maximum 1, 28 3, 28
Most frequently injected drug, n (%) 0.055
Heroin 8 (40) 22 (69)
Crack 1 (5) 0 (0)
Cocaine 2 (10) 2 (6)
Heroin and crack 8 (40) 3 (9)
Heroin and cocaine 0 (0) 1 (3)
Speedball 0 (0) 1 (3)
Amphetamine 1 (5) 2 (6)
Methadone, mephedrone 0 (0) 1 (3)
Any drugs injected in the last month, n (%)
Heroin 18 (90) 30 (94) 0.634
Crack 11 (55) 10 (31) 0.146
Amphetamine (speed) 1 (5) 3 (9) 1
Ketamine 1 (5) 0 (0) 0.385
Methadone 0 (0) 0 (0)
Cocaine 4 (20) 8 (25) 0.747
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TABLE 24 Participant characteristics by compliance (total) (continued )
Participant characteristic
Compliance
p-value for
differencea
Attended at least one
intervention session (N= 20)
Attended no intervention
sessions (N= 32)
Mephedrone 0 (0) 1 (3) 1
Methamphetamine 0 (0) 0 (0)
Other 1 (5) 1 (3) 1
Injected heroin and cocaine in last
month (speedball), n (%)
9 (45) 12 (38) 0.772
Any drugs used in the last month, n (%)
Cocaine 11 (55) 12 (38) 0.260
Amphetamine 2 (10) 4 (13) 1
Crack 16 (80) 23 (72) 0.743
Heroin 16 (80) 31 (97) 0.291
Mephedrone 1 (5) 2 (6) 1
Methamphetamine 0 (0) 0 (0)
Ecstasy/E 2 (10) 2 (6) 0.623
Cannabis 13 (65) 17 (53) 0.237
Solvents or glue 0 (0) 0 (0)
Ketamine 0 (0) 0 (0)
Benzodiazepines 11 (55) 18 (56) 1
Other drugs 1 (5) 7 (22) 0.224
Used needle exchange in the last month 17 (85%) 30 (94) 0.361
Number of individual needles 0.056
Mean (SD) 31.3 (30.60) 61.5 (70.86)
Median 20 31
Minimum, maximum 10, 100 8, 280
Current detox/maintenance drug use,
n (%)
16 (80) 27 (84) 1
Length of time on current script, n (%) 0.374
< 1 month 1 (5) 1 (3)
1–6 months 2 (10) 8 (25)
> 6 months 14 (70) 18 (56)
HIV positive, n (%) 1 (5) 0 (0) 1
HCV positive, n (%) 7 (35) 15 (47) 0.395
a Mann–Whitney U-test or Fisher’s exact test as appropriate.
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TABLE 25 Participant characteristics by compliance (by gender)
Participant characteristic
Compliance
Attended at least one
intervention session
Attended no intervention
sessions
Male (N= 15) Female (N= 5) Male (N= 19) Female (N= 13)
Age (years)
Mean (SD) 44.0 (6.45) 33.8 (3.03) 39.9 (6.69) 36.5 (6.84)
Median 44 35 41 35
Minimum, maximum 33, 57 29, 37 26, 50 26, 48
Number of years since first injected
Mean (SD) 23.3 (6.66) 10.6 (2.70) 20.0 (8.82) 12.4 (8.84)
Median 23 9 21 12
Minimum, maximum 9, 36 8, 14 3, 32 0, 34
Homeless, n (%) 3 (20) 2 (40) 12 (63) 6 (46)
Number of days injected drugs in last month
Mean (SD) 13.0 (10.42) 12.8 (13.95) 19.1 (9.56) 19.7 (9.76)
Median 8 5 25 28
Minimum, maximum 2, 28 1, 28 3, 28 4, 28
Most frequently injected drug, n (%)
Heroin 5 (33) 3 (60) 10 (53) 12 (92)
Crack 1 (7) 0 (0) 0 (0) 0 (0)
Cocaine 2 (13) 0 (0) 2 (11) 0 (0)
Heroin and crack 6 (40) 2 (40) 2 (11) 1 (8)
Heroin and cocaine 0 (0) 0 (0) 1 (5) 0 (0)
Speedball 0 (0) 0 (0) 1 (5) 0 (0)
Amphetamine 1 (7) 0 (0) 2 (11) 0 (0)
Methadone, mephedrone 0 (0) 0 (0) 1 (5) 0 (0)
Any drugs injected in the last month, n (%)
Heroin 13 (87) 5 (100) 17 (89) 13 (100)
Crack 9 (60) 2 (40) 7 (37) 3 (23)
Amphetamine (speed) 1 (7) 0 (0) 3 (16) 0 (0)
Ketamine 1 (7) 0 (0) 0 (0) 0 (0)
Methadone 0 (0) 0 (0) 0 (0) 0 (0)
Cocaine 4 (27) 0 (0) 6 (32) 2 (15)
Mephedrone 0 (0) 0 (0) 1 (5) 0 (0)
Methamphetamine 0 (0) 0 (0) 0 (0) 0 (0)
Other 0 (0) 1 (20) 1 (5) 0 (0)
Injected heroin and cocaine in last month
(speedball)
7 (47) 2 (40) 8 (42) 4 (31)
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Follow-up attendance (one or both times) was associated with fewer days of injecting drugs in the last
month (median 14 vs. 27 days; p = 0.030) and fewer injections of cocaine (13% vs. 30%; p = 0.063), but
none of the other characteristics identified for compliance above to a substantial extent (see Table 26).
More participants were followed up in London (83%) and Wrexham (63%) than in Glasgow (55%) and
York (43%) (see Table 26), which may in part be linked to factors associated with higher injecting
frequencies in Glasgow and York. In addition, at the 1-month follow-up, two female participants in
London were in hospital; one male participant was in prison in Wrexham; and in Glasgow, three female
and three male participants were in residential rehabilitation, one male participant was in prison and one
male participant was in hospital. As these participants were not contactable, it was not possible to conduct
follow-up interviews.
TABLE 25 Participant characteristics by compliance (by gender) (continued )
Participant characteristic
Compliance
Attended at least one
intervention session
Attended no intervention
sessions
Male (N= 15) Female (N= 5) Male (N= 19) Female (N= 13)
Any drugs used in the last month, n (%)
Cocaine 8 (53) 3 (60) 8 (42) 4 (31)
Amphetamine 2 (13) 0 (0) 4 (21) 0 (0)
Crack 11 (73) 5 (100) 13 (68) 10 (77)
Heroin 12 (80) 4 (80) 18 (95) 13 (100)
Mephedrone 1 (7) 0 (0) 2 (11) 0 (0)
Methamphetamine 0 (0) 0 (0) 0 (0) 0 (0)
Ecstasy/E 2 (13) 0 (0) 2 (11) 0 (0)
Cannabis 10 (67) 3 (60) 11 (58) 6 (46)
Solvents or glue 0 (0) 0 (0) 0 (0) 0 (0)
Ketamine 0 (0) 0 (0) 0 (0) 0 (0)
Benzodiazepines 8 (53) 3 (60) 9 (47) 9 (69)
Other drugs 0 (0) 1 (20) 5 (26) 2 (15)
Used needle exchange in the last month, n (%) 14 (93) 3 (60) 17 (89) 13 (100)
Number of individual needles
Mean (SD) 30.0 (31.00) 36.0 (33.15) 62.9 (73.67) 59.6 (69.95)
Median 20 32 30 40
Minimum, maximum 0, 100 0, 80 8, 220 20, 280
Current detox/maintenance drug use, n (%) 11 (73) 5 (100) 15 (79) 12 (92)
Length of time on current script, n (%)
< 1 month 0 (0) 1 (20) 0 (0) 1 (8)
1–6 months 0 (0) 2 (40) 3 (16) 5 (38)
> 6 months 12 (80) 2 (40) 12 (63) 6 (46)
HIV positive, n (%) 1 (7) 0 (0) 0 (0) 0 (0)
HCV positive, n (%) 6 (40) 1 (20) 11 (58) 4 (31)
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TABLE 26 Participant characteristics by follow-up attendance (total)
Participant characteristic
Compliance
p-value for
differencea
Attended at least one
follow-up (N= 62)
Attended no
follow-up (N= 37)
Gender, n (%) 0.153
Male 43 (69) 20 (54)
Female 18 (29) 17 (46)
Transgender 1 (2) 0 (0)
Age (years) 0.347
Mean (SD) 40.5 (8.25) 38.8 (5.92)
Median 41 40
Minimum, maximum 22, 62 28, 50
Number of years since first injected 0.097
Mean (SD) 19.4 (9.63) 16.2 (9.27)
Median 19.5 15
Minimum, maximum 0, 44 0, 35
Homeless, n (%) 25 (40) 17 (46) 0.675
Number of days injected drugs in last month 0.030
Mean (SD) 15.8 (10.63) 20.1 (9.50)
Median 14 27
Minimum, maximum 1, 28 2, 28
Most frequently injected drug, n (%) 0.591
Heroin 37 (60) 26 (70)
Crack 3 (5) 0 (0)
Cocaine 3 (5) 3 (8)
Heroin and crack 10 (16) 6 (16)
Heroin and cocaine 2 (3) 0 (0)
Heroin and amphetamine 1 (2) 0 (0)
Speedball 1 (2) 0 (0)
Amphetamine 5 (8) 1 (3)
Methadone, mephedrone 0 (0) 1 (3)
Any drugs injected in the last month, n (%)
Heroin 56 (90) 36 (97) 0.252
Crack 26 (42) 16 (43) 1
Amphetamine (speed) 10 (16) 5 (14) 0.781
Ketamine 1 (2) 1 (3) 1
Methadone 0 (0) 0 (0)
Cocaine 8 (13) 11 (30) 0.063
Mephedrone 0 (0) 1 (3) 0.374
Methamphetamine 1 (2) 1 (3) 1
Other 1 (2) 4 (11) 0.063
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Outcome measures
Outcome measures that were collected from participants at baseline and at the end of the intervention
and 1 month post intervention are summarised by randomised allocation in Table 27 (total) and Tables 28
and 29 (by gender).
Following advice from the DMEC, outcomes were further grouped by compliance [i.e. participants who
attended at least one intervention session compared with those who attended none (Table 30)]. See
Outcome measures for a full description of the derivation and interpretation of each outcome.
TABLE 26 Participant characteristics by follow-up attendance (total) (continued )
Participant characteristic
Compliance
p-value for
differencea
Attended at least one
follow-up (N= 62)
Attended no
follow-up (N= 37)
Injected heroin and cocaine in last month
(speedball), n (%)
24 (39) 16 (43) 0.677
Any drugs used in the last month, n (%)
Cocaine 25 (40) 17 (46) 0.675
Amphetamine 13 (21) 6 (16) 0.609
Crack 46 (74) 28 (76) 1
Heroin 55 (89) 36 (97) 0.081
Mephedrone 7 (11) 3 (8) 0.739
Methamphetamine 2 (3) 2 (5) 0.623
Ecstasy/E 6 (10) 1 (3) 0.256
Cannabis 42 (68) 19 (51) 0.195
Solvents or glue 0 (0) 0 (0)
Ketamine 2 (3) 0 (0) 0.530
Benzodiazepines 40 (65) 19 (51) 0.289
Other drugs 13 (21) 6 (16) 0.600
Used needle exchange in the last month 53 (85) 36 (97) 0.147
Number of individual needles 0.413
Mean (SD) 46.9 (43.6) 79.9 (144.23)
Median 32.5 30
Minimum, maximum 0, 210 2, 840
Current detox/maintenance drug use, n (%) 53 (85) 32 (86) 1
Length of time on current script, n (%) 0.695
< 1 month 4 (6) 3 (8)
1–6 months 9 (15) 7 (19)
> 6 months 41 (66) 22 (59)
HIV positive, n (%) 0 (0) 1 (3) 0.352
HCV positive, n (%) 24 (39) 19 (51) 0.287
a Mann–Whitney U-test or Fisher’s exact test as appropriate.
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TABLE 27 Trial outcomes: total – groups as randomised
Trial outcome
Trial arm
Intervention Control
Baseline
(n= 52)
End of
intervention
(n= 24)
1 month
post
intervention
(n= 22)
Baseline
(n= 47)
End of
intervention
(n= 27)
1 month
post
intervention
(n= 23)
Injecting risk practicesa
Mean (SD) 2.5 (2.44) 1.9 (2.16) 1.7 (2.82) 2.7 (2.93) 2.6 (2.69) 2.6 (3.20)
Median (minimum, maximum) 2 (0, 9) 1 (0, 9) 1 (0, 9) 1 (0, 9) 1 (0, 9) 1 (0, 9)
Sexual risk behavioursb
Mean (SD) 3.8 (2.08) 4.3 (1.31) 4.4 (1.92) 3.8 (1.80) 3.7 (1.98) 3.1 (1.73)
Median (minimum, maximum) 5 (0, 7) 4.5 (2, 7) 5 (0, 7) 4 (0, 7) 4 (0, 6) 3 (0, 6)
Self-efficacyc
Mean (SD) 24.1 (4.76) 24.8 (3.23) 25.3 (3.24) 23.9 (4.75) 23.7 (5.55) 25.0 (5.26)
Median (minimum, maximum) 25 (10, 31) 26 (17, 31) 25 (17, 32) 23 (16, 32) 23 (14, 32) 25 (11, 32)
HIV transmission knowledged
Mean (SD) 10.4 (2.53) 11.3 (1.92) 11.4 (1.59) 10.5 (2.23) 11.3 (1.98) 11.1 (2.19)
Median (minimum, maximum) 11 (4, 14) 11.5 (7, 14) 12 (7, 14) 11 (4, 14) 12 (6, 14) 12 (4, 14)
HCV transmission knowledgee
Mean (SD) 23.8 (3.98) 24.9 (3.49) 24.2 (3.75) 24.8 (3.15) 25.1 (2.18) 24.3 (2.99)
Median (minimum, maximum) 24.5 (13, 30) 26 (14, 29) 24 (15, 29) 25 (20, 29) 25 (20, 29) 25 (14, 28)
HBV transmission knowledgef
Mean (SD) 10.2 (3.01) 11.1 (2.10) 11.0 (2.42) 10.4 (2.45) 10.6 (2.40) 10.0 (2.70)
Median (minimum, maximum) 11 (0, 14) 11 (7, 14) 11 (7, 15) 11 (4, 14) 11 (6, 14) 11 (3, 14)
Withdrawal prevention
g
Mean (SD) 6.2 (4.05) 6.5 (4.19) 5.8 (3.94) 6.9 (4.32) 6.3 (4.42) 5.6 (3.45)
Median (minimum, maximum) 6 (0, 19) 6 (0, 17) 6 (0, 13) 7 (0, 17) 4 (0, 17) 5 (0, 15)
Motivation to change (for self)h
Mean (SD) 4.5 (0.83) 4.5 (0.66) 4.6 (0.49) 4.4 (0.80) 4.7 (0.45) 4.6 (0.58)
Median (minimum, maximum) 5 (2, 5) 5 (3, 5) 5 (4, 5) 5 (2, 5) 5 (4, 5) 5 (3, 5)
Motivation to change (for others)h
Mean (SD) 4.4 (0.82) 4.3 (0.70) 4.5 (0.51) 4.4 (0.85) 4.9 (0.36) 4.7 (0.54)
Median (minimum, maximum) 5 (2, 5) 4 (3, 5) 4.5 (4, 5) 5 (0, 5) 5 (4, 5) 5 (3, 5)
a Range: 0–9 (higher number =more risk events).
b Range: 0–7 (higher number =more risk behaviours).
c Range: 8–32 (higher score = greater self-efficacy).
d Range: 0–14 (higher score = better knowledge).
e Range: 0–31 (higher score = better knowledge).
f Range: 0–15 (higher score = better knowledge).
g Range: 0–20 (higher score = better prevention tactics).
h Range: 0–5 (higher score =more motivation).
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TABLE 28 Trial outcomes: males – groups as randomised
Trial outcome
Trial group
Intervention Control
Baseline
(n= 34)
End of
intervention
(n= 18)
1 month
post
intervention
(n= 17)
Baseline
(n= 30)
End of
intervention
(n= 20)
1 month
post
intervention
(n= 14)
Injecting risk practicesa
Mean (SD) 2.6 (2.56) 1.8 (1.60) 1.5 (2.23) 2.2 (2.49) 2.4 (2.94) 2.3 (3.02)
Median (minimum, maximum) 1.5 (0, 9) 1 (0, 5) 1 (0, 9) 1 (0, 8) 1 (0, 9) 0.5 (0, 9)
Sexual risk behavioursb
Mean (SD) 4.2 (1.98) 4.4 (1.34) 4.7 (1.53) 3.8 (1.89) 3.6 (2.14) 3.1 (1.59)
Median (minimum, maximum) 5 (0, 7) 4.5 (2, 7) 5 (1, 7) 5 (0, 7) 4.5 (0, 6) 3 (0, 6)
Self-efficacyc
Mean (SD) 24.5 (4.97) 25.4 (2.85) 25.2 (3.41) 24.3 (4.38) 24.0 (5.71) 25.9 (4.55)
Median (minimum, maximum) 25 (10, 31) 26 (21, 31) 25 (17, 32) 23.5 (16, 32) 23.5 (14, 32) 23.5 (20, 32)
HIV transmission knowledged
Mean (SD) 10.2 (2.44) 11.2 (1.95) 11.2 (1.74) 10.8 (2.50) 11.3 (2.13) 10.7 (2.49)
Median (minimum, maximum) 11 (4, 13) 11 (7, 14) 11 (7, 14) 11 (4, 14) 11.5 (6, 14) 11.5 (4, 13)
HCV transmission knowledgee
Mean (SD) 23.3 (3.87) 24.9 (3.33) 23.6 (3.66) 24.8 (3.53) 25.0 (2.08) 24.6 (3.46)
Median (minimum, maximum) 24 (13, 29) 26 (14, 29) 24 (15, 29) 26 (14, 30) 25 (20, 29) 25 (14, 28)
HBV transmission knowledgef
Mean (SD) 9.9 (3.13) 11.1 (2.25) 11.2 (2.41) 10.3 (2.38) 10.9 (2.25) 10.2 (2.29)
Median (minimum, maximum) 10 (0, 14) 11.5 (7, 14) 11 (7, 15) 11 (4, 14) 12 (6, 14) 10.5 (6, 14)
Withdrawal prevention
g
Mean (SD) 5.6 (4.40) 6.3 (4.61) 5.5 (4.42) 6.7 (4.20) 6.5 (4.78) 5.6 (4.09)
Median (minimum, maximum) 5.5 (0, 19) 6 (0, 17) 6 (0, 13) 7 (0, 14) 5.5 (0, 17) 5.5 (0, 15)
Motivation to change (for self)h
Mean (SD) 4.3 (0.94) 4.6 (0.61) 4.6 (0.51) 4.5 (0.63) 4.7 (0.47) 4.6 (0.50)
Median (minimum, maximum) 5 (2, 5) 5 (3, 5) 5 (4, 5) 5 (3, 5) 5 (4, 5) 5 (4, 5)
Motivation to change (for others)h
Mean (SD) 4.4 (0.81) 4.3 (0.69) 4.4 (0.51) 4.6 (0.50) 4.8 (0.41) 4.8 (0.43)
Median (minimum, maximum) 5 (2, 5) 4 (3, 5) 4 (4, 5) 5 (4, 5) 5 (4, 5) 5 (4, 5)
a Range: 0–9 (higher number =more risk events).
b Range: 0–7 (higher number =more risk behaviours).
c Range: 8–32 (higher score = greater self-efficacy).
d Range: 0–14 (higher score = better knowledge).
e Range: 0–31 (higher score = better knowledge).
f Range: 0–15 (higher score = better knowledge).
g Range: 0–20 (higher score = better prevention tactics).
h Range: 0–5 (higher score =more motivation).
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TABLE 29 Trial outcomes: females – groups as randomised
Trial outcome
Trial group
Intervention Control
Baseline
(n= 18)
End of
intervention
(n= 6)
1 month
post
intervention
(n= 5)
Baseline
(n= 17)
End of
intervention
(n= 7)
1 month
post
intervention
(n= 9)
Injecting risk practicesa
Mean (SD) 2.1 (2.17) 2.4 (3.71) 3.0 (5.20) 3.5 (3.48) 3.0 (1.90) 3.0 (3.63)
Median (minimum, maximum) 2 (0, 9) 1 (0, 9) 0 (0, 9) 1 (0, 9) 3 (1, 6) 1 (0, 9)
Sexual risk behavioursb
Mean (SD) 3.2 (2.15) 4.0 (1.26) 3.4 (2.88) 3.9 (1.68) 4.0 (1.53) 3.1 (2.03)
Median (minimum, maximum) 3 (0, 6) 4.5 (2, 5) 4 (0, 7) 4 (0, 7) 4 (1, 6) 3 (0, 6)
Self-efficacyc
Mean (SD) 23.4 (4.38) 22.8 (3.76) 25.6 (2.88) 23.2 (5.40) 22.9 (5.43) 23.7 (6.24)
Median (minimum, maximum) 24.5 (12, 29) 22 (17, 27) 25 (22, 30) 23 (16, 32) 22 (17, 32) 24 (11, 31)
HIV transmission knowledged
Mean (SD) 10.8 (2.73) 11.7 (1.97) 12.0 (0.71) 10.0 (1.62) 11.3 (1.60) 11.7 (1.58)
Median (minimum, maximum) 12 (5, 14) 12.5 (8, 13) 12 (11, 13) 10 (7, 12) 12 (9, 13) 12 (9, 14)
HCV transmission knowledgee
Mean (SD) 24.8 (4.09) 24.8 (4.26) 26.4 (1.67) 24.8 (2.44) 25.6 (2.57) 23.9 (2.20)
Median (minimum, maximum) 26 (16, 30) 26.5 (19, 29) 26 (24, 28) 24 (21, 30) 25 (22, 29) 25 (21, 27)
HBV transmission knowledgef
Mean (SD) 10.7 (2.78) 11.0 (1.79) 10.4 (2.61) 10.5 (2.62) 10.0 (2.89) 9.7 (3.35)
Median (minimum, maximum) 12 (3, 13) 11 (9, 13) 10 (8, 14) 11 (7, 14) 10 (6, 14) 11 (3, 13)
Withdrawal prevention
g
Mean (SD) 7.3 (3.12) 7.2 (2.79) 6.8 (1.48) 7.2 (4.65) 6.0 (3.46) 5.7 (2.35)
Median (minimum, maximum) 8 (1, 11) 6.5 (4, 11) 7 (5, 9) 6 (0, 17) 4 (4, 12) 5 (3, 10)
Motivation to change (for self)h
Mean (SD) 4.8 (0.38) 4.2 (0.75) 4.8 (0.45) 4.2 (1.03) 4.9 (0.38) 4.6 (0.73)
Median (minimum, maximum) 5 (4, 5) 4 (3, 5) 5 (4, 5) 5 (2, 5) 5 (4, 5) 5 (3, 5)
Motivation to change (for others)h
Mean (SD) 4.4 (0.85) 4.3 (0.82) 4.8 (0.45) 4.1 (1.22) 5.0 (0.00) 4.7 (0.71)
Median (minimum, maximum) 5 (2, 5) 4.5 (3, 5) 5 (4, 5) 4 (1, 5) 5 (5, 5) 5 (3, 5)
a Range: 0–9 (higher number =more risk events).
b Range: 0–7 (higher number =more risk behaviours).
c Range: 8–32 (higher score = greater self-efficacy).
d Range: 0–14 (higher score = better knowledge).
e Range: 0–31 (higher score = better knowledge).
f Range: 0–15 (higher score = better knowledge).
g Range: 0–20 (higher score = better prevention tactics).
h Range: 0–5 (higher score =more motivation).
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TABLE 30 Trial outcomes: total – groups by compliance
Trial outcome
Compliance
Attended at least one intervention
session
Attended none of the intervention
sessions
Baseline
(n= 20)
End of
intervention
(n= 14)
1 month
post
intervention
(n= 16)
Baseline
(n= 79)
End of
intervention
(n= 37)
1 month
post
intervention
(n= 29)
Injecting risk practicesa
Mean (SD) 2.3 (2.45) 1.7 (2.40) 1.4 (2.40) 2.6 (2.73) 2.5 (2.46) 2.6 (3.28)
Median (minimum, maximum) 1 (0, 9) 1 (0, 9) 1 (0, 9) 1.5 (0, 9) 1 (0, 9) 1 (0, 9)
Sexual risk behavioursb
Mean (SD) 4.1 (2.04) 4.3 (1.07) 3.9 (1.89) 3.8 (1.92) 3.9 (1.90) 3.7 (1.97)
Median (minimum, maximum) 5 (0, 7) 4 (3, 6) 4 (0, 7) 4 (0, 7) 4 (0, 7) 4 (0, 7)
Self-efficacyc
Mean (SD) 23.3 (5.14) 25.1 (3.12) 25.9 (3.47) 24.2 (4.64) 23.9 (5.04) 24.7 (4.76)
Median (minimum, maximum) 24.5 (12, 31) 26.5 (21, 31) 25.5 (17, 32) 24 (10, 32) 24 (14, 32) 25 (11, 32)
HIV transmission knowledged
Mean (SD) 10.8 (2.22) 11.9 (1.23) 11.4 (1.59) 10.4 (2.43) 11.1 (2.11) 11.1 (2.08)
Median (minimum, maximum) 11 (7, 14) 12 (10, 14) 12 (7, 14) 11 (4, 14) 11 (6, 14) 12 (4, 14)
HCV transmission knowledgee
Mean (SD) 23.5 (3.78) 26.1 (2.53) 24.1 (3.55) 24.5 (3.59) 24.6 (2.89) 24.4 (3.06)
Median (minimum, maximum) 24 (15, 29) 26.5 (20, 29) 24 (15, 29) 25 (13, 30) 25 (14, 29) 25 (14, 29)
HBV transmission knowledgef
Mean (SD) 10.3 (2.45) 11.1 (2.48) 11.1 (2.72) 10.3 (2.83) 10.7 (2.19) 10.2 (2.51)
Median (minimum, maximum) 11 (5, 13) 11.5 (7, 14) 11.5 (7, 15) 11 (0, 14) 11 (6, 14) 11 (3, 14)
Withdrawal prevention
g
Mean (SD) 5.4 (3.36) 6.5 (4.26) 5.9 (4.13) 6.8 (4.32) 6.4 (4.34) 5.6 (3.45)
Median (minimum, maximum) 5 (0, 12) 6.5 (1, 17) 6 (0, 13) 7 (0, 19) 6 (0, 17) 6 (0, 15)
Motivation to change (for self)h
Mean (SD) 4.4 (0.82) 4.5 (0.52) 4.6 (0.51) 4.4 (0.81) 4.7 (0.58) 4.7 (0.55)
Median (minimum, maximum) 5 (2, 5) 4.5 (4, 5) 5 (4, 5) 5 (2, 5) 5 (3, 5) 5 (3, 5)
Motivation to change (for others)h
Mean (SD) 4.4 (0.59) 4.2 (0.70) 4.4 (0.51) 4.4 (0.88) 4.8 (0.49) 4.7 (0.53)
Median (minimum, maximum) 4 (3, 5) 4 (3, 5) 4 (4, 5) 5 (1, 5) 5 (3, 5) 5 (3, 5)
a Range: 0–9 (higher number =more risk events).
b Range: 0–7 (higher number =more risk behaviours).
c Range: 8–32 (higher score = greater self-efficacy).
d Range: 0–14 (higher score = better knowledge).
e Range: 0–31 (higher score = better knowledge).
f Range: 0–15 (higher score = better knowledge).
g Range: 0–20 (higher score = better prevention tactics).
h Range: 0–5 (higher score =more motivation).
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In addition to the summary statistics, outcomes were analysed by longitudinal regression analysis, predicting
each outcome from treatment arm and follow-up point (and their interaction), the outcome at baseline,
gender and recruitment site. Estimated group differences and CIs from these analyses are presented in
Table 31. Following advice from the DMEC, both ITT and per-protocol analyses (by attendance of at least
one intervention session) were conducted with both 95% and 80% CIs.
The summary of group differences for each outcome (see Table 31) is based on longitudinal regression
analyses, adjusting for gender, recruitment site and the outcome in question at baseline. See Outcome
measures for a full description of each outcome. Analyses revealed improved (fewer) injecting risk
practices, improved self-efficacy, better HCV and HBV transmission knowledge and greater use of
withdrawal prevention techniques in the intervention arm. This was true at both follow-up time points and
both analyses for randomised groups and groups based on attendance of the intervention. Little change
for any group was seen for HIV transmission knowledge.
A number of results appeared counterintuitive. Participants in the randomised intervention group engaged
in a greater number of sexual risk behaviours at both follow-up time points, although group differences
were reduced to minimal in the attendance-based analysis. Motivation to change both to protect the
participant themselves and to protect others was greater for control arm participants/participants who did
not attend any interventions. This outcome was highly skewed, with most participants indicated being
highly motivated. There is no explanation for this high motivation, and this could potentially be a result of
these participants hoping to be randomly allocated to the intervention group.
Sample sizes were too small to investigate possible interactions with baseline characteristics and outcomes
(e.g. whether or not score changes can only be seen in a subset of the participant population). A larger
pilot might have revealed meaningful trends for such subgroups.
All outcome measures were reviewed with regard to the number of missing items that contribute to each
outcome (Table 32). Overall, data completeness was very high across all questionnaire responses, and most
items were only missing sporadically. Notable exceptions were items 4 and 6 of the sexual risk behaviours.
Both of these are questions relating to a casual sexual partner rather than a regular one, which may not
have been applicable to some participants, although the question does ask to answer the question
hypothetically if not applicable.
Adverse outcomes and events
Table 33 highlights that at 1 month post intervention no increase in self-reported injecting in more ‘risky’
sites (e.g. groin, neck) was observed among participants who had attended at least one session of the
intervention.
Table 34 presents a trend towards injecting on fewer days in the past 28 days for those who had attended
at least one session at 1 month post intervention. Therefore, exposure to sessions on improving injecting
techniques as part of a BBV harm reduction psychosocial intervention does not appear to encourage riskier
injecting practices or frequency of injecting.
No adverse events were recorded as a result of participating in the feasibility trial.
Results: health economics
The PROTECT intervention costs included a training event, which involved staff time and materials. We do
not include travel time and cost as these costs would not be borne if the intervention was rolled out in
practice, as training would take place at local facilities. The first stage of costing is the estimation of
training costs. These costs are included in the cost per-session calculations. However, in this study the costs
are higher per session because we have allocated training costs on a per-session basis, assigning the costs
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TABLE 31 Summary of mean group differences for outcome measuresa
Trial outcome
Analysis by
Randomised groups (ITT)
Attendance of at least one
intervention session
Mean 95% CI 80% CI Mean 95% CI 80% CI
Injecting risk practicesb
End of intervention –0.45 –1.50 to 0.61 –1.14 to 0.24 –0.52 –1.78 to 0.74 –1.35 to 0.30
1 month post intervention –0.25 –1.33 to 0.82 –0.96 to 0.45 –0.25 –1.51 to 1.01 –1.08 to 0.57
Sexual risk behavioursc
End of intervention 0.57 –0.20 to 1.34 0.06 to 1.07 0.08 –0.85 to 1.02 –0.53 to 0.70
1 month post intervention 1.26 0.43 to 2.08 0.71 to 1.80 0.13 –0.80 to 1.06 –0.48 to 0.74
Self-efficacyd
End of intervention 1.17 –0.71 to 3.05 –0.06 to 2.40 2.20 0.02 to 4.38 0.77 to 3.62
1 month post intervention 0.08 –1.90 to 2.07 –1.22 to 1.38 1.65 –0.51 to 3.82 0.24 to 3.07
HIV transmission knowledgee
End of intervention –0.06 –0.88 to 0.75 –0.60 to 0.47 0.04 –0.91 to 0.99 –0.58 to 0.66
1 month post intervention 0.18 –0.70 to 1.06 –0.39 to 0.76 –0.07 –1.00 to 0.87 –0.68 to 0.55
HCV transmission knowledgef
End of intervention 0.16 –1.37 to 1.68 –0.84 to 1.15 2.13 0.41 to 3.85 1.01 to 3.26
1 month post intervention 0.12 –1.52 to 1.75 –0.96 to 1.19 0.30 –1.40 to 1.99 –0.81 to 1.41
HBV transmission knowledge
g
End of intervention 0.79 –0.31 to 1.89 0.07 to 1.51 0.79 –0.51 to 2.08 –0.06 to 1.63
1 month post intervention 0.75 –0.41 to 1.91 –0.01 to 1.51 0.88 –0.41 to 2.18 0.03 to 1.73
Withdrawal preventionh
End of intervention 0.28 –1.37 to 1.93 –0.80 to 1.36 0.38 –1.54 to 2.31 –0.88 to 1.64
1 month post intervention 1.41 –0.34 to 3.17 0.26 to 2.57 1.83 –0.10 to 3.76 0.57 to 3.09
Motivation to change (for self)i
End of intervention –0.20 –0.47 to 0.07 –0.38 to –0.03 –0.21 –0.52 to 0.09 –0.42 to –0.01
1 month post intervention –0.01 –0.30 to 0.28 –0.20 to 0.18 –0.21 –0.51 to 0.10 –0.41 to –0.01
Motivation to change (for others)i
End of intervention –0.40 –0.67 to –0.13 –0.58 to –0.22 –0.53 –0.84 to –0.23 –0.73 to –0.33
1 month post intervention –0.14 –0.43 to 0.15 –0.33 to 0.05 –0.29 –0.59 to 0.01 –0.49 to –0.10
a Mean differences represent the estimated mean group difference following regression analysis adjusted for outcome at
baseline, gender and recruitment site. Positive mean difference= higher score in the intervention arm; negative mean
difference = higher score in the control arm.
b Range: 0–9 (higher number =more risk events).
c Range: 0–7 (higher number =more risk behaviours).
d Range: 8–32 (higher score = greater self-efficacy).
e Range: 0–14 (higher score = better knowledge).
f Range: 0–31 (higher score = better knowledge).
g Range: 0–15 (higher score = better knowledge).
h Range: 0–20 (higher score = better prevention tactics).
i Range: 0–5 (higher score =more motivation).
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TABLE 32 Missingness for outcome measures
Trial outcome
Time point, n (%)
Baseline (N= 99) End of intervention (N= 51) 1 month post intervention (N= 45)
Injecting risk practices
Item 1 0 (0.0) 0 (0.0) 1 (2.2)
Item 2 0 (0.0) 0 (0.0) 0 (0.0)
Item 3 1 (1.0) 0 (0.0) 0 (0.0)
Item 4 0 (0.0) 0 (0.0) 0 (0.0)
Item 5 0 (0.0) 0 (0.0) 0 (0.0)
Item 6 1 (1.0) 0 (0.0) 0 (0.0)
Item 7 0 (0.0) 0 (0.0) 0 (0.0)
Item 8 0 (0.0) 0 (0.0) 0 (0.0)
Item 9 0 (0.0) 0 (0.0) 0 (0.0)
Sexual risk behaviours
Item 1 2 (2.0) 1 (2.0) 2 (4.4)
Item 2 0 (0.0) 1 (2.0) 2 (4.4)
Item 3 4 (4.0) 1 (2.0) 0 (0.0)
Item 4 11 (11.1) 4 (7.8) 0 (0.0)
Item 5 6 (6.1) 1 (2.0) 0 (0.0)
Item 6 11 (11.1) 3 (5.9) 0 (0.0)
Item 7 0 (0.0) 1 (2.0) 0 (0.0)
Self-efficacy
Item 1 0 (0.0) 0 (0.0) 0 (0.0)
Item 2 0 (0.0) 0 (0.0) 0 (0.0)
Item 3 0 (0.0) 0 (0.0) 0 (0.0)
Item 4 1 (1.0) 0 (0.0) 0 (0.0)
Item 5 0 (0.0) 0 (0.0) 0 (0.0)
Item 6 4 (4.0) 1 (2.0) 1 (2.2)
Item 7 0 (0.0) 0 (0.0) 1 (2.2)
Item 8 0 (0.0) 0 (0.0) 0 (0.0)
HIV transmission knowledge
Item 1 0 (0.0) 0 (0.0) 0 (0.0)
Item 2 0 (0.0) 0 (0.0) 0 (0.0)
Item 3 0 (0.0) 0 (0.0) 0 (0.0)
Item 4 0 (0.0) 0 (0.0) 0 (0.0)
Item 5 0 (0.0) 0 (0.0) 0 (0.0)
Item 6 0 (0.0) 0 (0.0) 0 (0.0)
continued
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TABLE 32 Missingness for outcome measures (continued )
Trial outcome
Time point, n (%)
Baseline (N= 99) End of intervention (N= 51) 1 month post intervention (N= 45)
Item 7 1 (1.0) 1 (2.0) 0 (0.0)
Item 8 0 (0.0) 0 (0.0) 0 (0.0)
Item 9 0 (0.0) 1 (2.0) 0 (0.0)
Item 10 0 (0.0) 1 (2.0) 0 (0.0)
Item 11 0 (0.0) 0 (0.0) 0 (0.0)
Item 12 0 (0.0) 0 (0.0) 0 (0.0)
Item 13 0 (0.0) 0 (0.0) 0 (0.0)
Item 14 0 (0.0) 0 (0.0) 0 (0.0)
HCV transmission knowledge
Item 1 0 (0.0) 0 (0.0) 0 (0.0)
Item 2 0 (0.0) 0 (0.0) 0 (0.0)
Item 3 0 (0.0) 0 (0.0) 0 (0.0)
Item 4 0 (0.0) 0 (0.0) 0 (0.0)
Item 5 0 (0.0) 0 (0.0) 0 (0.0)
Item 6 0 (0.0) 0 (0.0) 0 (0.0)
Item 7 1 (1.0) 0 (0.0) 0 (0.0)
Item 8 0 (0.0) 0 (0.0) 0 (0.0)
Item 9 0 (0.0) 1 (2.0) 0 (0.0)
Item 10 0 (0.0) 0 (0.0) 0 (0.0)
Item 11 1 (1.0) 0 (0.0) 0 (0.0)
Item 12 0 (0.0) 0 (0.0) 0 (0.0)
Item 13 0 (0.0) 0 (0.0) 0 (0.0)
Item 14 0 (0.0) 0 (0.0) 0 (0.0)
Item 15a 0 (0.0) 0 (0.0) 0 (0.0)
Item 16 0 (0.0) 0 (0.0) 0 (0.0)
Item 17 0 (0.0) 1 (2.0) 0 (0.0)
Item 18 0 (0.0) 0 (0.0) 0 (0.0)
Item 19 0 (0.0) 0 (0.0) 0 (0.0)
Item 20 0 (0.0) 0 (0.0) 0 (0.0)
Item 21 0 (0.0) 0 (0.0) 0 (0.0)
Item 22 0 (0.0) 0 (0.0) 0 (0.0)
Item 23 0 (0.0) 1 (2.0) 0 (0.0)
Item 24 0 (0.0) 0 (0.0) 0 (0.0)
Item 25 0 (0.0) 0 (0.0) 0 (0.0)
Item 26 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 32 Missingness for outcome measures (continued )
Trial outcome
Time point, n (%)
Baseline (N= 99) End of intervention (N= 51) 1 month post intervention (N= 45)
Item 27 0 (0.0) 1 (2.0) 0 (0.0)
Item 28 0 (0.0) 0 (0.0) 0 (0.0)
Item 29a 0 (0.0) 0 (0.0) 0 (0.0)
Item 30 0 (0.0) 0 (0.0) 0 (0.0)
Item 31 0 (0.0) 0 (0.0) 0 (0.0)
Item 32 0 (0.0) 0 (0.0) 0 (0.0)
Item 33 0 (0.0) 0 (0.0) 0 (0.0)
HBV transmission knowledge
Item 1 0 (0.0) 0 (0.0) 0 (0.0)
Item 2 0 (0.0) 0 (0.0) 0 (0.0)
Item 3 0 (0.0) 0 (0.0) 0 (0.0)
Item 4 0 (0.0) 0 (0.0) 0 (0.0)
Item 5 0 (0.0) 0 (0.0) 0 (0.0)
Item 6 0 (0.0) 0 (0.0) 0 (0.0)
Item 7 0 (0.0) 0 (0.0) 0 (0.0)
Item 8 0 (0.0) 0 (0.0) 0 (0.0)
Item 9 0 (0.0) 0 (0.0) 0 (0.0)
Item 10 0 (0.0) 0 (0.0) 0 (0.0)
Item 11 0 (0.0) 0 (0.0) 0 (0.0)
Item 12 0 (0.0) 0 (0.0) 0 (0.0)
Item 13 0 (0.0) 0 (0.0) 0 (0.0)
Item 14 0 (0.0) 0 (0.0) 0 (0.0)
Item 15 0 (0.0) 0 (0.0) 0 (0.0)
Withdrawal prevention
Item 1 1 (1.0) 0 (0.0) 0 (0.0)
Item 2 1 (1.0) 0 (0.0) 0 (0.0)
Item 3 0 (0.0) 0 (0.0) 0 (0.0)
Item 4 0 (0.0) 0 (0.0) 0 (0.0)
Item 5 0 (0.0) 0 (0.0) 0 (0.0)
Motivation to change
Item 1 0 (0.0) 0 (0.0) 0 (0.0)
Item 2 0 (0.0) 0 (0.0) 0 (0.0)
a Items not used in the outcome calculation.
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to the 12 sessions delivered in the trial. In practice, the cost per session would be lower as those trained
would deliver more sessions than within the trial, therefore reducing the cost of training per session.
Summing the staff and other costs gives a total training cost of £2013. This cost is divided across the
12 sessions delivered to give a cost per session of £167.78.
A proportion of training cost is assigned to each session (Tables 35 and 36). Centre-specific costs are
allocated to each centre and then a cost per attendee is calculated. Table 35 details the items included in
the costing. Total intervention costs are calculated per-session delivered. These included training costs, staff
time (including contact and preparation time), costs of printed materials and text messages to patients.
Costs for sessions 1–3 are estimated for each of the treatment centres (see Table 36). The total cost of
session delivery is calculated for each session at each service and divided by the number of patients to give
a cost per patient. Each cost per patient is attributed to the patient, then the cost per session is added to
derive a total cost of treatment. Total patient treatment costs are derived by summing the costs of the
sessions attended (maximum = three).
TABLE 34 Number of days injected by session attendance
Number of
days injected
Time point
Baseline End of intervention 1 month post intervention
Attended
at least
one session
Attended
no sessions
Attended
at least
one session
Attended
no sessions
Attended
at least
one session
Attended
no sessions
n 20 78 14 36 16 29
Mean 13.0 18.6 18.4 15.3 11.6 15.4
SD 11.00 9.98 9.23 10.95 10.00 12.02
Median 6.5 22.5 21 14 9 17
Minimum 1 1 3 0 0 0
Maximum 28 28 28 28 28 28
TABLE 33 Injection sites by session attendance
Injection site
Time point, n (%)
Baseline End of intervention 1 month post intervention
Attended
at least
one session
Attended
no sessions
Attended
at least
one session
Attended
no sessions
Attended
at least
one session
Attended
no sessions
Arms 8 (50) 13 (45) 9 (75) 14 (38) 8 (50) 13 (45)
Feet 1 (6) 1 (3) 2 (17) 3 (8) 1 (6) 1 (3)
Hands 1 (6) 8 (28) 2 (17) 8 (22) 1 (6) 8 (28)
Neck 0 (0) 0 (0) 1 (8) 0 (0) 0 (0) 0 (0)
Groin 6 (38) 12 (41) 5 (42) 16 (43) 6 (38) 12 (41)
Genitals 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Legs 5 (31) 7 (24) 5 (42) 9 (24) 5 (31) 7 (24)
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TABLE 35 Training costs (£)
Category
Location in the UK
London
Cost per
session Glasgow
Cost per
session Wales
Cost per
session York
Cost per
session
Intervention training event,
11 January 2016: staff time
(£24.42 per hour)
Two people × 6 hours × 24.42 293.04 Three people ×
6 hours × 24.42
439.56 Two people ×
6 hours × 24.42
293.04 One person ×
6 hours × 14.29;
1 person × 6 × 9.87
144.96
Intervention training event,
11 January 2016:
peer educators’ time
(£100 for full day)
Two people × 100.00 200.00 N/A N/A N/A
Intervention training event,
11 January 2016: (trainer)
time
585.18 total 585.18 N/A N/A N/A
Intervention training event,
11 January 2016: printing
and binding intervention
manuals
16 manuals × 65 pages × 0.04
per page (printing)
41.60 N/A N/A N/A
16 manuals × 1.00 (binding) 16.00
Training costs 1135.82 439.56 293.04 144.96
N/A, not applicable.
Source of data: all data presented were collected by trial researchers.
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We should note that the costs of these sessions are higher than would be expected in practice because the
costs of the training are allocated only across the trial sessions delivered. In a pragmatic setting we would
expect these training costs to be delivered to more patients, thus reducing the per-session costs as average
cost is reduced as clinical centre throughput increases.
A mean cost was estimated based on number of sessions attended, whereby total cost of treatment is
presented per patient based on the number of sessions attended. The mean cost was £58.17 (note that
this is a coincidence that this figure is the same as the cost for London) for patients attending one session,
£148.54 for those attending two sessions and £270.67 for those attending all three sessions in the
intervention group. This is because costs are allocated on a per-patient basis. The overall session cost is not
changed, but costs are allocated specifically to attendees. The control intervention included 2 minutes of
staff time to hand out and briefly explain printed material. A cost of £0.86 was allocated to each patient in
the control. No variability was observed in the control groups as treatment was provided as a standard
2 minutes of staff time plus a leaflet.
Further costs were incurred at one of the services in which six sessions were arranged but no patients
attended. A total cost of £293 was estimated for each of these programmes of three sessions based on
the staff time spent preparing for the sessions and waiting for no show clients.
TABLE 36 Intervention and control costs (£) per session by centre
Intervention session Patients attending (n)
Cost
Total Per patient Excluding training
Location in the UK
London
Session 1 6 349.02 58.17 30.21
Session 2 5 333.35 66.67 33.12
Session 3 5 333.20 66.64 33.09
London (2)
Session 1 2 316.56 158.28 74.39
Session 2 3 323.43 107.81 51.89
Session 3 2 316.44 158.22 74.33
Scotland
Session 1 3 310.83 103.61 47.69
Session 2 3 310.38 103.46 47.54
Session 3 2 308.80 154.40 70.51
Wales
Session 1 6 318.48 53.08 25.11
Session 2 4 313.16 78.29 36.55
Session 3 6 319.38 53.23 53.23
Control cost
Cost item Unit cost
Staff time 0.81
Leaflet 0.05
Cost per patient 0.86
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EuroQol-5 Dimensions, five-level version
The EQ-5D-5L was completed at baseline and at follow-up time points.242 Table 37 shows the EQ-5D-5L
scores valued using the social tariff at the three points using paired analysis. Both baseline and control
show increases in scores on EQ-5D-5L across the time period. However, we should note that the change in
the control group is greater than the intervention although starting from a lower initial health state
valuation there is greater capacity for change.
The EQ-5D-5L responses were converted to health-related quality-of-life utility scores using the UK tariff
(Table 38).246 Differences in the changes between groups were calculated based on patients with complete
EQ-5D scores at each time point. These differences were not significant for the change from baseline to
the end of the intervention. The mean difference between groups was 0.04648 (95% CI –0.08172 to
0.17467) and from end of the intervention to 1 month post intervention the difference between groups
was 0.10512 (95% CI –0.11455 to 0.32478). We do not present quality-adjusted life-years (QALYs)
because of the short follow-up and the expectation that health utility gains would become evident over a
period longer than 1 month.
For patients not attending any sessions the mean changes were –0.0254 (n = 11) between baseline and
follow-up 1 and +0.0718 (n = 13) between follow-up 1 and follow-up 2. The changes for those attending
at least one session were +0.0985 (n = 4) and +0.179 (n = 13), respectively. However, as a result of the
small sample sizes available, statistical significance was not achieved.
TABLE 38 The EQ-5D-5L mean tariff scores by number of sessions attended
Time point
Mean tariff score by number of sessions attended (SD)
One Two Three
Baseline 0.85800 (0.029698), n= 2 0.70938 (0.124112), n= 8 0.69220 (0.152066), n= 10
End of intervention 0.83750 (0.058690), n= 2 0.73700 (0.280407), n= 4 0.79775 (0.117116), n= 8
1 month post intervention 0.87400 (0.178191), n= 2 0.77517 (0.210201), n= 6 0.82075 (0.283898), n= 8
TABLE 37 The EQ-5D-5L mean tariff scores at baseline and follow-up
Trial arm
Time point
Baseline End of intervention 1 month post intervention
EQ-5D-5L mean tariff score (SD)
Control 0.617 (0.323), n= 46 0.646 (0.314), n= 27 0.788 (0.258), n= 23
Intervention 0.672 (0.247), n= 52 0.754 (0.193), n= 24 0.775 (0.256), n= 22
Baseline to end of
intervention End of intervention to 1 month post intervention
EQ-5D-5L changes (paired cases)
Control +0.0738 (0.216), n = 26 +0.1420 (0.375), n= 17
Intervention +0.0273 (0.233), n = 24 +0.0369 (0.232), n= 17
Difference between
groups
0.04648
(95% CI –0.08172 to 0.17467)
0.10512 (95% CI –0.11455 to 0.32478)
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Service use
Service use questionnaires were completed at baseline and follow-up. Quantities of service use recorded
were multiplied by the national average unit costs of health care and criminal justice contacts to derive
a health-care cost. Follow-up costs are defined by summing costs at the end of the intervention and
1 month post intervention. The unit costs and sources of unit costs are presented in Table 39. The price
year is 2014/15. Costs that were only available for previous years are inflated to 2014/15 prices using the
Hospital and Community Health Services Index for health and social care and the retail prices index for
criminal justice items.
TABLE 39 Unit costs (£) of service use (2014/15 prices)
Service use Unit cost Source
Health and social care
GP consultation (in surgery) 38.00 Curtis247
GP consultation (home visit) 62.00 Curtis247
Practice nurse consultation (in surgery) 11.00 Curtis247
Practice nurse consultation (home visit) 18.00 Curtis247
NHS walk-in clinic 56.00 Curtis247
Inpatient admission (per night) 562.00 Department of Health248
Emergency medicine 124.00 Department of Health248
Ambulance convey 231.00 Department of Health248
Patient transport service 61.58 Curtis249
Hospital day case 704.00 Curtis247
Outpatient attendance 114.00 Department of Health248
Prescription cost per year (average per head) £8.15 NHS Digital250
Social worker (at office) 55.00 Curtis247
Outreach worker £34.0 Curtis247
Key worker 34.00 Curtis247
Mental health specialist 118.00 Curtis247
Pharmacy methadone 10.79 Curtis251
Needle exchange 24.00a See notesa
Criminal justice service
Arrest, caution or penalty disorder notice 2796 Curtis;251 Field;252 and HM Treasury253
Magistrates’ court appearance 639b See notesb
Crown Court appearance 11,586b
Prison day 102.45 Ministry of Justice254
HMCTS, Her Majesty's Courts and Tribunals Service; NDTMS, National Drug Treatment Monioting System.
a Figures derived from the new economy unit cost (cost of needle exchange is per visit). Database URL: http://
neweconomymanchester.com/downloads/2701-140207-Unit-Cost-Database-v1-2-xls (accessed 8 April 2016). Original
source from the ‘NDTMS Unit Cost Report – National And Regional Totals’.
b Phillips and Brown, 1998; HM Courts & Tribunals Service, 2013; Legal Services Commission, 2013; Crown Prosecution
Service, 2013; HMCTS Governance and Assurance Data and Information Disclosures, Ministry of Justice, Freedom of
Information request by e-mail (9 April 2014), Crown Prosecution Service, Freedom of Information request by e-mail
(7 April 2014) (Steve Parrott, University of York, 7 April 2014, personal communication).
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Table 40 shows the mean wider health-care costs, criminal justice costs and total social costs at baseline
and follow-up points for the intervention and control groups. There were no significant differences
between groups at any time point for any of the cost categories.
Health-care and criminal justice costs were also assessed at baseline and follow-up by compliance.
Table 41 shows no significant differences based on whether a patient had attended one or more
treatment sessions compared with those who had attended no sessions.
Service utilisation questionnaires
Analysis of the service use questionnaires was undertaken to identify key areas where data collection could
be improved or included in greater or less detail in a full trial. Twelve categories of cost were identified
where > 90% of responses at all three time periods were zero (Table 42). Of these categories, six had
> 95% of responses as zero. The results will enable the questionnaires to be revised for future use with
areas with high positive response rates identified for more detailed questions and other items not collected
as part of the routine data set. Appendix 15 reports the service use utilisation scores based on treatment
allocation (by ITT) and presents CIs around the mean difference for each item.
Conclusion
The mean cost was £58.17 for patients attending one session, £148.54 for those attending two sessions and
£270.67 for those attending all three sessions in the intervention group. This is a cost weighted across centres
by the numbers of patients attending as costs varied by centre as shown above. These costs compared with
£0.86 in the control group. EQ-5D-5L scores in both groups improved from baseline through the two
follow-ups showing potential for health improvement and associated QALY gains. However, any differences
between groups must be treated with extreme caution because of the small sample size.
Wider NHS costs and criminal justice costs also showed a reduction from baseline through follow-up
periods, suggesting a potential for a full randomised controlled trial to detect cost savings to society,
although cost changes in this sample do not necessarily mean that such changes would be seen in a full
trial. Again, caution must be exercised when interpreting these results because of the small sample sizes
and the short follow-up period.
Analysis of the questionnaires identified several categories that could be excluded from the assessment
battery in a full randomised controlled trial making the collection of data simpler and quicker. Other items,
such as key workers and needle exchange services, were used by > 70% of the trial population indicating
that these areas should be the subject of more detailed data collection in a full trial.
Results: qualitative analysis
Acceptability of the intervention to participants who attended at least one session and
staff who delivered or intended to deliver the intervention
The participant focus groups lasted between 15 minutes and 1 hour, depending on the number of
participants in the group. The facilitator focus groups lasted approximately 1 hour. Five focus groups were
conducted with intervention participants (Table 43) and four focus groups with intervention facilitators
(Table 44) across the four locations in the UK.
PROTECT study participant focus groups report
Most useful aspects of the intervention
When asked what they most liked or found most useful about the intervention, focus group participants
cited content from all three sessions and also aspects of the delivery of the intervention. In terms of
content, participants cited the information on BBV transmission, safer drug use, hygiene and handwashing,
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TABLE 40 Wider health-care, criminal justice and societal costs (2014/15 prices): mean cost (£) (SD) per patient
Category of cost
Time point
Baseline End of intervention 1 month post intervention
Intervention Control
Difference in cost
between groups
(95% CI) Intervention Control
Difference in cost
between groups
(95% CI) Intervention Control
Difference in cost
between groups
(95% CI)
Total wider
health-care cost
1109.00
(1696.14)
1257.00
(2177.61)
148.00 (–657.94 to
954.54)
705.00
(673.39)
997.00
(786.04)
292.00
(–137.81 to 721.34)
662.00
(682.47)
1466.00
(2885.66)
804.00
(–611.92 to 2220.61)
Total criminal
justice cost
1239.00
(2581.51)
1284.00
(3953.47)
45.00 (–1344.95 to
1434.14)
439.00
(2060.80)
289.00
(1348.13)
–151.00
(–1191.45 to 890.34)
236.00
(1053.86)
521.00
(1465.97)
285.00
(–520.06 to 1091.05)
Total social cost 2489.00
(3397.65)
2494.00
(4498.24)
5.00 (–2107.85 to
2117.58)
1194.00
(2178.38)
1328.00
(1563.11)
134.00
(–1034.59 to 1303.28)
908.00
(1279.79)
1909.00
(3077.46)
1001.00
(–662.53 to 2665.44)
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TABLE 41 Health-care and criminal justice costs (£) by compliance
Compliance Number of patients Mean cost (SD) Difference in cost (95% CI)
Baseline
Total wider health-care cost
Attended no sessions 31 989.55 (1282.19) 150.76 (–1317.41 to 1015.89)
Attended at least one session 18 1140.31 (2189.63)
Total criminal justice cost
Attended no sessions 33 1251.55 (2483.27) 36.16 (–1725.08 to 1652.76)
Attended at least one session 17 1287.71 (2897.17)
End of intervention
Total wider health-care cost
Attended no sessions 10 681.72 (515.14) 41.99 (–612.74 to 528.76)
Attended at least one session 13 723.72 (794.65)
Total criminal justice cost
Attended no sessions 9 0.00 (0.00) 743.54 (–2363.57 to 876.49)
Attended at least one session 13 743.54 (2680.87)
1 month post intervention
Total wider health-care cost
Attended no sessions 5 501.67 (154.97) 49.20 (–334.15 to 235.75)
Attended at least one session 15 550.87 451.15)
Total criminal justice cost
Attended no sessions 4 1178.25 (2356.50) 1178.25 (–2571.47 to 4927.97)
Attended at least one session 15 0.00 (0.00)
TABLE 42 Numbers (percentages) of patients recording positive contacts with each service use questionnaire item
(all groups)
Service use category
Time point, n (%)
Baseline End of intervention 1 month post intervention
A&E visits 17 (17.2) 7 (13.7) 6 (13.3)
Inpatient nights 8 (8.1) 4 (7.8) 4 (8.9)
Hospital outpatient visits 15 (15.2) 9 (17.6) 10 (22.2)
Day hospital attendances 5 (5.1) 3 (5.9) 6 (13.3)
Emergency ambulance 5 (5.1) 3 (5.9) 2 (4.5)
Hospital transport by PTA 5 (5.1) 6 (11.8) 1 (2.2)
GP surgery visits 49 (49.5) 27 (52.9) 22 (49.4)
GP home visits 4 (4.0) 3 (5.9) 1 (2.2)
Practice nurse surgery visits 17 (17.2) 10 (19.6) 7 (15.6)
Practice nurse at home 2 (2.0) 1 (2.0) 1 (2.2)
Prescriptions 81 (81.9) 47 (92.2) 41 (91.1)
Other health-care professionals 9 (9.1) 3 (6.1) 2 (4.9)
Key worker at drug service 87 (87.9) 43 (84.3) 37 (82.2)
Group work sessions 16 (16.2) 9 (17.6) 8 (17.8)
continued
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TABLE 42 Numbers (percentages) of patients recording positive contacts with each service use questionnaire item
(all groups) (continued )
Service use category
Time point, n (%)
Baseline End of intervention 1 month post intervention
Specialist drug service 18 (18.2) 5 (8.8) 0 (0)
Pharmacist 78 (78.8) 44 (88.0) 37 (82.2)
Nurse at drug service 29 (29.3) 11 (22.0) 11 (24.4)
Needle exchange 84 (84.8) 42 (82.4) 32 (71.1)
Outreach worker 25 (25.3) 6 (11.8) 9 (20.0)
HIV or HCV test 13 (13.1) 5 (10.8) 9 (20.0)
HIV infection treatment 0 (0) 0 (0) 0 (0)
HCV infection treatment 1 (1.0) 0 (0) 0 (0)
HBV infection treatment 1 (1.0) 0 (0) 1 (2.2)
Mental health specialist 18 (18.2) 9 (17.6) 3 (6.7)
Social worker 7 (7.1) 5 (9.8) 4 (9.1)
Dentist 11 (11.1) 7 (13.7) 6 (13.3)
Family planning 1 (1.0) 0 (0) 1 (2.2)
Sexual health clinic 2 (2.0) 2 (3.9) 1 (2.2)
Arrest or caution 15 (15.2) 3 (6.0) 3 (6.6)
Magistrates’ court appearances 15 (15.2) 3 (6.0) 4 (9.7)
Crown Court appearances 3 (3.0) 0 (0) 0 (0)
Prison 1 (1.0) 0 (0) 0 (0)
A&E, accident and emergency; PTA, patient transport ambulance.
Note
Figures in bold show categories where > 90% were zero at all baseline and follow-up time points.
TABLE 43 Number of intervention participants in each focus group per location in the UK
Location in the UK
Gender of focus group (n)
Male Female
Wrexham 3 1
London 5 2
York N/Aa N/Aa
Glasgow 3 N/Aa
N/A, not applicable.
a There was no PROTECT intervention group for females in Glasgow and no participants attended the intervention in York.
TABLE 44 Number of intervention facilitators in each focus group per location in the UK
Location in the UK Number of facilitators
Wrexham 2
London 4
York 2
Glasgow 3
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bleaching and preparedness planning as particularly useful. In terms of format and delivery, participants
cited exposure to professional and service user points of view, intervention games and exercises, having
the opportunity to talk about topics that are not normally discussed, and the amount and variety of
information provided.
Information regarding blood-borne virus transmission risks
Participants in all five focus groups cited the information regarding BBV transmission (‘how it’s passed on’)
as particularly useful content and said they had gained new knowledge regarding transmission risks (‘some
new ways of catching BBVs’):
. . . the way like a drop of blood can be transferred from the water to the other needle . . . if you were
using that day you could understand that better.
. . . well I got to ask questions . . . I got to . . . find out even some, some of the . . . some information
that I might not have brought up anywhere else. So it was helpful for me in that way. Like such as . . .
contacting or picking up like viruses. How many different ways there were of picking up viruses.
I wouldn’t have known that unless I’ve come to the group.
M2: It opened my eyes up(?) about Hep C.
M1: Yeah it’s definitely opened my eyes up a lot more about things, because I can assure you on
some of them questions [BBV Knowledge questionnaires] I give at the beginning, when you have to
do your questionnaire thing, I know that I got quite a few of them wrong, which now I know I would
get right, you know what I mean, which I’m very happy about.
One participant reported that information about the consequences of BBV infection was the most
useful content:
I liked the third one the most likely ’cos you’re giving more information on what would happen to you
with the disease like and I just learnt more out of it.
Safer using
The ‘information on safer injecting’ and ‘safer using’, generally, and in terms of BBV prevention, was
highlighted as particularly useful and increasing knowledge:
And also the awareness of, you know, certain things you can do to prevent it, which is helpful,
because I didn’t know that before, you know.
Hygiene
The material on hygiene and handwashing was particularly liked, with many participants referring to ‘the
cleanliness’, ‘using [a] clean surface’, and ‘washing your hands’ as useful aspects of the intervention. The
usefulness of this information was evident in reports by some participants that they had shared this
information with their peers:
I think for me, you know, like cleaning sites before you inject, I didn’t realise how relevant that was.
I thought oh that’s people being overcautious. But it’s not, that’s how you get abscesses.
. . . for me anyway, anytime when I’m using drugs I never do it myself anyway. It’s like me and my
friend, you know. We’re always together, you know what I mean, you know when we’re having our
hit. So any points o’ view that I think that he doesnae know anything about, like I was talking about
wi’ the hygiene o’ the hands, things like that, maybe talking about hep C, things like that, cleaning
our tools. Just a’ different wee points I would say tae him.
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Bleaching
Information on bleaching injecting equipment if re-using was considered useful by some participants and a
couple had shared this information with others. The efficacy of bleaching was new learning for some:
And I think the bleach thing as well for me, that’s very informative, ‘cos I didn’t know that can actually
kill HIV and Hep C, like that I think it’s really useful. [Focus group facilitator: And you said you told
other people about that as well?] Yeah me and my partner.
However, one participant in Wrexham disagreed that this was useful:
Focus group facilitator: . . . You know we talked about for instance the session about bleaching
needles, was that new to anybody?
Person 2: Yeh, never heard of it. Thought there would be trouble it you bleached the pin.
Focus group facilitator: So that was new for you learnt if you did it properly you could bleach your
equipment and its quite safe.
Person 1: No, I don’t think it is safe.
Focus group facilitator: You don’t?
Person 1: Why bleaching needles with bleach when you can do it with cold water and it’s alright. Do it
with hot water and it’s the same again.
Focus group facilitator: So you didn’t think that when we went through that session about bleaching
equipment that it was useful?
Person 1: No.
Preparedness planning
The materials and discussions on preparedness planning were considered useful and participants felt they
could draw on these strategies to reduce future risks:
. . . it was things like having a back-up plan, you know, of what you’re gonna do if you run out of
this, the risks, making me more aware of the risks that I put myself in sometimes when, you know,
with sharing and not having a back-up plan. Just, you know, it was just certain situations, it made me
more aware of what I would do that I could do more safely.
Service user/professional point of view
Participants in London particularly liked that the intervention was co-delivered by a drug worker and a peer
educator. Participants could relate to the peer educators as they had similar life experiences (‘he’s one of
your own. He knows, he’s been down the same trip as most of us’). In Glasgow, although the intervention
was delivered by two drugs workers, hearing the perspectives of their peers within the intervention group,
as well as the perspectives of the drugs workers, was considered one of the most useful aspects of
the intervention:
. . . it was good hearing it from like . . . from like an addict’s point o’ view and from a professional’s
point o’ view as well, you know. So from that point o’ view I thought the group was really good.
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Games and exercises
Female participants in London preferred the games and exercises to the didactic parts of the intervention
as they enabled more interaction and discussion:
Yeah I like interactive stuff. It was good, the sessions, if there were other things they could do to be
interactive it would be a bit more . . . I like it that way, yeah.
Opportunity to talk about topics not normally discussed
For the male participants in Glasgow, the opportunity provided by the intervention to discuss topics not
normally talked about was one of the aspects most valued:
. . . fae my point o’ view fae the group, what I got out of it was it was good tae talk about things that
people don’t usually talk about, you know what I mean.
Variety and amount of information
One of the male participants in London noted that the variety, and the amount, of information provided in
the intervention was good:
. . . there was a bit of everything there which I quite liked, a bit of variety.
It was the right amount of sort of information that was needed.
New learning from the intervention
Participants were asked what, if anything, they had learned from the intervention that was new. Their
responses overlapped to a large extent with the content they most liked or found most useful above.
Participants reported new learning on BBV transmission; how to use/inject drugs more safely; the importance
of hygiene (especially handwashing – ‘proper way to wash your hands’, cleaning injecting sites before
injecting and cleaning surfaces on which drugs are being prepared); how to bleach equipment (‘found out
about bleach and water’); and how abscesses are formed. Other learning points identified by participants
were the prevalence of BBVs; the consequences of BBV infections; how long HCV can survive on a needle;
how germs can transfer from one’s mouth to injecting equipment’ and to rub the injecting site after injecting.
Behaviour changes as a result of the intervention
Participants reported making behavioural changes as result of what they had been taught in the intervention.
Hygiene and handwashing
The most common changes reported were handwashing, wiping the injection site and making sure the
surface area on which drugs are being prepared is clean:
I suppose the one thing that I got out of it was washing hands and stuff like that that. I never thought
I would have done before so I do that now.
. . . loads of things have been on my mind, making sure the area’s clean, making sure I’m clean.
Using sterile equipment
Participants in Wrexham reported that they had begun to ensure that they used new equipment for each
injection since taking part in the intervention:
. . . just made sure I used new everything now, wouldn’t use a spoon if I’d used it before, it if anybody
else had used it. New everything every time.
. . . make sure I go the (name of needle exchange) all the time, you know to get clean works.
DOI: 10.3310/hta21720 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 72
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilchrist et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137
Planning ahead
In addition to the behavioural changes they had already made, some participants thought that they would
implement more of the learning gained from the intervention in the future. For example, a couple of
participants noted that the preparedness planning session had given them strategies which they would use
in the future for reducing their risks:
Focus group facilitator: . . . Did you do anything sort of around the planning? Did you use any o’ the
kind of tools, you know, like that?
R1: What any of these like advice sheets?
Interviewer: Mmhmm.
R1: Well I know, I know I will do. You know, it’s there, you know, for me to use information that I’ve
been taught.
Interviewer: Yeah.
R1: So but cause lately I’ve been using by myself. So I’ve not been in the sort of situations that we
might have, I might have otherwise, you know. So when the time comes around then yeah I definitely
will use the information.
Sense of empowerment and control
As well as changes in behaviour, changes in motivation and self-efficacy were also reported. For example,
participants in London reported gaining a sense of empowerment and self-efficacy regarding their ability
to manage and prepare for risk situations:
It’s empowering as well, knowing that you can take control back of a situation, do you know what I
mean, you don’t have to let the situation control you. You know that there is steps that you can take,
you know, to prevent anything happening.
Greater awareness
Similarly, some participants reported an increased sense of mindfulness or awareness around safer
injecting practices as a result of taking part in the intervention:
I’m just a bit more, just a bit more switched on when it comes to like . . . what do you call it, like my
hygiene and cooking up.
I have learnt a lot more about blood-borne viruses . . . when you’re in a mix and you’re doing what
you’re doing every day, that don’t really come to the forefront of your using, but in all consideration it
should be . . . it has made me a bit more aware about things, it has yeah.
Other changes
Other changes that participants reported were altering their tourniquet use, beginning to store
methadone, reducing their benzodiazepine use and injecting less often with others:
R3: It’s made me cut doon since I’ve started coming tae the sessions. My valium intake man is . . . the
bit o’ valium I’ve had in the last four days man, I’d have had that in the morning, one morning.
R2: Same wi’ me, I’ve cut down my benzos as well.
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Least useful aspects of the intervention
When asked what was least useful in the intervention, most participants reported that all of the
intervention content was useful and nothing should be omitted (‘it was all useful’; ‘I don’t think there’s
anything that should have been left out’; ‘everything was alright for me . . . I liked it all.’). Exceptions to
this were as follows.
Language in ‘rate the risk’ activity cards was confusing
The male participants in London disliked the verbatim language used in the ‘rate the risk’ activity cards:
. . . them little paper things, they was knacker. ‘Yeah, but no, but ‘em,’ all that, whatever it was.
Handwashing video was too long
One of the male participants in London thought that the handwashing video was too long:
Just like that the washing hands, OK do a video about washing hands but make it 30 seconds,
a minute long, not 5 minutes long.
Would have liked a bigger group for more input
Female participants in London would have liked a bigger group:
F1: Maybe bigger groups might have been better.
F2: Yeah, bigger groups, yeah, there was like more of an input.
Not enough information on blood-borne virus symptoms
One of the male participants in Wrexham thought that there was not enough information on the
symptoms of BBV infections:
Person 3: There were parts when you kept repeating yourselves, like got to keep cleaning the spoon,
got to keep boiling this, it could have gone further I thought.
Focus group facilitator: So more in depth.
Person 3: In depth into the symptoms of the disease that you could catch, it was more like skirting
round them, you could catch this, you could catch that, but what would be the symptoms of catching
that and how would you know if somebody else has catched that.
Videos and handouts
Participants in Glasgow thought that the videos and handouts looked dated, although the content was
considered useful:
R2: And I’m not saying it, it doesn’t cover everything but I just think to make it look a wee bit more
professional, I just think if you’ve got something that’s maybe a wee bit more up to date. I think that
would maybe help. I just felt that . . . it was an illustration thing that looked a bit dated. [. . .]
R1: Yeah I think you got a point there [R2] cause especially like, not so much us but the younger
bodies aye might look at that and think, ‘I can’t relate to that’. That was made in 19 bloody I wasn’t
even born then [interviewer laughs].
Suggestions for improving the intervention/additional information required
Participants were asked for their thoughts on how to improve the intervention and whether or not there
was anything important that we had left out.
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Make more visual
The most common suggestion for improving the intervention was to make the content even more visual
(i.e. more pictures, videos and animations):
. . . maybe more videos incorporated because I’m a visual person.
More information on blood-borne virus prevention
Two participants suggested having more information on BBV infection prevention. However, one of the
participants had missed session 3 on BBV transmission risks. The other noted a discrepancy between the
questions asked at the baseline assessment (BBV knowledge questionnaires) and the material covered in
the sessions:
On that questionnaire though, there’s things you didn’t go in to. It’s like, you know, it asks you about
the female condom and if you can get Hep C and all that if she uses that but I’m not quite sure, I
weren’t quite sure on that, but we’ve not gone into that, you know, there’s been no mention of that
really, you know what I mean, so . . .
Potential injecting sites
In London, male participants indicated they would have liked more information and advice regarding
potential injecting sites, as venous access was diminishing for some and several participants wanted to
sustain their use for as long as possible:
I would liked to have got a bit more information about maybe places to go, you know . . . it’s got to
the stage where I’m using the sole of my feet and things like that, where it’s like, you know, like even
walking on it after is painful and all that, you know what I mean . . . I’d like someone to maybe, say
like, you know like you get these doctors and that. ‘Cos when I’ve been in jail and that before and the
nurses or whatever can’t take blood from me, the doctor ’ll sit me down . . . I mean one time he done
it, it wasn’t in me groin, but it was up near here somewhere. And he stuck it, boom, within two
seconds, boom, done. So it’s things like that I’d like to know.
More practical regarding injecting technique
In the women’s group in London, participants felt that more practical hands-on demonstrations of injecting
skills would have been beneficial:
F1: . . . yeah physical things, obviously you wouldn’t be able to do it on the person but there must
have been some kind of like module or that you can . . . I don’t know . . . something like that.
Focus group facilitator 2: More sort of hands on?
F2: Yeah.
More exercises and games
Female participants in London recommended making the intervention even more interactive:
Focus group facilitator 1: Did you find those good, the kind of exercises and games that
we incorporated?
F2: Yeah, I think a few more exercises [GF1: More of those, yeah] and that, yeah, so you’re not just
sitting here being talked at like, you know. But yeah I think for a trial, yeah, I think it was alright actually.
Focus group facilitator 1: So on balance do you think there was a little bit too much of being talked to
or at and not enough maybe of the interactive or the visual stuff, you’d like to see more of that and
less of the . . .?
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F2: Ahm no, I think they actually balanced it quite well to tell you the truth, considering the materials
that they had, for me they done alright. I just think the videos for someone like myself, I just . . .
F1: Yeah I like interactive stuff. It was good, the sessions, if there were other things they could do to
be interactive it would be a bit more . . . I like it that way, yeah.
Use of scare tactics: graphic videos of injecting side effects instead of animations
Male participants in London thought that real-life depictions would be more motivational than animations:
That’s one thing you should have done is to put more videos on of the side effects, you know, of say
someone with a big abscess on their arms or on their groins, you know, to scare other people or show
them what the side effects of injecting are, and make them think ‘I better wash me hands or I better
. . .’ you know what I mean.
Use of social media: Facebook, YouTube
Male participants in Glasgow recommended making more use of social media to attract younger injectors
to the intervention.
Maybe having a wee bit more up tae date, seeing if you could actually post things on YouTube or go
ontae a Facebook. All these sorta things, you know.
Information on legal highs: relevant to younger injectors
They also advised including information on legal highs so that the intervention is more relevant to
younger people:
R1: . . . I’ve heard that people, you can inject legal highs, you know. I think maybe examples to do
with that. [. . .]
R1: It’s, a lot of these viruses are getting picked up by kids using legal highs.
Other suggestions for improvement offered by participants included personalising the ‘rate the risk’ activity
exercise, providing a bit more information on abscesses and vein collapse and also more information on
BBV symptoms.
Logistics: venue/timing/duration
The intervention was held at different times of the day and in different settings at each of the three sites.
London
The intervention took place at a drug treatment service, which many of the participants attended for OST.
The male group was held at 11 a.m. and the female group at 2 p.m., except for the final week, when the
female session was held at 11 a.m. (because of room scheduling conflicts).
Both male and female participants reported that the venue was fine as they attend the service anyway
(‘where we get our scripts’, ‘come here anyway’) and the location was relatively central. Male participants
thought that the time the sessions were held at was fine; however, one of the two female participants
who took part in the focus group noted that 11 a.m. was too early a start for her:
I’m just not used to doing things at this time of the morning, so I just know I’m a bit . . . If I was doing
something every day, then obviously I would get used to it and be here at that time but yeah, if it’s
just randomly then obviously afternoon’s better.
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Wrexham
In Wrexham, the intervention was held at a homeless service and the male group took place at 11.30 a.m.
and the female group at 2 p.m. Just one female participated in the focus group in Wales. She thought
that the timing of the session was fine. One of the male participants found that the 11.30 a.m. start
problematic and suggested having the intervention at 3 p.m. instead:
Person 2: Yeh a bit late in the day cos one of the appointments I actually came here and I spent the
day trying to score first thing and I was actually wasted during one of the sessions.
Focus group facilitator: So what do you think earlier or later?
Person 2: Later, cos then I can get sorted and be awake for the actual lesson.
Both male and female participants thought that the venue was fine. One participant who was homeless
noted that she also appreciated the opportunity to get in somewhere warm.
Glasgow
In Glasgow, the intervention was held at 2.30 p.m. Three participants took part in the focus group. They
reported that the time was fine. However, the venue was difficult for one participant to get to:
But me personally it’s a wee bit o’ pain in the arse tae get tae (name of street), you know what I
mean. Cause it’s like being on the edge o’ the town, you know.
Gendered groups
We were interested to know how participants found having a gender-specific intervention group and
whether or not they would have preferred a mixed gender group. Males in all areas were open to having a
mixed gender intervention group and some clearly thought that some degree of mixing of genders would
have been beneficial:
Focus group facilitator: And were people happy that it was an all-male group?
M3: I don’t know. I don’t know. I was a bit iffy about that one.
M4: Like I said last week I think you should do two all-male and all-females group and one group
where it’s mixed. [. . .]
M2: But it’s the same thing though isn’t it, it could be a man or a woman sitting here but Hep C is
Hep C, no matter who transmits it or who gets it.
However, one of the male participants in Wrexham noted that he would not have disclosed personal
information regarding sexual behaviour/risk if the group was mixed gender:
Focus group facilitator: Was it easier to share stories or disclose personal information with the single
sex groups, so do you think you would have disclosed as much as you did if there were females in
the group?
Person 3: I wouldn’t not, not sexually anyway.
In total, just three women participated in focus groups across the sites. Two of the three women ‘didn’t mind’ if
the group was mixed gender. However, one female participant said that she finds women-only groups ‘safer’:
I’ve done mixed groups before and sometimes it just stops you from talking about certain issues as
such, like I don’t get shy that often but I just prefer it, I think it’s more safer being with women, yeah.
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Thoughts on intervention facilitation
Participants were asked what they thought of the facilitators’ delivery of the intervention. Participants
reported that the information had been well communicated by the facilitators and they had explained
anything that participants did not understand. Participants appreciated that facilitators listened to them,
looked up additional information for them and created a comfortable and relaxed atmosphere. London
participants particularly liked that the intervention was co-facilitated by a peer educator and drugs worker.
Motivation for attending intervention
Participants were asked why they had attended the PROTECT study intervention. They cited a range of
motivations and also a range of enabling influences.
New learning
Participants were motivated to participate in the study and to attend the intervention to avail of the
learning opportunities it offered:
£10.00 voucher and I was in the area anyway and thought I might learn something.
Personally I wanted to find out more about what I’ve been doing for so long that I might be missing
out on that I could do better.
I wanted to do this . . . Not just ‘cos obviously it’s a chance to get a bit of money but for the knowledge.
Recovery aspirations
Some participants reported aspirations towards recovery and towards improving their lives and associated
their engagement with the intervention with these broader goals:
Maybe it’s just at the time you’ve got us all, you know what I mean. Maybe a time o’ our lives that
maybe we are wanting tae dae something wi’ our lives.
I’m also at a place where I’m ready I think to make changes, like I said I want to do the (name of a
recovery intervention service), I want some structure, you know, I’m not happy just sitting at home
getting high or whatever every day anymore.
Cash or vouchers
As intended, the cash and voucher incentives were motivating factors in attendance at the intervention:
If I’m honest the extra tenner, yeah, that really motivated me . . . That really motivated you to make
sure you get to all three. And I even changed one of my things, like, with my other trial, yeah [GF1:
Ah did ya reshuffle things to be able to come to this?], yeah, come here, so money is a motivating
factor for people in our circumstances, yeah.
Social interaction/group dynamic
The group dynamic and social interaction afforded by the intervention was reported by some to have
encouraged them to attend:
But now that I’ve started coming I’ve enjoyed, I enjoy the company cause I feel lonely at times.
I enjoy doing groups, so I don’t mind coming to them so, you know.
it’s good tae hear different points o’ view.
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Something to do/break up routine
A couple of participants reported that the intervention offered a structure and a valued activity to fill
their time:
Tae be honest just it was for something tae dae.
I like to come and do something with my day, I have nothing to do.
Reminders: text
Receiving reminders, including text reminders from the researchers, facilitated attendance at the
intervention sessions. Additional motivators for attending the intervention were the desire to maintain
one’s veins to sustain drug use, wanting to improve one’s injecting practices, wanting to protect oneself
and others from HCV infection, wanting to help others through participating in the research, and not
wanting to let people down who were investing their time and effort in the intervention. Additional
enablers that facilitated engagement with the intervention were being more stable, and the fact that the
intervention was not promoting abstinence and was not patronising.
What deterred others from attending
Participants were asked what they thought might have deterred others from attending the intervention.
Withdrawal
Some thought that withdrawal might have prevented others attending:
. . . if they are rattling and needed to score and they haven’t got money . . .
Not motivated/interested/ready to change
Participants highlighted the role that intrinsic motivation plays in willingness to engage with this kind of
intervention. It was suggested that others may not have attended because they were not interested or
ready to change:
You’ve got to remember a lot of people don’t want to change. They’re quite happy with where they are.
. . . what I would maybe think is is maybe people have been put off. And the reason being is it’s
maybe having tae look at their own sorta lifestyle and maybe not too many people at this time in their
life the now are ready tae maybe judge their selves or want tae go that other bit forward, you know,
or do things like that.
Do not perceive any benefit to them
It was also suggested that some people may not perceive that the intervention would be of any benefit to
them or would offer anything new:
Nothing that they dae see that’s gonnae benefit them.
A lot of people think it’s just the same old, same old.
Other barriers to engagement, which people identified, were the prioritisation of drug use, legal issues and
concealing drug use.
Suggestions for improving uptake of/engagement with the intervention
Participants’ views were sought on how to improve uptake of and attendance at the intervention.
Better advertising: posters in women’s hostel
Participants recommended more advertising of the intervention, particularly in women’s hostels.
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Cash
Participants in Glasgow thought that cash may provide more of an incentive than vouchers, but were
concerned that cash may promote attendance without genuine engagement:
R1: They’d be turning up for the wrong reason yeah. And it’s not gonna do, do . . . the person any
favours. All this would go out the window and all their mind would be on is the cash. [. . .]
R2: So they’d want tae do it as quick as they can and then out the door, you know.
Bus fares
Participants in Glasgow also suggested covering people’s bus fares:
I know like you reimburse us all, you know, wi’ our vouchers, fantastic but I think another thing that
would be good is if you’d reimbursed people for their bus fares as well.
Nothing more we could do
Female participants in London thought that there was no more we could have done to facilitate
attendance as we gave cash, covered transport costs and provided lunch (‘I think you’ve done all you can
really to get us here’). A summary of the main findings are shown in Tables 45 and 46.
TABLE 45 Summary of the findings regarding aspects of intervention
Most liked (n) Least liked Improvement (n)
l BBV transmission (5)
l Safer drug use (3)
l Hygiene (3)
l Peer/staff views (3)
l Preparedness planning
l Consequences of
BBVs
l Bleaching
l Games and exercises
l Opportunity to talk
l Variety of information
l Not in-depth enough on BBV symptoms
l Videos/handouts look dated
l Small group
l Handwashing video too long
l Language on ‘rate the risk’ activity cards
l Prefer ‘real-life’ video instead of animation
l More visual (3)
l More on BBV prevention (2)
l Potential injecting sites
l More practical regarding injecting
technique
l More exercises/games
l Use of scare tactics: graphic videos
instead of animations
l Social/online media
l Legal highs
l Personalise rate the risk activity
l More information on abscesses/vein
collapse
l More information on BBV symptoms
TABLE 46 Summary of the findings regarding aspects of participation
Motivation (n) Improving uptake (n)
l New learning (4)
l Recovery aspirations (3)
l Cash/vouchers (3)
l Group dynamic (2)
l Break up routine (2)
l Reminders (2)
l To maintain veins
l Improve injecting practices
l HCV infection prevention
l Was not promoting abstinence
l Was not patronising
l Not wanting to let people down
l Help others through research
l Better advertising (2)
l Cash (1)
l Bus fares (1)
l Nothing more we could do
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PROTECT study facilitator focus group reports
The facilitators in Wrexham, London, York and Glasgow took part in focus groups following the delivery of
the PROTECT study group sessions. The focus groups were facilitated by experienced researchers and views
were sought on the PROTECT study training event, intervention materials and delivery, facilitator learning,
and participant engagement and attendance.
Training event
The facilitators thought that the training event in London was useful and helped them prepare for the
delivery of the intervention. They especially mentioned the benefits of being involved in the structure of
the final intervention manual, with ideas from the day taken on board and added to the manual. This
fitted well with the needs and practices of the different localities and service users. The training day also
introduced new learning for the facilitators with regard to injecting practices, which could then be used in
future discussions with needle exchange clients. The inclusion and input from the peer mentors provided
new insights for the staff facilitators in relation to the differences in individual injecting practices and this
combined with input from the clinician and project lead provided a good balance of information:
Yeah it was good. We were able to run through it as a group and make changes that suited each
locality as well because obviously the people from, from Wales and London and obviously Glasgow, it
meant we could change how we, the things we were saying. And we could suit it to our service users
which was good.
I really thought it was useful how they had service users involved in it and talking openly about it,
I thought that was really good.
Although the delivery and format of the training event was generally well regarded, the venue (a large
lecture theatre) was considered inappropriate and limited interaction between the attendees. The training
would have benefited from being held in a smaller room that would be more reflective of the local venues
the intervention sessions would be delivered in. There was almost unanimous agreement that the training
would also have benefited from being conducted over (at least) 2 days rather than 1 to allow equal time
spent on each of the three intervention sessions and to provide time to conduct mock practice sessions:
I would prefer if, for example, if we can practice some of these exercises or some of the workshop, if
we can practice it, because for me I would better know and better understand how for example how
easy or difficult it is to deliver it and how long time I need for each exercise.
One facilitator suggested that future training events could be held locally and that the facilitators from
each area attending training could be introduced prior to the training event so they are familiar with who
they will be training and delivering alongside. Other ideas included having a ‘conversation café’-style
format, which may help encourage more interaction and networking between the attendees, and a venue
in a more central UK location. The consensus was that the training is better held face to face rather than
delivery through video conferencing.
Intervention materials
Implementation of the intervention in keeping with the manual was not without some challenges. For
some, the manual was considered well laid out and easy to follow (‘Well the way the sessions were laid
out was, you just ran with it. You didn’t have to think about it. It was there, everything you needed was
there’); however, for others it was more challenging. Although the manual was colour coded to indicate
the facilitators’ notes (blue font) and text to be read out verbatim (black font), it was difficult for those
who only had black and white printed copies to distinguish between the two:
FKW: And I think me, I have to say it’s the format a little bit I struggled – that it was written
facilitator’s section, then this section when we deliver – and when we were sometimes like [FPE: Yeah,
that was a bit hard] ‘So where are you . . . in which . . . ?’ I would like to have two different – one s
[. . .] One, it’s that I just read out for the client, and then I have another one which is for me.
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FPE: Yes. Because they got a bit mixed, they could get a bit mixed up if you were trying to look quickly
and yeah that was a bit tricky.
Perhaps it needs a bit of tweaking. We haven’t got colour printing so it would have perhaps worked
better to have the guidance and what you actually say separated out a bit more because it was all
black and white to us so it wasn’t easy to see on the day.
The content in session 1 was considered excessive for a 1-hour session and it was suggested that this
could be split into two sessions to allow more time for participants to ask questions and engage in
discussions. Sessions 2 and 3 were easy to follow and there was more time for participant feedback.
Reading out the text verbatim was considered too formal for some of the facilitators – as trainers or group
workers they are used to following a looser format that encourages greater participant engagement. One
facilitator thought that the sessions were more ‘theoretical than practical’ and that participants benefit
more from practical information.
In terms of the teaching materials, the videos were generally thought to be relevant in terms of the
information provided, although it was recommended they be updated. The cross-contamination video was
almost unanimously criticised for the poor quality of filming (although the content was considered valid
and useful). One site thought that the videos could have been grouped together to assist the flow of the
session (e.g. hygiene, handwashing, abscesses, vein care) and only one video was needed for handwashing.
There was mixed opinion regarding the group activities. For instance, although some were thought to
work well there were issues around the size of the groups. The activities were designed for groups of
around eight participants, so there was some concern that these did not work as well as they could
because the numbers attending sessions were lower, which inhibited a fuller discussion. There were also
some reservations around discussing sexual risk behaviours in groups, although this related more to
facilitators’ confidence rather than the information/activities per se. The TALK activity was thought to be
good by one site, but another changed the point at which it was delivered and a third site thought that it
did not fit well with the rest of the material in session 2.
One criticism of the PowerPoint slides was that the key messages were not always clear. The handouts that
were provided, on needle exchange sites and for the personal preparedness plan, were not as useful as
anticipated, largely because the participants left them at the venues following the sessions. Nevertheless,
one facilitator noted that, although the handouts were left behind, the participants had at least taken the
information on board and returned the following week having made changes to their injecting practices.
Moreover, he felt that the intervention should ‘not be an exercise of work for them . . . You know, it
should be more like information, informative’.
Despite reservations around some of the materials, overall the content and information provided in the
manual and training materials were thought to be concise, up to date and informative, particularly the first
session, which was centred on injecting practices. It was appreciated that, following the facilitator training
event in London, elements of the manual were updated to include comments from the day and there was
service user input in the content of the intervention:
It was well laid out, it was well thought up and you could see how much detail and how much time
was put into it because it suited our service users straight away. You could see the service user input
in it. As much as we don’t know what their input was, you could see it in the design of it.
An unexpected outcome mentioned during the facilitator focus groups was the intention to use elements
of the manual for staff training and for future use with clients.
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Intervention delivery
The facilitators spent, on average, 1 hour preparing for the intervention – familiarising themselves with the
session, and ensuring that information technology (IT) equipment was working and that the materials were
ready for use. Incorporating the intervention into their existing workloads was relatively easy for those who
had planned ahead and had block-booked the time needed to deliver the intervention and/or adjusted
their workload accordingly. For one team it was more difficult as they had to include the intervention in an
already busy schedule:
I don’t think it made the 3 weeks any, feel any busier, because there was a lot of other things going
on that made my workload heavier, it was just so hard to find two hours when there wasn’t
something else already booked in.
Facilitators were most comfortable delivering the first session on safe injecting practices because this is a
familiar topic for the workers and they also found this session interesting, particularly in relation to feedback
from participants around bleaching and cleaning needles. Although they did not deliver the intervention to
a group, the York facilitators also mentioned that they would be comfortable delivering the TALK activity.
The parts of the intervention that the facilitators found challenging to deliver were keeping to time in the
first session as a result of the volume of content; discussions around sexual risk behaviours because
of facilitators feeling less skilled to answer some questions; and reading verbatim from the manual
(sometimes long sections of text), which the facilitators thought hindered their own natural style of delivery.
The first session worked well in Glasgow as it generated discussion, taught the participants the importance
of hygiene, engaged the participants enough to attend the second session and resulted in safer injecting
practices (e.g. handwashing, tourniquet use). In London, the facilitators thought that all of the content was
important and the myths and facts and question/answer activities worked well. In Wrexham, the third
session worked best as the facilitators reported a better balance between the narrative and interactive
elements plus the activities opened up discussion among the group, allowing the facilitators and
participants to talk more openly than they might when attending services for usual care.
The didactic elements of the intervention worked less well for the facilitators as they felt that participants
engaged better with the interactive exercises. The ‘rate the risk’ activity cards used in session 2 used direct
quotations from peers – these were considered ambiguous or not clear in the key message that was to be
explored and some participants did not like the use of colloquial language. Repetition of the handwashing
message and the flow of some of the sessions were criticised by the London team.
In London, the sessions were facilitated by one drug worker and one peer mentor in each of the gendered
groups. The female facilitators were comfortable co-facilitating and appeared to have enjoyed the
experience, with the key worker reporting that she learnt from the peer mentor during practice sessions.
However, because of the narrative text the key worker felt that there was too little space to bring in the
peer mentor’s experiences during the actual sessions:
. . . you see because when we practised and you talked, even I just learned from her (referring to peer
mentor) when we were practising, you know . . . But when it was in the session I felt almost like that
there’s so much stuff we didn’t have time to . . . we didn’t show our complementarity, we were just
repeating you know the same kind of . . . The only maybe one passage when you started to say
something, I remember that it was a little bit similar to when we practiced, but because we tried to
follow the protocol it gives a little bit less space for the facilitator or the peer mentor to bring a little
bit their person.
When asked what they would change in the intervention, the Glasgow facilitators said they would ensure
that participants were forewarned that the first session would take longer than 1 hour. In London, Wrexham
and York they would make it less didactic and more interactive. The facilitators in Wrexham also suggested
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updating the videos and having a video in the planning for risk situations section that relays a hypothetical
situation that participants can discuss rather than having them talk about personal risk situations:
I think the session about planning, or the reasons why, there could be more to go on that. So maybe
some videos. We don’t want people to do role play but maybe we could see a little film that would give
people a discussion point to say have you got any suggestions, what would you have done in her
situation. And take it away from being personal, especially in the girls group, especially with people who
may or may not get on with each other or trust each other. I think you need something impersonal, I
don’t think it really works people talking about themselves and in a group that people were made to go
to and weren’t getting paid to go to, I could see a service user turning round to someone else ‘oh, that’s
like you, someone told me you never wear a condom’. I think it’s to get away from it being personal. I
think maybe something with actors, a couple of little scenarios done as a video.
In London, the facilitators suggested bringing in BBV nurses, practitioners who can teach proper injecting
techniques/demonstrate use of vein finders and sexual health workers to provide specialist knowledge for
relevant sections of the intervention.
York, Wrexham and London held their men’s groups in the morning and women’s groups in the afternoon
(no participants attended the groups in York); Glasgow held their men’s group in the afternoon. All
facilitators thought that the times allocated were reasonable and made sure that none was too early in the
day. In York, London and Glasgow the interventions were held at a local drug service and in Wales at a
homeless drop-in service. York thought that there may have been issues with the venue being in the
centre of York and the cost of travel to attend. Wrexham and Glasgow both thought that the familiarity
and centrality of the venues were good and London reported no concerns.
None of the facilitators would use the PROTECT study intervention in its entirety, but would use elements
from the manual in their own practice. In Glasgow, the safe injecting practice videos, the TALK activity and
the preparedness plan would be used on a one-to-one basis (the last two especially with female service users).
Glasgow would not use the ‘rate the risk’ activity cards (session 2) and had some reservations regarding
discussion of sexual behaviour risks and information on bleaching. Wrexham would use elements from the
first session utilising the videos, but they would leave out the narrative and shorten it to the most salient
points required by the individual clients. York would also use the videos and some of the PowerPoint slides.
When asked what clients they would target for the intervention, new referrals, new injectors and ‘hidden
clients’ (those not accessing services) were suggested, as were people attending recovery groups, NPS
users, IPED users, needle exchange attenders not accessing drug treatment, sex workers and people
engaging in chemsex.
In addition to the changes already recommended, facilitators suggested that further development of the
intervention could include the use of bite-size information for clients using the needle exchanges, use of
mobile phone applications or quick response (QR) scanners, and an online resource for services to access
with clients and/or as a staff training tool.
Facilitator learning
Attending the training and delivering the intervention was instructive for the facilitators. For example,
in Glasgow the facilitators were surprised at the range of injecting techniques and risk behaviours that
participants engaged in and the participants’ lack of knowledge around risk behaviours and acceptance of
conditions such as BBVs and soft-skin tissue infections:
People see abscesses, cellulitis, that kinda thing as part and parcel of being an injecting drug user as
opposed to a, something that you can prevent . . . And I think that’s why education’s never been
picked up because folk are still getting the end result of a hit and that they see it being part of, you
know, part of being a drug user is that you’re gonnae get abscesses and cellulitis.
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In London, the female key worker reported learning a lot from the peer mentors, particularly around use
of citric acid and alcohol swabs. In Wrexham, as with Glasgow, they were surprised at the reluctance of
participants to accept the information given on bleaching needles, but they were also pleased that they
were able to engage in a dialogue with clients that normally would not happen during usual service
contact, ‘We kind of make lots of assumptions so it’s good for them to have a little space to tell us
things’. Although York did not deliver to participants, they had gained information on different injecting
practices at the training event, particularly from the peer mentors, which they reported as useful to know
and giving them more confidence when talking to needle exchange clients in future practice.
Participant engagement and attendance
Glasgow and Wrexham reported that the participants were engaged in the intervention, particularly
during the first session. Suggestions for increasing attendance were widening out the services recruited
from, and using, social media (Glasgow); changing the design of the recruiting leaflet; engaging with staff
to enhance recruitment; and meeting briefly with prospective participants to introduce the facilitator(s) and
intervention content (London); recruiting more people and widening the geographical area from which
participants are recruited (Wrexham); moving to a community-based venue; and making staff more aware
of the intervention and need to recruit (York). Overall, however, the facilitators felt there was little more
that could have been done within the parameters of the recruitment strategy of the study.
PROTECT study session feedback questionnaires
Facilitators
Facilitator questionnaires were completed by two facilitators after each intervention session. Data are
presented for only London and Glasgow (Tables 47 and 48), as no intervention sessions were conducted in
York. Facilitator questionnaires were erroneously completed by participants in Wrexham.
TABLE 47 Overall evaluation
Evaluation of sessions
Gender, mean rating
Male Female
Session 1 (n= 6)
Preparedness 4.3 4.0
Ability to answer questions 4.0 4.5
Overall rating 4.5 4.0
Session 2 (n= 6)
Preparedness 4.3 5.0
Ability to answer questions 4.5 3.5
Overall rating 4.5 4.5
Session 3 (n= 6)
Preparedness 4.5 5.0
Ability to answer questions 4.0 4.5
Overall ratinga 4.5 4.5
a Responses on a scale of 1 (very poor) to 5 (excellent).
Responses on a scale of 1 (strongly disagree) to 5 (strongly agree).
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Intervention facilitator evaluation forms
Session 1
There were five responses to the question ‘What do you think worked best in today’s session?’ Facilitators
thought that the information on vein collapse (n = 2), vein care (n = 2) and the videos (n = 2) worked best
(Table 49).
There were six responses to the question ‘What do think worked less well in today’s session?’ (Table 50).
Facilitators thought that there was too much content to be covered in this session (n = 3), leading to
problems with timing (n = 2), parts of the session being rushed through (n = 2) and the session over
running (n = 2). The handwashing video was considered unnecessary by two facilitators.
TABLE 48 Session-specific questions
Evaluation of sessions
Gender
Male Female
Number of
participants
Mean
score
Number of
participants
Mean
score
Session 1
Participants understood the purpose of the intervention 4 4.5 2 3.5
Participants understood the group agreement and the
commitment to confidentiality
4 4.3 2 4.5
Participants increased their knowledge around injecting
techniques
4 4.3 2 4.0
Participants increased their knowledge around good vein care 4 4. 3 2 4.0
Participants increased their motivation to improve their injecting
techniques
4 4.0 2 3.5
The videos used were relevant and informative 4 4.5 2 3.5
Session 2
Participants have a better understanding of injecting risk
behaviours
4 4.5 2 5.0
Participants have a better understanding of sexual risk behaviours 4 4.0 2 3.0
I am confident participants can use some or all of the plan to
avoid risk behaviours
4 4.3 2 4.5
I am confident participants can apply TALK to reduce/avoid risks 4 4.3 2 4.0
I am confident participants can prepare for and avoid risky
situations
4 4.5 2 5.0
The handouts were helpful 3 4.7 2 5.0
The exercises used where relevant and informative 4 4.5 2 5.0
Session 3
Participants have a better understanding of BBVs 4 4.8 2 4.5
Participants have a better understanding of BBV transmission risk 4 4.5 2 4.5
Participants enjoyed the myths and facts exercise 4 4.5 2 4.5
Participants appear confident they can reduce their BBV
transmission risk behaviours
4 4.5 2 4.5
Participants showed increased their motivation for safer injecting 4 4.3 2 4.5
The handouts were helpful 4 4.3 2 4.5
The videos use were relevant and informative 4 4.5 2 5.0
Data are mean responses on a scale of 1 (strongly disagree) to 5 (strongly agree).
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There were six responses to the question ‘How do you think today’s session could be improved?’ (Table 51).
Facilitators’ suggestions for improvement involved shortening the session (n = 3) and having less content
(n = 2). One facilitator suggested dividing this session into two sessions. Another facilitator suggested
having a three-dimensional image of the body in the background when doing the section on injecting sites
(section 1.5).
TABLE 50 Responses to question ‘What do think worked less well in today’s session?’
What worked less well in the session Number of responses
Too much content 3
Timing 2
Rushed parts 2
Session ran over 2
Handwashing video not necessary 2
Handwashing video not well received 1
Not well prepared 1
Omitted material 1
TABLE 51 Responses to question ‘How do you think today’s session could be improved?’
What could be improved in the session Number of responses
Shorten session 3
Less content 2
Finish on time 1
Divide session into two sessions 1
Keeping an eye on the time 1
Being better prepared 1
Use a three-dimensional image of the body, with veins and arteries in
background while doing injection sites (section 1.5)
1
TABLE 49 Responses to question ‘What do you think worked best in today’s session?’
What worked best in the session Number of responses
Vein collapse information 2
Vein care information 2
Videos 2
Questions (regarding injecting difficulties – section 1.3) 1
New learning for clients 1
Understanding of service users’ injecting practices 1
Participant engagement 1
Attendance 1
Refreshments 1
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Three facilitators offered ‘additional comments’, with two of the three noting that the session had been
informative for them (Table 52).
Session 2
Table 53 shows the five responses to the question ‘What do you think worked best in today’s session?’
Facilitators thought that the risk situations exercise and discussion worked best (n = 2) and also that
participants were well engaged (n = 2).
There were five responses to the question ‘What do think worked less well in today’s session?’ Facilitators
thought that the ‘rate the risk’ activity cards worked less well (i.e. reading the cards was difficult or
uncomfortable for participants) (n = 2) and the language used may be perceived to be stigmatising (n = 1)
(Table 54). Two facilitators noted that there was ‘nothing’ that worked less well.
There were four responses to the question ‘How do you think today’s session could be improved?’
(Table 55). Two facilitators suggested shortening the ‘rate the risk’ activity cards or having less cards.
TABLE 53 Responses to question ‘What do you think worked best in today’s session?’
What worked best in the session Number of responses
Participant engagement 2
Discussion/dealing with risk situations 2
Discussion/exercises 1
Structure of session 1
Less content 1
Clock in room 1
Risk scenario exercise 1
TALK 1
TABLE 52 Responses to option of providing additional comments
Additional comments Number of responses
Informative for facilitators/informative for facilitators regarding injecting
drug use in area and participants’ own injecting experiences
2
Simplify information in section on injecting sites (section 1.5) 1
Session went well 1
Participants contributed a lot to the session 1
TABLE 54 Responses to question ‘What do think worked less well in today’s session?’
What worked less well in the session Number of responses
Reading the ‘rate the risk’ activity cards was difficult/uncomfortable for participants 2
Nothing 2
Language in ‘rate the risk’ activity cards is stigmatising 1
Timing 1
Too much content 1
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One facilitator offered ‘additional comments’, noting that session 2 had been better than session 1 as
there was more time for participant discussion and interaction (Table 56).
Session 3
There were six responses to the question ‘What do you think worked best in today’s session?’ All six
facilitators thought that the myths and facts exercise about BBVs worked best (Table 57). The discussion
and participants’ questions (n = 2), and the timing of the session (n = 2) were also thought to work well.
There were six responses to the question ‘What do think worked less well in today’s session?’ The main
issue raised by facilitators was the poor quality of the DUIT cross-contamination video (n = 3) (Table 58).
TABLE 55 Responses to question ‘How do you think today’s session could be improved?’
What could be improved in the session Number of responses
Shorten/sharpen the scenarios on ‘rate the risk’ activity cards/use less cards
for rate the risk activity
2
Focus the session more on participant’s own risks and solutions 1
Difficulty following the manual and not being able to use own notes 1
Not being ill 1
TABLE 57 Responses to question ‘What do you think worked best in today’s session?’
What worked best in the session Number of responses
Myths and facts cards 6
Questions/discussion 2
Timing 2
Statistics on prevalence of BBVs in UK 1
Participants had many questions 1
Video 1
Whole session worked well 1
Attendance 1
TABLE 58 Responses to question ‘What do think worked less well in today’s session?’
What worked less well in the session Number of responses
Video was slow/difficult to see/poor quality 3
Had difficulty answering participants’ BBV questions 1
Preparedness plan 1
Attendance 1
TABLE 56 Responses to option of providing additional comments
Additional comments Number of responses
Session was better as there was more time for discussion/interaction 1
No 1
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Table 59 shows the four responses to the question ‘How do you think today’s session could be improved?’
Responses were varied and included having more visual presentation of information (n = 1), having less
information on bleaching (n = 1) and having more time to prepare the room for the session (n = 1).
Three facilitators offered ‘additional comments’ (Table 60). Comments included that the intervention had
gone well (n= 1) and the discussion had been valuable (n = 1). One facilitator noted that they had enjoyed
delivering the intervention and one suggested having a greater focus on participants’ own injecting difficulties.
Participants
No intervention sessions were conducted in York. In Wrexham, feedback questionnaires were stored in
one place; therefore, the appropriate gender group could not be determined. Tables 61 and 62 show an
overview of the feedback.
TABLE 59 Responses to question ‘How do you think today’s session could be improved?’
What could be improved in the session Number of responses
More visual presentation of information 1
Less on bleaching 1
Having time to prepare room for session 1
Not sure 1
TABLE 60 Responses to option of providing additional comments
Additional comments Number of responses
Enjoyed facilitation 1
Went very well 1
Discussion was valuable 1
Focus more on participants own injecting difficulties 1
TABLE 61 Overall evaluation
Evaluation of sessions
Gender, mean rating
Unknown (mean)Male Female
Session 1 (n= 17)
Trainer knowledgeable 4.4 5.0 4.8
Questions answered 4.6 5.0 4.8
Overall rating 4.4 4.3 4.8
Session 2 (n= 13)
Trainer knowledgeable 4.6 4.7 4.5
Questions answered 4.5 4.7 5.0
Overall rating 4.5 4.7 4.0
Session 3 (n= 15)
Trainer knowledgeable 4.7 5.0 5.0
Questions answered 4.7 5.0 4.8
Overall ratinga 4.5 4.5 5.0
a Responses on a scale of 1 (very poor) to 5 (excellent).
Responses on a scale of 1 (strongly disagree) to 5 (strongly agree).
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Intervention participant evaluation forms
Session 1
There were 15 responses to the question ‘What did you like most about today’s session?’ Responses were
varied and referred to the content and process of the group intervention (Table 63). The most common
responses were the opportunity afforded to learn new information (n = 4), the information on safer
injecting/drug use (n = 3), the vein care information (n = 2) and the openness of the group (n = 2).
TABLE 62 Session-specific questions
Evaluation of sessions
Gender
UnknownMale Female
Number of
responses
Mean
score
Number of
responses
Mean
score
Number of
responses
Mean
score
Session 1
I understood the purpose of the intervention 8 4.5 3 5.0 6 4.8
I understood the group agreement and the
commitment to confidentiality
8 4.4 3 5.0 6 4.5
I have increased my knowledge around injecting
techniques
8 4.0 3 5.0 6 4.2
I have increased my knowledge around good vein
care
8 4.0 3 5.0 6 4.5
I have increased my motivation to improve my
injecting techniques
8 4.3 3 5.0 6 4.2
I have increased my motivation to improve my vein
care
8 4.3 3 5.0 6 4.7
The videos used were relevant and informative 8 4.0 3 5.0 6 4.5
Session 2
I have a better understanding of injecting risk
behaviours
8 4.1 3 4.7 2 4.0
I have a better understanding of sexual risk
behaviours
8 4.0 3 4.7 2 4.0
I am confident I can use some or all of the plan to
avoid risk behaviours
8 4.4 3 5.0 2 4.5
I am confident I can apply TALK to reduce/avoid risks 8 4.0 3 4.3 2 3.5
I am confident I can prepare for and avoid risky
situations
8 4.3 3 4.7 2 4.5
The handouts were helpful 8 4.5 3 4.3 2 4.5
The exercises used where relevant and informative 8 4.4 3 4.3 2 4.5
Session 3
I have a better understanding of BBVs 7 4.9 2 5.0 6 4.8
I have a better understanding of BBV transmission
risk behaviours
7 4.9 2 5.0 6 4.8
I enjoyed the myths and facts exercise 7 4.6 2 5.0 6 4.8
I am confident I can reduce my BBV transmission risk
behaviours
7 4.9 2 5.0 6 5.0
I have increased my motivation for safer injecting 7 4.7 2 5.0 6 5.0
The handouts were helpful 7 4.3 2 4.5 6 5.0
The videos use were relevant and informative 7 4.4 2 5.0 6 5.0
Data are mean responses on a scale of 1 (strongly disagree) to 5 (strongly agree).
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There were 13 responses to the question ‘What did you like least about today’s session?’ The most
common response was that there was ‘nothing’ least liked (n = 6). Remaining responses varied greatly
(Table 64). One participant thought that the session was too long, whereas another thought that it was
too short. One participant thought that the handwashing video was condescending. Other comments
referred to the circumstances of the session in particular localities on that day (e.g. delay before the session
started, having to hurry at the end of the session).
There were 13 responses to the question ‘How do you think today’s session could be improved?’ The most
common response was that the session required no improvements (n = 7). Other responses included
improving the sound quality of the videos (n = 1), making the session even more interactive (n = 1), having
more people in the group (n = 1), making the session longer (n = 1) and having more information (n = 1)
(Table 65).
TABLE 64 Responses to question ‘What did you like least about today’s session?’
What was liked the least in the session Number of responses
Nothing 6
Handwashing video is condescending 1
People telling war stories 1
People talking out of the side of their neck 1
Session was too long 1
Session was not long enough 1
Lengthy delay before session started 1
Having to hurry at end 1
The ending 1
TABLE 63 Responses to question ‘What did you like most about today’s session?’
What was liked the most in the session Number of responses
Learning new information 4
Safer using/injecting 3
Vein care information 2
Openness of group 2
Learning how to keep clean while injecting 1
Information was well explained 1
Group discussion 1
Unclear 1
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Session 2
There were eight responses to the question ‘What did you like most about today’s session?’ (Table 66).
Participants most liked learning new information (n = 3) and the TALK exercise (n = 2).
There were seven responses to the question ‘What did you like least about today’s session?’ The most
common response was that there was ‘nothing’ least liked (n = 6). One participant disliked the language
used in the ‘rate the risk’ activity cards (Table 67).
There were six responses to the question ‘How do you think today’s session could be improved?’ Two
participants noted that the session required no improvement. One participant suggested having ‘better’
‘rate the risk’ activity cards, whereas another suggested removing ‘slang’ from the cards (Table 68). Other
responses referred to the circumstances of the session in particular localities on that day (e.g. session
starting late, room too warm).
TABLE 66 Responses to question ‘What did you like most about today’s session?’
What was liked the most in the session Number of responses
Informative/learning new information 3
TALK/knowing your boundaries (bottom line – TALK) 2
All of it 1
Openness of group 1
Group discussion 1
Patience (unclear) 1
TABLE 67 Responses to question ‘What did you like least about today’s session?’
What was liked the least in the session Number of responses
Nothing/enjoyed it all 4
Language in ‘rate the risk’ activity cards 1
Too quick 1
My motivation (unclear) 1
TABLE 65 Responses to question ‘How do you think today’s session could be improved?’
What could be improved in the session Number of responses
Could not be improved on/nothing/good enough as is 7
Sound quality of videos 1
Make it more interactive 1
More people in group 1
Make the session longer 1
Have more information 1
Punctual attendance 1
On the whole it was OK 1
Maybe a lot cause I’m trying to stay clean (unclear) 1
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Session 3
Table 69 shows the 15 responses to the question ‘What did you like most about today’s session?’
Participants most liked learning new information (n = 3), and the information about BBVs (n = 2), HCV
transmission (n = 2) and safer drug use (n = 2).
There were 10 responses to the question ‘What did you like least about today’s session?’ (Table 70). The
most common response was that there was ‘nothing’ least liked (n = 6), followed by people talking over
each other (n = 2). One participant disliked the DUIT video.
There were 12 responses to the question ‘How do you think today’s session could be improved?’ (Table 71).
Most participants thought that the session needed no improvement (n = 7). Two participants wanted more
sessions or a longer session.
TABLE 69 Responses to question ‘What did you like most about today’s session?’
What was liked the most in the session Number of responses
Informative/learning new information 3
Information about HCV/BBV 2
Learning how HCV is transmitted 2
Information on safer using/how to look after myself better 2
Learned how long HCV and HIV live outside the body 1
Video (cross-contamination) 1
Good to revisit information 1
Corrected misinformation 1
The questions that came up 1
Feedback was good 1
Revising material from earlier sessions 1
Politeness of group 1
It was all good 1
Enjoyable 1
TABLE 68 Responses to question ‘How do you think today’s session could be improved?’
What could be improved in the session Number of responses
Fine as is/nothing 2
Remove slang from ‘rate the risk’ activity cards 1
Better (rate the risk activity) cards 1
Allocate time to each section 1
Trainers ready to start session on time 1
Room could be cooler 1
Enough sleep beforehand 1
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Summary/discussion
Intervention group participants who attended the PROTECT study sessions rated the sessions highly.
Participants reported that they had gained valuable knowledge on BBV transmission, safer drug use,
hygiene and handwashing, cleaning equipment and preparing for risk situations such as withdrawal.
Participants also valued being exposed to both service user and professional points of view, the
opportunity afforded by the intervention to talk about topics not normally discussed and the variety of
information included in the intervention. When asked how the PROTECT study intervention could be
improved, participants suggested making the intervention more visual and interactive, and incorporating
more practical instruction around injecting technique and injecting sites. It was also suggested that the
videos illustrating the side effects of injecting should be more graphic and feature real people rather than
animations. Incorporating online/social media (YouTube and Facebook) and including information on legal
highs were also suggested to make the intervention more relevant and attractive to younger people.
Facilitators who delivered the PROTECT study intervention thought that the training event had prepared them
for delivery. However, they suggested using a more suitable venue for the training and delivering the training
event over 2 days, with equal time devoted to each of the three PROTECT study sessions and incorporating
opportunities for mock delivery. Facilitators liked that peer educators were involved in the training event.
They also appreciated that their input had been incorporated into the final version of the PROTECT study
manual. Facilitators who delivered the PROTECT study sessions rated them highly and thought that the
content was relevant and up to date. They reported that being involved in the intervention had improved
their knowledge and led to changes in their practice with needle exchange clients. However, it was felt that
session 1 had too much content and could not realistically be delivered within 1 hour. Facilitators were less
comfortable delivering the didactic parts of the intervention and discussing sexual risk behaviour. When
asked how the intervention could be improved, they suggested making it more interactive, improving the
quality of the videos and including specialist workers for specific components (e.g. injecting instructors, BBV
nurses or sexual health practitioners). Other potential modes of delivery for the PROTECT study intervention,
which facilitators suggested, were delivery in bite-size pieces to clients, developing as an application or QR
code scanner or as an online resource for staff training. It was also suggested that the preparedness plans
could be incorporated into clients’ care plans. Key target groups for the intervention, which facilitators
identified, were new referrals to treatment, new injectors, sex workers, people who inject who engage in
chemsex, people who inject IPEDs and people who inject NPSs.
The facilitator and participant evaluation forms reflected the findings from the focus groups in that there
was an overall positive rating of each of the three sessions, with some suggestions for improvement
around the timing of session 1 and some of the activities and visual imagery.
TABLE 70 Responses to question ‘What did you like least about today’s session?’
What was liked the least in the session Number of responses
Nothing 6
People interrupting and talking over each other 2
Video of woman using needle 1
Was interesting 1
TABLE 71 Responses to question ‘How do you think today’s session could be improved?’
What could be improved in the session Number of responses
Fine as is/nothing/could not be improved on/good 7
More sessions/larger session for more information? 2
Make the (myths and facts) game more interesting 1
Bigger group 1
Ask group what refreshments they would like 1
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Chapter 7 Protocol changes
There were no changes to the protocol. Two minor amendments were submitted to the East Midlands –Leicester South Research Ethics Committee. The committee did not consider these to be substantial
amendments, as defined in the Standard Operating Procedures for Research Ethics Committees. These
amendments did not therefore require an ethics opinion from the committee and were implemented
immediately following approval letters being signed by the Research Ethics Committee assistant.
Minor amendment 1
The first request for a minor amendment was submitted on 17 December 2015 and written permission
was given on 31 December 2015 to implement the changes. The first minor amendment was to include
the name of the drug treatment service where the intervention was being delivered in London and to
change that participants would receive a ‘shopping voucher’ to ‘a small sum of money’ in the PIS for the
feasibility trial for only London participants, as London was the only site to reimburse participants with cash
rather than shopping vouchers.
Minor amendment 2
The second minor amendment was a request to include additional questions in the follow-up
questionnaire for the feasibility trial. The request was submitted on 18 February 2016 and approved on
26 February 2016. The additional questions were included in an attempt to better understand the reasons
for the low uptake of, and retention in, the PROTECT study intervention reported in some sites during the
feasibility trial. The additional questions were as follows.
For all participants:
l Why did you decide to take part in the study?
l How did you find the randomisation process?
For intervention group participants only:
l Why did you decide to attend/not attend the sessions?
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Chapter 8 Implications and dissemination
of findings
Key findings from this study have been provided to a wide range of audiences described below.
Dissemination events
Key findings from the feasibility trial and presentation of the PROTECT study manual have taken place or
are planned. Details of dissemination events and other presentations of study findings are described below.
l Lambeth Consortium Clinical Governance Meeting (the consortium being a partnership between South
London and the Maudsley NHS Foundation Trust, Addaction, Phoenix Futures, Blenheim and Lambeth
Local Authority) in London on 4 July 2016.
l Betsi Cadwaladr University Health Board Substance Misuse Service, North Wales. Two separate events
on 20 and 21 July 2016.
l Commissioner and Provider Research Engagement Event in Huddersfield on 28 July 2016.
l Lambeth service user group meeting in London on 19 August 2016.
l London Joint Working Group on Substance Use and Hepatitis C Annual Conference in London on
24 October 2016.
Individual dissemination meetings to discuss implementation of the
intervention in real-world settings and engagement in future research
The extensive stakeholder consultation carried out as part of this work clearly illuminated a wide range of
service designs, resources and priorities across the NHS and voluntary sector service providers and the
groups commissioning substance misuse services across the UK. We thus considered it as essential that the
results and conclusions of this study, in terms of intervention design and trial feasibility, were considered
against the real-world back drop of current and likely future funding to the health sector responsible for
delivering BBV infection prevention initiatives.
To address this we conducted post-study consultations with the following key stakeholders from across the
study regions, as well as regions that had stated an interest in being involved in a future trial of the
PROTECT study intervention:
l The Hepatitis C Trust, 1 June 2016.
l London Joint Working Group on Substance Use and Hepatitis C, 3 June 2016.
l Cardiff & Vale University Health Board (Wales), 13 June 2016.
l Aneurin Bevan University Health Board (Wales), 13 June 2016.
l Betsi Cadwaladr University Health Board (Wales), 14 and 15 June 2016.
l Public Health England, 29 June 2016.
l Surrey and Borders Partnership NHS Foundation Trust (England), 6 July 2016.
l The University of Dundee (Scotland), 18 July 2016.
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These consultations took the form of an informal presentation of the findings and discussion with senior
management and staff from these organisations. The discussions sought to determine:
l any challenges with conducting the feasibility trial
l anticipated challenges and opportunities presented were the PROTECT psychosocial intervention to be
introduced into their service
l development of the PROTECT study intervention
l key target areas for future research.
There was overall support for the approach and content of the intervention.
One service where dissemination took place had been a research site for the feasibility trial. They
highlighted specific issues that had arisen with regard to lack of readily available technology within their
organisation to deliver the intervention. Moreover, they highlighted, as did others from the other localities
where dissemination took place, the need for local areas to have the flexibility to deliver the intervention
content as they feel would best meet local service users’ needs. Many services reflected that the group
format and manualised delivery of the intervention content was not considered feasible if the intervention
were to be rolled out. In some areas, groups were not considered the most appropriate method for the
intervention delivery. Rather, individual, opportunistic discussions or bite-size messages with key workers,
or when a client presents to needle exchange or to a service with an injection problem (e.g. abscess) may
be more suitable. Given the considerable variation in risk profiles of PWID and in service profiles, a tailored
bespoke intervention in each locality would be required.
During the feasibility trial, CM was used to encourage retention in the intervention and transport was
reimbursed in some areas. This is not usual practice for most areas and additional funding would have to
be sought to continue with this if the intervention were to be rolled out.
Other modes of delivery suggested were (1) weekly themes to be advertised and addressed at needle
exchange sessions (e.g. finding a vein, abscesses, etc.); (2) delivering the three-session intervention in one
session; (3) developing the intervention as a mobile application, QR code scanner or video resource; or
(4) developing the intervention as an online training resource for harm reduction staff. It was also
recommended that the development of preparedness plans could be incorporated into clients’ care plans.
These harm reduction messages could also be given to new injectors at assessment or following BBV
infection testing. These were considered windows of opportunity to address any BBV transmission risk
behaviours. Other key target groups for this type of intervention were PWID who are engaged in sex work,
PWID who are engaged in chemsex, people who inject performance-enhancing drugs and those who
inject NPSs. Additional delivery sites suggested by facilitators, policy-makers, practitioners and academics
were needle exchanges (including brief interventions delivered by pharmacy needle exchanges), opiate
substitution treatment programmes, hostels for homeless people and in prison.
The intervention could also be used as a stand-alone training document for key workers and needle
exchange staff. Those who delivered the intervention reported that being involved in the intervention had
improved their knowledge and led to changes in their practice with delivering harm reduction messages
and advice to needle exchange clients. However, with the budget for continuing professional development
being cut by 40% by Health Education England, it is currently unclear who would be able to develop and
deliver training courses related to this type of intervention. One of the key discussions going forward with
public health and providers of services is how important staff development training can be delivered, by
whom and how it is resourced.
All health authorities consulted during the dissemination phase were supportive of being involved in
further development of the PROTECT study intervention to address the needs of other groups of PWID
who may be at risk of acquiring BBVs, such as those involved in chemsex, sex work, new injectors and
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those who were injecting NPSs. In addition, all health authorities offered to be research sites for future
studies to test the feasibility and effectiveness of any modified PROTECT study intervention for these
suggested groups of PWID.
Policy briefing
A briefing of key findings and recommendations has been e-mailed to all alcohol and drug commissioners
in the UK.
Conferences
The following poster and oral presentations have been presented at conferences or have been accepted
for presentation:
l Swan D. The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk
Behaviours Among People Who Inject Drugs: A Systematic Review and Meta-Analysis (poster
presentation). Society for the Study of Addiction Annual Symposium. York, UK. 5 and 6 November 2015.
l Swan D. Blood Borne Virus Risk Behaviours Among People Who Inject Drugs in the UK: A Qualitative
Exploration (poster presentation). Society for the Study of Addiction Annual Symposium. York, UK.
5 and 6 November 2015.
l Gilchrist G. Feasibility of the PROTECT Group Intervention to Improve Injecting Skills and Reduce
Bloodborne Virus Risk Behaviours Among People Who Inject Drugs. Society for the Study of Addiction
Annual Symposium. York, England. 9–10 November 2016.
l Swan D. Blood Borne Virus Risk Behaviours Among People Who Inject Drugs in the UK: A Qualitative
Exploration (oral presentation). The 5th International Symposium on Hepatitis Care in Substance Users.
Oslo, Norway. 7–9 September 2016.
l Swan D. The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk
Behaviours Among People Who Inject Drugs: A Systematic Review and Meta-Analysis (poster
presentation). 5th International Symposium on Hepatitis Care in Substance Users. Oslo, Norway.
7–9 September 2016.
l Gilchrist G, Swan D, Shaw A, Towers S, Craine N, Munro A, et al. Feasibility of the PROTECT Group
Intervention to Improve Injecting Skills and Reduce BBV Risk Behaviours in People Who Inject Drugs
(poster presentation). Sydney, NSW, Australia. Australian Professional Society for Alcohol and other
Drugs Scientific Alcohol and Drug Conference 2016. 30 October–2 November 2016.
l Gilchrist G, Swan D, Widyaratna K, Marquez JE, Hughes L, Mdege ND, et al. Influences on Blood Borne
Virus Risk Behaviours by People Who Inject Drugs in the UK: A Qualitative Exploration (poster
presentation). Australian Professional Society for Alcohol and other Drugs Scientific Alcohol and Drug
Conference 2016. Sydney, NSW, Australia. 30 October–2 November 2016.
l Gilchrist G, Swan D, Shaw A, Towers S, Craine N, Munro A et al. The PROTECT Study; A Feasibility Trial
of a Psychosocial Intervention to Reduce Blood Borne Virus Risk. Public Health Wales, Public Health
Research, Policy and Practice: Working Together in Wales (Research Showcase Event). Cardiff, UK.
2 March 2017.
l Gilchrist G, Swan D, Widyaratna K, Marquez JE, Hughes L, Mdege ND, et al. A Systematic Review and
Meta-Analysis of Psychosocial Interventions to Reduce Drug and Sexual Blood Borne Virus Risk
Behaviours Among People Who Inject Drugs. Lisbon Addictions 2017. 2nd European Conference on
Addictive Behaviours and Dependencies. Lisbon, Portugal. 24–26 October 2017.
l Gilchrist G, Swan D, Shaw A, Towers S, Craine N, Munro A, et al. Improving Injecting Skills and
Preventing Blood Borne Virus Infection in People Who Inject Drugs in the UK: A Feasibility Randomised
Control Trial of a Psychosocial Intervention (PROTECT). Lisbon Addictions 2017. 2nd European
Conference on Addictive Behaviours and Dependencies. Lisbon, Portugal. 24–26 October 2017.
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Published peer-review publications
l Gilchrist G, Swan D, Widyaratna K, Marquez-Arrico J, Hughes E, Mdege N, et al. A systematic review
and meta-analysis of psychosocial interventions to reduce drug and sexual blood borne virus risk
behaviours among people who inject drugs. AIDS Behav 2017;21:1791–11.
l Gilchrist G, Swan D, Shaw A, Keding A, Towers S, Craine N, et al. The acceptability and feasibility of a
brief psychosocial intervention to reduce blood-borne virus risk behaviours among people who inject
drugs: a randomised control feasibility trial of a psychosocial intervention (the PROTECT study) versus
treatment as usual. Harm Reduct J 2017;14:14.
Peer-review publications in preparation
l Swan D, Shaw A, Towers S, Mdege N, Craine N, Widyaratna K, et al. Blood borne virus transmission
risk behaviours among people who inject drugs in the UK: a qualitative exploration.
l Crank-Burnet N, Swan D, Gilchrist G. Chemsex and injecting drug use: an interpretative
phenomenological analysis of blood borne virus risk behaviours.
Social media
Links to key publications and to the key outputs from the study will be tweeted via the National Addiction
Centre at King’s College London Twitter account (Twitter, Inc., San Francisco, CA, USA).
Website
The intervention manual and related materials are available to download free of charge on the project
website [URL: www.kcl.ac.uk/ioppn/depts/addictions/research/drugs/bloodborneviruses.aspx (accessed
10 October 2017)].
Intervention recommended in other resources
Public Health England has included the link to the PROTECT study intervention manual and related
materials in its Joint Strategic Needs Assessment Support Pack to assess and respond to local needs. The
final HTA programme report and educational materials will be hosted on the Public Health Network Cymru
internet site, R&D, resources, publications and report page [URL: http://research.publichealthnetwork.
cymru/en/resources?keyword=&cat=1 (accessed 10 October 2017)].
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Chapter 9 Discussion and conclusions
Main findings
We interviewed 60 PWID in depth from harm reduction services, pharmacy needle exchanges, hostels for
homeless people and sexual health clinics in Glasgow, London, North Wales and York. Findings highlight
that withdrawal and craving created an urgency to inject which led to needle, syringe and equipment
sharing. Homeless PWID had difficulties accessing the resources needed for safer injecting (e.g. sterile
water, hygienic environment). Inexperience in injecting and difficulties with venous access created
dependence on others to administer injections. Trust in intimate relationships often took precedence over
safer practice. In group injecting situations, younger, newer PWID may feel pressured to go along with
unsafe practices. Needle exchange access, mental health, personal values and perceptions of risk also
influenced risk behaviour. Participants ascribed risk behaviours to pressures of withdrawal, craving and
intoxication. Lack of BBV transmission knowledge, inexperience in the physical process of injecting and
poor vascular access also resulted in unsafe injecting practices. Interpersonal relationships based on trust,
intimacy and/or dominance, and group norms and dynamics, also influenced risk. Unstable housing and
sex work diminished participants’ agency to manage risk.
Despite over a decade of national and UK plans to reduce BBV and strategies to reduce harm to PWID,
PWID continue to engage in BBV injecting and sexual risk-taking behaviours.
Individual, situational and structural factors drive vulnerability to BBV infection among PWID. Priorities and
risks other than BBV transmission are often paramount for PWID. BBV prevention initiatives should address
‘symbiotic’ goals for PWID, such as improving injecting techniques and maintaining venous access to
promote the use of sterile injecting equipment. Protective practices and strategies to avoid risk situations,
such as withdrawal, should also be considered.
We conducted a systematic review with meta-analysis that found that psychosocial interventions are
effective in reducing sexual and drug risk behaviours among PWID.
We developed a three-session, gender-specific psychosocial group intervention to reduce BBV transmission
behaviours among PWID, informed by evidence resulting from our research and expert opinion. The
PROTECT study intervention included skills to improve injecting techniques and thus vein care, and
strategies to avoid and plan for risk situations that PWID had themselves identified in in-depth interviews.
Ninety-nine PWID from needle exchanges and harm reduction services in London, York, Glasgow and
Wrexham were randomised to receive the intervention plus a BBV transmission leaflet (n = 52) or the leaflet
only (n = 47). Contingency management, in the form of a small voucher or cash payment (£10 per session
and additional £10 if all three sessions were attended), was used to encourage intervention attendance.
Baseline characteristics were comparable between randomised treatment groups for males, despite the
relatively small number of participants. Potential imbalances were observed in the smaller group of women
(e.g. with a greater number of heroin users and homeless women in the intervention arm). Although it is
not known why attendance and compliance was lower among women, it may be that women were more
likely to be responsible for child care and household duties than men. These competing priorities may have
contributed to the lower attendance and compliance.
More participants attended at least one intervention session in London (10/16, 63%) and Wrexham (7/13,
54%) than in Glasgow (3/12, 25%) and York (0/11, 0%). Participants from Glasgow and York reported
higher levels of homelessness, injected on a greater number of days and used more needles from a needle
exchange in the last month which may have contributed towards lower attendance. Forty-five per cent
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(45/99) were followed up 1 month post intervention. Follow-up was associated with fewer days of
injecting in the last month. Follow-up attendance (one or both times) was associated with fewer days of
injecting drugs in the last month (median 14 vs. 27 days; p = 0.030) and fewer injections of cocaine
(13% vs. 30%; p = 0.063). Compared with participants who did attend at least one intervention session
(n = 20), participants who did not attend any sessions (n = 32) were more likely to be homeless (56% vs.
25%; p = 0.044), injected drugs for a greater number of days in the last month (median 25 vs. 6.5 days;
p = 0.019) and used a greater number of needles from a needle exchange in the last month (median 31 vs.
20 needles; p= 0.056). They were more likely to be predominant heroin injectors (69% vs. 40%; p= 0.055 for
type of drug) and less likely to inject crack (31% vs. 55%; p= 0.146). These differences were true for males and
females, apart from homelessness, which did not show differences for women, although numbers were small.
Analyses revealed improved (fewer) injecting risk practices, improved self-efficacy, better HCV and HBV
transmission knowledge and greater use of withdrawal prevention techniques in the intervention arm.
This was true at both follow-up time points and both analyses for randomised groups and groups based
on attendance of the intervention. Little change for any group was seen for HIV transmission knowledge.
Compared with those who attended no sessions, a trend towards greater reductions in injecting risk
behaviours, increases in withdrawal planning and increased self-efficacy around finding a vein, not sharing
equipment, cleaning equipment and talking about safe drug use was reported by those who attended at
least one session. More importantly, we did not observe any increase in either self-reported injecting in
more ‘risky’ sites (e.g. groin, neck) among participants who had been exposed to at least one session of
the intervention, and a trend towards injecting on fewer days in the past 30 days for those who had
attended at least one session was reported. No adverse events were recorded as a result of participating in
the feasibility trial. Therefore, we conclude that the PROTECT study intervention, focusing on improving
injecting techniques and providing strategies and skills to avoid and plan for risk situations where BBV
transmission risk behaviours were more likely to occur, did not result in injecting in more risky injecting
sites despite being taught the skills to do so.
Attendance at at least one intervention session was highest in London (63%) and Wrexham (54%),
whereas only 25% attended in Glasgow and no participants attended in York. Follow-up at a minimum of
one time point (at the end of the intervention or 1 month post intervention) was also highest in London
(83%) and Wrexham (63%), and significantly lower in Glasgow (55%) and York (43%). Participants from
Glasgow and York reported higher levels of homelessness, and participants injected for a greater number
of days and used more needles from a needle exchange, which may have contributed towards lower
attendance rates. In addition, in York, text messages were sent to remind participants of intervention
session times and dates from the service (reported preference of participants), whereas in other sites the
researcher contacted participants by telephone to remind them of session dates and times a day in
advance and also sent a reminder text the day of the intervention. Thus, talking with the researcher and
the additional reminder may have resulted in increased attendance at the other sites. Moreover, as a result
of the dedicated researcher leaving their position at the University of York, four staff from the CRN: York
Teaching Hospitals NHS Trust were responsible for recruitment and follow-up of participants, whereas in
other sites participants had contact with the same named researcher throughout the trial and this established
relationship could also have contributed to increased attendance. Additional potential contributing factors for
the differences in compliance and attendance across trial sites include reimbursement of travel (bus tickets),
reimbursement of time and CM paid in cash (vs. high-street vouchers in other sites) and co-facilitation of the
intervention by peer educators in the London site only.
It appears that the intervention did not meet the complex needs of PWID, particularly in York and
Glasgow, potentially resulting in limited engagement of those potentially most at risk of engaging in BBV
transmission behaviours (e.g. homeless PWID, more frequent injectors, people who inject crack, women).
These findings are supported from the reflections of staff and researchers in York, Glasgow and Wrexham
who believed that the clients recruited to the feasibility trial often had complex social, mental and physical
health needs and were often not well engaged with services. Irrespective, those hard-to-reach PWID were
the target group for this intervention.
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Although the PROTECT study intervention has the potential to positively influence some PWID BBV risk
behaviour and improve vein care, non-attendance at the intervention at the York trial site substantially
influenced the results, highlighting the need for flexible adaptation of the intervention delivery according
to local need to ensure that all PWID are reached. Local service users should be involved in the decisions
about how best to adapt the intervention to meet their needs. Alternative intervention delivery methods
may achieve greater reach and suggestions are discussed below.
A number of challenges for trial implementation were highlighted. There are many factors that may have
contributed to the different uptake of, and retention in, the feasibility study across sites and, therefore, it is
not possible to provide a definitive explanation of the differences in rates reported.
Feasibility parameters and the decision whether or not to progress to a definitive
randomised controlled trial
Progression criteria for a definitive RCT were not predetermined prior to undertaking the feasibility trial.
However, stop/go criteria would include (1) that the intervention is acceptable to staff and participants;
(2) recruitment is at least 60%; and (3) at least 70% of participants are followed up at 3 months. Acceptability
was assessed by facilitators and participants completion of feedback forms at the end of each session, and
their participation in focus groups about their experience of delivering and attending the PROTECT study
intervention. Feasibility parameters assessed were the proportion of PWID who consented to participate in the
trial and were randomised to treatments arms, as well as intervention compliance and attrition rates over the
course of the study. These parameters were summarised by location, setting and treatment arm.
Despite full recognition of the need for the intervention, and high acceptability of the usefulness and
interest of its content, the recruitment (56%), intervention attendance (19% attended all three sessions)
and 1 month post-intervention follow-up (47%) rates suggest that a future RCT of the intervention, in its
current format, is not warranted.
Only 24% (8/34) of male [ranging from no men in York to 44% (4/9) in London] and 11% (2/18) of
female participants (both from London) attended all three intervention sessions. No women attended any
sessions at the York or Glasgow trial sites and no men attended any sessions at the York trial site. More
participants attended at least one intervention session in London (10/16, 63%) and Wrexham (7/13, 54%)
than in Glasgow (3/12, 25%) and York (0/11, 0%). The delivery of the intervention proved more feasible
in London than other sites, with high attendance at the intervention (44% of males and 29% of females
attended all three sessions) and high follow-up rates (89% of males and 71% of females). Potential
reasons for the marked differences in attendance and compliance across sites and by gender have already
been mentioned.
Overall, 50% (17/34) of men and 33% (6/18) of women randomised to the intervention group and 47%
(14/30) of men and 53% (9/17) of women randomised to the control group were followed up 1 month
post intervention. Follow-up at a minimum of one time point was also highest in London (83%) and
Wrexham (63%) and significantly lower in Glasgow (55%) and York (43%), which may in part be linked to
factors associated with higher homelessness and injecting frequencies in Glasgow and York.
Despite the difficulties in recruitment and intervention attendance, the intervention content was considered
acceptable and no adverse events were reported. Considering that 57% of eligible participants agreed to
be randomised, this suggests support for addressing BBV risk behaviours among PWID. Evidence that the
intervention increased injecting frequency, or resulted in riskier injecting practices or injecting in riskier sites
(e.g. neck or groin), would stop progression to a definitive RCT. Providing participants with information
and skills to improve injecting techniques did not result in riskier injecting practices or in injecting in riskier
injection sites, such as the neck or groin.
In summary, although the intervention content was acceptable to both staff and participants, and those
attending at least one session of the intervention reported a trend towards greater reductions in injecting
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risk behaviours and increases in planning for withdrawal and increased self-efficacy around finding a vein,
the feasibility parameters suggest that it would not be practical to proceed to a full definitive trial.
The need for current harm reduction services to incorporate the PROTECT study
intervention to routine practice
Despite over 30 years of needle exchange provision in many parts of the UK, around one in seven PWID
continue to share needles and syringes,55 highlighting the need to improve harm reduction services to
prevent PWID from acquiring BBV infection. A recent report concludes that ‘Current drug policy is failing
to protect people from the risks of blood-borne virus infection, at huge cost to drug users, the community
and the taxpayer’ and recommends ‘All services (both pharmacy-based and specialist needle exchanges)
should be staffed and equipped to provide: Information and practical advice on safer injecting practices,
avoiding site infections, prevention of transmission, safe disposal of used equipment’.255 Harm reduction
approaches mostly address risk factors associated with the sharing of injecting equipment and unprotected
sex. Our research confirmed that PWID sometimes have different priorities, from improving their injecting
techniques and maintaining venous access to preparing for situations where they may be more likely to
take risks. PWID and staff confirmed that such advice and support was not routinely available or provided
in harm reduction services, despite the belief by some key stakeholders that it was part of these services’
core business. Possible reasons for this are discussed later in this chapter.
Although the feasibility trial identified issues with retention in the intervention, this does not mean that the
PROTECT study intervention, or components of the intervention, should not be taken on board as a routine
intervention to offer PWID as part of harm reduction provision. Findings from this research indicate that the
PROTECT study intervention could be delivered as part of routine advice and support to PWID by key workers
and in needle exchange services. Preliminary findings suggest that the intervention has the potential to
positively influence BBV infection prevention, with benefits reported among PWID who attended at least one
intervention session. Furthermore, the content of the co-developed intervention was highly valued by both
participants and facilitators, highlighting the need for flexibility to adapt the intervention to ensure that the
needs of local PWID are met. Further detailed proposals are described below, including staff training to ensure
that all harm reduction staff incorporate the PROTECT study intervention into their routine consultations and
interactions with PWID to improve injecting techniques, venous access and care and prevent BBV.
Harm reduction services should ensure that the intervention content is routinely delivered to PWID to
improve vein care and prevent BBV.
The qualitative research in this study identified circumstances that lead to risky injecting that may result in
BBV transmission. The PROTECT study intervention responded with strategies on how to avoid or manage
these situations and offers up-to-date evidence-based content and delivery approaches. Consideration of
how best to train and motivate staff to deliver this intervention is required and, again, local solutions
should be reached.
Current harm reduction services may be failing to address the needs of PWID, resulting in poor clinical
outcomes and high health- and social-care costs for this client group. Therefore, there is a consequent
benefit of offering this type of intervention adapted to local need as appropriate, including its routine
delivery, whether in full to groups or individuals, or via more tailored information or advice offered by key
workers, peer educators and needle exchange staff.
Specific lessons from the feasibility trial
Trial implementation
The importance of management and of service staff buy-in was stressed by the researchers. An approach
used in some settings was a presentation of the study at staff meetings to facilitate recruitment of research
participants. In addition, facilitators valued being involved in the development of the intervention. Training
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of intervention facilitators should be delivered locally (we carried this out centrally in London, creating
challenges for more distantly located staff), and we recommend that sufficient time be allocated to allow
quality assurance of the delivery of the intervention, before the intervention is delivered in practice.
Facilitators should have the competency to deliver the intervention, and services that use the intervention
should ensure that sufficient resource is provided to ensure that interventions are comprehensively
delivered and to maximise participant engagement.
Several sites that had previously offered to host the research had, by the time we came to start the trial,
been retendered or had changes in management. This resulted in delays in order to find additional sites
and secure buy-in with new management. In future, it may be useful to engage additional potential sites
from the outset to address such eventualities.
It is important to consider the technology available at intervention sites in advance of trial implementation.
Some sites did not have facilities to play the online YouTube videos that were part of the intervention and
the use of a Dropbox (Dropbox Inc., San Francisco, CA, USA) was not permitted by IT at sites, making it
difficult to share the video resources as these were too large to send by e-mail.
Offering the intervention on an individual delivery basis at the time of randomisation may have ensured
that more participants received the intervention.
Delivery of intervention
The mapping exercise with drug and alcohol commissioners (see Chapter 2) and the consultation with
policy-makers and practitioners (see Chapter 4) confirmed that there was no current intervention fit for
purpose to meet the needs identified by PWID (see Chapter 2).
Although the separate focus groups with facilitators and intervention participants demonstrated the
acceptability of the intervention, several key findings for its improvement were described.
Facilitators welcomed peer-educator involvement in the training event as they had gained new knowledge in
the process. Although only one site (London) included peer educators as co-facilitators, it is recommended
that this approach be used in future, as intervention participants highly valued the skill and experience mix of
facilitators. However, it should be recognised that peer educators may also require support depending on
where they are in their recovery. In York, peer educators were identified to co-deliver the intervention with
staff; however, because of personal circumstances, they were not able to do so. In Glasgow, a service user
organisation had agreed to deliver the intervention. However, this was not possible due to the resource
requirements of this excess treatment cost.
Intervention participants in the feasibility trial welcomed gender-specific groups, reporting that they felt
more comfortable discussing sensitive topics in a safe environments. Where groups are being delivered,
services should consider the need to have gender-specific groups. Some participants and recent research177
stressed the importance of delivering the intervention to reduce BBV transmission risks to couples. This
may be appropriate for couples where domestic violence is not present.
Potential contributing factors for the differences in engagement, compliance and attendance across trial
sites may include travel reimbursement, reimbursement of time and CM paid in cash compared with
high-street vouchers. Where vouchers were used instead of money, it was because the services had
requested this. However, to facilitate engagement and attendance at interventions and in research, we
recommended that participants receive cash rather than vouchers for the reimbursement of time and CM,
that refreshments are provided during intervention sessions and that travel costs are reimbursed. The small
costs involved in encouraging engagement and retention are not comparable to the vast health- and
social-care costs resulting from injection-related infection and BBVs.
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There have been concerns raised in some ethics committees over the payment in cash to people who use
substances that participate in research (as they believe this could facilitate illicit drug purchases). Instead,
their preference would be for vouchers to be used to reimburse research participants. However, recent
research has confirmed that modest cash payments increase participation in research among people who
use substances, and very few participants reported they planned to spend the research cash payment on
substances, rather they planned to spend it on food, cigarettes and transport/fuel.256 More recently, Neale
et al.257 found that service users stressed there were many benefits of cash payments over vouchers for
participating in research. They believed that ‘on a practical level, cash was considered simple, easy, and
convenient: you can spend it on what you want, when you want, and where you want’. In addition, cash
has important symbolic value, signifying ‘a genuine appreciation of the participant’s time and contribution’.
Furthermore, giving a research participant cash indicates ‘respect’ and ‘trust’ in the participant, so ‘treating
them like an adult’. As such, cash was perceived as ‘empowering’, ‘non-stigmatising’ and ‘potentially
encouraging of recovery’, cash was ‘king’. Although service users also accepted that cash from research
participation could easily be spent on drugs or alcohol, they felt that the amounts of cash given for research
participation were ‘nearly always too small to raise any significant safety or ethical concerns, even when
study payments were used to buy substances’. Therefore, we recommend that future studies offer cash
rather than vouchers to research participants as our and other studies suggests this may enhance
participation in research, and that this is supported by research ethics committees.
Intervention content
There was support for addressing symbiotic goals and teaching injecting skills to PWID. Indeed, some
intervention participants stressed the need for more practical assistance on injecting technique, including
observation and feedback on their own injecting technique.
Facilitators felt that session 1 had too much content and could not realistically be delivered within 1 hour.
The manual could be improved by being more flexible and allowing facilitators to introduce and cover the
information in each section, without having to follow the text verbatim.
Facilitators suggested that the intervention could be improved by making it more interactive, improving the
quality of the videos and including specialist workers for specific components (e.g. injecting instructors,
BBV nurses or sexual health practitioners).
When asked how the PROTECT study intervention could be improved, participants who attended at least
one PROTECT study intervention session suggested making the intervention more visual and interactive
and incorporating more practical instruction around injecting technique and injecting sites. It was also
suggested that the videos illustrating the side effects of injecting should be more graphic and feature real
people rather than animations. Making the intervention available online and including information on NPSs
was also suggested to make the intervention more relevant and attractive to younger people.
The content of the intervention was rated highly by facilitators and intervention participants alike. We plan
to seek funding to incorporate these suggestions into the PROTECT study intervention to further refine the
intervention manual and materials.
Recruitment rates
We reported difficulties in recruiting particular groups of PWID, mainly women and new injectors. Future
studies could consider the use of ‘chain referral sampling’ where existing study participants recruit future
participants from among their acquaintances to target participants who may be hidden or difficult to reach
for researchers. Participants who assist with the recruitment of other participants would be rewarded for
every additional participant they helped recruit.
Retention rates
Feedback from trial participants suggests that payment for participating in the research and CM may be
best given in cash rather than as vouchers, and that transport costs should be reimbursed because of the
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distance often required to travel to attend the service for the intervention session or for follow-up
interview. Provision of refreshments was also welcomed by trial participants.
Dedicated researchers are required to assertively follow up participants and remind them of intervention
session times and dates. In all sites, except York (which was done by text from the service at the
preference of the participants), the researcher rang participants’ mobile phones the day before an
intervention session or research follow-up and followed this up on the day of the intervention session or
research follow-up with a text message, to increase attendance. However, this method was not without
difficulties. In Wrexham, the researcher reported that many participants had lost or sold their mobiles,
which hindered follow-up contact. However, as the researcher was also the line manager of the service,
she had local knowledge of the service users that allowed her to call on participants at home or via other
contact numbers, at the mobile unit or visit their regular meeting places in an attempt to follow them up.
This relationship and familiarity may have resulted in greater participation in the intervention and retention
in the feasibility trial.
Assessment
For those participants who attended the intervention sessions, all candidate outcome measures had very
good completion rates. The number of injecting risk practices, and self-efficacy in particular, showed
improvements in the intervention group that were maintained up to 1 month follow-up. These outcomes
might be considered in a larger-scale study in the future. BBV transmission knowledge was more likely
to show short-term improvements only, whereas withdrawal prevention questions had only limited
applicability in this study population. Our systematic review highlights the need for a core outcome set to
be developed to reduce selective outcome reporting issues when measuring BBV risk behaviours among
PWID. Such a core outcome set could be used in future research including trials.
Recommendations for collection of data for health economics
Analysis of the questionnaires identified several categories that could be excluded from the assessment
battery in a full RCT, making the collection of data simpler and quicker. The feasibility trial results suggest
that some questionnaire items with low utilisation rates can be omitted.
Key workers and needle exchange services were used by > 70% of the trial population, indicating that
these areas should be the subject of more detailed data collection in a full trial.
The mean cost was £58.17 for patients attending one session, £148.54 for those attending two sessions
and £270.67 for those attending all three sessions in the intervention group. These costs compared with
£0.86 in the control.
The EQ-5D-5L scores in both groups improved from baseline through the two follow-ups, showing
potential for health improvement and associated QALY gains. Differences between groups must be treated
with extreme caution because of the small sample size.
The use of case vignettes
Although the use of case vignettes, developed by service users, was considered a novel way to assess
changes in risk behaviour, it was difficult to systematically and reliably analyse these data as many of the
open-ended responses were ambiguous, creating a significant risk of researcher bias in coding. Therefore,
the use of our case vignettes to assess changes in risk behaviour is not recommended.
Summary of implications for practice
Some PWID who were interviewed (see Chapter 3) and had been injecting long term reported that they
still required help injecting, especially if venous access was difficult. Over half those participants
interviewed recommended that the intervention include being taught injecting skills, requesting practical
demonstrations of injecting to reduce risks such as skin and soft-tissue infections, amputations and venous
damage. More importantly, they stated that although they had been given information about BBV
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transmission, this had been in the past and had been conflated or forgotten over time, with many myths
about transmission still being believed. This is important as older PWID may in turn influence the
knowledge of younger, more recent-onset injectors. Few participants interviewed had ever attended
interventions focused specifically on BBV transmission or injecting/sexual behaviour change. This finding is
supported by the brief survey sent to all alcohol and drug commissioners in the UK, highlighting the lack
of specific interventions to address BBV transmission risks.
People who inject drugs who attended at least one session of the intervention, many of whom also had
long injecting careers, welcomed the opportunity to talk about topics in the intervention that they felt
were not normally discussed. They liked that the intervention approach was not patronising and did not
promote abstinence. The former finding is worrying, as it was assumed by many policy-makers and
practitioners who we consulted both prior to the intervention, and post intervention in the dissemination
phase of our project, that such BBV information and education were incorporated into ‘usual’ harm
reduction conversations by key workers in drug and alcohol services and practitioners in needle exchange
and specialist services. PWID have not confirmed this is currently happening. Therefore, clients’ needs may
not be currently being met by existing harm reduction services.
There are two potential reasons why this harm reduction advice may not be being delivered. First, this may
be a result of the de-skilling of the substance use workforce as a result of the cuts in service provision. In
some areas, needle exchanges that were previously staffed by experienced and specialist (BBV) nurses,
were now staffed by unqualified drug workers with little training or experience. Moreover, needle
exchange interactions in pharmacies had limited the opportunity for harm reduction. Second, as a result of
the UK drug policy shift in recent years from harm reduction to recovery, it may be that the needs of those
who are not engaged in treatment and who continue to inject drugs are being neglected. Our findings
suggest that current harm reduction services may not meet the needs of all PWID, especially those not
engaged in treatment.
The NICE quality standard for drug use disorders258 recommends that people are given a range of information
and advice about treatment options from harm reduction to abstinence, albeit that no definition of harm
reduction is given. The guidance does not include advice on improving injecting techniques for PWID and
strategies to avoid or plan for BBV risk behaviours.
Further development of the PROTECT study intervention
As described in Chapter 7, all services where the intervention was presented following the feasibility trial
were supportive of the intervention content and aims, and believed that they could meaningfully use the
intervention content messages and exercises with clients. All services wanted to be involved in further
development of the intervention and suggested that there was benefit in refining the intervention further
by adapting it for delivery in specific settings (e.g. needle exchange, pharmacy needle exchange, prison),
and to specific groups of PWID including those living in homeless hostels, people receiving OST, young
injectors when they are transferred from adolescent to adult addiction services, steroid injectors, those
engaged in chemsex and those injecting NPSs. As previously discussed, the intervention delivery is required
to be flexible to suit local needs.
Funding is being sought to further develop the intervention.
Summary of recommendations for further research
Three key areas for further research were identified.
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Ethnography
Difficulties in recruiting females who inject drugs and new injectors, especially those who were injecting
NPSs, had proved difficult despite recruiting from a variety of services (e.g. pharmacy needle exchanges,
harm reduction services, sexual health clinics, homeless hostels). There remains a need to understand the
needs of these injectors to ensure that key BBV transmission messages are appropriately targeted. As it
proved difficult to engage these groups of PWID into the research (for both the in-depth interviews and
the feasibility trial), we recommend ethnographic research is undertaken to better understand the typology
and potentially changing risk of contemporary drug use in the UK by exploring the specific concerns and
barriers from the lived experience of PWID in terms of accessing help, advice and treatment, as well as
what mode of delivery would work best for these groups.
Feasibility of the intervention for males involved in chemsex who inject
‘Chemsex’ is used to describe the use of psychoactive substances (typically crystal methamphetamine,
mephedrone and gamma-hydroxybutyric acid/gamma-butyrolactone) either immediately before or during
sex.259 High rates of injecting and other drug use and unsafe sexual practices259,260 leading to increased
rates of BBV infection have been reported among this group.261,262
We interviewed five males involved in chemsex who inject from London who had injected in the previous
month, mostly crystal methamphetamine and mephedrone. They reported injecting risks such as being
injected and injecting others, inadvertent mixing up of injecting equipment, potential needlestick injury and
vein damage. Non-condom use (‘bare backing’) was driven by a desire for sexual intensity, but it was also
reported that willingness to take sexual risks increased under the influence of drugs. These participants
suggested outreach and online media as potential modes of delivering an intervention to address the
needs of PWID and engaged in chemsex.
Current service provision around harm reduction for PWID may not address the ‘specific and acute needs
of gay men engaging in chemsex’.263 We propose to adapt the PROTECT study intervention to meet the
needs of chemsex injectors and develop a mobile application to be tested in a future feasibility trial.
Workforce development
This research has confirmed the need and support for providing interventions to PWID to improve their
injecting techniques, vein care, strategies to avoid risk and to increase their knowledge about BBV
transmission, even among people who have injected drugs over a long period of time. Several suggestions to
increase the reach of the intervention were suggested by both staff and participants, including provision of
information on an individual basis to PWID presenting to needle exchanges. This approach could be tested in
a future trial of worker training on the intervention content for use in needle exchange consultations with
PWID, using similar outcome measures as the current feasibility trial. A quasi-experimental design comparing
areas with and without additional training is proposed.
Patient and public involvement
Working with service users to co-produce all study materials, the intervention and dissemination materials
were invaluable and ensured that the key messages could be understood and reached participants. Having
peer educators as co-facilitators to deliver the intervention was highlighted as beneficial by both facilitators
at the training event, those co-delivering and by participants who attended a co-facilitated group.
Service users, service providers and policy-makers all participated in Steering Group meetings throughout
the research study, including the final meeting where the results of the feasibility trial were presented and
the implications for practice of the findings discussed to inform the conclusions presented in this report.
In London, service user representatives and peer educators were involved in developing a feedback
summary of the key findings for service users. People who participated in the research were invited to
attend a dissemination event in London (also open to other service users). These service user
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representatives and peer educators assisted researchers in the delivery and discussion of the study findings
at the dissemination event in London.
Copies of the feedback summary developed by service users in London were also made available to service
users attending the site where the trial took place in Glasgow.
In Huddersfield, a dissemination event was held to present the study findings to key stakeholders.
One ex-service user attended, who is now a harm reduction worker.
Conclusions
The research project has successfully developed and evaluated an evidence-based, group psychosocial
intervention to reduce BBV risk behaviours among PWID. Although there was high satisfaction and
acceptability of the intervention aims and content among participants and intervention facilitators, and the
intervention showed the potential to positively influence BBV risk behaviours, the findings demonstrate
that a future definitive RCT of the PROTECT study intervention is not feasible in the UK. Despite this,
considerable and valuable insight has been obtained showing the need for a greater embedding of BBV
risk reduction in the work of substance misuse services. In addition, this research highlights an urgent
unmet health need for PWID. Furthermore, the research provides a body of evidence as to how this might
best be achieved, and has generated important learning about the feasibility, delivery and implementation
of the PROTECT study intervention, which should inform future studies in the field.
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Appendix 1 Patient information sheet and
consent form for interviews with people who
inject drugs
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[Organisational logos and headers] 
Title of Project: Preventing blood borne virus infection in people who inject drugs in the UK 
 
Please initial the following box if you agree with the following statement. Your participation in 
this research study will not be affected if you do not agree with this statement 
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Appendix 2 Topic guide for interviews with
people who inject drugs
 
Feasibility of psychosocial interventions for preventing blood borne 
virus infection in people who inject drugs 
 
ID number  
 
  
Type of service recruited from 1  Drug treatment service  
2  Needle Exchange  
3  Sexual Health Clinic  
4  Hostel/ Homeless service  
  
Gender 
 
 
1  Male  
2  Female  
3  Transgender  
 
 
Age  
 
 
 
Time interview started  
 
 
 
Time interview finished  
 
 
 
As we previously discussed, we are doing this research to inform the 
development of an intervention to reduce blood borne viruses and increase 
knowledge about how you get or pass on HIV, Hepatitis C and Hepatitis B 
among people who inject drugs in the UK.  Today I want to talk to you about 
injecting and sexual risk behaviours among people who inject drugs to work 
out whether there is a need for an intervention and also ask you about the 
kind of intervention you would find useful and acceptable.   
 
 
Before we start, I just wanted to check  
 
 
Have you injected drugs at least once in the past 4 weeks?  
 
Yes   1                 No  0   (if no, thank and end interview)  
 
 
 
 
 
 
 
What drug/s have you injected at least once in the past 4 weeks? 
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(Interviewer: Read all options and mark all relevant responses) 
 
Heroin  
1 
Cocaine 
2 
Crack cocaine 
3 
Methadone  
4 
Amphetamines 
5 
Methamphetamines 
6 
Hallucinogenics 
7 Benzodiazepines 8 Novel Psychoactive Drugs 10 
Cannabis  
11 Steroids or other performance 
enhancing drugs 
12 Other (specify) 13 
 Specify: 
 
 
 
 
What drugs did you inject most often in the past 4 weeks? 
 
Heroin  
1 
Cocaine 
2 
Crack cocaine 
3 
Methadone  
4 
Amphetamines 
5 
Methamphetamines 
6 
Hallucinogenics 
7 Benzodiazepines 8 Novel Psychoactive Drugs 10 
Cannabis  
11 Steroids or other performance 
enhancing drugs 
12 Other (specify) 13 
 Specify: 
 
 
 
 
How long have you been injecting drugs for?  
 
< 2 years  0       ≥ 2 years  1                  
 
 
 
Are you currently receiving treatment for problems related to drug use? 
(Interviewer: Mark only one response) 
 
 Yes, opiate substitution  1       Yes, other  2                 No  0    
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What are your current living arrangements? 
 
 
 
0 1 
With sexual 
partner alone  
 
2 
3 4 With family  5 
6 7 No stable arrangements 8 
10 11 
 
 
 
 
 Specify: 
 
 
Section 1.  Bloodborne viruses  
 
I would now like to ask you about bloodborne viruses such as HIV, Hepatitis B 
and Hepatitis C 
 
1.1. Can I ask you what you know or what you’ve heard about how 
people get blood borne viruses, like HIV, Hep C and Hep B? 
[probe for HIV, Hepatitis B and C]  
 
1.2. From what you know or you’ve heard, which do you think is the 
easiest virus to get? Why is that? 
 
 
1.3. From what you know or you’ve heard, which do you feel would be 
the worst virus to get/have? Why is that?  
 
 
1.4. Do you feel you are at any risk of HIV, Hepatitis B and/or C? Why is 
that? Why not? [probe for personal risk perception/risk behaviours 
engaged in] 
 
 
Section 2. Injecting drug use 
 
I would now like to ask you about injecting risk behaviours. 
 
2.1. Under what circumstances do you think people who inject drugs 
might be more likely to take risks when injecting (e.g. sharing needles, 
cookers, water etc in the preparation and administration of drugs for 
injection)?(Alternative phrasings if needed:  Are there certain situations 
in which people who inject drugs might be more likely to share needles 
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or syringes? Are there certain situations in which they might be more 
like to share other equipment such as filters, cookers, or water? Explore 
who injecting with/ context (location, intimate partner violence etc) in which 
risks occur – injecting couples, dyads, groups and therefore explore sharing of 
equipment/ preparation/‘aftermath’ – including potential cleaning and disposal 
of equipment and potential risk of transmission. [Explore any issues of 
power and/or dominance in injecting dyads/groups, gender, sex work, 
withdrawal and negative mood].   
 
Some probes I have found useful: 
Where would you normally be when you are injecting? Would you ever inject 
anywhere else? 
Would you ever inject in the company of other people? 
Do you/have you ever needed help injecting? Why is/was that? 
Have you ever had to help someone else inject? Why is/was that? How do 
you/did you feel about helping them?  
Have you ever found yourself in a situation where you have had to share 
injecting equipment? 
Are there certain people you’d feel comfortable sharing equipment with? 
When you have had to share, would you always get an opportunity to clean 
the equipment? 
How would you normally clean it? 
Are there certain times when people are more likely to share injecting 
equipment? 
Who disposes of the equipment and how is it disposed of? 
 
 
2.2. Do you think there are different risks involved in preparing and 
injecting different drugs (e.g. heroin vs. cocaine or methamphetamine)? 
What are the different risks?   
 
 
2.3. Are there times, however rare, when you think people who inject 
drugs lose control over how they inject? If so describe these 
circumstances/ drugs used etc 
• What about you, is that the same for you? 
 
 
2.4. What help or support [ie explore about more knowledge, more 
motivation, more skills?] do you think could be given to people who 
inject drugs to help them inject more safely? [PROBE: barriers/ what 
would motivate them]  
 
Probes: Is there anything that might stop people from changing or make 
it difficult for them to change? 
What might help people in that situation? 
 
• Have you ever had any help or support or education around safer 
injecting? Can you tell me about it and what you found most/least 
helpful 
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Now I would like to talk about sexual risks for blood borne viruses 
 
 
Section 3. Sexual behaviour 
 
3.1.       Do you have intimate relationships with .? 
 
Men 1 
Women 0 
Both men and women 2 
  
 
 
3.2. Under what circumstances do you think people who inject drugs 
might be more likely to have unsafe sex or engage in riskier sexual 
practice? (Alternative phrasing if needed: Are there certain situations in 
which people who inject drugs might be more likely to have unprotected 
sex or engage in riskier sex?) (Explore who having sex with/ context 
(sex trading, CHEMSEX, intimate partner violence, withdrawal, negative 
mood etc) in which risks occur. [Explore any issues of power and/or 
dominance, gender]. 
• What about you, is that the same for you? 
 
Probes:  
What do you think stops people using a condom or having safer sex in 
these situations? 
Would it be easy do you think for you/others in that situation to use a 
condom if you wanted? 
 
 
3.3. What help or support [ie explore about more knowledge, more 
motivation, more skills?] do you think could be given to people who 
inject drugs to help them have safer sex? [PROBE: barriers/ what would 
motivate them]  
 
Probes: Is there anything that might stop people from changing or make 
it difficult for them to change?  
What might help people in that situation? 
 
• Have you ever had any help or support or education around safer sex? 
Can you tell me about it and what you found most/least helpful 
 
 
 
Section 4. Development/need for intervention 
 
The next stage of this project is to develop a specific intervention to help 
people who inject drugs reduce the risk of getting or passing on blood borne 
viruses such as HIV, and hepatitis B and C, by reducing drug and sexual risk 
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behaviours and increasing knowledge around transmission and re-infection.  
Interventions might include i) information to increase knowledge, ii)teach skills 
to practice safer injecting and sex, and iii)motivate people to practise safer 
injecting and sex. We would like to ask you whether you would find such an 
intervention useful and if so, what kind of intervention you would find useful. 
 
 
4.1. What sort of information/skills do you think the intervention should 
focus on to help people who inject drugs to practice safer drug use and 
safer sex? [PROBE for whether this is already happening/ experience of 
interventions in the past they have attended]   
 
 
4.2. Would you participate in something like that? Why/ why not? 
 
 
4.3. Who do you think would be best to deliver it? [PROBE peer, drug 
worker, Needle Exchange, GP etc.] Why is that? Where do you think it 
would be best delivered? 
 
 
4.4. How do you think it should be delivered? [PROBE in group, 
individual sessions, by leaflet, mobile app, online etc.] Why?    
 
 
4.5. How many sessions do you think would be realistic? And how long 
should they be? 
 
 
4.6. Sometimes it is difficult to get people to attend interventions, what 
do you think some of the barriers might be to people attending? 
What could be done to improve uptake of this type of intervention? 
 
 
Thank you so much for taking part that is the end of the interview. 
Is there anything else you would like to add that we haven’t covered? 
  
  
 
Version 3  19 May 2015 
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Appendix 3 Topic guides for consultation with
key stakeholders
 
TOPIC GUIDE POLICYMAKERS/GOVT (Phase 3) 
 
Feasibility of psychosocial interventions for preventing blood borne 
virus infection in people who inject drugs 
  
As we previously discussed, we are doing this research to inform the development of 
an evidence based psychosocial intervention to reduce blood borne viruses and 
increase blood borne virus transmission knowledge among people who inject drugs 
in the UK.  By psychosocial intervention we mean any intervention that emphasizes 
psychological or social factors rather than biological’1.  We wish to speak to you 
about your views on the current priorities for reducing BBVs among PWID and 
delivery and effectiveness of psychosocial interventions to reduce blood borne 
viruses among people who inject drugs, as well as your views on any barriers or 
facilitators you can identify around their delivery.   
 
1. Can I ask what your job title is? 
 
2. Could you describe what your job/role entails, and particularly in 
relation to BBVs? 
 
1. In your opinion what are the key priorities for reducing BBVs among 
PWID in [country]?  
a. What might be the issues, if any, in delivering on these priorities? 
 
2. Do you think there is a need to develop psychosocial interventions to 
reduce the spread of blood borne viruses among people who inject 
drugs?  
a. Why/why not? 
b. (IF YES) How important is their development in relation to the 
priorities you’ve mentioned? 
 
3. How do you think a psychosocial intervention to reduce BBV risk 
behaviour would complement existing service requirements? 
 
4. If a psychosocial intervention SPECIFICALLY AIMED AT REDUCING 
BBVs for PWID was developed what do you think would be the criteria 
(e.g. evidence-based, funding, trained workforce, quality assessment etc.) 
needed to ensure its EFFECTIVE delivery:  
c. NATIONALLY 
d. LOCALLY?  
 
5. Are you aware of any current barriers (e.g. funding) /facilitators (e.g. 
joint strategic needs assessment) to delivering psychosocial 
interventions to people who inject drugs? 
e. Nationally  
f. Locally? 
 
6. Are psychosocial interventions a priority in your joint strategic needs 
assessment? 
g. (WHY/WHY NOT?) 
 
9. Are there any key performance indicators around BBV? 
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 As I said previously, the overall aim of the research is develop and test the feasibility 
of delivering a psychosocial intervention to reduce blood borne virus risk behaviours 
among people who inject drugs. The feasibility study will be conducted in London, 
Yorkshire, Glasgow and Wales.  However, if the intervention is feasible we would 
apply for funding to conduct the study on a larger scale – throughout the UK. 
 
10. Can you envisage any issues with rolling out psychosocial 
interventions across all drug treatment settings locally or nationally? 
How could these be addressed?  
 
11. How should we measure if the intervention was effective? 
 
 
TOPIC GUIDE STAFF (Phase 3) 
 
Feasibility of psychosocial interventions for preventing blood borne 
virus infection in people who inject drugs 
  
As we previously discussed, we are doing this research to inform the development of 
an evidence based psychosocial intervention to reduce blood borne viruses and 
increase knowledge of blood borne virus transmission among people who inject 
drugs in the UK.  By psychosocial intervention we mean any intervention that 
emphasizes psychological or social factors rather than biological’1.  We wish to speak 
to you about your views on the current delivery and effectiveness of psychosocial 
interventions to reduce blood borne viruses among people who inject drugs, get your 
views on how you think such interventions should be delivered and any barriers or 
facilitators you can identify around their delivery.   
 
3. Can I ask what your job title is? 
 
4. Could you describe what your job/role entails, and particularly in 
relation to BBVs? 
 
3. Are you aware of, 
a. Any psychosocial interventions to reduce BBV that are delivered to people 
who inject drugs within (NAMED COUNTRY)? (duration, content, mode of 
delivery, group based or individual based interventions, area delivered 
etc) 
b. To whom? (probe whether general IDU population or targeted groups e.g. 
prisoners/gender specific etc).  
c. By whom? Generalist or specialist delivered? Specify (If the intervention 
consists of different components, probe if these different intervention 
components are delivered by the same or different teams).  
d. In your opinion/or from evidence – are these effective? Why/why not? 
e. Can you talk us through what helps or hinders the delivery of the 
interventions 
f. Were/Are these interventions part of a research study or are they an 
ongoing intervention? (If ongoing are they being evaluated?) 
g. If you do not have all the details of these interventions could you signpost 
us to someone who may be able to provide more information? 
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4. Do you think there is a need to develop psychosocial interventions to 
reduce the spread of blood borne viruses among people who inject 
drugs?  
h. Why/why not? 
 
5. How do you think a psychosocial intervention to reduce BBV risk 
behaviour would complement existing service requirements? 
 
 
6. What would they look like? 
i. Content, duration (e.g., mode of delivery, group based or individual based 
interventions, 
. 
j. What behavioral, psychological or social factors should the interventions 
aim to promote or change for people who inject drugs in relation to blood 
borne viruses? Why?  
k. Who should deliver? generalist or specialist (e.g.staff, peers etc)  
delivered (When the intervention consists of different components, probe 
if these different intervention components should be delivered by the 
same or different teams).  
l. To whom should they be delivered (should they be targeted to specific 
groups of people who inject drugs) and should there be different 
interventions for different groups of people who inject drugs. If so why? 
m. Should they be delivered at a particular stage in the trajectory of an 
individual’s drug use (e.g. whilst on opiate substitution treatment? whilst 
engaged in a pattern of chaotic behavior etc?) 
n. Where should they be delivered – in drug treatment services, needle 
exchanges etc 
o. Do you have any views on payments or incentives to encourage 
engagement in interventions? 
 
7. What are the current barriers (e.g. funding) /facilitators (e.g. joint 
strategic needs assessment) to delivering psychosocial interventions to 
people who inject drugs? 
p. In your locality (if appropriate)  
q. Nationally  
 
As I said previously, the overall aim of the research is develop and test the feasibility 
of delivering a psychosocial intervention to reduce blood borne virus risk behaviours 
among people who inject drugs. The feasibility study will be conducted in London, 
Yorkshire, Glasgow and Wales.  However, if the intervention is feasible we would 
apply for funding to conduct the study on a larger scale – throughout the UK. 
 
8. Can you envisage any issues with rolling out psychosocial 
interventions across all drug treatment settings locally or nationally? 
How could these be addressed?  
 
9. How should we measure if the intervention was effective?  
 
Version 3  09 June 2015 
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Appendix 4 Intervention development
group members
[Organisational logos and headers] 
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Appendix 5 Study summary
NHS and third-sector community
addiction and harm reduction clinics
and needle exchange programmes
PWID aged ≥ 18 years who have
injected drugs at least once in the past 
4 weeks and plan to stay in the area for
the next 3 months
Screened for eligibility Eligible but not interestedNot eligible
Eligible, willing to
participate and written
informed consent obtained
TAU from service TAU from service
Baseline data collected
Randomisation by telephone
Intervention arm plus leaflet Control arm plus leaflet
Session 1
Session 2
Session 3
End of intervention interview
1 month post-intervention
interview
Interview at time equivalent to
end of intervention
Interview at time equivalent to
1 month post-intervention
interview
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Appendix 6 Eligibility screening questions
Eligibility criteria
Potential participants are eligible for the study if ALL of the following inclusion criteria apply.
Inclusion criteria
l Aged ≥ 18 years.
l Attending a participating site [i.e. NHS and third-sector community addiction/harm reduction clinics and
needle exchange programmes (static and mobile)].
l Have injected drugs at least once in the past 4 weeks (if only injected performance-enhancing drugs
they would not be eligible – therefore important to check what drugs injected).
l Plan to stay in the area for the next 3 months.
l Is able to complete the assessment and communicate in a group intervention in English.
Potential participants are NOT eligible for the study if ANY of the following exclusion criteria apply.
Exclusion criteria
l Is too intoxicated to give informed consent.
l Is in withdrawal.
l Has only injected performance-enhancing drugs in the past 4 weeks.
Screening questions
l Have you injected drugs at least once in the past 4 weeks?
l What drugs have you injected?
l What age are you?
l Do you plan to stay in the area for the next 3 months?
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Appendix 7 Patient information sheet and
consent form
[Organisational logos and headers] 
Participant information sheet (Phase 5) 
Improving injecting skills and preventing blood borne virus infection in people 
who inject drugs in the UK 
           
We would like to invite you to take part in our research study. Before you decide we would like you 
to understand why the study is being done and what it would involve for you if you decide to take 
part. One of our team will go through the information sheet with you and answer any questions you 
have. This should take about 10 minutes. Do feel free to talk to others (friends, family, staff) about the 
study if you wish.  Thank you for taking the time to learn more about this study. 
 
Why are we doing this study? 
There is a high risk of blood borne viruses (e.g. HIV, Hepatitis C and Hepatitis B) as a result of 
sharing injecting equipment (needles and syringes, water, spoons, cotton etc.) and unsafe sex. It is in 
everyone’s interest to prevent the spread of these viruses. Opiate substitution therapy (methadone or 
buprenorphine) and needle exchanges have helped to reduce blood borne viruses but programmes that 
give people the skills and knowledge to be able to avoid or reduce these risks could help prevent the 
spread of these viruses.  
 In order to address skills and knowledge around safer drug use, we have developed a 3-
session group programme to help people who inject to learn how to improve their injecting skills in 
order to avoid or reduce their sexual and drug related blood borne virus risk behaviours. This has been 
based on what people who inject drugs have told us about what they think would help them be safer.  
We are doing this study to see whether it is possible to deliver a programme like this in drug 
treatment services, whether people who inject drugs would come to such a programme and what they 
thought about taking part in it. We need to know if this new programme is any better than similar 
information provided in an information leaflet. We will also look at how the costs of the programme 
compares to the leaflet. This study is being conducted in London, Glasgow, Yorkshire and North 
Wales to allow the results to be compared across different areas in the UK. 
 
Why have I been approached? 
We are interested in talking to people who have injected drugs at least once in the past month and who 
are attending drug treatment or needle exchanges and inviting them to take part. 
 
If you decide to take part 
If you agree to take part in this research project you will be asked to complete the contact form (with 
your preferred ways of being contacted) and sign the consent form. The contact information will be 
used during the study to remind you of appointments for the study. If you consent to take part in the 
study, the researcher will then invite you to take part in an interview where you will be asked 
questions about your drug use, sexual practices, knowledge of blood borne viruses and use of 
services. This should take around 45 minutes.  You will be interviewed two more times – in about one 
month and then one month after that. After completing the first interview with the researcher, you will 
have a 50/50 chance of being allocated to one of two groups: 
 
• Group one will receive an information leaflet about transmission risk behaviours for 
blood borne viruses AND will be invited to attend a 3 session group programme 
• Group two will receive the information leaflet only. 
 
Version 2 (20/10/15)  
 
As the allocation process is done by an independent researcher after the questionnaire is completed, 
we can’t say at this stage whether you will get the group programme option or not.  It is also 
important to mention that the research team have no influence over what group you are allocated to.   
 
Why are we allocating people to the group by chance? 
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If we allowed people to choose, we may end up with more people who like group programmes 
specifically who would then find it more favourable and this could influence the findings.  It makes 
for a fairer comparison if people are allocated to groups by chance. 
 
How will I be allocated? 
Following completion of the first questionnaire, we will call the University of York Clinical Trials 
Unit in your presence who will use a computer programme to allocate you by chance to one of the two 
options.  To do this, they need a limited amount of information on you (your initials, sex and age) and 
your drug use (the main drug you inject). This information is confidential and protected. We will tell 
you immediately following the end of the phone call which group you have been allocated to. 
 
Option  1 – GROUP PROGRAMME AND INFORMATION LEAFLET   
If you are allocated to the group programme we will let you know the time, date and location of the 
first session shortly.  
 
The intervention will be delivered by trained staff. The sessions will take place at the drug treatment 
service from which you are recruited and will include three one-hour interactive sessions to help you 
learn how to:  
 
1) Improve your injecting skills to inject more safely 
2) Learn good vein care 
2)   Understand blood borne virus transmission risks, and  
3)   Develop strategies to reduce these risks (e.g. when injecting with others, planning for 
withdrawal, being prepared, negotiating with others).  
 
The group programme will last 3 weeks, with one session per week. There will be up to 8 people in 
the group and separate groups will be held for women and men.   
 
A small number of you will also be invited to take part in a focus group to talk about your experience 
of taking part in the programme. Even if you agree to take part in the programme you are under no 
obligation to take part in the focus group. 
 
You will also be given an information leaflet on injection and sex transmission risks for blood borne 
viruses.  You will also still be able to receive the care that is offered to all people attending needle 
exchanges or drug treatment.    
 
Option 2 - INFORMATION LEAFLET   
If you are allocated to this group you will be provided with an information leaflet on injection and sex 
transmission risks for blood borne viruses.  You will receive the care that is usually offered to all people 
attending needle exchanges or drug treatment.   We will also be inviting you to complete the same 
questionnaire at 2 time intervals in order to compare the information from people in option 1 with option 
2.   
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The questionnaires will contain only your study ID (not your name) and will be stored on 
a secure computer. Only the researchers conducting the study will have access to these questionnaires 
(not the staff at the needle exchange or drug service). The information will be kept on a university  
 
Version 2 (20/10/15) 
 
computer secure drive and will be stored separately from your contact details.  Data will be kept 
securely for 7 years after publication of the findings and then destroyed.  
 
Limitations to confidentiality 
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 • The safety of yourself and others is very important to us.  If you express current or future 
intention to harm yourself or someone else, there would be no grounds for maintaining 
confidentiality. Your key worker or a duty worker at the drug treatment service where the 
interview has taken place will be told by the researcher of your intentions and the worker will 
conduct a risk assessment.  We will inform you that we need to breach confidentiality at the point 
of disclosure.  
 
What are the possible benefits of taking part? 
Whether you take part in option 1 or 2, you will have a chance to take part in an exciting new study 
which could influence future developments around safer injecting and sexual practices.  No matter 
what option you are allocated to, you will receive leaflets on safer injecting and sexual practices, and 
information on blood borne virus risk behaviours.  If you are allocated to the option 1 group, you will 
have an opportunity to take part in a new group and learn some new skills to keep yourself and your 
friends and loved ones safer. You will also have the opportunity to give some feedback on how useful 
it is.  
 
What are the possible disadvantages and risks of taking part?  
There is low risk of harm by taking part.  However, you may find talking about sensitive topics 
including potential risks for the spread of blood borne viruses could make you feel worried or 
anxious.  If during any stage of the study you become worried or anxious about these topics or wish to 
find out more about blood borne viruses, you will be given the opportunity to speak to a member of 
staff at a local drug treatment service should you want to.  We have also provided you with a range of 
contact numbers and websites that will be able to help.  
 
What will happen if I don’t want to carry on with the study? 
Taking part is completely up to you.  It is voluntary and you are free to withdraw from the study at 
any time without giving any reason.  There are no consequences to this and this will have no bearing 
on your treatment.  If you do choose to withdraw from the study, we will delete your contact details 
from our records, but we will need to use the data collected up to the point of your withdrawal. This 
will not affect your rights or your future care in any way. 
 
Expenses   
You will receive a shopping voucher for each of the three interviews completed. In addition, you will 
receive compensation for your time and expenses to attend the group sessions and also if you attend a 
focus group.   
 
Will I get to hear about the findings from the study? 
Yes, this is important. Summaries of the findings will be made available in the drug treatment services 
involved in this study in June 2016. You will not be identifiable from any of the results presented. 
They will be presented in an easy to understand format. 
 
If I am not happy with something related to the study who can I speak to? 
In the first instance you can raise any queries or concerns with the local study lead [local lead contact 
details].  If you're not happy with the care or treatment you've received as part of this study, you have 
the right to complain.  Your local Patient Advice and Liaison Service (PALS) will be able to help you 
make a complaint. Phone NHS 111 for details of your nearest PALS. 
 
Version 2 (20/10/15) 
 
Who has reviewed this study? 
All research that takes place in the NHS and other healthcare providers is looked at by an independent 
group called a Research Ethics Committee. They make sure that the research is fair and that the 
research team are properly qualified and have plans to ensure the comfort and safety of all 
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participants. The study has been reviewed by the East Midlands – Leicester South Research Ethics 
Committee (reference: 15/EM/0413). 
 
Who is organising and funding the research?  
The research is being led by Dr Gail Gilchrist, from the National Addiction Centre at King’s College 
London, and is funded by the National Institute for Health Research. If you wish to talk to someone 
about the research please contact Dr Gilchrist on [telephone number]. 
 
Useful contact numbers 
 
For information about local drug treatment services call the Frank drugs helpline on
or visit the Frank website http://www.talktofrank.com/need-support?ID=108   
 
The Hepatitis C Trust Helpline or  http://www.hepctrust.org.uk/ 
Open 10.30am to 4.30pm Monday to Friday (except Bank Holidays and the Christmas break, when 
dates and times may vary).Helpline is staffed solely by people with hepatitis C, some of whom have 
been through/or are currently undergoing treatment.  
 
British Liver Trust   
www.britishlivertrust.org.uk (Free helpline, Mon-Fri 09.00-17.00) The British Liver Trust is the 
national charity working to reduce the impact of liver disease in the UK through support, information 
and research. 
 
National Hepatitis Support Line  
http://www.hepbpositive.org.uk/ Help the public and patients overcome hepatitis B.  They clarify and 
reassure patients that hepatitis B is both easy to vaccinate against and caught early on an easy to 
manage common child acquired condition.   
 
National Sexual Health Line  
The National Sexual Health Line is UK-wide and provides confidential advice and information on all 
aspects of HIV, AIDS and sexual health. The Helpline can also provide UK wide referrals to 
specialist services. Open 24 hours a day, seven days a week. All calls are taken by trained and paid 
staff. It is not a counselling service, but gives you details of local helplines & services if needed. 
 
Terrence Higgins Trust Direct Helpline  
(open 10am - 10pm Monday - Friday, and 12 noon - 6pm on Saturday and Sunday). Terrence Higgins 
Trust Direct Helpline can give you HIV information, advice 
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(24 hours)
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 Title of Project: Improving injecting skills and preventing blood borne virus infection in people who 
inject drugs in the UK 
 
Name of Researcher: Dr Gail Gilchrist, local lead [local lead name]                                                                                          
 
Please initial all boxes 
  
1. I confirm that the researcher has explained the information sheet to me and that I understand 
the information sheet dated 20/10/15 (version 2) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to withdraw at from the study 
any time without giving any reason, without my care or legal rights being affected. 
 
3. The procedures regarding confidentiality have been clearly explained to me (e.g. anonymization 
of data, use of pseudonyms in reports etc.).  I understand that if I express current or future 
intention to harm myself or someone else that the researcher will inform my key worker or a 
duty worker at the drug treatment service where the interview has taken place and the worker 
will conduct a risk assessment.  
 
4. I understand that I will be allocated to the group intervention or information leaflet at random. 
 
5. I understand that the findings will be published at the end of the study but that I will not be 
identified from the findings.    
 
6. I agree to my anonymous data being shared with researchers at the five institutions where the 
research is being carried out – King’s College London, University of the West of Scotland, 
University of York, NHS Wales and University of Huddersfield. 
 
7. I agree to take part in the above study and be re-interviewed two more times – approximately one 
and two months from today.    
   ___        _________ 
Name of Participant   Date    Signature 
                       
   ___        _________ 
Name of researcher   Date    Signature  
  
 
[Organisational logos and headers] 
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 Title of Project: Improving injecting skills and preventing blood borne virus infection in people who 
inject drugs in the UK 
f I express 
current or future intention to harm myself or someone else that the researcher will inform my 
key worker or a duty worker at the drug treatment service where the interview has taken place 
and the worker will conduct a risk assessment
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Appendix 8 Data collection forms
 
Baseline: 
 
 
[Organisational logos and headers] 
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Appendix 9 Participant focus group topic guides
[Organisational logos and headers] 
 
Participant Focus Group 
 
1. Introductory Question 
1.1 What did you think of the intervention as a whole?  
Prompts:  Individual Sessions 1, 2, 3.  
Can you tell me what made you decide to attend the sessions you did?  (or 
what made you decide not to attend?) 
 
1.2 Do you have any comments or thoughts about the randomisation process? 
2. Content  
2.1 What did you find most/least useful about the intervention?   
Prompts:  Information provided (Injecting skills, risks, BBVs & Transmission risks) 
The chance to Reflect on your own injecting behaviour and skills 
Planning ahead etc. 
Hearing about other people’s experience 
 
2.2 What did you learn if anything, that was new?  
2.3 Have you shared any of the information you learnt with others? Who? Why? 
2.4 Was there other information you would have liked us to provide/ that you think we’ve 
missed out?  
 
3. Logistics 
3.1 What did you think about the delivery of the intervention?  
Prompts:  How easy or difficult was it to get to group/fit in with life? 
  Was the location and timing ok? 
What would have made it more convenient? 
What might have put people off signing up/attending? 
What would have helped more people attend/how could we improve uptake? 
 
4. Quality, Safety and Comfort 
4.1 What are your thoughts on the quality of the intervention? 
Prompts:  What did you think of the Facilitators? e.g. Empathic, knowledgeable, 
confident, engaging, listening, etc. 
  What did you think of the Materials? videos/handouts 
 
4.2  Did you feel that the group was a safe place to be open about injecting behaviour?  
Prompts:  Did you have any worries about talking in the group about injecting? 
Did any of the content make you feel uncomfortable, worried or embarrassed? 
If so, were you able to talk about this in the group or with a worker 
afterwards? 
 
5. Gendered Groups 
5.1 How did you find having single sex groups rather than mixed?  
5.2 Was it easier to share stories/disclose personal information in a single sex group? 
5.3 Would it have mattered to you if it had been mixed sex? 
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6. Behaviour Changes 
6.1 What changes in behaviour, if any, have you made as a result of taking part/what you've 
learned in the intervention? Why?   
 
Finally 
7. Would you recommend this intervention to others? Why/why not? 
8. Any final comments  
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
274
Appendix 10 Participant focus group consent
form and patient information sheet
[Organisational logos and headers] 
Title of Project: Improving injecting skills and preventing blood borne virus infection in people who 
inject drugs in the UK 
f I express 
current or future intention to harm myself or someone else that the researcher will inform my 
key worker or a duty worker at the drug treatment service where the interview has taken place 
and the worker will conduct a risk assessment
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[Organisational logos and headers] 
Title of Project: Improving injecting skills and preventing blood borne virus infection in people who 
inject drugs in the UK 
f I express 
current or future intention to harm myself or someone else that the researcher will inform my 
key worker or a duty worker at the drug treatment service where the interview has taken place 
and the worker will conduct a risk assessment
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[Organisational logos and headers] 
 
Participant information sheet (Phase 5. Focus group) 
Improving injecting skills and preventing blood borne virus infection in people 
who inject drugs in the UK 
           
Thank you once again for taking part in the study. We would now like to invite you to take part in a 
focus group about your experiences of taking part in the group programme. Before you decide we 
would like you to understand why the research is being done and what it would involve for you. One 
of our team will go through the information sheet with you and answer any questions you have. This 
should take about 5 minutes. Do feel free to talk to others about the study if you wish.  We appreciate 
you taking the time to decide whether or not to participate.   
 
Why are we doing this study? 
People who inject drugs are at risk of blood borne viruses (e.g. HIV, Hepatitis C and Hepatitis B) as a 
result of sharing injecting equipment (needles and syringes, water, spoons, cotton etc.) and unsafe sex. 
Preventing people who inject drugs from getting or passing on these viruses is an important health 
issue. Opiate substitution therapy (methadone or buprenorphine) and needle exchanges have reduced 
blood borne viruses but programmes that give people the skills and knowledge to be able to reduce 
these risks could further prevent the spread of these viruses.  
 You took part in a study to see whether it was feasible to deliver the programme in drug 
treatment settings, whether people who inject drugs would come to the programme and what they 
thought about taking part in the programme. Therefore, we would like to ask you to participate in a 
focus group with other people who attended the programme to find out what you thought about it. 
 
Why have I been chosen? 
You recently took part in a 3-session group programme to help people who inject to be able to reduce 
sexual and drug related blood borne virus risk behaviours.  Even if you only attended one session, we 
would like to hear about your experiences so that we can improve the programme if necessary. 
 
If you decide to take part 
If you agree to take part in the focus group you will be asked to complete and sign the consent form. 
If you consent to take part in the study, we will invite you to take part in a focus group that will last 
about 60 minutes. There will be about 8 people in the focus group with you so you can discuss your 
participation together as a group. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The focus group will be audio-recorded with your consent.  We cannot guarantee that 
others participating in the research will keep what you say confidential but we will encourage people 
to do so, so that people feel comfortable discussing their experiences.  The focus group will be 
analysed as a whole and participants' names will not be used in any analysis of the discussion.  The 
transcript and audio recording will be stored on a secure computer and the audio recording will be 
deleted from the recording device. What you say in the focus group will be typed out word for word. 
Only the researchers conducting the study will have access to these typed copies. The researcher will 
check them to make sure that neither you nor any other person is identifiable from what you have 
said. Any references to names or addresses will be removed. The data will be kept on a computer and 
will be stored separately from your contact details.  Data will be kept securely for 7 years after 
publication of the findings and then destroyed.  
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Limitations to confidentiality 
 
• If you express current or future intention to harm yourself or someone who is specifically 
identified, there would be no grounds for maintaining confidentiality. Your key worker or a 
duty worker at the drug treatment service where the interview has taken place will be told by the 
researcher of your intentions and the worker will conduct a risk assessment.   
 
What are the possible benefits of taking part? 
Your feedback on taking part in this programme will help us improve the programme that will 
potentially help people who inject drugs reduce the risk of blood borne viruses transmission. 
 
What are the possible disadvantages and risks of taking part?  
There is low risk of harm by taking part.  However, talking about sensitive topics including potential 
risks for the transmission of blood borne viruses may make you feel worried or anxious.  If you are 
worried or anxious or wish to find out more about blood borne viruses, you will be given the 
opportunity to speak to a member of staff at a local drug treatment service if you want to.  We have 
also provided you with a range of contact numbers and websites that will be able to help.  
 
Do I have to take part? 
No. It is up to you to decide whether or not you want to take part in the focus group. If you agree to 
take part, we will then ask you to sign a consent form. This study is independent of your treatment.  
You are free to withdraw at any time without giving a reason. This will not affect the care that you are 
receiving.   
 
Expenses   
This study is funded by the National Institute for Health Research. You will receive a shopping 
voucher for participating in the focus group.   
 
Results of the research study 
The results of this research study will be available after we have analysed the data. Summaries of the 
results will be made available in the drug treatment settings involved in this study in June 2016. You 
will not be identifiable from any of the results presented. 
 
What happens if something goes wrong? 
If you're not happy with the care or treatment you've received as part of this study, you have the right 
to complain.  Your local Patient Advice and Liaison Service (PALS) will be able to help you make a 
complaint. Phone NHS 111 for details of your nearest PALS. 
 
Who reviewed the study 
All research in the NHS is looked at by an independent group called a Research Ethics Committee. 
They make sure that the research is fair. The study has been reviewed by the East Midlands – 
Leicester South Research Ethics Committee (reference: 15/EM/0413). 
 
Who is organising and funding the research?  
The research is being led by Dr Gail Gilchrist, from the National Addiction Centre at King’s College 
London, and is funded by the National Institute for Health Research. If you wish to talk to someone 
about the research please contact Dr Gilchrist on [telephone number] 
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Useful contact numbers 
 
For information about local drug treatment services call the Frank drugs helpline on  
or visit the Frank website http://www.talktofrank.com/need-support?ID=108   
 
The Hepatitis C Trust Helpline or  http://www.hepctrust.org.uk/ 
Open 10.30am to 4.30pm Monday to Friday (except Bank Holidays and the Christmas break, when 
dates and times may vary).Helpline is staffed solely by people with hepatitis C, some of whom have 
been through/or are currently undergoing treatment.  
 
British Liver Trust   
www.britishlivertrust.org.uk (Free helpline, Mon-Fri 09.00-17.00) The British Liver Trust is the 
national charity working to reduce the impact of liver disease in the UK through support, information 
and research. 
 
National Hepatitis Support Line  
http://www.hepbpositive.org.uk/ Help the public and patients overcome hepatitis B.  They clarify and 
reassure patients that hepatitis B is both easy to vaccinate against and caught early on an easy to 
manage common child acquired condition.   
 
National Sexual Health Line  
The National Sexual Health Line is UK-wide and provides confidential advice and information on all 
aspects of HIV, AIDS and sexual health. The Helpline can also provide UK wide referrals to 
specialist services. Open 24 hours a day, seven days a week. All calls are taken by trained and paid 
staff. It is not a counselling service, but gives you details of local helplines & services if needed. 
 
Terrence Higgins Trust Direct Helpline  
(open 10am - 10pm Monday - Friday, and 12 noon - 6pm on Saturday and Sunday). Terrence Higgins 
Trust Direct Helpline can give you HIV information, advice and support over the phone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
version 2 (20/10/15) 
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[Organisational logos and headers] 
 
 
Participant information sheet (Phase 5. Focus group) 
Improving injecting skills and preventing blood borne virus infection in people 
who inject drugs in the UK 
           
Thank you once again for taking part in the study. We would now like to invite you to take part in a 
focus group about your experiences of taking part in the group programme. Before you decide we 
would like you to understand why the research is being done and what it would involve for you. One 
of our team will go through the information sheet with you and answer any questions you have. This 
should take about 5 minutes. Do feel free to talk to others about the study if you wish.  We appreciate 
you taking the time to decide whether or not to participate.   
 
Why are we doing this study? 
People who inject drugs are at risk of blood borne viruses (e.g. HIV, Hepatitis C and Hepatitis B) as a 
result of sharing injecting equipment (needles and syringes, water, spoons, cotton etc.) and unsafe sex. 
Preventing people who inject drugs from getting or passing on these viruses is an important health 
issue. Opiate substitution therapy (methadone or buprenorphine) and needle exchanges have reduced 
blood borne viruses but programmes that give people the skills and knowledge to be able to reduce 
these risks could further prevent the spread of these viruses.  
 
You took part in a study to see whether it was feasible to deliver the programme in drug treatment 
settings, whether people who inject drugs would come to the programme and what they thought about 
taking part in the programme. Therefore, we would like to ask you to participate in a focus group with 
other people who attended the programme to find out what you thought about it. 
 
Why have I been chosen? 
You recently took part in a 3-session group programme to help people who inject to be able to reduce 
sexual and drug related blood borne virus risk behaviours.  Even if you only attended one session, we 
would like to hear about your experiences so that we can improve the programme if necessary. 
 
If you decide to take part 
If you agree to take part in the focus group you will be asked to complete and sign the consent form. 
If you consent to take part in the study, we will invite you to take part in a focus group that will last 
about 60 minutes. There will be about 8 people in the focus group with you so you can discuss your 
participation together as a group. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The focus group will be audio-recorded with your consent.  We cannot guarantee that 
others participating in the research will keep what you say confidential but we will encourage people 
to do so, so that people feel comfortable discussing their experiences.  The focus group will be 
analysed as a whole and participants' names will not be used in any analysis of the discussion.  The 
transcript and audio recording will be stored on a secure computer and the audio recording will be 
deleted from the recording device. What you say in the focus group will be typed out word for word. 
Only the researchers conducting the study will have access to these typed copies. The researcher will 
check them to make sure that neither you nor any other person is identifiable from what you have 
said. Any references to names or addresses will be removed. The data will be kept on a computer and 
will be stored separately from your contact details.  Data will be kept securely for 7 years after 
publication of the findings and then destroyed.  
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Limitations to confidentiality 
 
• If you express current or future intention to harm yourself or someone who is specifically 
identified, there would be no grounds for maintaining confidentiality. Your key worker or a 
duty worker at the drug treatment service where the interview has taken place will be told by the 
researcher of your intentions and the worker will conduct a risk assessment.   
 
What are the possible benefits of taking part? 
Your feedback on taking part in this programme will help us improve the programme that will 
potentially help people who inject drugs reduce the risk of blood borne viruses transmission. 
 
What are the possible disadvantages and risks of taking part?  
There is low risk of harm by taking part.  However, talking about sensitive topics including potential 
risks for the transmission of blood borne viruses may make you feel worried or anxious.  If you are 
worried or anxious or wish to find out more about blood borne viruses, you will be given the 
opportunity to speak to a member of staff at a local drug treatment service if you want to.  We have 
also provided you with a range of contact numbers and websites that will be able to help.  
 
Do I have to take part? 
No. It is up to you to decide whether or not you want to take part in the focus group. If you agree to 
take part, we will then ask you to sign a consent form. This study is independent of your treatment.  
You are free to withdraw at any time without giving a reason. This will not affect the care that you are 
receiving.   
 
Expenses   
This study is funded by the National Institute for Health Research. You will receive a small sum of 
money for participating in the focus group.   
 
Results of the research study 
The results of this research study will be available after we have analysed the data. Summaries of the 
results will be made available in the drug treatment settings involved in this study in June 2016. You 
will not be identifiable from any of the results presented. 
 
What happens if something goes wrong? 
If you're not happy with the care or treatment you've received as part of this study, you have the right 
to complain.  Your local Patient Advice and Liaison Service (PALS) will be able to help you make a 
complaint. Phone NHS 111 for details of your nearest PALS. 
 
Who reviewed the study 
All research in the NHS is looked at by an independent group called a Research Ethics Committee. 
They make sure that the research is fair. The study has been reviewed by the East Midlands – 
Leicester South Research Ethics Committee (reference: 15/EM/0413). 
 
Who is organising and funding the research?  
The research is being led by Dr Gail Gilchrist, from the National Addiction Centre at King’s College 
London, and is funded by the National Institute for Health Research. If you wish to talk to someone 
about the research please contact Dr Davina Swan on [telephone number] 
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Useful contact numbers 
 
For information about local drug treatment services call the Frank drugs helpline on
or visit the Frank website http://www.talktofrank.com/need-support?ID=108   
 
The Hepatitis C Trust Helpline or  http://www.hepctrust.org.uk/ 
Open 10.30am to 4.30pm Monday to Friday (except Bank Holidays and the Christmas break, when 
dates and times may vary).Helpline is staffed solely by people with hepatitis C, some of whom have 
been through/or are currently undergoing treatment.  
 
British Liver Trust   
www.britishlivertrust.org.uk (Free helpline, Mon-Fri 09.00-17.00) The British Liver Trust is the 
national charity working to reduce the impact of liver disease in the UK through support, information 
and research. 
 
National Hepatitis Support Line  
http://www.hepbpositive.org.uk/ Help the public and patients overcome hepatitis B.  They clarify and 
reassure patients that hepatitis B is both easy to vaccinate against and caught early on an easy to 
manage common child acquired condition.   
 
National Sexual Health Line  
The National Sexual Health Line is UK-wide and provides confidential advice and information on all 
aspects of HIV, AIDS and sexual health. The Helpline can also provide UK wide referrals to 
specialist services. Open 24 hours a day, seven days a week. All calls are taken by trained and paid 
staff. It is not a counselling service, but gives you details of local helplines & services if needed. 
 
Terrence Higgins Trust Direct Helpline  
(open 10am - 10pm Monday - Friday, and 12 noon - 6pm on Saturday and Sunday). Terrence Higgins 
Trust Direct Helpline can give you HIV information, advice and support over the phone.  
 
 
version 3 (26/01/16) 
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Appendix 11 Staff focus groups consent form
and patient information sheet
[Organisational logos and headers] 
 
 
 
 
 
Participant information sheet (Phase 5. Staff focus group) 
Improving injecting skills and preventing blood borne virus infection in people 
who inject drugs in the UK 
           
Thank you for delivering the PROTECT group programme for our research study. We would now like 
to invite you to take part in a focus group about your experiences of delivering the programme. Before 
you decide whether or not to take part, we would like you to understand why the focus group is being 
done and what it would involve for you. One of our team will go through this information sheet with 
you and answer any questions you have. Do feel free to talk to others about the study if you wish.  We 
appreciate you taking the time to decide whether or not to participate.   
 
Why are we doing the focus group? 
You recently delivered the PROTECT group programme to help people who inject to be able to 
reduce sexual and drug related blood borne virus risk behaviours. We would like to hear about your 
experiences so that we can improve the programme if necessary. 
 
What will participation entail? 
If you agree to take part in the focus group you will be asked to complete and sign the consent form. 
The focus group will last about 30 minutes and will include the other facilitator(s) in your locality 
who delivered the programme so that you can discuss your participation together as a group. 
 
The focus group will be audio-recorded with your consent. The recording will be uploaded to a secure 
computer and deleted from the recording device. The recording will be typed out word for word by a 
professional transcriber. Only the researchers conducting the study will have access to these typed 
copies. The researcher will check the transcripts for accuracy and remove any references to names. A 
study number will identify you. The transcript and audio-recording will be stored on a secure 
computer separately from your contact details. Data will be kept securely for 7 years after publication 
of the findings and then destroyed.  
 
What are the possible benefits of taking part? 
Your feedback on delivering this programme will help us to improve the programme and potentially 
help people who inject drugs reduce the risk of blood borne viruses transmission. 
 
What are the possible disadvantages and risks of taking part?  
There is low risk of harm by taking part. In order to minimise the risk of your identity being revealed, 
once the focus group has been transcribed a code number will be assigned to the transcript to prevent 
identification. A study number will identify you. Your name will not be used. However, given the 
small number of people who delivered this group programme, it is possible that you may still be 
identifiable to some people. We will send the anonymised, password-protected transcript to you in 
advance of analysing it so that you have an opportunity to review and edit the information before we 
use it. 
 
 
version 1 (24/02/16) 
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Do I have to take part? 
No. It is up to you to decide whether or not you want to take part in the focus group. If you agree to 
take part, we will then ask you to sign a consent form. You are free to withdraw at any time without 
giving a reason.  
 
Results of the research study 
The results of this research study will be available after we have analysed the data. We will present 
the results at conferences and in relevant scientific journals. Reports will contain quotes from the 
focus group to emphasise important points made by participants but your name will not be used.  
 
Who reviewed the study 
The study has been reviewed by the East Midlands – Leicester South Research Ethics Committee 
(reference: 15/EM/0413). 
 
Who is organising and funding the research?  
The research is being led by Dr Gail Gilchrist, from the National Addiction Centre at King’s College 
London, and is funded by the National Institute for Health Research. If you wish to talk to someone 
about the research please contact Dr Gail Gilchrist on [telephone number]. 
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 [Organisational logos and headers] 
Title of Project: Improving injecting skills and preventing blood borne virus infection in people who 
inject drugs in the UK 
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Appendix 12 Staff focus groups topic guide
 
Staff Feedback 
1. Training Event 
 
1.1. How useful was the training event in London / how well did it prepare you to 
deliver the intervention?  
 
1.2. Do you have any comments on the training format? 
 Venue 
 Duration 
 Delivery style 
 
1.3. Do you have any suggestions for alternative format/venue/delivery (e.g. 
video conference)? 
 
1.4. Following the training, did you do anything else to prepare for the delivery of 
the intervention? 
 
2. Intervention Materials 
 
2.1. Do you have any comments on the Intervention Manual?  
Prompts:  
 Was it clear and easy to understand? 
 Did it flow well? 
 Was the lay-out/notes for facilitators helpful? 
 Any comments on the content/information in each of the sessions? 
 Any comments on the Activities? 
 Any comments on the Videos?  
 Any comments on the Overheads? 
 Any comments on the Hand-outs? 
 
2.2. How easy did you find it to implement the intervention in keeping with the 
manual (i.e., fidelity to content and timing)? 
Prompt  - What were the challenges, if any? 
 
3. Intervention delivery 
 
3.1. How much time did it take you to prepare for each of the sessions? Sessions 
1, 2, 3. 
 
3.2. Was it easy to incorporate the intervention into your workload? 
 
3.3. What parts of the intervention did you feel most confident/comfortable 
delivering? Why? 
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3.4. Were there any parts of the intervention which you found challenging to 
deliver? Why? 
 
3.5. FOR LONDON: How did you find co-facilitating the intervention with a 
peer worker/ drug worker?   
 
3.6. FOR LONDON: How did you decide who would do what parts of the 
intervention? 
 
3.7.What worked well about the intervention and why? 
 
3.8. What worked less well and why? 
 
3.9. What would you change and why?  
 
3.10. Do you think anything was missing? What would you add? 
 
3.11.  What did you think of the day/time for the sessions? 
 
3.12. What did you think of the venue for the sessions? 
 
3.13. Would you use the PROTECT intervention in its entirety in your own 
practice? 
Prompt: If no, would you use elements of the intervention? If yes, which ones and 
why? 
 
3.14. Which clients would you target? 
 
3.15. How else do you think the intervention could be used/developed? 
[examples: training of needle exchange staff, bite size info for needle 
exchange attenders, mobile phone apps] 
 
4. Facilitator learning  
4.1. Was there anything you learnt about injecting practices from the clients that you 
weren’t aware of before delivering the intervention? E.g. clients’ knowledge, practice, 
BBV awareness 
 
5. Participant engagement and attendance 
 
5.1.Do you feel those that attended were engaged? 
5.2.As you are aware not everyone recruited to the intervention attended. What 
do you think we could have done differently to increase attendance?   
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Appendix 13 Human immunodeficiency virus:
a 2016 update leaflet
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Appendix 14 Participant and staff evaluation
forms
Evaluation session 1 : Improving injecting techniques & good vein care 
[participant] 
 
We would be grateful if you could give us some feedback on today’s session 
to help us evaluate it and improve future sessions if necessary. Your 
answers are confidential, so we appreciate your honesty. 
 
Please answer all the questions indicating the degree of agreement or 
disagreement with each, with 5 being "strongly agree" and 1 being "strongly 
disagree". Circle the number that best describes your rating of the session 
today.  The researcher can help you if you would prefer someone to read 
out the questions and ratings. 
 
 Strongly 
disagree 
 Strongly 
agree 
 
1. I understood the purpose of the 
intervention  
 
1 
 
2 
 
3 
 
4 
 
5 
 
2. I understood the group agreement 
and the commitment to confidentiality 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
3. I have increased my knowledge 
around injecting techniques 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
4. I have increased my knowledge 
around good vein care 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
5. I have increased my motivation to 
improve my injecting techniques 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
6. I have increased my motivation to 
improve my vein care 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
7. The videos used were relevant 
and informative 
 
1 
 
2 
 
3 
 
4 
 
5 
 
8. The trainer was knowledgeable 
 
1 
 
2 
 
3 
 
4 
 
5 
 
9. Any questions I had were clearly 
answered 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
10. In general, how would you rate today’s session? Circle the number that 
best describes your rating, where 5 is “excellent” and 1 is “poor”  
 
Poor       Excellent 
1 2 3 4 5 
 
11. What did you like most about today’s session? 
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12. What did you like least about today’s session? 
 
 
 
 
 
 
 
 
 
 
13. How do you think today’s session could be improved? 
 
 
 
 
 
 
 
 
 
 
Thanks 
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Evaluation Session 2: Planning for Risk situations [participant] 
We would be grateful if you could give us some feedback on today’s session 
to help us evaluate it and improve future sessions if necessary. Your 
answers are confidential, so we appreciate your honesty. 
 
Please answer all the questions indicating the degree of agreement or 
disagreement with each, with 5 being "strongly agree" and 1 being "strongly 
disagree". Circle the number that best describes your rating of the session 
today.  The researcher can help you if you would prefer someone to read 
out the questions and ratings. 
 
 Strongly 
disagree 
 Strongly 
agree 
 
1. I have a better understanding of 
injecting risk behaviours 
 
1 
 
2 
 
3 
 
4 
 
5 
 
2. I have a better understanding of 
sexual risk behaviours 
 
1 
 
2 
 
3 
 
4 
 
5 
 
3. I am confident I can use some or 
all of the plan to avoid risk 
behaviours 
 
1 
 
2 
 
3 
 
4 
 
5 
 
4. I am confident I can apply TALK 
to reduce/avoid risks 
 
1 
 
2 
 
3 
 
4 
 
5 
 
5. I am confident I can prepare for 
and avoid risky situations 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6. The handouts were helpful 
 
1 
 
2 
 
3 
 
4 
 
5 
7. The exercises used were relevant 
and informative 
 
1 
 
2 
 
3 
 
4 
 
5 
 
8. The trainer was knowledgeable 
 
1 
 
2 
 
3 
 
4 
 
5 
9. Any questions I had were clearly 
answered 
 
1 
 
2 
 
3 
 
4 
 
5 
 
10. In general, how would you rate today’s session? Circle the number that 
best describes your rating, where 5 is “excellent” and 1 is “poor”  
 
Poor       Excellent 
1 2 3 4 5 
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11. What did you like most about today’s session? 
 
 
 
 
 
 
 
 
 
 
12. What did you like least about today’s session? 
 
 
 
 
 
 
 
 
 
 
13. How do you think today’s session could be improved? 
 
 
 
 
 
 
 
 
 
 
Thanks 
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Evaluation of Session 3: Understanding Blood Borne Virus 
Transmission risks [participant] 
We would be grateful if you could give us some feedback on today’s session 
to help us evaluate it and improve future sessions if necessary. Your 
answers are confidential, so we appreciate your honesty. 
 
Please answer all the questions indicating the degree of agreement or 
disagreement with each, with 5 being "strongly agree" and 1 being "strongly 
disagree". Circle the number that best describes your rating of the session 
today.  The researcher can help you if you would prefer someone to read 
out the questions and ratings. 
 
 Strongly 
disagree 
 Strongly 
agree 
 
1. I have a better understanding of 
blood borne viruses  
 
1 
 
2 
 
3 
 
4 
 
5 
 
2. I have a better understanding of 
BBV transmission risk behaviours  
 
1 
 
2 
 
3 
 
4 
 
5 
 
3. I enjoyed the Myths and Facts 
exercise 
 
1 
 
2 
 
3 
 
4 
 
5 
 
4. I am confident I can reduce my 
BBV transmission risk behaviours 
 
1 
 
2 
 
3 
 
4 
 
5 
 
5. I have increased my motivation for 
safer injecting 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6. The handouts were helpful 
 
1 
 
2 
 
3 
 
4 
 
5 
7. The videos used were relevant 
and informative 
 
1 
 
2 
 
3 
 
4 
 
5 
 
8. The trainer was knowledgeable 
 
1 
 
2 
 
3 
 
4 
 
5 
 
9. Any questions I had were clearly 
answered 
 
1 
 
2 
 
3 
 
4 
 
5 
 
10. In general, how would you rate today’s session? Circle the number that 
best describes your rating, where 5 is “excellent” and 1 is “poor”  
 
Poor       Excellent 
1 2 3 4 5 
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11. What did you like most about today’s session? 
 
 
 
 
 
 
 
 
 
 
12. What did you like least about today’s session? 
 
 
 
 
 
 
 
 
 
 
13. How do you think today’s session could be improved? 
 
 
 
 
 
 
 
 
 
 
Thanks 
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Evaluation session 1 : Improving injecting techniques & good vein care 
[facilitator] 
 
We would be grateful if you could give us some feedback on today’s session 
to help us evaluate it and improve future sessions if necessary. Your 
answers are confidential, so we appreciate your honesty. 
 
Please answer all the questions indicating the degree of agreement or 
disagreement with each, with 5 being "strongly agree" and 1 being "strongly 
disagree". Circle the number that best describes your rating of the session 
today.     
 
I think that . Strongly 
disagree 
 Strongly 
agree 
 
1. Participants understood the 
purpose of the intervention  
 
1 
 
2 
 
3 
 
4 
 
5 
 
2. Participants understood the group 
agreement and the commitment to 
confidentiality 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
3. Participants increased their 
knowledge around injecting 
techniques 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
4. Participants increased their 
knowledge around good vein care 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
5. Participants increased their 
motivation to improve their injecting 
techniques 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
6. The videos used were relevant 
and informative 
 
1 
 
2 
 
3 
 
4 
 
5 
 
7. I was well prepared to deliver 
the session 
 
1 
 
2 
 
3 
 
4 
 
5 
 
8. I was able to clearly answer 
any questions participants had during 
the session 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
9. In general, how would you rate today’s session? Circle the number that 
best describes your rating, where 5 is “excellent” and 1 is “poor”  
 
Poor       Excellent 
1 2 3 4 5 
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10. What do you think worked best in today’s session? 
 
 
 
 
 
 
 
 
 
 
 
 
11. What do you think worked less well in today’s session? 
 
 
 
 
 
 
 
 
 
 
 
 
12. How do you think today’s session could be improved? 
 
 
 
 
 
 
 
 
 
13. Any additional comments 
 
 
 
 
 
 
 
 
 
 
Thanks 
APPENDIX 14
NIHR Journals Library www.journalslibrary.nihr.ac.uk
298
 
Evaluation Session 2: Planning for Risk situations [facilitator] 
We would be grateful if you could give us some feedback on today’s session 
to help us evaluate it and improve future sessions if necessary. Your 
answers are confidential, so we appreciate your honesty. 
 
Please answer all the questions indicating the degree of agreement or 
disagreement with each, with 5 being "strongly agree" and 1 being "strongly 
disagree". Circle the number that best describes your rating of the session 
today.   
 
I think,,, Strongly 
disagree 
 Strongly 
agree 
1.Participants have a better 
understanding of injecting risk 
behaviours 
 
1 
 
2 
 
3 
 
4 
 
5 
2. Participants have a better 
understanding of sexual risk 
behaviours 
1 2 3 4 5 
3. I am confident participants can use 
some or all of the plan to avoid risk 
behaviours 
1 2 3 4 5 
4. I am confident participants can 
apply TALK to reduce/avoid risks 
1 2 3 4 5 
 
5. I am confident participants can 
prepare for and avoid risky situations 
 
1 
 
2 
 
3 
 
4 
 
5 
 
1. The handouts were helpful 
 
1 
 
2 
 
3 
 
4 
 
5 
2. The exercises used were relevant 
and informative 
1 2 3 4 5 
 
3. I was well prepared to deliver the 
session 
 
1 
 
2 
 
3 
 
4 
 
5 
 
4. I was able to clearly answer 
any questions participants had during 
the session 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
5. In general, how would you rate today’s session? Circle the number that 
best describes your rating, where 5 is “excellent” and 1 is “poor”  
 
Poor       Excellent 
1 2 3 4 5 
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6. What do you think worked best in today’s session? 
 
 
 
 
 
 
 
 
 
 
 
 
7. What do you think worked less well in today’s session? 
 
 
 
 
 
 
 
 
 
 
 
 
8. How do you think today’s session could be improved? 
 
 
 
 
 
 
 
 
 
9. Any additional comments 
 
 
 
 
 
 
 
 
 
 
Thanks 
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Evaluation of Session 3: Understanding Blood Borne Virus 
Transmission risks [facilitator] 
We would be grateful if you could give us some feedback on today’s session 
to help us evaluate it and improve future sessions if necessary. Your 
answers are confidential, so we appreciate your honesty. 
 
Please answer all the questions indicating the degree of agreement or 
disagreement with each, with 5 being "strongly agree" and 1 being "strongly 
disagree". Circle the number that best describes your rating of the session 
today.     
 
I think  Strongly 
disagree 
 Strongly 
agree 
1.Participants have a better 
understanding of blood borne viruses   
 
1 
 
2 
 
3 
 
4 
 
5 
2. Participants have a better 
understanding of BBV 
transmission risk behaviours  
 
1 
 
2 
 
3 
 
4 
 
5 
3. Participants enjoyed the Myths 
and Facts exercise 
1 2 3 4 5 
 
4. Participants appear confident they 
can reduce their BBV 
transmission risk behaviours 
 
1 
 
2 
 
3 
 
4 
 
5 
 
5. Participants showed increased 
their motivation for safer injecting 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6. The handouts were helpful 
1 2 3 4 5 
7. The videos used were relevant 
and informative 
1 2 3 4 5 
 
8. I was well prepared to deliver the 
session 
 
1 
 
2 
 
3 
 
4 
 
5 
 
9. I was able to clearly answer 
any questions participants had during 
the session 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
10. In general, how would you rate today’s session? Circle the number that 
best describes your rating, where 5 is “excellent” and 1 is “poor”  
 
Poor       Excellent 
1 2 3 4 5 
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11. What do you think worked best in today’s session? 
 
 
 
 
 
 
 
 
 
 
 
 
12. What do you think worked less well in today’s session? 
 
 
 
 
 
 
 
 
 
 
13. How do you think today’s session could be improved? 
 
 
 
 
 
 
 
 
 
 
 
14. Any additional comments 
 
 
 
 
 
 
 
 
 
 
 
Thanks 
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Appendix 15 Mean service use values from the
service use questionnaire
TABLE 72 Mean attendances for service use: control group
Cost category
Time point
Baseline Follow-up 1 Follow-up 2
n Mean SD n Mean SD n Mean SD
A&E visits 47 0.468 1.0805 27 0.296 0.8234 23 0.261 0.6887
Inpatient nights 47 0.447 2.1245 27 0.296 0.8689 23 0.783 3.1328
Hospital outpatient visits 47 0.872 4.0946 27 0.667 1.1767 23 0.652 1.1123
Day hospital attendances 47 0.191 0.7413 27 0.111 0.4237 23 0.348 0.8847
Emergency ambulance 47 0.064 0.2471 27 0.185 0.6225 22 0.091 0.4264
Taken from hospital by PTA 47 0.149 0.6587 27 0.444 1.5525 23 0.043 0.2085
GP surgery visits 47 0.872 1.1348 27 1.074 1.1068 23 0.696 0.8221
GP home visits 47 0.064 0.2471 27 0.148 0.4560 23 0.000 0.0000
Practice nurse surgery visits 47 0.511 1.7178 27 0.296 0.5417 23 0.217 0.5184
Practice nurse at home 47 0.340 2.0566 27 0.037 0.1925 23 4.304 20.6429
Prescriptions 47 2.638 3.6856 27 2.481 1.3408 23 2.348 1.6127
Other health-care professionals 44 0.136 0.5099 26 0.038 0.1961 20 0.100 0.3078
Key worker at drug service 47 2.489 1.9322 27 2.370 1.2449 23 2.217 2.1941
Group work 47 0.830 2.7609 27 0.852 2.0325 23 0.783 1.9761
Specialist drug service 47 0.468 1.2132 27 0.296 1.0675 23 0.000 0.0000
Pharmacist 47 19.340 11.1887 26 19.962 9.0354 23 16.130 11.4507
Nurse at drug service 47 0.809 1.7525 26 1.231 4.6845 23 0.739 1.7637
Needle exchange 47 6.000 7.2891 27 4.630 6.8956 23 2.870 4.8082
Outreach worker 47 1.830 5.7760 27 0.852 2.4916 23 1.826 6.2570
HIV or HCV infection test 47 0.404 1.5695 27 0.111 0.3203 23 0.478 1.0388
HIV infection treatment 47 0.000 0.0000 27 0.000 0.0000 23 0.000 0.0000
HCV infection treatment 47 0.000 0.0000 27 0.000 0.0000 23 0.000 0.0000
HBV infection treatment 47 0.000 0.0000 27 0.000 0.0000 23 0.043 0.2085
Mental health specialist 47 0.340 0.8412 27 0.370 0.9667 23 0.043 0.2085
Social worker 47 0.043 0.2040 27 0.259 0.8590 23 0.217 0.5997
Dentist 47 0.085 0.3508 27 0.148 0.4560 23 0.261 0.6192
Family planning 47 0.021 0.1459 27 0.000 0.0000 23 0.087 0.4170
continued
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TABLE 72 Mean attendances for service use: control group (continued )
Cost category
Time point
Baseline Follow-up 1 Follow-up 2
n Mean SD n Mean SD n Mean SD
Sexual health clinic 47 0.149 0.8841 27 0.037 0.1925 23 0.087 0.4170
Arrest or caution 47 0.298 1.1017 27 0.074 0.3849 23 0.130 0.4577
Magistrates’ court appearances 45 0.200 0.8146 26 0.115 0.4315 21 0.190 0.5118
Crown Court appearances 45 0.022 0.1491 26 0.000 0.0000 21 0.000 0.0000
Prison days 44 0.000 0.0000 27 0.000 0.0000 23 0.000 0.0000
A&E, accident and emergency; PTA, patient transport ambulance.
TABLE 73 Mean attendances for service use: intervention group
Cost category
Time point
Baseline Follow-up 1 Follow-up 2
n Mean SD n Mean SD n Mean SD
A&E visits 52 0.269 0.9725 24 0.083 0.2823 22 0.091 0.2942
Inpatient nights 52 0.519 2.4454 24 0.208 1.0206 22 0.182 0.8528
Hospital outpatient visits 52 0.135 0.4441 24 0.083 0.4082 22 0.136 0.4676
Day hospital attendances 52 0.019 0.1387 24 0.083 0.4082 22 0.091 0.4264
Emergency ambulance 52 0.058 0.3076 24 0.000 0.0000 22 0.045 0.2132
Taken from hospital by PTA 52 0.058 0.3076 24 0.042 0.2041 22 0.000 0.0000
GP surgery visits 52 0.750 0.8828 24 0.500 0.6594 22 0.864 1.1253
GP home visits 52 0.019 0.1387 24 0.000 0.0000 22 0.091 0.4264
Practice nurse surgery visits 52 0.385 1.6821 24 0.125 0.3378 22 0.136 0.3513
Practice nurse at home 52 0.000 0.0000 24 0.000 0.0000 22 0.000 0.0000
Prescriptions 52 2.115 2.4387 24 2.250 1.5393 22 2.227 1.3428
Other health-care professionals 51 0.059 0.3106 23 0.130 0.4577 21 0.000 0.0000
Key worker at drug service 52 2.404 3.1390 24 2.083 2.1247 22 1.818 1.0065
Group work 52 0.519 1.7091 24 0.542 2.0637 22 0.273 0.7025
Specialist drug service 51 1.118 4.1214 24 0.375 1.4390 22 0.000 0.0000
Pharmacist 52 18.154 11.3593 24 20.125 8.3630 22 20.545 9.0118
Nurse at drug service 52 0.846 2.0711 24 0.167 0.3807 22 0.227 0.5284
Needle exchange 52 6.788 8.3157 24 3.833 4.7973 22 3.045 3.1393
Outreach worker 52 1.077 4.0041 24 0.042 0.2041 22 0.273 0.7025
HIV or HCV infection test 52 0.135 0.3446 24 0.167 0.6370 22 0.364 0.9021
HIV infection treatment 52 0.000 0.0000 24 0.000 0.0000 22 0.000 0.0000
HCV infection treatment 52 0.538 3.8829 24 0.000 0.0000 22 0.000 0.0000
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TABLE 73 Mean attendances for service use: intervention group (continued )
Cost category
Time point
Baseline Follow-up 1 Follow-up 2
n Mean SD n Mean SD n Mean SD
HBV infection treatment 52 0.019 0.1387 24 0.000 0.0000 22 0.000 0.0000
Mental health specialist 52 0.481 1.9851 24 0.292 0.8587 22 0.136 0.4676
Social worker 52 0.327 1.0426 24 0.083 0.2823 22 0.045 0.2132
Dentist 52 0.231 0.6141 24 0.292 0.6903 22 0.227 0.7516
Family planning 52 0.000 0.0000 24 0.000 0.0000 22 0.000 0.0000
Sexual health clinic 52 0.000 0.0000 24 0.042 0.2041 22 0.000 0.0000
Arrest or caution 52 0.231 0.4693 23 0.174 0.6503 22 0.045 0.2132
Magistrates’ court appearances 51 0.176 0.4339 22 0.091 0.4264 20 0.150 0.6708
Crown Court appearances 51 0.039 0.1960 22 0.000 0.0000 20 0.000 0.0000
Prison days 51 0.137 0.9802 23 0.000 0.0000 22 0.000 0.0000
A&E, accident and emergency; PTA, patient transport ambulance.
TABLE 74 Mean scores on service use questionnaire items by treatment allocation (ITT): baseline
Baseline Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
A&E visits Control 47 0.468 1.0805 –0.2131 0.6108
Intervention 52 0.269 0.9725
Inpatient nights Control 47 0.447 2.1245 –0.9842 0.8393
Intervention 52 0.519 2.4454
Hospital outpatient visits Control 47 0.872 4.0946 –0.4702 1.9456
Intervention 52 0.135 0.4441
Day hospital attendances Control 47 0.191 0.7413 –0.0484 0.3930
Intervention 52 0.019 0.1387
Emergency ambulance Control 47 0.064 0.2471 –0.1047 0.1170
Intervention 52 0.058 0.3076
Taken from hospital by PTA Control 47 0.149 0.6587 –0.1188 0.3013
Intervention 52 0.058 0.3076
GP surgery visits Control 47 0.872 1.1348 –0.2869 0.5316
Intervention 52 0.750 0.8828
GP home visits Control 47 0.064 0.2471 –0.0369 0.1261
Intervention 52 0.019 0.1387
Practice nurse surgery visits Control 47 0.511 1.7178 –0.5536 0.8056
Intervention 52 0.385 1.6821
continued
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TABLE 74 Mean scores on service use questionnaire items by treatment allocation (ITT): baseline (continued )
Baseline Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
Practice nurse at home Control 47 0.340 2.0566 –0.2634 0.9443
Intervention 52 0.000 0.0000
Prescriptions Control 47 2.638 3.6856 –0.7414 1.7872
Intervention 52 2.115 2.4387
Other health-care professionals Control 44 0.136 0.5099 –0.0987 0.2538
Intervention 51 0.059 0.3106
Key worker at drug service Control 47 2.489 1.9322 –0.9454 1.1164
Intervention 52 2.404 3.1390
Group work Control 47 0.830 2.7609 –0.6203 1.2414
Intervention 52 0.519 1.7091
Specialist drug service Control 47 0.468 1.2132 –1.8573 0.5582
Intervention 51 1.118 4.1214
Pharmacist Control 47 19.340 11.1887 –3.3157 5.6889
Intervention 52 18.154 11.3593
Nurse at drug service Control 47 0.809 1.7525 –0.8008 0.7255
Intervention 52 0.846 2.0711
Needle exchange Control 47 6.000 7.2891 –3.9016 2.3246
Intervention 52 6.788 8.3157
Outreach worker Control 47 1.830 5.7760 –1.2548 2.7606
Intervention 52 1.077 4.0041
HIV or HCV infection test Control 47 0.404 1.5695 –0.2001 0.7394
Intervention 52 0.135 0.3446
HIV infection treatment Control 47 0.000 0.0000a
Intervention 52 0.000 0.0000a
HCV infection treatment Control 47 0.000 0.0000 –1.6195 0.5425
Intervention 52 0.538 3.8829
HBV infection treatment Control 47 0.000 0.0000 –0.0578 0.0194
Intervention 52 0.019 0.1387
Mental health specialist Control 47 0.340 0.8412 –0.7414 0.4607
Intervention 52 0.481 1.9851
Social worker Control 47 0.043 0.2040 –0.5802 0.0114
Intervention 52 0.327 1.0426
Dentist Control 47 0.085 0.3508 –0.3433 0.0519
Intervention 52 0.231 0.6141
Family planning Control 47 0.021 0.1459 –0.0216 0.0641
Intervention 52 0.000 0.0000
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TABLE 74 Mean scores on service use questionnaire items by treatment allocation (ITT): baseline (continued )
Baseline Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
Sexual health clinic Control 47 0.149 0.8841 –0.1107 0.4085
Intervention 52 0.000 0.0000
Arrest or caution Control 47 0.298 1.1017 –0.2796 0.4138
Intervention 52 0.231 0.4693
Magistrates’ court appearances Control 45 0.200 0.8146 –0.0772 0.2079
Intervention 51 0.176 0.4339
Crown Court appearances Control 45 0.022 0.1491 –0.2476 0.2947
Intervention 51 0.039 0.1960
Prison days Control 44 0.000 0.0000 –0.0871 0.0532
Intervention 51 0.137 0.9802
A&E, accident and emergency; PTA, patient transport ambulance.
a t cannot be computed because the SDs of both groups are 0.
TABLE 75 Mean scores on service use questionnaire items by treatment allocation (ITT): follow-up 1
Follow-up 1 Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
A&E visits Control 27 0.296 0.8234 –0.1302 0.5562
Intervention 24 0.083 0.2823
Inpatient nights Control 27 0.296 0.8689 –0.4499 0.6259
Intervention 24 0.208 1.0206
Hospital outpatient visits Control 27 0.667 1.1767 0.0923 1.0744
Intervention 24 0.083 0.4082
Day hospital attendances Control 27 0.111 0.4237 –0.2066 0.2621
Intervention 24 0.083 0.4082
Emergency ambulance Control 27 0.185 0.6225 –0.0611 0.4314
Intervention 24 0.000 0.0000
Taken from hospital by PTA Control 27 0.444 1.5525 –0.2162 1.0217
Intervention 24 0.042 0.2041
GP surgery visits Control 27 1.074 1.1068 0.0660 1.0822
Intervention 24 0.500 0.6594
GP home visits Control 27 0.148 0.4560 –0.0323 0.3286
Intervention 24 0.000 0.0000
Practice nurse surgery visits Control 27 0.296 0.5417 –0.0806 0.4232
Intervention 24 0.125 0.3378
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TABLE 75 Mean scores on service use questionnaire items by treatment allocation (ITT): follow-up 1 (continued )
Follow-up 1 Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
Practice nurse at home Control 27 0.037 0.1925 –0.0391 0.1132
Intervention 24 0.000 0.0000
Prescriptions Control 27 2.481 1.3408 –0.5869 1.0499
Intervention 24 2.250 1.5393
Other health-care professionals Control 26 0.038 0.1961 –0.3024 0.1185
Intervention 23 0.130 0.4577
Key worker at drug service Control 27 2.370 1.2449 –0.7177 1.2917
Intervention 24 2.083 2.1247
Group work Control 27 0.852 2.0325 –0.8456 1.4659
Intervention 24 0.542 2.0637
Specialist drug service Control 27 0.296 1.0675 –0.8020 0.6446
Intervention 24 0.375 1.4390
Pharmacist Control 26 19.962 9.0354 –5.1107 4.7837
Intervention 24 20.125 8.3630
Nurse at drug service Control 26 1.231 4.6845 –0.8334 2.9616
Intervention 24 0.167 0.3807
Needle exchange Control 27 4.630 6.8956 –2.5226 4.1152
Intervention 24 3.833 4.7973
Outreach worker Control 27 0.852 2.4916 –0.1785 1.7988
Intervention 24 0.042 0.2041
HIV or HCV infection test Control 27 0.111 0.3203 –0.3483 0.2372
Intervention 24 0.167 0.6370
HIV infection treatment Control 27 0.000 0.0000a
Intervention 24 0.000 0.0000a
HCV infection treatment Control 27 0.000 0.0000a
Intervention 24 0.000 0.0000a
HBV infection treatment Control 27 0.000 0.0000a
Intervention 24 0.000 0.0000a
Mental health specialist Control 27 0.370 0.9667 –0.4349 0.5924
Intervention 24 0.292 0.8587
Social worker Control 27 0.259 0.8590 –0.1806 0.5325
Intervention 24 0.083 0.2823
Dentist Control 27 0.148 0.4560 –0.1163 0.1070
Intervention 24 0.292 0.6903
Family planning Control 27 0.000 0.0000a
Intervention 24 0.000 0.0000a
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TABLE 75 Mean scores on service use questionnaire items by treatment allocation (ITT): follow-up 1 (continued )
Follow-up 1 Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
Sexual health clinic Control 27 0.037 0.1925 –0.1168 0.1075
Intervention 24 0.042 0.2041
Arrest or caution Control 27 0.074 0.3849 –0.4137 0.2140
Intervention 23 0.174 0.6503
Magistrates’ court appearances Control 26 0.115 0.4315 –0.2257 0.2746
Intervention 22 0.091 0.4264
Crown Court appearances Control 26 0.000 0.0000a
Intervention 22 0.000 0.0000a
Prison days Control 27 0.000 0.0000a
Intervention 23 0.000 0.0000a
A&E, accident and emergency; PTA, patient transport ambulance.
a t cannot be computed because the SDs of both groups are 0.
TABLE 76 Mean scores on service use questionnaire items by treatment allocation (ITT): follow-up 2
Follow-up 2 Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
A&E visits Control 23 0.261 0.6887 –0.1501 0.4900
Intervention 22 0.091 0.2942
Inpatient nights Control 23 0.783 3.1328 –0.7946 1.9962
Intervention 22 0.182 0.8528
Hospital outpatient visits Control 23 0.652 1.1123 0.0001 1.0315
Intervention 22 0.136 0.4676
Day hospital attendances Control 23 0.348 0.8847 –0.1620 0.6758
Intervention 22 0.091 0.4264
Emergency ambulance Control 22 0.091 0.4264 –0.1619 0.2528
Intervention 22 0.045 0.2132
Taken from hospital by PTA Control 23 0.043 0.2085 –0.0467 0.1336
Intervention 22 0.000 0.0000
GP surgery visits Control 23 0.696 0.8221 –0.7647 0.4287
Intervention 22 0.864 1.1253
GP home visits Control 23 0.000 0.0000 –0.2800 0.0981
Intervention 22 0.091 0.4264
Practice nurse surgery visits Control 23 0.217 0.5184 –0.1850 0.3471
Intervention 22 0.136 0.3513
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TABLE 76 Mean scores on service use questionnaire items by treatment allocation (ITT): follow-up 2 (continued )
Follow-up 2 Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
Practice nurse at home Control 23 4.304 20.6429 –4.6223 13.2310
Intervention 22 0.000 0.0000
Prescriptions Control 23 2.348 1.6127 –0.7706 1.0117
Intervention 22 2.227 1.3428
Other health-care professionals Control 20 0.100 0.3078 –0.0441 0.2441
Intervention 21 0.000 0.0000
Key worker at drug service Control 23 2.217 2.1941 –0.6312 1.4296
Intervention 22 1.818 1.0065
Group work Control 23 0.783 1.9761 –0.3887 1.4084
Intervention 22 0.273 0.7025
Specialist drug service Control 23 0.000 0.0000a
Intervention 22 0.000 0.0000a
Pharmacist Control 23 16.130 11.4507 –10.6020 1.7720
Intervention 22 20.545 9.0118
Nurse at drug service Control 23 0.739 1.7637 –0.2786 1.3024
Intervention 22 0.227 0.5284
Needle exchange Control 23 2.870 4.8082 –2.6161 2.2643
Intervention 22 3.045 3.1393
Outreach worker Control 23 1.826 6.2570 –1.1661 4.2728
Intervention 22 0.273 0.7025
HIV or HCV infection test Control 23 0.478 1.0388 –0.4697 0.6990
Intervention 22 0.364 0.9021
HIV infection treatment Control 23 0.000 0.0000a
Intervention 22 0.000 0.0000a
HCV infection treatment Control 23 0.000 0.0000a
Intervention 22 0.000 0.0000a
HBV infection treatment Control 23 0.043 0.2085 –0.0467 0.1336
Intervention 22 0.000 0.0000
Mental health specialist Control 23 0.043 0.2085 –0.3154 0.1296
Intervention 22 0.136 0.4676
Social worker Control 23 0.217 0.5997 –0.1008 0.4446
Intervention 22 0.045 0.2132
Dentist Control 23 0.261 0.6192 –0.3821 0.4493
Intervention 22 0.227 0.7516
Family planning Control 23 0.087 0.4170 –0.0934 0.2673
Intervention 22 0.000 0.0000
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TABLE 76 Mean scores on service use questionnaire items by treatment allocation (ITT): follow-up 2 (continued )
Follow-up 2 Allocation n Mean SD
95% CI of difference
Lower CI Upper CI
Sexual health clinic Control 23 0.087 0.4170 –0.0934 0.2673
Intervention 22 0.000 0.0000
Arrest or caution Control 23 0.130 0.4577 –0.1305 0.3005
Intervention 22 0.045 0.2132
Magistrates’ court appearances Control 21 0.190 0.5118 –0.3390 0.4199
Intervention 20 0.150 0.6708
Crown Court appearances Control 21 0.000 0.0000a
Intervention 20 0.000 0.0000a
Prison days Control 23 0.000 0.0000a
Intervention 22 0.000 0.0000a
A&E, accident and emergency; PTA, patient transport ambulance.
a t cannot be computed because the SDs of both groups are 0.
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